---
document_datetime: 2023-10-31 11:10:01
document_pages: 134
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/imjudo-h-c-006016-ii-0001-epar-assessment-report-variation_en.pdf
document_name: imjudo-h-c-006016-ii-0001-epar-assessment-report-variation_en.pdf
version: success
processing_time: 234.3295028
conversion_datetime: 2025-12-30 13:12:27.783823
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

22 Jun 2023 EMA/CHMP/213841/2023 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## IMJUDO

International non-proprietary name: tremelimumab

Procedure No. EMEA/H/C/006016/II/0001

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                  | ..............................................6                                                         |
|-----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................6  |                                                                                                         |
| 1.2. Steps taken for the assessment of the product.........................................................7                |                                                                                                         |
| 2. Scientific discussion                                                                                                    | ................................................................................7                       |
| 2.1. Introduction.........................................................................................................7 |                                                                                                         |
| 2.1.1. Problem statement                                                                                                    | ............................................................................................7           |
| 2.1.2. About the product..............................................................................................9     |                                                                                                         |
| 2.1.3. General comments on compliance with GCP........................................................11                    |                                                                                                         |
| 2.2. Non-clinical aspects                                                                                                   | ............................................................................................11          |
| 2.2.1. Introduction....................................................................................................11   |                                                                                                         |
| 2.2.2. Ecotoxicity/environmental risk assessment                                                                            | .........................................................12                                             |
| 2.2.3. Conclusion on non-clinical aspects                                                                                   | .....................................................................12                                 |
| 2.3. Clinical aspects                                                                                                       | ..................................................................................................12    |
| 2.3.1. Introduction....................................................................................................12   |                                                                                                         |
| 2.3.2. Pharmacokinetics.............................................................................................13      |                                                                                                         |
| 2.3.3. Pharmacodynamics..........................................................................................36         |                                                                                                         |
| 2.3.4. Discussion on clinical pharmacology...................................................................43             |                                                                                                         |
| 2.3.5. Conclusions on clinical pharmacology.................................................................47              |                                                                                                         |
| 2.4. Clinical efficacy                                                                                                      | ..................................................................................................47    |
| 2.4.1. Dose response study(ies)                                                                                             | .................................................................................47                     |
| 2.4.2. Main study(ies)                                                                                                      | ...............................................................................................48       |
| 2.4.3. Discussion on clinical efficacy............................................................................89        |                                                                                                         |
| 2.4.4. Conclusions on the clinical efficacy.....................................................................93          |                                                                                                         |
| 2.5. Clinical safety                                                                                                        | ....................................................................................................93  |
| 2.5.1. Discussion on clinical safety ............................................................................           | 122                                                                                                     |
| 2.5.2. Conclusions on clinical safety ..........................................................................            | 126                                                                                                     |
| 2.5.3. PSUR cycle                                                                                                           | ................................................................................................... 127 |
| 2.6. Risk management plan......................................................................................             | 127                                                                                                     |
| 2.7. Update of the Product information ......................................................................               | 128                                                                                                     |
| 2.7.1. User consultation...........................................................................................         | 128                                                                                                     |
| 3. Benefit-Risk Balance............................................................................128                      |                                                                                                         |
| 3.1. Therapeutic Context                                                                                                    | ......................................................................................... 128           |
| 3.1.1. Disease or condition.......................................................................................          | 128                                                                                                     |
| 3.1.2. Available therapies and unmet medical need.....................................................                      | 129                                                                                                     |
| 3.1.3. Main clinical studies                                                                                                | ....................................................................................... 129             |
| 3.2. Favourable effects ............................................................................................        | 129                                                                                                     |
| 3.3. Uncertainties and limitations about favourable effects...........................................                      | 130                                                                                                     |
| 3.4. Unfavourable effects.........................................................................................          | 130                                                                                                     |
| 3.5. Uncertainties and limitations about unfavourable effects                                                               | ....................................... 131                                                             |
| 3.6. Effects Table....................................................................................................      | 131                                                                                                     |
| 3.7. Benefit-risk assessment and discussion...............................................................                  | 132                                                                                                     |
| 3.7.1. Importance of favourable and unfavourable effects............................................                        | 132                                                                                                     |
| 3.7.2. Balance of benefits and risks...........................................................................             | 133                                                                                                     |

<div style=\"page-break-after: always\"></div>

3.7.3. Additional considerations on the benefit-risk balance ......................................... 133

3.8. Conclusions .....................................................................................................  133

4. Recommendations ...............................................................................  133

5. EPAR changes  ......................................................................................  134

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| Abbreviation   | Definition                                                                                    |
|----------------|-----------------------------------------------------------------------------------------------|
| 1L             | First-line                                                                                    |
| ADA            | Anti-drug antibody                                                                            |
| ADCC           | Antibody-Dependent Cellular Cytotoxicity                                                      |
| ADR            | Adverse drug reaction                                                                         |
| AE             | Adverse event                                                                                 |
| AESI           | Adverse event of special interest                                                             |
| ALB            | Serum albumin                                                                                 |
| ALK            | Anaplastic lymphoma kinase                                                                    |
| ALT            | Alanine aminotransferase                                                                      |
| AST            | Aspartate aminotransferase                                                                    |
| AUC            | Area under the serum concentration-time curve                                                 |
| BICR           | Blinded Independent Central Review                                                            |
| BOR            | Best objective response                                                                       |
| bTMB           | Blood tumor mutational burden                                                                 |
| CD             | Cluster of differentiation                                                                    |
| CI             | Confidence interval                                                                           |
| CL             | Clearance                                                                                     |
| C max          | Maximum serum concentration                                                                   |
| C min          | Minimum serum concentration                                                                   |
| CR             | Complete response                                                                             |
| CRF            | Case report form                                                                              |
| CSP            | Clinical study protocol                                                                       |
| CSR            | Clinical study report                                                                         |
| CTCAE          | Common Terminology Criteria for Adverse Events Cytotoxic T lymphocyte-associated antigen-4    |
| CTLA-4 DCO     | Data cut-off                                                                                  |
| DoR            | Duration of response                                                                          |
| ECG            | Electrocardiogram                                                                             |
| ECOG           | Eastern Cooperative Oncology Group                                                            |
| EGFR           | Epidermal growth factor receptor                                                              |
| EMA            | European Medicines Agency                                                                     |
| EORTC          | European Organization for Research and Treatment of Cancer                                    |
| ESMO           | European Society for Medical Oncology                                                         |
| ES-SCLC        | Extensive-stage small cell lung cancer                                                        |
| FAS            | Full Analysis Set                                                                             |
| FDA GCP        | Food and Drug Administration Good Clinical Practice                                           |
| HBV            | Hepatitis B virus                                                                             |
| HCC            | Hepatocellular carcinoma                                                                      |
| HR             | Hazard ratio                                                                                  |
| HRQoL          | Health-related quality of life                                                                |
| IA             | Interim analysis                                                                              |
| ICH            | International Council For Harmonization Of Technical Requirements For Pharmaceuticals For Use |
| ICI            | Human                                                                                         |
|                | Immune checkpoint inhibitor                                                                   |
| IDMC           | Independent Data Monitoring Committee                                                         |
| IgG ILD        | Immunoglobulin G Interstitial lung disease                                                    |
| imAE           |                                                                                               |
| ISS            | Immune-mediated adverse event of safety                                                       |
| ITT            | Integrated summary Intent-to-treat                                                            |
| IV             | Intravenous                                                                                   |
| IVRS/IWRS      | Interactive Voice Response System / Interactive Web Response System                           |
| KM             | Kaplan-Meier                                                                                  |
| LDH            | Lactate dehydrogenase                                                                         |
| MAA            | Marketing Authorization Application Monoclonal antibody                                       |
| mAb            | Multiple testing procedure                                                                    |
| MTP            |                                                                                               |

<div style=\"page-break-after: always\"></div>

| Abbreviation   | Definition                                                                                    |
|----------------|-----------------------------------------------------------------------------------------------|
| Mut/Mb         | Mutations per megabase                                                                        |
| nAb            | Neutralizing antibody                                                                         |
| NLR            | Neutrophil-to-lymphocyte ratio                                                                |
| NSCLC          | Non-small cell lung cancer                                                                    |
| ORR            | Objective response rate                                                                       |
| OS             | Overall survival                                                                              |
| PAR            | Proven Acceptable Range                                                                       |
| PD-1           | Programmed cell death-1                                                                       |
| PD-L1          | Programmed cell death ligand-1                                                                |
| PD-L2          | Programmed cell death ligand-2                                                                |
| PFS            | Progression-free survival                                                                     |
| Ph. Eur.       | European Pharmacopoeia                                                                        |
| PK             | Pharmacokinetic                                                                               |
| PopPK          | Population pharmacokinetics                                                                   |
| PR             | Partial response                                                                              |
| PRO            | Patient-reported outcome                                                                      |
| PT             | Preferred term                                                                                |
| QLQ-C30        | 30-item core quality of life questionnaire                                                    |
| QoL            | Quality of life                                                                               |
| QxW            | Every x week                                                                                  |
| RECIST         | Response Evaluation Criteria in Solid Tumors                                                  |
| SAE            | Serious adverse event                                                                         |
| SAP            | Statistical Analysis Plan                                                                     |
| SD             | Standard Deviation                                                                            |
| SoC            | Standard-of-care                                                                              |
| SOC            | System organ class                                                                            |
| T              | Tremelimumab                                                                                  |
| T300+D         | Tremelimumab 300 mg (4 mg/kg) for a single priming dose and durvalumab 1500 mg (20 mg/kg) Q4W |
| T75+D          | Tremelimumab 75 mg (1 mg/kg) Q4W x 4 doses and durvalumab 1500 mg (20 mg/kg) Q4W              |
| TMB            | Tumor mutation burden                                                                         |
| TTD            | Time to deterioration                                                                         |
| US             | United States                                                                                 |
| USP            | United States Pharmacopoeia                                                                   |
| V1             | Central volume of distribution                                                                |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, AstraZeneca AB submitted to the European Medicines Agency on 10 March 2023 an application for a variation.

The following variation was requested:

| Variation requested   | Type                                                                                                                           | Annexes affected   | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|--------------------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II            | I and IIIB         |

Extension of indication to include in combination with durvalumab and platinum-based chemotherapy, the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations for IMJUDO, based on the final analysis from the pivotal study D419MC00004, a Randomised, Multi-center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Patients with Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON). As a consequence, sections 2, 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2, 5.3 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to include editorial changes.

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet.

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0367/2022 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP EMEA-002029-PIP01-16-M03 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The applicant did not seek Scientific Advice at the CHMP.

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Aaron Sosa Mejia

Co-Rapporteur:

N/A

| Timetable                                                                                | Actual dates   |
|------------------------------------------------------------------------------------------|----------------|
| Submission date                                                                          | 10 March 2023  |
| Start of procedure:                                                                      | 27 March 2023  |
| CHMP Rapporteur Assessment Report                                                        | 2 May 2023     |
| CHMP members comments                                                                    | 15 May 2023    |
| Updated CHMP Rapporteur Assessment Report                                                | 17 May 2023    |
| Request for supplementary information and extension of timetable adopted by the CHMP on: | 25 May 2023    |
| MAH's responses submitted to the CHMP on:                                                | 30 May 2023    |
| Rapporteur's preliminary assessment report on the MAH's responses circulated on:         | 5 June 2023    |
| CHMP comments                                                                            | 12 June 2023   |
| Joint Rapporteur's updated assessment report on the MAH's responses circulated on:       | 16 June 2023   |
| CHMP opinion:                                                                            | 22 June 2023   |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

The applied indication is: IMJUDO in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.

## Epidemiology

Lung cancer is the second most commonly diagnosed cancer and remains the leading cause of cancer death around the globe (Sung et al 2021; GLOBOCAN 2021). In Europe, an estimated 312,645 patients will be diagnosed with lung cancer in 2021, accounting for approximately 25% of all cancer diagnoses, and an estimated 267,700 lung cancer associated deaths will occur, accounting for approximately one in 5 cancer related mortalities (Lung Cancer Europe 2021). In the US, an estimated

<div style=\"page-break-after: always\"></div>

235,760 new cases of lung cancer will be diagnosed in 2021, accounting for about 25% of all cancer diagnoses, and an estimated 131,880 lung cancer associated deaths will occur, accounting for approximately 1 in 4 cancer related mortalities (American Cancer Society 2021).

## Biologic features

Non-small cell lung cancer (NSCLC) comprises approximately 85% of all newly diagnosed lung cancer cases. It includes several histological subtypes of which non-squamous (e.g., adenocarcinoma, large cell carcinoma) and squamous cell carcinoma are the most common (Aisner and Marshall 2012).

## Clinical presentation, diagnosis and stage/prognosis

Despite advances made in screening, early detection, and staging, the majority of lung cancer patients are diagnosed when the disease has advanced into the metastatic stage and is not amenable to surgical resection (Herbst et al 2018). Furthermore, a significant percentage of patients with early stage NSCLC who have undergone surgery subsequently develop distant recurrence and die as a result of their metastatic disease (Pisters and Le Chevalier 2005).

## Management

The first line (1L) treatment of metastatic NSCLC has evolved from the empirical use of cytotoxic chemotherapies based on physician's preference to a hallmark of personalized medicine, with subsets of patients treated according to the genetic alterations of their tumour and the status of programmed cell death ligand 1 (PD-L1), which predict for benefit from targeted therapies or immune checkpoint inhibitors (ICIs), respectively (Herbst et al 2018; Peters et al 2019).

In the past 5 years, substantial progress has been made in the frontline treatment of metastatic NSCLC with immunotherapy-based regimens demonstrating improved outcomes in this patient population (NCCN Clinical Practice Guidelines in Oncology Version 1.2020; ESMO Guidelines Committee 2019). Treatment selection in clinical practice is usually based on PD-L1 expression or histology. For patients with high PD-L1 expression (i.e., PD-L1 expressed in ≥ 50% of tumour cells), monotherapy with either pembrolizumab or atezolizumab or cemiplimab have been authorised in the EU. Conversely, regardless of PD-L1 expression, a series of combinations of immunotherapy with histology-selected platinum-based chemotherapy have also shown survival benefits and were authorised in the EU:

- Pembrolizumab + carboplatin + paclitaxel/nab-paclitaxel for squamous histology
- Pembrolizumab + carboplatin + pemetrexed for non-squamous histology
- Atezolizumab + bevacizumab + carboplatin + paclitaxel for non-squamous histology
- Atezolizumab + carboplatin + nab-paclitaxel for non-squamous histology

The addition of chemotherapy to nivolumab + ipilimumab, a combination of PD-1/CTLA-4 inhibitors, showed efficacy benefit over chemotherapy alone with early disease control at all PD-L1 expression levels (Paz-Ares et al [Checkmate 9LA] 2021), receiving a positive opinion from the CHMP in September 2020 (EMEA/H/C/WS1783).

Unmet medical need: Immunotherapy-based treatments are the 1L standard-of-care in patients with advanced metastatic NSCLC whose tumours do not harbour driver mutations (NCCN Clinical Practice Guidelines in Oncology Version 2.2021). Notwithstanding these developments and the treatment options, the available treatment strategies extend long-term survival in only a minority of patients

<div style=\"page-break-after: always\"></div>

(Peters et al 2019; Grant et al 2021). Overall, newer treatment options are therefore required that can explore the potential of immunotherapy strategies and benefit a broader patient population.

## 2.1.2. About the product

Tremelimumab is a selective, fully human IgG2 monoclonal antibody (mAb) directed against cytotoxic T lymphocyte associated antigen 4 (CTLA-4). CTLA-4 is a critical regulatory signal for T cell expansion and activation following an immune response, and it serves as a natural braking mechanism that maintains T cell homeostasis. During T cell activation, T cells upregulate CTLA-4, which binds to CD80 and CD86 ligands on antigen-presenting cells, sending an inhibitory signal and preventing CD28mediated T cell co-stimulation, thus limiting T cell activation. Tremelimumab blocks these events, leading to prolongation and enhancement of T cell activation and expansion, resulting in increased Tcell diversity and enhanced anti-tumour activity.

In order to make the medicinal product available for health-care professionals and/or patients in the most optimal and timely way (related to Article 82 (1) of Regulation (EC) № 726/2004) the applicant has submitted two separate MAAs for tremelimumab:

- One MAA, under the name of TREMELIMUMAB ASTRAZENECA, in combination with durvalumab and platinum-based chemotherapy in non-small cell lung cancer (NSCLC), CHMP opinion issued on 15 December 2022.

- Another MAA, under the name of IMJUDO, in combination with durvalumab in the treatment of hepatocellular carcinoma (HCC), CHMP opinion issued on 15 December 2022.

This type II variation is being submitting to reflect the NSCLC indication from the TREMELIMUMAB ASTRAZENECA MAA into the IMJUDO Marketing Authorisation.

This variation presents a consolidation of the already assessed NSCLC data from the TREMELIMUMAB ASTRAZENECA MAA into the IMJUDO MA, together with an administrative update of the eCTD backbone.

The CHMP adopted a positive opinion for the following indication: IMJUDO in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.

Treatment with IMJUDO must be initiated and supervised by a physician experienced in the treatment of cancer.

## Posology

The recommended dose of IMJUDO is presented in Table 1.

<div style=\"page-break-after: always\"></div>

Table 1: Recommended dose of IMJUDO

| Indication       | Recommended IMJUDO dose                                                                                                                                                                                                                                                                                                                                                                        | Duration of therapy                                                                                                                                                                                             |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Metastatic NSCLC | During platinum chemotherapy: 75 mg a in combination with durvalumab 1 500 mg b and platinum-based chemotherapy c every 3 weeks (21 days) for 4 cycles (12 weeks) Post-platinum chemotherapy: Durvalumab 1 500 mg c every 4 weeks and histology-based pemetrexed maintenance c,d therapy every 4 weeks A fifth dose of IMJUDO 75 mg e,f should be given at week 16 alongside durvalumab dose 6 | Up to a maximum of 5 doses Patients may receive less than five doses of IMJUDO in combination with durvalumab 1 500 mg and platinum-based chemotherapy if there is disease progression or unacceptable toxicity |

Dose escalation or reduction is not recommended for IMJUDO in combination with durvalumab. Dose withholding or discontinuation may be required based on individual safety and tolerability.

## Method of administration

IMJUDO is for intravenous use, it is administered as an intravenous infusion after dilution, over 1 hour.

When IMJUDO is given in combination with durvalumab and platinum-based chemotherapy, IMJUDO is given first, followed by durvalumab and then platinum-based chemotherapy on the day of dosing.

When IMJUDO is given as a fifth dose in combination with durvalumab and pemetrexed maintenance therapy at week 16, IMJUDO is given first, followed by durvalumab and then pemetrexed maintenance therapy on the day of dosing.

IMJUDO, durvalumab, and platinum-based chemotherapy are administered as separate intravenous infusions. IMJUDO and durvalumab are each given over 1 hour. For platinum-based chemotherapy, refer to the SmPC for administration information. For pemetrexed maintenance therapy, refer to the SmPC for administration information. Separate infusion bags and filters for each infusion should be used.

During cycle 1, IMJUDO is to be followed by durvalumab starting approximately 1 hour (maximum 2 hours) after the end of the IMJUDO infusion. Platinum-based chemotherapy infusion should start approximately 1 hour (maximum 2 hours) after the end of the durvalumab infusion. If there are no clinically significant concerns during cycle 1, then at the physician's discretion, subsequent cycles of

<div style=\"page-break-after: always\"></div>

durvalumab can be given immediately after IMJUDO and the time period between the end of the durvalumab infusion and the start of chemotherapy can be reduced to 30 minutes.

## 2.1.3. General comments on compliance with GCP

A routine GCP inspection of study D419MC00004 (POSEIDON) was adopted at the CHMP meeting held in January 2022. No specific concerns were known to have been identified by the assessment at the time of adoption of the inspection request; general triggers were used in the choice of this dossier and the sites involved in line with the guideline 'Points to consider for assessors, inspectors and EMA inspection coordinators on the identification of triggers for the selection of applications for 'routine' and/or 'for cause' inspections, their investigation and scope of such inspections'. The purpose of the inspection was to verify efficacy and safety data reported by the applicant for a sample of patients to be determined by the inspectors. Moreover, the compliance with GCP and applicable regulations was to be verified, in particular where it had an impact on the validity of the data or the ethical conduct of the study.

This routine GCP inspection was conducted at one investigational site in Germany (21-25 February 2022), the main CRO in the USA (11-17 March 2022), and the sponsor in Canada (21-25 March 2022). One critical finding was reported during the CRO inspection; major and minor findings were observed at all sites.

Although departures from GCP compliance were identified as there were one critical and several major findings observed during the inspections at all sites, the study was considered by the inspection team to have been conducted ethically and in compliance with GCP. The findings were deemed unlikely to impact the overall quality of the data. The inspection team concluded that the overall quality of the trial with the reported data had not been negatively affected, and that the data documented and reported in the Clinical Study Report (CSR) submitted could be used as basis for the assessment. The sponsor was however requested for a CSR addendum including a complete list of mis-stratified subjects to report overall survival in long-term follow up as part of the corrective action proposed for one of the major findings at the sponsor site.

## 2.2. Non-clinical aspects

## 2.2.1. Introduction

Since the two indications for IMJUDO have different clinical dosing regimens, different population PK reports are used to calculate safety margins.

Safety margins are calculated using the clinical AUC from the 6-month cynomolgus monkey study at the highest non-severely toxic dose (HNSTD). A clinical AUC value of 19104 µg.hr/mL is used for the indication of tremelimumab in combination with durvalumab for the treatment of HCC (IMJUDO initial MAA) while a clinical AUC value of 6360 µg.hr/mL is used for the indication of tremelimumab in combination with durvalumab and platinum-based chemotherapy for the treatment of NSCLC (TREMELIMUMAB ASTRAZENECA initial MAA). This equates to a safety margin of 1.77 and 5.33 for each indication respectively.

No other new non-clinical data have been submitted to support this application.

<div style=\"page-break-after: always\"></div>

## 2.2.2. Ecotoxicity/environmental risk assessment

Tremelimumab is a protein, which is expected to biodegrade in the environment and not be a significant risk to the environment. Thus, according to the 'Guideline on the Environmental Risk assessment of Medicinal Products for Human Use' (EMEA/CHMP/SWP/4447/00), tremelimumab is exempt from preparation of an Environmental Risk Assessment as the product and excipients do not pose a significant risk to the environment.

## 2.2.3. Conclusion on non-clinical aspects

In accordance, the section 5.3 of the SmPC has been updated to include a range for the exposurebased safety margin (1.77-5.33). The non-clinical data submitted in the context of the initial MAA of Imjudo also support the intended use in the new indication submitted in this application.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

Table 2: Summary of clinical studies included in the application package

| Study name Status a DCO                       | Phase Design                                                  | Patient population                                                                                                                     | Key outcome measures                                                                              | No. of patients randomized                                  |
|-----------------------------------------------|---------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|-------------------------------------------------------------|
| Pivotal Phase III study                       | Pivotal Phase III study                                       |                                                                                                                                        |                                                                                                   |                                                             |
| POSEIDON Complete 24 Jul 2019 b 12 Mar 2021 c | Phase III Randomized, open- label, comparative, multicenter   | Patients with metastatic NSCLC who have not received prior 1L treatment, and who do not have EGFR or ALK target mutations              | OS, PFS, ORR Safety: AEs, laboratory evaluations, physical examinations, and vital signs          | T + D + SoC: 338 D + SoC: 338 SoC: 337                      |
| Supportive Phase I-II studies                 | Supportive Phase I-II studies                                 |                                                                                                                                        |                                                                                                   |                                                             |
| Study 1108 Complete 16 Oct 2017               | Phase I/IIb FTIH, open-label, dose-escalation, dose-expansion | Patients with advanced solid tumors, including NSCLC, that are refractory to standard therapy and for which no standard therapy exists | MTD or OBD Safety: AEs, laboratory evaluations, physical examinations, and vital signs            | Escalation - D: 48 Expansion - D: 980                       |
| Japan 02 Complete 31 Mar 2018                 | Phase I Open-label, multicenter                               | Patients with advanced solid tumors, that are refractory to standard therapy and for which no standard therapy exists                  | MTD or OBD Safety: AEs, laboratory evaluations, physical examinations, vital signs                | Escalation - D: 22 Expansion - D:116 Expansion - T + D: 124 |
| Study 06 Complete 19 Nov 2019                 | Phase I open-label, dose-escalation, dose-expansion           | Patients with advanced NSCLC                                                                                                           | MTD, ORR (Dose expansion) Safety: AEs, laboratory evaluations, physical examinations, vital signs | Escalation - T + D: 102 Expansion - T + D: 355              |
| Study 10 Complete 11 Apr 2018                 | Phase I open-label, multicenter                               | Patients with advanced solid tumors                                                                                                    | ORR (PD-L1 negative UC) Safety: AEs, laboratory evaluations, physical examinations, vital signs   | Exploration and Expansion - T + D: 379                      |
| ATLANTIC Complete 03 Jun 2016                 | Phase II Non-comparative, open-label, multicenter             | Patients with locally advanced or metastatic NSCLC (Stage IIIB - IV) who have received at least 2 prior systemic treatment regimens    | ORR Safety: AEs, laboratory evaluations, physical examinations, vital signs, ECG                  | D: 444                                                      |

<div style=\"page-break-after: always\"></div>

| Study name Status a DCO                  | Phase Design                                                          | Patient population                                                                                                                                                | Key outcome measures                                                                                     | No. of patients randomized                                               |
|------------------------------------------|-----------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|
| CONDOR Complete 27 Aug 2018              | Phase II Randomized, open-label, multicenter                          | Patients with recurrent or metastatic HNSCC not amenable to therapy with curative intent                                                                          | ORR Safety: AEs, laboratory evaluations, physical examinations, vital signs, ECG                         | D: 67 T: 67 T + D: 133                                                   |
| DETERMINE Complete 24 Jan 2016           | Phase IIb Randomized, double- blind                                   | Patients with pleural or peritoneal malignant mesothelioma who had progressed following 1 or 2 prior treatments                                                   | OS Safety: AEs, laboratory evaluations, physical examinations, vital signs, ECG                          | T: 382 Placebo: 189                                                      |
| D4884C000 01 Complete 17 Feb 2018        | Phase II Open-label, multicenter                                      | Patients with advanced solid tumors                                                                                                                               | ORR Safety: AEs, laboratory evaluations, physical examinations, vital signs, ECG                         | T: 64                                                                    |
| Study 22 Complete 06 Nov 2020            | Phase I/II, randomized, open-label, multicenter, multipart            | Patients with advanced hepatocellular carcinoma (HCC)                                                                                                             | Primary: safety and tolerability                                                                         | D: 107 T: 74 T + D: 205                                                  |
| Supportive Phase III studies             | Supportive Phase III studies                                          | Supportive Phase III studies                                                                                                                                      | Supportive Phase III studies                                                                             | Supportive Phase III studies                                             |
| ARCTIC Complete 09 Feb 2018              | Phase III Randomized, open-label, multicenter                         | Patients with locally advanced or metastatic NSCLC (Stage IIIB-IV) who received at least 2 prior systemic treatments and do not have EGFR or ALK target mutations | OS, PFS, ORR Safety: AEs, laboratory evaluations, physical examinations, vital signs                     | Sub-study A D: 62; SoC: 64 Sub-study B D: 117; T: 60 T + D: 174 SoC: 118 |
| PACIFIC Complete 22 Mar 2018             | Phase III Randomized, double- blind, placebo- controlled, multicenter | Patients with locally advanced, unresectable, Stage III NSCLC who have not progressed after definitive platinum-based concurrent chemoradiation                   | OS, PFS Safety: AEs, laboratory evaluations, physical examinations, vital signs, ECG                     | D: 476 Placebo: 237                                                      |
| MYSTIC Complete 01 Jun 2017 04 Oct 2018  | Phase III Randomized, open-label, multicenter                         | Patients with Stage IV NSCLC who have not received prior chemotherapy or other systemic therapy and who do not have EGFR or ALK target mutations                  | OS and PFS in PD- L1 TC≥25% Safety: AEs, laboratory evaluations, physical examinations, vital signs, ECG | D: 374 T + D: 372 SoC: 372                                               |
| CASPIAN Complete 11 Mar 2019 27 Jan 2020 | Phase III Randomized, open-label, comparative, multicenter            | Patients with ES-SCLC who have not received prior 1L treatment                                                                                                    | OS, PFS, ORR Safety: AEs, laboratory evaluations, physical examinations, and vital signs                 | T + D + EP: 268 D + EP: 268 EP: 269                                      |
| NEPTUNE Complete 24 Jun 2019             | Phase III Randomized, open-label, multicenter                         | Patients with Stage IV NSCLC who have not received prior chemotherapy or other systemic therapy and who do not have EGFR or ALK target mutations                  | OS, PFS, ORR Safety: AEs, laboratory evaluations, physical examinations, and vital signs                 | T + D: 410 SoC: 413                                                      |
| EAGLE Complete 10 Sep 2018               | Phase III Randomized, open-label, multicenter                         | Patients with recurrent or metastatic HNSCC not amenable to therapy with curative intent                                                                          | OS, PFS, ORR Safety: AEs, laboratory evaluations, physical examinations, vital signs, ECG                | D: 240 T + D: 247 SoC: 249                                               |

## 2.3.2. Pharmacokinetics

Tremelimumab and durvalumab are human monoclonal antibodies (mAb) that act as checkpoint inhibitors with distinct yet complementary mechanisms of action with respect to enhancing the antitumor immune response triggered by chemotherapy.

In 2018 durvalumab (Imfinzi) was approved in the EU for treatment of adults with locally advanced, unresectable non-small cell lung cancer (NSCLC), whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease had not progressed following platinum-based chemoradiation therapy.

The applicant is currently seeking approval for the use of tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations. The clinical pharmacology data that support this proposed indication is summarized below.

No dedicated human PK studies have been conducted for tremelimumab. The PK of tremelimumab and/or durvalumab has been investigated in patients enrolled in:

<div style=\"page-break-after: always\"></div>

- Three Phase I/Ib studies: D4190C00006 (Study 06), D4190C00010 (Study 10), and D4190C00002 (Japan Study 02).
- One Phase I/II study: D4190C00022 (Study 22).
- Three Phase II/IIb studies: D4193C00003 (CONDOR), D4880C00003 (DETERMINE), and D4884C00001.
- Six Phase III studies: D419MC00004 (POSEIDON), D419QC00001 (CASPIAN), D419AC00001 (MYSTIC), D419AC00003 (NEPTUNE), D4191C00004 (ARCTIC), and D4193C00002 (EAGLE).

The Phase III study POSEIDON is the pivotal study for this application, while the other studies are supportive studies.

The PK of tremelimumab as monotherapy has been determined in 5 supportive studies (Study 22, ARCTIC, CONDOR, DETERMINE, and D4884C00001). In these studies, however, only sparse sampling was performed for the assessment of PK.

Overall, the peak and trough concentrations of tremelimumab were in a similar range across studies at the same dosing regimens.

All studies included male and female patients aged 18 years and older with advanced solid tumors. No PK data has been obtained from healthy volunteers.

Table 3. Key tremelimumab PK results across studies

| Study Primary objectives Design                                                  | Phase   | Patient type N (M/F) Age (median [range])                                                                                    | Dosing regimen                                                                                                                                                        | Key pharmacokinetic results and conclusions                                                                                                                                                                                                      |
|----------------------------------------------------------------------------------|---------|------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| D419MC00004 (POSEIDON) Efficacy versus SoC Open-label, randomized                | III     | Patients with metastatic NSCLC with tumors lacking activating EGFR mutations and ALK fusions 1013 (770/243) 64.0 y (27-87 y) | T + D + SoC: Durvalumab IV 1500 mg Q3W for 4 doses then durvalumab IV 1500 mg Q4W until PD AND Tremelimumab IV 75 mg Q3W for 4 doses and 1 additional dose at Week 16 | Tremelimumab PK concentrations were within the expected exposure range following 75 mg Q3W. T + D + SoC: C max1 : 23.17 μ g/mL C trough,ss : 4.16 μg/mL (Week 3), 7.82 μg/mL (Week 12) Follow-up (last dose + 3 months): 0.86 μg/mL              |
| D4190C00006 (Study 06) Safety, tolerability, and efficacy Open-label             | I/Ib    | Advanced NSCLC Dose-escalation: 18 (9/9) 66 y (49-78 y) Dose-expansion: 277 (164/113) 63 y (35-87 y)                         | AND SoC Durvalumab IV 20 mg/kg Q4W AND Tremelimumab IV 1 mg/kg Q4W for 4 doses                                                                                        | 1 mg/kg Q4W (expansion): C max1 : 20.3 μg/mL C max,ss : 20.5 μg/mL C trough,ss : 5.59 μg/mL                                                                                                                                                      |
| D4190C00002 (Japan Study 02) Safety and tolerability. Open-label, non-randomized | I/Ib    | Biliary tract carcinoma 65 (43/22); 62 y (28-78 y) Esophageal carcinoma 59 (56/3); 62 y (42-77 y)                            | Dose-expansion phase: Durvalumab IV 20 mg/kg Q4W AND Tremelimumab IV 1 mg/kg Q4W for 4 doses                                                                          | 1 mg/kg Q4W - biliary tract carcinoma: C max1 : 19.5 μg/mL C max,ss : 22.5 to 22.8 μg/mL C trough,ss : 3.98 to 4.10 μg/mL 1 mg/kg Q4W - esophageal carcinoma: C max1 : 17.4 μg/mL C max,ss : 21.0 to 21.3 μg/mL C trough,ss : 4.02 to 4.50 μg/mL |
| D4190C00010 (Study 10) Safety, tolerability, and efficacy                        | I/Ib    | Advanced solid tumors 327 (168/159) 62 y (25-85 y)                                                                           | Durvalumab IV 20 mg/kg Q4W for 4 doses then IV 10 mg/kg Q2W AND                                                                                                       | The observed exposure levels of tremelimumab were within the expected ranges based on prior knowledge.                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| Open-label                                                            |      |                                                                                                                                                                   | Tremelimumab IV 1 mg/kg Q4W                                                                                                                                                                                                                                                                        | 1 mg/kg Q4W: C max1 : 22.0 μg/mL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-----------------------------------------------------------------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| D4190C00022 (Study 22) Safety and tolerability Open-label, randomized | I/II | Advanced HCC Part 1: 40 (30/10) 60.5 (47-87 y) Parts 2 and 3: 332 (284/48) 64.0 (26-89 y) China Cohort: 14 (13/1) 49.5 (26-66 y) Part 4: 47 (41/6) 64.0 (37-84 y) | for 4 doses Parts 2 and 3: T: Tremelimumab monotherapy 750 mg (10 mg/kg) Q4W × 7 doses IV followed by Q12W IV T75 + D: Tremelimumab 75 mg (1 mg/kg) × 4 doses IV + durvalumab 1500 mg (20 mg/kg) Q4W IV T300 + D: Tremelimumab 300 mg (4 mg/kg) × 1 dose IV + durvalumab 1500 mg (20 mg/kg) Q4W IV | C trough,ss : 4.89 μg/mL Parts 2 and 3: Similar exposures were observed following the weight-based 1 mg/kg and the equivalent fixed 75 mg dose and following the weight-based 10 mg/kg and the equivalent fixed 750 mg dose. C max values were 3.3- fold (arithmetic mean) or 3.7-fold geometric mean) higher following a 300 mg dose compared to a 75 mg dose. Exposures increased generally dose-roportionally with increasing weight- based doses from 1 to 10 mg/kg and fixed doses from 75 to 750 mg, respectively. No accumulation of tremelimumab exposure (C max or C trough ) was observed following repeated dosing in any of the cohorts. 1 mg/kg Q4W: C max1 : 22.22 μg/mL, C max,ss : 23.43 μg/mL C trough,ss : 4.545 μg/mL (Week 13) 10 mg/kg Q4W: C max1 : 214.7 μg/mL C max,ss : 203.7 μg/mL (Week 13), 202.4 μg/mL (Week 25) C trough,ss : 43.90 μg/mL (Week 13), 38.78 μg/mL (Week 25) 75 mg/kg Q4W: C max1 : 26.99 μg/mL, C max,ss : 27.80 μg/mL C trough,ss : 4.178 μg/mL (Week 5), 4.113 μg/mL (Week 13) 300 mg: C max1 : 99.06 μg/mL C trough,ss : 11.67 μg/mL (Week 5) 750 mg/kg Q4W: C max1 : 224.8 μg/mL, C max,ss : 225.2 μg/mL C trough,ss: 26.69 μg/mL (Week 5), 31.25 μg/mL (Week 13), 35.61 μg/mL (Week 25) |
| D419AC00001 (MYSTIC) Efficacy versus SoC Open-label, randomized       | III  | Advanced or metastatic NSCLC 372 (266/106) 66 y (28-87 y)                                                                                                         | Durvalumab IV 20 mg/kg Q4W AND Tremelimumab IV 1 mg/kg Q4W for 4 doses                                                                                                                                                                                                                             | Tremelimumab concentrations were consistent with the expected concentrations based on previous studies. 1 mg/kg Q4W: C max1 : 20. 8 μg/mL C max,ss : 21.7 μg/mL C trough,ss : 3.8 μg/mL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| D419AC00003 (NEPTUNE) Efficacy Open-label, randomized                 | III  | Patients with EGFR and ALK wild-type advanced or metastatic NSCLC 410 (297/113) 63 y (27-83 y)                                                                    | Durvalumab IV 20 mg/kg Q4W AND Tremelimumab IV 1 mg/kg Q4W for 4 doses                                                                                                                                                                                                                             | Tremelimumab concentrations were similar to those observed in previous studies. 1 mg/kg Q4W: C max1 : 20.3 μg/mL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|                                                                  |        |                                                                                                                                             |                                                                                                                                             | C max,ss : 20.8 μg/mL C : 3.4 μg/mL                                                                                                                                                                                                        |
|------------------------------------------------------------------|--------|---------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| D4191C00004 (ARCTIC) Efficacy versus SoC Open-label, randomized  | III    | Locally advanced or metastatic NSCLC Sub-study B: 60 (39/21) 63.5 y (45-81 y)                                                               | Tremelimumab IV 10 mg/kg Q4W for 24 weeks followed by 10 mg/kg Q12W for 24 weeks                                                            | trough,ss 10 mg/kg Q4W: C max1 : 170 μg/mL C max,ss : 133 μg/mL C trough,ss: 6.22 to 28.8 μg/mL                                                                                                                                            |
| D4191C00004 (ARCTIC) Efficacy versus SoC Open-label, randomized  | III    | Locally advanced or metastatic NSCLC Sub-study B: 174 (115/59) 62.5 y (26-81 y)                                                             | Durvalumab IV 20 mg/kg Q4W for 4 doses then IV 10 mg/kg Q2W for 18 doses AND Tremelimumab IV 1 mg/kg Q4W for 4 doses                        | 1 mg/kg Q4W: C max1 : 22.4 μ g/mL C trough,ss : 4.10 μg/mL                                                                                                                                                                                 |
| D419QC00001 (CASPIAN) Safety and efficacy Open-label, randomized | III    | Patients with ES-SCLC in combination with EP 268 (202/66) 63 y (36-88 y)                                                                    | Durvalumab IV 1500 mg Q3W for 4 doses then durvalumab IV 1500 mg Q4W until PD AND tremelimumab IV 75 mg Q3W for 4 doses AND EP for 4 cycles | The PK concentrations of tremelimumab were within the expected exposure at the dosing regimen. Tremelimumab 75 mg Q3W in combination with D and EP: Week 0 C max : 22.7 μg/mL Week 3 C trough : 4.245 μg/mL Week 12 C trough : 7.576 μg/mL |
| D4193C00003 (CONDOR) Efficacy Open-label, randomized             | II/IIb | Recurrent or metastatic HNSCC expressing low/no PD-L1 67 (53/14) 61 y (42-77 y)                                                             | Tremelimumab IV 10 mg/kg Q4W for 7 doses then Q12W for 2 doses                                                                              | Tremelimumab concentrations were broadly similar to previously reported tremelimumab PK data. 10 mg/kg Q4W: C max1 : 158 μg/mL C max,ss : 190 to 253 μg/mL C trough,ss : 33.5 to 35.1 μg/mL                                                |
| D4193C00003 (CONDOR) Efficacy Open-label, randomized             | II/IIb | Recurrent or metastatic HNSCC expressing low/no PD-L1 133 (113/20) 62 y (26-81 y)                                                           | Durvalumab IV 20 mg/kg Q4W for 4 doses then IV 10 mg/kg Q2W to complete 12 months of treatment AND Tremelimumab IV 1 mg/kg Q4W for 4 doses  | The observed exposure levels of tremelimumab were within the expected ranges based on prior knowledge. 1 mg/kg Q4W: C max1 : 20.5 μg/mL C max,ss : 29.2 μg/mL C trough,ss : 6.0 μg/mL                                                      |
| D4193C00002 (EAGLE) Efficacy versus SoC Open-label, randomized   | III    | Recurrent or metastatic HNSCC 247 (209/38) 61 y (23-81 y)                                                                                   | Durvalumab IV 20 mg/kg Q4W for 4 doses then IV 10 mg/kg Q2W for 12 months or until PD AND Tremelimumab IV 1 mg/kg Q4W for 4 doses           | Tremelimumab concentrations were similar to previously reported PK data. 1 mg/kg Q4W: C max1 : 15.2 μg/mL C max,ss : 19.3 μg/mL C trough,ss : 4.4 μg/mL                                                                                    |
| D4884C00001 Efficacy and safety. Open-label                      | II/IIb | Urothelial cancer: 32 (26/6); 66.5 y (44-81 y) TNBC: 12 (0/12); 58.5 y (42-85 y) Pancreatic ductal adenocarcinoma 20 (11/9); 60 y (41-72 y) | Tremelimumab IV 750 mg Q4W for 7 doses, then Q12W for 2 doses                                                                               | Tremelimumab concentrations were broadly similar to previously reported tremelimumab PK data from weight-based equivalent dosing. 750 mg Q4W: C max1 : 157 μg/mL C max,ss : 209 to 290 μg/mL C trough,ss : 28.5 to 33.9 μg/mL              |
| D4884C00001 Efficacy and safety. Open-label                      | II/IIb | Urothelial cancer: 32 (26/6); 66.5 y (44-81 y) TNBC: 12 (0/12); 58.5 y (42-85 y) Pancreatic ductal adenocarcinoma 20 (11/9); 60 y (41-72 y) | Durvalumab IV 1500 mg Q4W for 4 doses                                                                                                       | Tremelimumab concentrations were broadly                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|                                                                                          |        |                                                                             | AND Tremelimumab IV 75 mg/kg Q4W for 4 doses, then Durvalumab IV 1500 mg Q4W for up to 8 months   | similar to previously reported tremelimumab PK data from weight-based equivalent dosing. 75 mg Q4W: C max1 : 50.9 μg/mL C max,ss : 34.1 μg/mL C trough,ss : 3.59 to 12.9 μg/mL   |
|------------------------------------------------------------------------------------------|--------|-----------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| D4880C00003 (DETERMINE) Efficacy and safety. Double-blind, randomized, placebocontrolled | II/IIb | Unresectable pleural or peritoneal mesothelioma 382 (283/99) 66 y (28-87 y) | Tremelimumab IV 10 mg/kg Q4W for 7 doses (6 months), then Q12W                                    | Tremelimumab concentrations were similar to previously reported PK data. 10 mg/kg Q4W: C max1 : 207 μg/mL C max,ss : 233 to 250 μg/mL C trough,ss : 35.2 to 37.1 μg/mL           |

ALK, anaplastic lymphoma kinase; Cmax1, maximum serum concentration following the first dose; Cmax,ss, maximum serum concentration at steady state; Ctrough,ss, minimum serum concentration at steady state; D, durvalumab; DCO, data cutoff; EGFR, epidermal growth factor receptor; EP, etoposide and carboplatin or cisplatin; ES-SCLC, extensive-stage small cell lung cancer; F, female; HCC, hepatocellular carcinoma; HNSCC, head and neck squamous cell carcinoma; IV, intravenous; M, male; N, total number of patients; NCA, non-compartmental analysis; NSCLC, non-small cell lung cancer; PD, progression of disease; PD-L1, programmed death ligand-1; PK, pharmacokinetics; Q2W, every 2 weeks; Q3W, every 3 weeks; Q4W, every 4 weeks; Q12W, every 12 weeks; SoC, standard of care chemotherapy; T, tremelimumab; TNBC, triple-negative breast cancer.

## Key tremelimumab PK results from POSEIDON (D419MC00004)

Tremelimumab PK data were available for a total of 327 patients in the T + D + SoC arm.

Following tremelimumab 75 mg Q3W in combination with durvalumab and SoC chemotherapy, geometric mean (n, geometric %CV) of peak concentrations are shown in Table 4.

Tremelimumab PK concentrations were within the expected exposure range following 75 mg Q3W.

Table 4. Summary of Tremelimumab Serum Concentrations (μg/mL)

| Nominal time   | Concentration (μg/mL)      | T + D + SoC N = 327 Geometric mean (n, geometric %CV)   |
|----------------|----------------------------|---------------------------------------------------------|
| Week 0         | Peak concentration         | 23.17 (n = 294, 65.62%)                                 |
| Week 3         | Trough concentration       | 4.16 (n = 285, 80.83%)                                  |
| Week 12        | Trough concentration       | 7.82 (n = 183, 75.68%)                                  |
| Follow-up      | Last valid dose + 3 months | 0.86 (n = 105, 87.65%)                                  |

Trough concentrations on Weeks 3 and 12 are the pre-infusion concentrations of Weeks 3 and 12, respectively. Peak concentration on Week 0 is the post-infusion concentration of Week 0. Only PK visits as per protocol are summarized.

CV, coefficient of variation; D, durvalumab; n, number of samples; N, total number of patients with tremelimumab PK data; PK, pharmacokinetic(s); SoC, standard of care chemotherapy; T, tremelimumab.

## Dose rationale

In POSEIDON, a dose of 75 mg Q3W IV tremelimumab in combination with 1500 mg Q3W IV durvalumab and SoC for 4 cycles was administered, with one additional dose of tremelimumab 75 mg at Week 16, followed by 1500 mg Q4W IV durvalumab monotherapy to disease progression or unacceptable toxicity for the first-line treatment of patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations.

The chosen dose was based on the results from the dose finding study (Study 06), in which tremelimumab 1 mg/kg was selected, as patients in the 20 mg/kg durvalumab + 1 mg/kg tremelimumab group had a tolerable safety profile without dose-limiting toxicities and the dose showed

<div style=\"page-break-after: always\"></div>

evidence of clinical activity. There was evidence of augmented pharmacodynamic activity relative to durvalumab monotherapy with combination doses containing 1 mg/kg tremelimumab.

A fixed dose of tremelimumab 75 mg Q4W (equivalent to 1 mg/kg Q4W for an average body weight of 75 kg) was predicted to result in similar AUC and only a modest difference in median peak and trough levels at steady state compared to tremelimumab 1 mg/kg Q4W based on simulations in a Population PK model developed for tremelimumab using data from Study 10, Japan Study 02, Study 06, D4884C00001, DETERMINE, and POSEIDON.

Simulations indicated that both body weight-based and fixed dosing regimens of tremelimumab yield similar median steady state PK concentrations with slightly less between-patient variability with the fixed dose regimen.

In order to further evaluate the suitability of a fixed dosing regimen of tremelimumab versus body weight-based dosing, tremelimumab exposure was compared by body weight quartiles. The exposure difference was small (&lt; 20%) for all metrics (AUC, Cmax, Cmin), with a large overlap between body weight brackets (Table 5).

Table 5. Tremelimumab exposure across body weight quartiles.

|                      | Q1               | Q2               | Q3               | Q4               |
|----------------------|------------------|------------------|------------------|------------------|
| Individuals          |                  |                  |                  |                  |
| N                    | 84               | 81               | 80               | 81               |
| Body weight (kg)     |                  |                  |                  |                  |
| Geometric mean (%CV) | 51.4 (12.3)      | 63.4 (4.50)      | 73.1 (3.81)      | 90.2 (12.5)      |
| Median [min-max]     | 53.6 [34.0-58.0] | 63.7 [58.5-68.2] | 73.0 [68.5-78.5] | 87.0 [78.6-134]  |
| AUC Fifth dose       |                  |                  |                  |                  |
| Geometric mean (%CV) | 285 (15.9)       | 266 (15.0)       | 257 (17.2)       | 239 (13.4)       |
| Median [min-max]     | 291 [173-520]    | 266 [174-362]    | 256 [188-755]    | 241 [163-396]    |
| %change              | 9.12             | 1.64             | -1.61            | -8.68            |
| Cmax Fifth dose      |                  |                  |                  |                  |
| Geometric mean (%CV) | 29.9 (16.0)      | 27.5 (20.8)      | 25.0 (20.3)      | 22.5 (19.1)      |
| Median [min-max]     | 30.0 [20.9-44.7] | 26.2 [20.4-62.6] | 24.0 [16.2-49.7] | 21.9 [15.6-48.6] |
| %change              | 14.6             | 5.15             | -4.35            | -13.7            |
| Cmin Fifth dose      |                  |                  |                  |                  |
| Geometric mean (%CV) | 8.29 (23.8)      | 7.39 (26.6)      | 7.44 (26.8)      | 6.94 (26.4)      |
| Median [min-max]     | 8.73 [3.93-19.1] | 7.61 [2.80-12.0] | 7.63 [3.84-32.2] | 7.21 [1.68-14.5] |
| %change              | 10.5             | -1.60            | -0.919           | -7.53            |

Note: %change was computed with the geometric mean of the entire population as a reference.

AUC, area under the serum concentration-time curve; Cmax, maximum serum concentration; Cmin, 1 minimum serum concentration; CV, coefficient of variation; max, maximum; min, minimum; N, number of patients; PK, pharmacokinetic(s); Q1/2/3/4, 1st, 2nd, 3rd, 4th quartile

<div style=\"page-break-after: always\"></div>

Simulations were conducted to compare the tremelimumab exposure between the 75 mg Q3W dosing regimen and 1 mg/kg Q3W dosing regimen in order to evaluate the suitability of a fixed dosing regimen of tremelimumab versus body weight-based dosing. Tremelimumab serum concentrations were simulated based on the individual Empirical Bayes estimates obtained from the final model for the POSEIDON patients. The concentration profiles were summarized over time (Figure 1). The concentration profiles showed a good overlap between the 2 dosing regimens.

Figure 1. Comparison of tremelimumab 75 mg Q3W and 1 mg/kg Q3W - concentration profiles

<!-- image -->

Note:Theblue andredareasrepresent the9o%prediction intervalofthesimulatedconcentrations;theblue and redlinerepresent themedianconcentrationprofiles.

Conc,concentration;PK,pharmacokinetic(s);Q3W,every3weeks.

## Bioanalytical Methods

Bioanalysis methods for quantitation of tremelimumab drug concentration, anti-drug antibodies (ADA), and neutralizing antibodies (nAb) were developed and validated.

## Population PK analyses for tremelimumab and durvalumab

A population PK model was developed for tremelimumab based on a pooled dataset from 6 Studies: Study 02, Study 06, Study 10, DETERMINE, BASKET and POSEIDON, which comprised of 5455 serum concentrations from 1605 patients. The final Pop PK model of tremelimumab was a 2-compartment model with linear CL and an additional time-dependent CL component for patients on combination therapy only. The following covariates were identified as statistically significant and included in the final model: body weight and sex on both CL and V1; albumin, primary indication and combination therapy (chemotherapy vs. no chemotherapy) on CL. The effect of body weight was allometrically scaled with estimated exponents of 0.370 and 0.453 for CL and V1, respectively, indicating that the

<div style=\"page-break-after: always\"></div>

effect of body weight was less than proportional. The final model was evaluated by means of nonparametric bootstrap analysis (n=1000), RSEs, GOF-plots and pcVPCs.

The durvalumab PopPK model was updated by including 11683 serum PK samples from 2827 patients. The model was based on a pooled dataset from 5 Studies: Study 1108, POSEIDON, ATLANTIC, PACIFIC and CASPIAN. The final model of durvalumab PK was a 2-compartment model with timedependent CL. Residuals were described by a combined additive and proportional error model. The final durvalumab PopPK model included the following statistically significant covariate effects on CL: body weight, albumin, combination therapy, sex, creatinine clearance, lactate dehydrogenase, and eastern cooperative oncology group; and on V1: body weight and sex. The effect of body weight was allometrically scaled with estimated exponents of 0.337 and 0.494 for CL and V1. The final model was evaluated by means of non-parametric bootstrap analysis (n=500), RSEs, GOF-plots and pcVPCs.

Parameter estimates of the final model for tremelimumab and selected diagnostic plots are shown in Table 6 and Figure 2 and Figure 3.

<div style=\"page-break-after: always\"></div>

Table 6. Population PK model parameter estimates (Final model - run079)

| Parameter                       | Estimate   | RSE (%)   | bootstrap 95%CI    | Shrinkage (%)   | Unit   |
|---------------------------------|------------|-----------|--------------------|-----------------|--------|
| PopulationParameter             |            |           |                    |                 |        |
| CL                              | 0.309      | 1.56      | [0.298 ; 0.342]    |                 | L/day  |
| V1                              | 3.72       | 0.869     | [3.63 ; 3.78]      |                 | L      |
| Q                               | 0.454      | 1.37      | [0.378 ; 2.38]     |                 | L/day  |
| V2                              | 2.61       | 1.56      | [2.38 ; 3.60]      |                 | L      |
| Tmax change CL                  | -0.218     | 15.4      | [0.385 ; -0.127]   |                 |        |
| TC50 change CL                  | 81.5       | 3.18      | [35.9 ; 191]       |                 | days   |
| Covariate                       |            |           |                    |                 |        |
| Bodyweight on V1                | 0.453      | 6.31      | [0.401 ; 0.520]    |                 |        |
| Sex on V1                       | -0.149     | 9.27      | [-0.181 ; -0.123]  |                 |        |
| Bodyweight on CL                | 0.370      | 10.6      | [0.271 ; 0.477]    |                 |        |
| Albumin on CL                   | -0.809     | 6.66      | [-0.938 ; -0.666]  |                 |        |
| Sex on CL                       | -0.134     | 14.2      | [-0.174 ; -0.0905] |                 |        |
| Comb2 on CL                     | -0.115     | 20.7      | [-0.162;-0.0634]   |                 |        |
| Primary indication 6 or 7 on CL | -0.153     | 19.4      | [-0.210 ; -0.0877] |                 |        |
| Interindividual Variability     |            |           |                    |                 |        |
| ETA CL                          | 0.111      | 7.94      | [0.0908 ; 0.137]   | 19.2            |        |
| Covariance CL-V1                | 0.0520     | 14.2      | [0.0361 ; 0.0642]  |                 |        |
| ETAV1                           | 0.0402     | 16.4      | [0.0277 ; 0.0531]  | 25.3            |        |
| Covariance CL-V2                | 0.0649     | 24.5      | [0.0312 ;0.133]    |                 |        |
| CovarianceV1-V2                 | 0.0782     | 23.9      | [0.0393 ; 0.102]   |                 |        |
| ETA V2                          | 0.215      | 18.4      | [0.128 ; 0.316]    | 37.1            |        |
| ETA Tmax                        | 0.754      | 25.3      | [0.283 ; 1.40]     | 68.8            |        |
| Residual Variability            |            |           |                    |                 |        |
| Proportional component          | 0.279      | 2.47      | [0.264 ; 0.293]    | 15.9            |        |
| Additive component              | 0.146      | 15.2      | [0.0796 ; 0.198]   | 15.9            | μg/mL  |

Source: az-durvalumab-pk-model-study-v10.Rmd, Reference: 04e0e5:917e6f

Abbreviations: CI=confidence interval, CL=clearance, Comb2=durvalumab, tremelimumab and chemotherapy (standard of care), as compared to treatment arms without chemotherapy, ETA=random effect, IIV=interindividual variability, PK=pharmacokinetics, V1=central volume of distribution, primary indication 6=biliary volume of distribution, RSE=relative standard error, TC50=time to 50% clearance feduction, Tmax=maximum change of CL over time.

<div style=\"page-break-after: always\"></div>

Figure 2. Final Model GOF Plots for serum tremelimumab concentration: Observations vs Predictions

<!-- image -->

Source: az-tremelimumab-pk-gof-v10.docx, Reference: 80bb8e:3794d8

Note: Dots are individual data; the grey solid lines are lines ofidentity. Blue solid lines are smoothed LOESS lines, with confidence areas shown as light blue areas. Predictions below the LLOQ are not shown. Abbreviation:LLOQ=lower limit of quantification

Figure 3. VPC of the Final Model vs TAD, POSEIDON Study

ObservedPercentiles....

95% Cl (areas)

Median (lines)

Median (lines)

SimulatedPercentiles

95% Cl (areas)

<!-- image -->

Source: az-treme-PK-Model-Evaluation\\_VPC-v6.Rmd

Note: the solid and dashed lines represent the median, 10th, and 90th percentiles of the observations. Red and blue lines are the respective model-predicted percentiles, and the shaded red and blue areas represent the 95% confidence intervals around these predictions. The x-axis is truncated to 90 days, as observed data get too sparse thereafter.

Abbreviations: CI=confidence interval, TAD=time after dose, VPC=visual predictive check

10%

50%

90%

10%

50%

90%

<div style=\"page-break-after: always\"></div>

Parameter estimates of the final model for durvalumab and selected diagnostic plots are shown in Table 7, Figure 4 and Figure 5.

Table 7. Population PK Model Parameter Estimates durvalumab (Final Model-run131.mod)

<!-- image -->

| Parameter                   | Estimate   | RSE (%)   | Bootstrap 95%CI    | Shrinkage (%)   | Unit   |
|-----------------------------|------------|-----------|--------------------|-----------------|--------|
| PopulationParameter         |            |           |                    |                 |        |
| CL                          | 0.297      | 1.57      | [0.281 ; 0.313]    |                 | L/day  |
| V1                          | 3.40       | 0.737     | [3.35 ; 3.45]      |                 | L      |
| V2                          | 2.07       | 3.04      | [1.92 ; 2.22]      |                 | L      |
| Q                           | 0.451      | 4.98      | [0.376 ; 0.543]    |                 | L/day  |
| Tmax                        | -0.487     | 5.01      | [-0.542 ;-0.423]   |                 |        |
| TC50                        | 68.9       | 7.32      | [47.8 ; 100]       |                 | day    |
| LAM                         | 1.00       |           |                    |                 |        |
| Covariates                  |            |           |                    |                 |        |
| Albumin on CL               | -0.605     | 15.5      | [-0.824 ; -0.449]  |                 |        |
| Creatinine clearance on CL  | 0.112      | 19.5      | [0.0626;0.151]     |                 |        |
| ECOG status on CL           | -0.0505    | 27.3      | [-0.0770;-0.0221]  |                 |        |
| LDH on CL                   | 0.0492     | 25.1      | [0.0246; 0.0730]   |                 |        |
| Sex on CL                   | -0.168     | 7.83      | [-0.195 ; -0.140]  |                 |        |
| COMB1 on CL                 | -0.166     | 9.87      | [-0.202;-0.133]    |                 |        |
| COMB 2 on CL                | -0.0958    | 25.4      | [-0.141 ; -0.0505] |                 |        |
| Bodyweight on CL            | 0.337      | 10.5      | [0.268 ; 0.420]    |                 |        |
| Sex on V1                   | -0.141     | 8.76      | [0.163 ; -0.119]   |                 |        |
| Bodyweight on V1            | 0.494      | 6.07      | [0.438 ; 0.554]    |                 |        |
| Interindividual Variability |            |           |                    |                 |        |
| ETA CL                      | 0.0801     | 6.18      | [0.0694;0.0898]    | 19.2            |        |
| Cov CL-V1                   | 0.0358     | 7.72      | [0.0303 ;0.0415]   |                 |        |
| ETAV1                       | 0.0565     | 8.35      | [0.0480 ; 0.0647]  | 26.0            |        |
| ETA Tmax                    | 0.0644     | 17.1      | [0.0419 ; 0.0933]  | 56.3            |        |
| Residual Variability        |            |           |                    |                 |        |
| Proportional component      | 0.248      | 1.85      | [0.239 ; 0.256]    | 13.6            |        |
| Additive component          | 5.12       | 12.6      | [3.86 ; 6.38]      | 13.6            | μg/mL  |

Source: az-durvalumab-pk-model-poseidon-v3.Rmd, Reference: 3781a5:7d4acc

Abbreviations: CI=confidence interval, COMB1=durvalumab+SOC,

COMB2=durvalumab+tremelimumab+SOC, Cov=Covariance, ECOG=Easterm Cooperative Oncology Group ETA=random effect, LAM=Hill factor, LDH=lactate dehydrogenase, RSE=relative standard error,

CL=clearance, V1=central volume of distribution, Q=inter-compartmental clearance, PK=pharmacokinetics, SOC=standard of care, V2=peripheral volume of distribution, Tmax=maximum change of CL over time, TC50: time to 50% change of CL over time.

Note: 38 runs with minimization terminated were skipped when calculating the bootstrap results.

<div style=\"page-break-after: always\"></div>

Figure 4. Final model - basic Goodness of Fit Plots (run131.mod)

<!-- image -->

Time since first dose (day)

Individual predicted concentration (μg/mL)

Source:az-durvalumab-pk-final-model-poseidon-v4.Rmd(references:Source:az-durvalumab-pk-modelposeidon-v3.Rmd,Reference:d4d6c7:18aff6,9a3886:78e195,38da4d:5276c2,2209f2:ad2e4b,57538e:60fc4c, f94879:df7ae9)

Note: theblue line is a trend line through the data points,the blue area is the 95% confidence interval around it. Abbreviations:CWRES=conditional weighted residuals,IWRES=individualweightedresiduals

<div style=\"page-break-after: always\"></div>

## Figure 5. PcVPC of the Final Model vs Time per Dose - POSEIDON Study (Linear scale)

<!-- image -->

Source:az-durva-pk-model-evaluation-final-v3.docx,Reference:3a16fe:60f8ee Note:The solid and dashedlinesrepresent themedian,1oth,and 9o\"percentiles of the observations; the shaded red and blue areas represent the 95% confidence interval of the median, 5th, and 95th percentiles predicted by the model.

Abbreviations: CI=confidence interval, peVPC=prediction-corrected visual predictive check

## Tremelimumab &amp; durvalumab exposure-response modelling analyses

The final PopPK models of tremelimumab and durvalumab were used to derive individual predicted exposure metrics for the E-R analyses. The tremelimumab/durvalumab E-R relationship for OS, PFS and ORR were analysed using data from POSEIDON, which included 326 patients administered tremelimumab (T) + durvalumab (D) + SoC arm. Both OS and PFS were analysed by Kaplan-Meier plots stratified by model-predicted exposure metrics and CPH models with T + D + SoC. Cmin of tremelimumab following dose 5 and tumour type were statistically significant for OS.

The parameter estimates from the final OS CPH model are presented in Table 8 and parameter estimates from the final PFS CPH model are presented in Table 9.

The following covariates for PFS were statistically significant: patients having high tumour mutational burden (&gt;12 mutations per megabase), high percentage of PD-L1 T cells (&lt;25%), non-squamous tumour lesions and low NLR (Q1). Models were evaluated by graphically superimposing modelpredictions over the observed data.

<div style=\"page-break-after: always\"></div>

Table 8. Final CPH Model for OS

| Predictor   |         B |   exp(β) | 95%CIβ           | p-value   |     AIC |
|-------------|-----------|----------|------------------|-----------|---------|
| PCMINSST    | -0.192984 | 0.824495 | [-0.272; -0.114] | <0.001    | 2490.77 |
| TUMTYP22    |  0.539607 | 1.71533  | [0.280; 0.799]   | <0.001    | 2490.77 |

Note:p-valuefromWald test.

β, coefficient of the final CPH model, AIC, Akaike information criterion; CI, confidence interval; Cmin, Dose 5 Treme, minimum serumconcentrationfortremelimumabfollowing the5thdosingcycle;CPH,Coxproportional-hazards;exp(β),hazardratio; OS, overall survival; PCMINSST, predicted Cmin, Dose 5 Treme; PK, pharmacokinetic(s); TUMTYP22, tumor type (squamous cells).

Source: Table 28, Population PK and Exposure-Response Report, Module 5.3.3.5.

Table 9. Final CPH Model for Progression-Free Survival

| Predictor   |         B |   exp(β) | 95% CIβ            | P value   |     AIC |
|-------------|-----------|----------|--------------------|-----------|---------|
| PCMINSST    | -0.118413 | 0.888329 | [-0.190 ; -0.0472] | 0.00113   | 2696.95 |
| TUMTYP22    |  0.748023 | 2.11282  | [0.489 ; 1.01]     | <0.001    | 2696.95 |
| logNLR      |  0.436555 | 1.54737  | [0.209 ; 0.664]    | <0.001    | 2696.95 |
| PDTC251     | -0.519256 | 0.594963 | [-0.781 ; -0.257]  | <0.001    | 2696.95 |
| TMB1221     |  0.290467 | 1.33705  | [0.0281 ; 0.553]   | 0.0300    | 2696.95 |
| TMB1222     | -0.382058 | 0.682456 | [-0.741;-0.0233]   | 0.0369    | 2696.95 |

Source: az-durvalumab-pfs-triplet-v25.Rmd,Reference:1956bf:aa8a26

Abbreviation:AIC=Akaike'sinformationcriteria,TMB=tumormutationalburden

ORR was analysed with linear logistic regression models. None of the effects of exposure metrics on the probability of being a responder were statistically significant based on the likelihood-ratio-test (see Table 10).

<div style=\"page-break-after: always\"></div>

Table 10. Summary of the Effect of Different Exposures Metrics on the Probability of Being a Responder (PR or CR)

| Exposure metric                    | Estimate (% Relative   | 95% Confidence interval   |   P-value (based on LRT) |   Loglikelihood |   AIC |   Number of patients |
|------------------------------------|------------------------|---------------------------|--------------------------|-----------------|-------|----------------------|
| Durvalumab Cmax after first dose   | -0.00149 (62.8)        | (-0.00335, 0.000325)      |                    0.108 |          -219.4 | 442.7 |                  319 |
| Durvalumab Cmin after first dose   | 0.00236 (196)          | (-0.00673,0.0115)         |                    0.61  |          -220.5 | 445.1 |                  319 |
| Durvalumab AUC after first dose    | -8.68e-05 (195)        | (-0.000421, 0.000246)     |                    0.609 |          -220.5 | 445.1 |                  319 |
| Durvalumab Cmax steady-state       | -0.000464 (146)        | (-0.0018, 0.00086)        |                    0.492 |          -220.4 | 444.8 |                  319 |
| Durvalumab Cmin steady-state       | 0.00106 (112)          | (-0.00127, 0.00342)       |                    0.372 |          -220.3 | 444.5 |                  319 |
| Durvalumab AUC steady-state        | 2.32e-05 (165)         | (-5.19e-05, 9.91e- 05)    |                    0.545 |          -220.5 | 445   |                  319 |
| TremelimumabC'max after first dose | 0.0287 (59.2)          | (-0.00382,0.0632)         |                    0.084 |          -218.5 | 441.1 |                  318 |
| Tremelimumab Cmin after first dose | 0.19 (64.5)            | (-0.0475, 0.436)          |                    0.117 |          -218.8 | 441.6 |                  318 |
| TremelimumabAUC after first dose   | 0.0061 (53.4)          | (-2e-04, 0.0126)          |                    0.058 |          -218.2 | 440.4 |                  318 |
| Tremelimumab Cmax,Dose 5           | 0.0349 (52.3)          | (-7.03e-05, 0.0719)       |                    0.05  |          -218.1 | 440.2 |                  318 |
| Tremelimumab Cmin,Dose 5           | 0.0523 (106)           | (-0.0504, 0.17)           |                    0.326 |          -219.5 | 443.1 |                  318 |
| Tremelimumab AUC,Dose 5            | 0.00434 (59.5)         | (-0.00042, 0.00968)       |                    0.075 |          -218.4 | 440.9 |                  318 |

Source: az-durvalumab-orr-poseidon-v5.Rmd, Reference: 06b67a:e2bec8

Abbreviations:AIC=Akaike'sinformationcriteria,AUC=area under theserum concentration-timecurve,

Cmax=maximum serum concentration, Cmin=minimum serum concentration, CR=complete response,

LRT=likelihood ratio test, PR=partial response, SOC=standard of care

Safe endpoints were graphically evaluated and results were confirmed by logistic regression models that did not identify any significant impact of tremelimumab/durvalumab exposure on the incidence of the investigated AEs.

## QTcF modelling analysis

Linear mixed-effects exposure-response modelling with an intercept was conducted to characterize the relationship of change from baseline of QTcF (ΔQTcF) with durvalumab or tremelimumab serum concentrations. The concentrationΔQTcF analysis population cons isted of 293 observations from 67 patients administered durvalumab and 254 observations from 66 patients administered tremelimumab from Study 06. Unscheduled concentration-QTcF observations and non-central ECG records were excluded from the analysis.

For d urvalumab, the slope for the relationship of ΔQTcF to durvalumab concentration was 0.0048 ms per μg/mL (p = 0.112), with a mean intercept of 0.082 ms (p = 0.950; 90% CI: -2.24, 2.24 ms; Table 11).

The slope or the intercept for tremelimumab and durvalumab were significantly different from 0. The slope for the relationship of ΔQTcF to tremelimumab concentration was -0.012 ms per μg/mL (p = 0.531), and the mean intercept was 0.581 ms (p = 0.629; 90% CI: 1.41, 2.57 ms; Error! Reference source not found. ).

<div style=\"page-break-after: always\"></div>

Table 11. Parameter estimates of durvalumab PK - ∆QTcF relationship

| Parameter estimates                       | Parameter estimates   | Parameter estimates   | Parameter estimates   | Parameter estimates   | Parameter estimates   | Parameter estimates   |
|-------------------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| Parameter                                 | Estimate              | Standard error        | p- value              | 90% confidence limits | 90% confidence limits | Gradient              |
| Intercept (ms)                            | 0.08205               | 1.2916                | 0.9495                | -2.0726               | 2.2367                | 0.000012              |
| Slope (ms/μg/mL)                          | 0.004841              | 0.003007              | 0.1123                | -0.00018              | 0.009858              | 0.003814              |
| Inter individual variability on intercept | 7.8721                | 0.8472                | <.0001                | 6.4588                | 9.2855                | 0.000021              |
| Model error                               | 9.4501                | 0.4275                | <.0001                | 8.7369                | 10.1633               | -8.91E-6              |

PK pharmacokinetic

Table 12. Parameter estimates of tremelimumab PF - ∆QTcF relationship

| Parameterestimates                        | Parameterestimates   | Parameterestimates   | Parameterestimates   | Parameterestimates    | Parameterestimates    | Parameterestimates   |
|-------------------------------------------|----------------------|----------------------|----------------------|-----------------------|-----------------------|----------------------|
| Parameter                                 | Estimate             | Standard error       | p- value             | 90% confidence limits | 90% confidence limits | Gradient             |
| Intercept (ms)                            | 0.5806               | 1.1952               | 0.6288               | -1.4137               | 2.5749                | -1.01E-6             |
| Slope (ms/ μg/mL)                         | -0.01225             | 0.01945              | 0.5312               | -0.04470              | 0.02021               | -0.00007             |
| Inter individual variability on intercept | 7.5385               | 0.8414               | <.0001               | 6.1345                | 8.9425                | -2.99E-6             |
| Model error                               | 9.2338               | 0.4544               | <.0001               | 8.4755                | 9.9921                | 4.764E-6             |

PK pharmacokinetic

The upper bound of the 90% 2sided CI for ΔQTcF was less than 10 ms, and the highest observed concentration of durvalumab and tremelimumab had a predicted mean ΔQTcF of less than 5 ms ( Figure 6, Figure 7 and Table 13).

<div style=\"page-break-after: always\"></div>

Figure 6. QTcF (change from baseline) versus concentration of durvalumab on intercept full data

<!-- image -->

Cmax,ss maximum plasma concentration at steady state; IQR interquartile range; IV intravenous; Q2W every 2 weeks; Q4W every 4 weeks

Note: Red line is the linear regression line and the shaded area is the 90% CI based on the linear mixed-effects model prediction. Red short dashed horizontal line is 5 msec change from baseline identity line. Red long dashed horizontal line is 10 msec change from baseline identity line. Green dashed vertical lines are observed median +/- IQR predicted Cmax,ss for a 10 mg/kg Q2W IV durvalumab dosing. Green solid line is median predicted Cmax,ss for a 10 mg/kg Q2W IV durvalumab dosing. Blue dashed vertical lines are observed median +/- IQR(interquartile range) predicted Cmax,ss for a 20 mg/kg Q4W IV durvalumab dosing. Blue solid line is median predicted Cmax,ss for a 20 mg/kg Q4W IV durvalumab dosing. Treatment cohorts are 1: 3 mg/kg durvalumab (Q4W) + 1 mg/kg Tremelimumab; 2: 10 mg/kg durvalumab (Q4W) + 1 mg/kg Tremelimumab;3: 15 mg/kg durvalumab (Q4W) + 1 mg/kg Tremelimumab; 4: 10 mg/kg durvalumab (Q4W) + 3 mg/kg Tremelimumab; 5: 20 mg/kg durvalumab (Q4W) + 1 mg/kg Tremelimumab; 6: 15 mg/kg durvalumab (Q4W) + 3 mg/kg Tremelimumab; 7: 15 mg/kg durvalumab (Q4W) + 10 mg/kg

<div style=\"page-break-after: always\"></div>

Figure 7. QTcF (change from baseline) versus concentration of tremelimumab on intercept full data

<!-- image -->

Cmax,ss maximum plasma concentration at steady state; IQR interquartile range; IV intravenous; Q2W every 2 weeks; Q4W every 4 weeks

Note: Red line is the linear regression line and the shaded area is the 90% CI based on the linear mixed-effects model prediction. Red short dashed horizontal line is 5 msec change from baseline identity line. Red long dashed horizontal line is 10 msec change from baseline identity line. Treatment cohorts are 1: 3 mg/kg durvalumab (Q4W) + 1 mg/kg Tremelimumab; 2: 10 mg/kg durvalumab (Q4W) + 1 mg/kg Tremelimumab;3: 15 mg/kg durvalumab (Q4W) + 1 mg/kg Tremelimumab; 4: 10 mg/kg durvalumab (Q4W) + 3 mg/kg Tremelimumab; 5: 20 mg/kg durvalumab (Q4W) + 1 mg/kg Tremelimumab; 6: 15 mg/kg durvalumab (Q4W) + 3 mg/kg Tremelimumab; 7: 15 mg/kg durvalumab (Q4W) + 10 mg/kg Tremelimumab; 8: 20 mg/kg durvalumab (Q4W) + 3 mg/kg Tremelimumab; 9: 10 mg/kg durvalumab (Q2W) + 1 mg/kg Tremelimumab; 10: 10 mg/kg durvalumab (Q2W) + 3 mg/kg Tremelimumab; 11: 20 mg/kg durvalumab (Q4W) + 1 mg/kg tremelimumab (Q4W)/ 20 mg/kg durvalumab (Q4W)

Table 13: Summary of maximum observed durvalumab or Tremelimumab serum concentration and predicted mean and CI of ∆QTcF

|              |   Observed Cmax (μg/mL) |    | Cohort Dosing regimen                         | Predicted mean △QTcF (ms)   | 90% CI of predicted mean △QTcF (ms)   |
|--------------|-------------------------|----|-----------------------------------------------|-----------------------------|---------------------------------------|
| Durvalumab   |                   866.6 | 10 | 20mg/kg durvalumab, 1mg/kg tremelimumab       | ， 4.28                      | (0.36, 8.20)                          |
| Tremelimumab |                   233   |  4 | 10mg/kg durvalumab,-2.27 15mg/kg tremelimumab |                             | (-9.49, 4.96)                         |

<div style=\"page-break-after: always\"></div>

## Absorption

The product is intended for intravenous administration. Clinical studies have not been conducted to evaluate the bioavailability or bioequivalence compared to other formulations.

Dose-normalized tremelimumab PK Parameters (Cmax and AUC0-28) from the dose finding study (Study 06) following administration of tremelimumab in combination with durvalumab are given in Table 14.

Table 14. Dose-normalized tremelimumab PK parameters following administration of tremelimumab and durvalumab combination (Study 06)

| Dose level                 | Tremelimumab geometric mean (n, geometric %CV)   | Tremelimumab geometric mean (n, geometric %CV)   |
|----------------------------|--------------------------------------------------|--------------------------------------------------|
|                            | Cmax_D (μg/mL/mg)                                | AUC0-28_D (μg·day/mL/mg)                         |
| T1 Q4W Escalation (N = 59) | 0.319 (55, 37.8)                                 | 2.82 (36, 39.3)                                  |
| T3 Q4W Escalation (N = 34) | 0.258 (32, 60.7)                                 | 2.83 (17, 21.1)                                  |
| T10 Q4W Escalation (N = 9) | 0.261 (9, 26.1)                                  | 2.45 (9, 32.2)                                   |
| T1 Q4W Expansion (N = 251) | 0.288 (200, 41.3)                                | 3.41 (14, 45.9)                                  |

Note: All data are depicted as geometric mean (n, geometric %CV), and rounded to 3 significant digits. AUC0-28\\_D, dose-normalized area under the serum concentration-time curve from Day 1 to Day 29; Cmax\\_D, dose-normalized maximum serum concentration after the first dose; CV, coefficient of variation; PK, pharmacokinetic; Q4W, every 4 weeks; T1, tremelimumab 1 mg/kg; T3, tremelimumab 3 mg/kg; T10, tremelimumab 10 mg/kg.

## Distribution

No distribution studies have been conducted in patients with NSCLC. However, Study 22 evaluated PK parameters in patients with advanced hepatocellular carcinoma, who received a single IV dose of 300 mg on Day 1. In a subset of patients from this study (N=11): for whom intensive PK sampling was done, the estimated volume of distribution was 7.6 L (Table 15).

Based on population PK analysis that included 1605 patients who received tremelimumab monotherapy or in combination with durvalumab with or without chemotherapy in the dose range of ≥ 1 mg/kg, the geometric mean steady-state volume of distribution (Vss) was 6.33 L.

<div style=\"page-break-after: always\"></div>

Table 15.  Individual values and descriptive statistics of tremelimumab serum PK parameters following single IV dose of 300 mg tremelimumab on Day 1 of Week 1 to patients with advanced hepatocellular carcinoma (PK analysis set) (Study 22)

| Allocationnumber        | TremelimumabPKparameters   | TremelimumabPKparameters   | TremelimumabPKparameters   | TremelimumabPKparameters   | TremelimumabPKparameters    | TremelimumabPKparameters   | TremelimumabPKparameters   |
|-------------------------|----------------------------|----------------------------|----------------------------|----------------------------|-----------------------------|----------------------------|----------------------------|
| Allocationnumber        | AUClast (μg/mL*day)        | AUCinf (μg/mL*day)         | Cmax (μg/mL)               | Tmax (h)                   | Apparent terminal ti2 (day) | CL (L/day)                 | Vz (L)                     |
| D4190C00022/20015120016 | 1814                       | 1903                       | 102.7                      | 1.58                       | 28.2                        | 0.158                      | 6.42                       |
| D4190C00022/20015220014 | 1212                       | 1469                       | 100.9                      | 3.24                       | 67.9                        | 0.204                      | 20.0                       |
| D4190C00022/20015240015 | 1784                       | 1828                       | 73.60                      | 1.18                       | 23.6                        | 0.164                      | 5.59                       |
| D4190C00022/20016520005 | 1009                       | 1022                       | 95.40                      | 1.01                       | 16.0                        | 0.293                      | 6.76                       |
| D4190C00022/20018500022 | 1362                       | 1377                       | 68.50                      | 1.08                       | 25.7                        | 0.218                      | 8.09                       |
| D4190C00022/20021190008 | 1422                       | 1636                       | 117.8                      | 1.25                       | 21.7                        | 0.183                      | 5.73                       |
| D4190C00022/20021190009 | 1267                       | 1310                       | 89.30                      | 1.13                       | 24.3                        | 0.229                      | 8.02                       |
| D4190C00022/20021200007 | 1225                       | 1728                       | 122.1                      | 1.22                       | 18.3                        | 0.174                      | 4.59                       |
| D4190C00022/20021200010 | 1223                       | 1273                       | 84.60                      | 1.27                       | 19.4                        | 0.236                      | 6.58                       |
| D4190C00022/20021210007 | 1303                       | 1597                       | 92.10                      | 1.06                       | 39.4                        | 0.188                      | 10.7                       |
| D4190C00022/20021210011 | 895.5                      | 913.5                      | 80.30                      | 1.13                       | 18.6                        | 0.328                      | 8.83                       |
| Nunber of patients      | 11                         | 11                         | 11                         | 11                         | 11                          | 11                         | 11                         |
| Arithmeticmean          | 1320                       | 1460                       | 93.39                      | NR                         | 27.6                        | 0.216                      | 8.30                       |
| Standard deviation      | 279.5                      | 317.4                      | 16.87                      | NR                         | 14.8                        | 0.0539                     | 4.24                       |
| ACV (%)                 | 21.2                       | 21.7                       | 18.1                       | NR                         | 53.8                        | 25.0                       | 51.1                       |
| Median                  | 1267                       | 1469                       | 92.10                      | 1.18                       | 23.6                        | 0.204                      | 6.76                       |
| Minimum                 | 895.5                      | 913.5                      | 68.50                      | 1.01                       | 16.0                        | 0.158                      | 4.59                       |
| Maxinum                 | 1814                       | 1903                       | 122.1                      | 3.24                       | 67.9                        | 0.328                      | 20.0                       |
| Geometricmean           | 1294                       | 1426                       | 92.02                      | NR                         | 25.1                        | 0.210                      | 7.64                       |
| GCV (%)                 | 21.1                       | 23.7                       | 18.2                       | NR                         | 43.0                        | 23.7                       | 41.3                       |
| 95% CI                  | (1124, 1489)               | (1219, 1668)               | (81.50, 103.9)             | NR                         | (19.1,33.2)                 | (0.180, 0.246)             | (5.85, 9.97)               |

ACV, arithmetic coefficient of variation is calculated in the original scale with the equation:1oo×(SD/AM); AUCinf, area under the concentrationversus time curve from 0 to infinity, AUClast, area under the concentration versus time curve from O to the time of the last quantifiable sample; AUCinf, area under the concentration versus time curve firom O to infinity after dosing; CI, confidence interval of the geometric mean; CL, clearance; Cmax, concentration at the end of infusion (TAD &lt; 1 day) in that visit; GCV, geometric coefficientofvariation is calculatedin the naturallogscalewith theequation:1o0xsqrt(exp(o²)-1),whereo²is theobservedvarianceonthenaturallogscale; IV, intravenous; NR, not reported; PK, pharmacokinetic; t1/2, apparent first-order terminal elimination half-life; TAD, time after dose; Tmax, time to maximum serum concentration; Vz, volume of distribution during the terminal phase.

## Elimination

Tremelimumab, as a typical mAb, is not cleared renally due to its large molecular weight. The primary elimination pathways are protein catabolism via the reticuloendothelial system (RES) or targetmediated disposition.

Based on the findings from the subset of patients from Study 22, for whom intensive PK sampling was done, the clearance was 0.21 L/day and the apparent half-life (apparent terminal t½) was 25.1 days (Table 15).

Based on population PK analysis, the geometric mean steady-state clearance (CLss) was 0.309 L/day and the geometric mean terminal half-life was approximately 14.2 days.

## Dose proportionality and time dependencies

In Study 06 an approximately dose-proportional increase in PK exposure (Cmax and AUC0-28) of tremelimumab was observed over the dose range of 1 to 10 mg/kg tremelimumab Q4W when administered in combination with durvalumab (Table 14). Exposure following multiple doses demonstrated accumulation consistent with PK parameters estimated from the first dose. The PK profile for tremelimumab is shown in Figure 8.

Based on the final Population PK model using POSEIDON data, time-dependent CL was identified for tremelimumab in combination with durvalumab, but not with tremelimumab monotherapy.

<div style=\"page-break-after: always\"></div>

Figure 8. Mean (SD) tremelimumab PK concentration-time profiles after the first dose by tremelimumab dose following IV administration of the combination of durvalumab and tremelimumab (Study 06)

BLQ.below thelimitofquantification;IV,intravenous:PK,pharmacokinetic:Q4W,every4weeks; Q12W,every12weeks;SD,standard deviation.

<!-- image -->

## Intra- and inter-individual variability

For tremelimumab, all fixed and random effects were estimated with good precision (&lt; 25% RSE). The IIV was 33%, 20%, 46% and 87% for CL, V1, V2 and Tmax, respectively.

For durvalumab, the IIV was limited, amounting to 28%, 24% and 25% on CL, V1 and Tmax, respectively.

## Special populations

The effect of intrinsic factors (i.e., renal impairment, hepatic impairment, age, race, gender, and body weight) on the PK of tremelimumab has not been studied through specific dedicated studies.

The effect of renal impairment, hepatic impairment, age, race, gender, and body weight on the PK of tremelimumab, however, has been evaluated in the Population PK analysis. In summary, the final Population PK modeling indicated that the baseline patient characteristics of age, race, renal function, and hepatic function had no effect on the PK of tremelimumab.

In contrast, the Population PK analysis identified several covariates that were statistically significant on tremelimumab CL and V1: body weight, serum albumin (ALB), sex, combination therapy and primary indication on CL; and body weight and sex on V1, all identified covariates changed tremelimumab exposure by less than ± 20% and were regarded as of minor clinical relevance.

## Impaired renal function

Mild (creatinine clearance (CrCL) 60 to 89 ml/min) and moderate renal impairment (creatinine clearance (CrCL) 30 to 59 ml/min) had no clinically significant effect on the PK of tremelimumab. The effect of severe renal impairment (CrCL 15 to 29 ml/min) on the PK of tremelimumab is unknown.

<div style=\"page-break-after: always\"></div>

## Impaired hepatic function

Mild hepatic impairment (bilirubin ≤ ULN and AST &gt; ULN or bilirubin &gt; 1.0 to 1.5 × ULN and any AST) had no clinically significant effect on the PK of tremelimumab. The effect of moderate hepatic impairment (bilirubin &gt; 1.5 to 3 x ULN and any AST) or severe hepatic impairment (bilirubin &gt; 3.0 x ULN and any AST) on the PK of tremelimumab is unknown.

## Gender

Based on the final PopPK model of tremelimumab, gender was identified as a statistically significant covariate on PK of tremelimumab. Based on the final Population PK model using POSEIDON data, the geometric mean CLss and V1 values were 13.4% and 14.9% lower, respectively, in female patients compared to the respective population mean values.

These differences in CLss and V1 (&lt; 20%) were not considered clinically meaningful given the lack of exposure-safety and exposure-efficacy relationships in POSEIDON.

## Age

Age (range 22 to 97 years) was not identified as a significant covariate in the final PopPK model of tremelimumab

|                    | Durvalumab + Tremelimumab + SoC   | Durvalumab + SoC   | SoC         | All patients in PopPK   |
|--------------------|-----------------------------------|--------------------|-------------|-------------------------|
| N                  | 326                               | 322                | 333         | 1605                    |
| Age sub-group (yr) |                                   |                    |             |                         |
| <65                | 185 (56.7%)                       | 164 (50.9%)        | 175 (52.6%) | 834 (52.0%)             |
| >=65-75            | 107 (32.8%)                       | 124 (38.5%)        | 120 (36.0%) | 595 (37.0%)             |
| >=75               | 34 (10.4%)                        | 34 (10.6%)         | 38 (11.4%)  | 176 (11.0%)             |

## Race

Race was not identified as a significant covariate in the final PopPK model of tremelimumab and race did not seem to influence PK of tremelimumab.

## Weight

Based on the final PopPK model of tremelimumab, body weight was identified as a statistically significant covariate on PK of tremelimumab. The impact of body weight on CLss or V1, evaluated based on the difference in geometric mean parameter values at the 95th or 5th percentile of the weight distribution from that of the overall population, was within -11.8% to +14.7% for CLss and 14.2% to +18.3% for V1.

Table 16 shows the simulated tremelimumab AUC, Cmax, and Cmin at steady state across body weight quartiles. At the highest weight quartile, the simulated geometric mean AUCss, Cmax,ss, and Cmin,ss decreased by 8.68%, 13.7%, and 7.53%, respectively, compared to the geometric mean of the overall population. At the lowest quartile, the simulated AUCss, Cmax,ss, and Cmin,ss increased by 9.12%, 14.6%, and 10.5%, respectively, compared to the mean of the overall population.

These differences in exposure were not considered clinically meaningful given the lack of exposureefficacy and exposure-safety relationships in POSEIDON.

<div style=\"page-break-after: always\"></div>

Table 16. Tremelimumab exposure across body weight quartiles.

|                      | 10               | Q2               | Q3               | Q4               |
|----------------------|------------------|------------------|------------------|------------------|
| Individuals          |                  |                  |                  |                  |
| N                    | 84               | 81               | 80               | 81               |
| Body weight (kg)     |                  |                  |                  |                  |
| Geometric mean (%CV) | 51.4 (12.3)      | 63.4 (4.50)      | 73.1 (3.81)      | 90.2 (12.5)      |
| Median [min-max]     | 53.6 [34.0-58.0] | 63.7 [58.5-68.2] | 73.0 [68.5-78.5] | 87.0 [78.6-134]  |
| AUCFifth dose        |                  |                  |                  |                  |
| Geometric mean (%CV) | 285 (15.9)       | 266 (15.0)       | 257 (17.2)       | 239 (13.4)       |
| Median [min-max]     | 291 [173-520]    | 266 [174-362]    | 256 [188-755]    | 241 [163-396]    |
| %change              | 9.12             | 1.64             | -1.61            | -8.68            |
| Cmas Fifth dose      |                  |                  |                  |                  |
| Geometric mean (%CV) | 29.9 (16.0)      | 27.5 (20.8)      | 25.0 (20.3)      | 22.5 (19.1)      |
| Median [min-max]     | 30.0 [20.9-44.7] | 26.2 [20.4-62.6] | 24.0 [16.2-49.7] | 21.9 [15.6-48.6] |
| %change              | 14.6             | 5.15             | -4.35            | -13.7            |
| Cmin Fifth dose      |                  |                  |                  |                  |
| Geometric mean (%CV) | 8.29 (23.8)      | 7.39 (26.6)      | 7.44 (26.8)      | 6.94 (26.4)      |
| Median [min-max]     | 8.73 [3.93-19.1] | 7.61 [2.80-12.0] | 7.63 [3.84-32.2] | 7.21 [1.68-14.5] |
| %ochange             | 10.5             | -1.60            | -0.919           | -7.53            |

Note: %change was computed with the geometric mean of the entire population as a reference.

AUC, area under the serum concentration-time curve; Cax, maximum serum concentration; Cuin, minimum serum concentration; CV, coefficient of variation; max, maximum; min, minimum; N, number of patients; PK, pharmacokinetic(s); Q1/2/3/4, 1st, 2nd, 3rd, 4th quartile.

## Pharmacokinetic interaction studies

No formal drug-drug interaction studies have been conducted with tremelimumab or durvalumab.

In POSEIDON, no clinically meaningful PK drug-drug interactions between tremelimumab or durvalumab and SoC were identified. In addition, PK of abraxane and gemcitabine were similar between SoC only, durvalumab + SoC, and durvalumab + tremelimumab + SoC groups, suggesting that combination with durvalumab and tremelimumab does not have an impact on the PK of abraxane and gemcitabine.

Additionally, based on population PK analysis, concomitant durvalumab and platinum-based chemotherapy treatment did not seem to impact the PK of tremelimumab in terms of Cmax, CL or AUC.

## Pharmacokinetics using human biomaterials

No in vitro permeability, in vitro metabolism, or in vitro metabolic drug-drug interaction studies that used human biomaterials have been performed.

<div style=\"page-break-after: always\"></div>

## Immunogenicity

As with all therapeutic proteins, there is a potential for immunogenicity. Immunogenicity of tremelimumab is based on pooled data in 1337 patients who were treated with tremelimumab 75 mg or 1 mg/kg and evaluable for the presence of anti-drug antibodies (ADAs). One-hundred forty-three patients (10.7%) tested positive for treatment-emergent ADAs. Neutralizing antibodies against tremelimumab were detected in 8.9% (119/1337) of patients.

In the POSEIDON study, of the 278 patients who were treated with tremelimumab 75 mg in combination with durvalumab 1 500 mg every 3 weeks and platinum-based chemotherapy and evaluable for the presence of ADAs, 38 (13.7%) patients tested positive for treatment-emergent ADAs. Neutralizing antibodies against tremelimumab were detected in 11.2% (31/278) of patients. Both ADA incidence and prevalence were numerically similar between the T + D + SoC and D + SoC arms, indicating that the presence of tremelimumab did not have an apparent effect on the immunogenicity of durvalumab.

## 2.3.3. Pharmacodynamics

## Mechanism of action

Tremelimumab is a human IgG2 mAb directed against cytotoxic T lymphocyte-associated antigen-4 (CTLA-4). CTLA-4 is a critical regulatory signal for T-cell expansion and activation following an immune response, and it serves as a natural braking mechanism that maintains T-cell homeostasis. During Tcell activation, T cells upregulate CTLA-4, which binds to CD80 and CD86 ligands on antigenpresenting cells, sending an inhibitory signal and preventing CD28-mediated T-cell co-stimulation, thus limiting T-cell activation. Tremelimumab blocks these events, leading to prolongation and enhancement of T-cell activation and expansion.

Durvalumab is a human IgG1k mAb that binds to programmed cell death ligand-1 (PD-L1) and blocks the interaction of PD-L1 with PD-1 and CD80 (B7.1). Expression of PD-L1 can be induced by inflammatory signals and can be expressed on both tumour cells and tumour-associated immune cells in the tumuor microenvironment. PD-L1 blocks T-cell function and activation through interactions with PD-1 and CD80 (B7.1). By binding to its receptors PD-L1 reduces cytotoxic T-cell activity, proliferation, and cytokine production. Blockade of PD-L1/PD-1 and PD-L1/CD80 interactions releases the inhibition of immune responses, without inducing antibody-dependent cell-mediated cytotoxicity (ADCC).

Tremelimumab and durvalumab are checkpoint inhibitors with distinct yet complementary mechanisms of action with respect to enhancing the antitumor immune response triggered by chemotherapy. Tremelimumab mediated blockade of CTLA-4 functions early in the immune response, lowering the threshold for T cell activation, allowing more T cells to be activated and increasing the diversity of the T cell population. This increases the probability that a T cell recognizing a tumour neoantigen can become activated. Durvalumab blockade of PD-L1 is expected to function mainly during the effector phase of T cell function, once T cells enter the tumour, where it acts to block local suppression of T-cell function by PD-L1, enhancing the ability of activated anti-tumor T cells to target and kill tumour cells.

## Primary and secondary pharmacology

## Primary pharmacology

<div style=\"page-break-after: always\"></div>

Data from Study 06, Study 10 and Study 22 indicate that a pharmacodynamic effect exists on proliferating CD4+ and CD8+ T cell quantities consistent with the proposed mechanisms of action of both therapeutic agents.

Data from Study 1108, Japan Study 02, Study 06 and Study 10 indicate that durvalumab treatment (with or without tremelimumab) reduces free Soluble Programmed Cell Death Ligand-1 (sPD-L1) in serum.

No PD biomarkers are proposed for monitoring of effect.

## Secondary pharmacology

## Concentration-QTc Analysis

Overall, concentration-QTc-analysis did not identify a significant linear relationship between tremelimumab or durvalumab serum concentrations and ΔQTcF. The predicted mean ΔQTcF and upper 90% CI at the maximum observed concentration for tremelimumab or durvalumab in the dataset were below the threshold of clinical concern.

## Exposure-response relationships

Assessment of an exposure-efficacy relationship was conducted using overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) as efficacy parameters in patients from POSEIDON, for whom the different exposure metrics could be calculated. The total number of patients included in the analysis of the exposure-efficacy relationship was 326 receiving T + D + SoC, 322 receiving D + SoC, and 333 receiving SoC.

Both OS and PFS were explored by Kaplan-Meier estimates and analyzed by Cox proportional-hazards models based on data from patients in the T + D + SoC arm.

## Exposure-efficacy relationship

Overall survival (OS)

<div style=\"page-break-after: always\"></div>

Figure 9. OS Kaplan-Meier plots for tremelimumab exposure metrics by quartiles at dose 1

<!-- image -->

Note:Shadedareasare the95%CI around theKaplan-Meier curves.Vertical ticksrepresent theright censoring. AUC,areaundertheserumconcentration-timecuve;CI,confidenceinterval;Cmaxmaximumserumconcentration;Cmnminimum serumconcentration;Os,overall suvival; PKpharmacokinetic(s);Q1/2/3/4,1st,2nd,3rd,4thquartile;SoC,standardofcare chemotherapy;treme,tremelimumab.

Figure 10. OS Kaplan-Meier plots for tremelimumab exposure metrics by quartiles at dose 5

<!-- image -->

Time in days

Note:Shaded areas are the95%CIaround theKaplan-Meiercurves.Vertical ticksrepresent theright censoring. AUC,areaunderthe serum concentration-time curve;CI,confidenceinterval;Cmaxmaximum serum concentration;Cminminimum serum concentration;Os,overall suvival; PK,pharmacokinetics);Q1/2/3/4,1st,2nd,3rd,4thquartile;SoC,standardofcare chemotherapy;treme,tremelimumab.

For AUCDose 5 Treme, Cmin, Dose 5 Treme, and Cmin, Dose 1 Treme, there was a trend that patients with exposure in the 1st quartile had shorter OS compared to those in the 2nd quartile (Figure 9 and Figure 10). Similarly, patients in the 2nd quartile had also a shorter OS than those in the 3rd quartile. However, no difference was observed between 3rd and 4th quartile. Further, for all quartiles but the 1st, the Kaplan-Meier curves of OS were above that of the SoC arm.

<div style=\"page-break-after: always\"></div>

In order to assess whether confounding factors could explain the fact that the 1st quartile had a worse OS than SoC, a case match analysis was performed (see below).

Progression-free survival (PFS)

Figure 11. PFS Kaplan-Meier plots for tremelimumab exposure metrics by quartiles at dose 1

<!-- image -->

Note:Shaded areas arethe95%CIaround theKaplan-Meiercurves.Vertical ticksrepresent therightcensoring. AUC,areaunder theserum concentration-time curve;CI,confidenceinterval;Cmax,maximum serum concentration;Cmin,minimum serum concentration;PFS,progression-free survival;PKpharmacokinetic(s);Q1/2/3/4,1st,2nd,3rd,4thquartile;SoC,standardofcare chemotherapy,treme,tremelimumab.

Figure 12. PFS Kaplan-Meier plots for tremelimumab exposure metrics by quartiles at dose 5

<!-- image -->

Note:Shaded areasare the95%CI around theKaplan-Meiercurves.Verticalticksrepresent therightcensoring. AUC,area undertheserum concentration-time curve;CI,confidenceinterval;Cmaxmaximum serum concentration;Cminminimum serum concentration;PFS,progression-free

<div style=\"page-break-after: always\"></div>

For AUCDose 5 Treme, Cmin, Dose 5 Treme, and Cmin, Dose 1 Treme, and similarly to what was observed for OS, for all quartiles but the 1st, the Kaplan-Meier curves of PFS were above that of the SoC arm (Figure 11 and Figure 12).

Exposure-response analyses demonstrated that the Cmin after tremelimumab dose at Cycle 5 was the most significant exposure metric that influenced OS and PFS in patients enrolled in the POSEIDON study. In addition to tremelimumab exposure, the following covariates also influence OS and PFS: tumour type (both OS and PFS), NLR (PFS), PD-L1 T cells (PFS), and tumor mutational burden (PFS).

## Case Match Analysis

The exploratory analysis of OS and PFS by exposure metrics of tremelimumab revealed that the patients in Q1 of Cmin, Dose 5 Treme were associated with a lower survival than those in the SoC arm; however, several confounding covariates could have influenced this observation.

To supplement the CPH models for OS and PFS, patients from the SoC arm were matched with those in Q1 of Cmin, Dose 5 Treme of the T + D + SoC arm. Matching was performed based on the distributions of the following 10 disease-related covariates: baseline tumor size, Eastern Cooperative Oncology Group (ECOG) score at baseline, aspartate aminotransferase (AST), serum albumin (ALB), lactate dehydrogenase (LDH), neutrophil-to-lymphocyte ratio (NLR), tumor burden (&gt; or &lt; 12 mutations per megabase), tumor type (non-squamous vs squamous), 25% of PD-L1 TC, and the chemotherapy used in SoC (abraxane based vs gemcitabine based vs pemetrexed based). All the 82 treated patients in the Q1 subgroup were successfully matched to 82 patients in the SoC arm. All covariates in the selected 82 SoC patients were balanced after matching.

The HR for the comparison of patients in the Q1 subgroup with matched patients from the SoC arm was 1.04 (95% CI: 0.76-1.44) for OS and 0.99 (95% CI: 0.72-1.36) for PFS (Table 17). These results contrast with the HR calculated for the unmatched population. For OS, the HR was 1.42 (95% CI: 1.10-1.84) and was 1.23 (95% CI: 0.95-1.58) for PFS. The 95% CI of PFS HR for both unmatched and matched patients includes 1, suggesting that the apparent difference between groups in the KaplanMeier plot is not statistically significant. In conclusion, the case match analysis suggested that the observed relationship with tremelimumab exposure is possibly confounded by disease-related covariates.

Table 17. HR for OS and PFS in patients of Cmin, Dose 5 Treme Q1 subgroup and SoC group

|          |                                         | Median survival (days)   | Median survival (days)   | HR (95% CI)      |
|----------|-----------------------------------------|--------------------------|--------------------------|------------------|
| Endpoint | Analysis                                | SoC                      | Cimin, Dose 5 Treme      |                  |
| oS       | Unmatched                               | n=333 349                | 1n1=82 205               | 1.42 (1.10-1.84) |
| OS       | Matched with disease-related covariates | n= 82 242                | n=82 205                 | 1.04 (0.76-1.44) |
| PFS      | Unmatched                               | n=333 161                | 1n =82 128               | 1.23 (0.95-1.58) |
| PFS      | Matched with disease-related covariates | n = 82 133               | n=82 128                 | 0.99 (0.72-1.36) |

CI, confidence interval; Cmin, Dose 5 Treme, minimum serum concentration for tremelimumab following the 5th dosing cycle; HR, hazard ratio, n, number of patients in subgroup; OS, overall survival, PFS, progression-free survival, PK, pharmacokinetic(s); Q1, 1st quantile, SoC, standard of care chemotherapy.

No relationship between durvalumab exposure and OS or PFS was identified in the POSEIDON T + D + SoC arm.

<div style=\"page-break-after: always\"></div>

## Objective Response Rate (ORR)

The ORR was dichotomized as partial response (PR) or complete response (CR), vs. stable disease or progression of disease (PD) and analyzed using a logistic regression model relating the probability of being a responder to durvalumab and tremelimumab exposure metrics. This analysis focused on the combination treatment arm of T + D + SoC in which 330 patients received treatment. The ORR in 8 of the patients was not evaluable and excluded from this analysis. Of the remaining 322 patients, 3 patients did not have durvalumab exposure metrics and 4 patients did not have tremelimumab exposure metrics. Therefore, logistic regression models for assessing effect of durvalumab and tremelimumab were based on 319 and 318 patients, respectively.

In general, there appeared to be no clear trend between durvalumab exposure and the probability of being a responder. For tremelimumab, the plots appear to suggest an increase in the probability of being a responder with increasing exposure (Figure 13). However, the relatively large p-values show that none of the exposure metrics has a statistically significant impact (at the prespecified significance level of α = 0.001) on the probability of being a responder. It should be noted that for tremelimumab, the distribution of AUC after Dose 5, trough concentration after first dose, and after Dose 5 is somewhat narrow and there are a few potentially outlying patients.

In general, there was no clear trend between the covariates and the probability of being a responder.

Figure 13. Relationship between the probability of being a responder (PR or CR) and AUC after first dose of durvalumab and tremelimumab

<!-- image -->

Note: The black solid circles are the observed probability of Response and the error bars are the standard errors for quartiles (25%, 50% and 75%, green vertical dotted lines) of exposures (plotted at the median value within each quartile). The black lines the logistic regression between 2 variables and the gray area represents the associated CI.

AUC, area under the serum concentration-time curve; CI, confidence interval; CR, complete response; PK, pharmacokinetic(s); PR, partial response.

## Exposure-safety relationship

The safety endpoints of interest were Grade 3 and above treatment-related adverse events (AEs), Grade 3 and above adverse events of special interest (AESIs), AEs leading to durvalumab treatment discontinuation and AEs leading to tremelimumab treatment discontinuation, focusing on the durvalumab + tremelimumab + SoC arm only.

<div style=\"page-break-after: always\"></div>

Of the 330 patients in this arm, 3 did not have durvalumab exposure metrics while 4 did not have tremelimumab exposure metrics hence 327 and 326 patients were analyzed in the logistic regression models for durvalumab and tremelimumab respectively.

The relationship between the probability of having Grade 3 and above treatment-related AEs and AUC after the first dose of durvalumab and tremelimumab is shown in Figure 14. The relationship between the probability of having Grade 3 and above treatment-related AESIs and AUC after the first dose of durvalumab and tremelimumab is shown in Figure 15.

In general, there appears to be no clear trend between increasing exposure and the probability of AEs. The p-values associated with exposure effects were relatively large (in comparison to the prespecified significance level of α = 0.001) i ndicating that the relationship was not statistically significant.

Although not statistically significant, it was notable that the coefficients for the effect of durvalumab on probability of Grade 3 and above treatment-related AEs were negative, suggesting a counterintuitive decrease in the probability of AEs with increasing exposure. However, these effects were small and not statistically significant. In general, the apparent overlap in the distribution of exposure between the patients that had and those that did not have AEs suggested no clear relationship between exposure and the probability of having AEs.

Figure 14. Relationship between the probability of having Grade 3 and above treatmentrelated AEs and AUC after the first dose of durvalumab and tremelimumab

<!-- image -->

Note: The black solid circles are the observed probability of Response and the error bars are the standard errors for quartiles (25%, 50% and 75%, green vertical dotted lines) of exposures (plotted at the median value within each quartile). The black lines the logistic regression between 2 variables and the gray area represents the associated CI.

AE, adverse event; AUC, area under the seium concentration-time curve; CI, confidence interval; PK, pharmacokinetic(s).

<div style=\"page-break-after: always\"></div>

Figure 15. Relationship between the probability of having grade 3 and above AESI and AUC after first dose for durvalumab and tremelimumab

<!-- image -->

Abbreviations: AE=adverse event, AESI=adverse event of special interest, AUC=area under the serum

Source: az-durvalumab-ae-poseidon-v5.Rmd, Reference: 400028:5b2d38 concentration-time curve

Note: the black solid circles are the observed probability of Response and the error bars are the standard errors for quartiles (25%, 50% and 75%, green vertical dotted lines) of exposures (plotted at the median value within each quartile). The black lines the logistic regression between two variables and the gray area represents the associatedconfidenceinterval.

## 2.3.4. Discussion on clinical pharmacology

The PK of tremelimumab alone or in combination with durvalumab have been investigated in patients enrolled in 3 Phase I/Ib studies, 1 Phase I/II study, 3 Phase II/IIb studies and 6 Phase III studies.

The pharmacokinetics (PK) of tremelimumab was assessed as monotherapy and in combination with durvalumab and platinum-based chemotherapy.

The pharmacokinetics of tremelimumab was studied in patients with doses ranging from 75 mg to 750 mg (or 10 mg/kg) administered intravenously once every 4 or 12 weeks as monotherapy. PK exposure increased dose proportionally (linear PK) at doses ≥ 75 mg. Steady-state was achieved at approximately 12 weeks. Based on population PK analysis that included 1605 patients who received tremelimumab monotherapy or in combination with durvalumab with or without chemotherapy in the dose range of ≥ 75 mg (or 1 mg/kg) every 3 or 4 weeks, the geometric mean steady-state volume of distribution (Vss) was 6. 33 L. Tremelimumab clearance (CL) decreased over time in combination with durvalumab and chemotherapy resulting in a geometric mean steady-state clearance (CLss) of 0.309 L/day; the decrease in CLss was not considered clinically relevant. The geometric mean terminal half life was approximately 14.2 days. The primary elimination pathways of tremelimumab are protein catabolism via reticuloendothelial system or target mediated disposition.

<div style=\"page-break-after: always\"></div>

In the POSEIDON study, overall PK profiles of durvalumab were similar between T + D + SoC and D + SoC arms, suggesting tremelimumab or SoC do not have an impact on PK of durvalumab when administered as combination therapy.

Overall, PK results of gemcitabine and Abraxane were similar between T + D + SoC, D + SoC, and SoC alone arms, suggesting durvalumab or tremelimumab do not have an impact on PK of SoC chemotherapy (gemcitabine or Abraxane) when administered as combination therapy.

In spite of these differences in study design, the assessed PK data (Cmax and Ctrough) for tremelimumab appear to be broadly comparable across studies.

A population PK model was developed for tremelimumab based on a pooled dataset from 6 Studies: Study 02, Study 06, Study 10, DETERMINE, BASKET and POSEIDON, which comprised of 5455 serum concentrations from 1605 patients. The final Pop PK model of tremelimumab was a 2-compartment model with linear CL and an additional time-dependent CL component for patients on combination therapy only. The following covariates were identified as statistically significant and included in the final model: body weight and sex on both CL and V1; albumin, primary indication and combination therapy (chemotherapy vs. no chemotherapy) on CL. The effect of body weight was allometrically scaled with estimated exponents of 0.370 and 0.453 for CL and V1, respectively, indicating that the effect of body weight was less than proportional. Residual unexplained variability is low (28%) and low-to-moderate inter-individual random effects were identified on CL (39%), V1 (21%) and V2 (49%). In addition, an omega was included on Tmax to account for a random variation on the timedependency effect on CL. No trends were observed on the ETA distribution of Tmax across the different covariates evaluated, suggesting that the large IIV on Tmax is caused by a large and random distribution of inter-individual differences that are not linked to any covariate tested. The final model was evaluated by means of non-parametric bootstrap analysis (n=1000), RSEs, GOF-plots and pcVPCs. The evaluation of the GOF confirmed the adequacy of the structural population PK model proposed, but some bias have been observed in the DV vs IPRED plot, where large deviation (&gt;10-fold) were observed between IPRED and DV. Slight model over-prediction was observed in these 22 observations out of 5238 observations. Most of the observations (12/22) were around the Cmax, suggesting that the model slightly over-predicts Cmax concentrations in those individuals. Based on the small proportion of observations that were over-predicted (0.42%), the model misspecification is considered of minor relevance. A large number of bootstrap runs failed to converge (474/1000) due to rounding errors which may indicate an unstable model. However, it seems termination status was not an important indicator of the quality of bootstrap parameter estimates and all median estimates and 95% CI of each parameter were close to the final model parameter estimates. The overall model performance was observed based on the pcVPC, suggesting no significant trends across the different percentiles. No relevant trends were observed across the different pcVPC stratified by the significant covariates, suggesting the overall adequacy of the model to capture the different sub-groups of populations.

Age (22 - 97 years), body weight (34 - 149 kg), gender, positive anti-drug antibody (ADA) status, albumin levels, LDH levels, creatinine levels, tumour type, race or ECOG/WHO status had no clinically significant effect on the PK of tremelimumab.

The effect of mild hepatic impairment and mild or moderate renal impairment was evaluated in pop PK analyses showing no impact on the exposure of tremelimumab. Accordingly, no dose adjustment is required in these special populations. There are insufficient data in patients with severe renal impairment for dosing recommendations However, as IgG monoclonal antibodies are not primarily cleared via renal pathways, a change in renal function is not expected to influence tremelimumab exposure. Data from patients with moderate and severe hepatic impairment are limited. However, as IgG monoclonal antibodies are not primarily cleared via hepatic pathways, a change in hepatic function

<div style=\"page-break-after: always\"></div>

is not expected to influence tremelimumab exposure and as a consequence, no dose adjustment of Imjudo is recommended for patients with hepatic impairment. No dose adjustment is required for elderly patients ( ≥ 65 years of age) (see Special populations in section 2.3.2). Data on patients aged 75 years of age or older are limited.

The presence of tremelimumab ADA did not impact tremelimumab PK, as it was not identified as a significant covariate in the tremelimumab PopPK analysis. There was no clear evidence that the presence of tremelimumab ADA had any potential impact on the safety in POSEIDON study.

The durvalumab PopPK model was updated by including 11683 serum PK samples from 2827 patients. The model was based on a pooled dataset from 5 Studies: Study 1108, POSEIDON, ATLANTIC, PACIFIC and CASPIAN. The final model was evaluated by means of non-parametric bootstrap analysis (n=500), RSEs, GOF-plots and pcVPCs. Changes on AUCss due to sex, durva+chemo and low ALB and on Cmax due to low body weight and sex are very close to the clinical relevance of 20%. Predictioncorrected VPCs stratified by clinical treatment, body weight, sex and albumin suggested that the durvalumab PopPK model adequately captures different subgroups of populations and no dose adjustments may be needed based on the clinical relevance analysis.

Both overall survival (OS) and progression-free survival (PFS) were explored by Kaplan-Meier (KM) estimates and analysed by Cox proportional hazard (CPH) models based on data from patients receiving the durvalumab + tremelimumab + SOC. Models were evaluated by graphically superimposing model-predictions over the observed data. The proportional hazard assumption was supported by a non-significant relationship between residuals and time except for the covariate logNLR. Linear mixed-effects exposure-response modelling with an intercept was conducted to characterize the relationship of change from baseline of QTcF (ΔQTcF) with durvalumab or tremelimumab serum concentrations. The slope or the intercept for tremelimumab and durvalumab were significantly different from 0. However, for both tremelimumab and durvalumab, the upper bound of the 90% CI for ΔQTcF was less than 10 ms, and the highest observed co ncentration had a predicted mean ΔQTcF of less than 5 ms. These values were lower than the prolongation levels of concern as established in the ICH E14 industry guidance for clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. The normality assumption was largely met and no hysteresis was apparent in the ΔQTcF vs. tremelimumab concentration plots.

A weight-based dosing regimen of 1 mg/kg 3W of tremelimumab was proposed for patients weighting 30 kg or less, to align the dosing recommendation with that of durvalumab for which a 30 kg cut-off was set based on a FDA-requested change to the endotoxin acceptance criteria during review of the initial durvalumab Investigational New Drug submission (June 2015). The predicted tremelimumab dose 5 (AUCdose5, Cmin,dose5) exposures for 30 kg or 20 kg body weights were generally lower compared to those observed in POSEIDON across the body weight quartiles. The lack of safety concern with this proposal was acknowledged. In addition, the MAH argued that since no clinically meaningful relationship between exposure and efficacy (OS and PFS) was observed for tremelimumab, and the efficacy results were similar across BW quartiles, the efficacy for patients with body weights less than or equal to 30 kg is expected to be similar to those weighing over 30 kg and receiving equivalent fixed doses in POSEIDON. The fixed dosing regimen of 75 mg Q3W was evaluated through a model-based analysis in patients between 30-34 kg (not enrolled in POSEIDON), and a &gt;30% higher AUCss was predicted compared to patients between 34-58 kg. This increase in exposure gave raise to concerns regarding safety because (1) the predicted AUCss range with the fixed dosing regimen was higher (250-600 micrograms·h/mL) compared to the evaluated AUCss range in the exposure-safety analysis (&lt;300 micrograms·h/mL), and (2) the slight positive exposure-safety relationship observed. A body weight regimen would provide more similar exposure to that observed in patients with higher body weight (&gt;34 kg). Even in case of (slightly) lower exposure, lack of efficacy is not considered a concern,

<div style=\"page-break-after: always\"></div>

as discussed above. Considering all this, the cut-off below which tremelimumab is to be administered according to body weight was finally fixed at 34kg and reflected in section 4.2 of the SmPC.

The use of systemic corticosteroids or immunosuppressants before starting tremelimumab, except physiological dose of systemic corticosteroids ( ≤ 10 mg/day prednisone or equivalent), is not recommended because of their potential interference with the pharmacodynamic activity and efficacy of tremelimumab. However, systemic corticosteroids or other immunosuppressants can be used after starting tremelimumab to treat immune-related adverse reactions.

No formal pharmacokinetic (PK) drug-drug interaction studies have been conducted with tremelimumab. Since the primary elimination pathways of tremelimumab are protein catabolism via reticuloendothelial system or target-mediated disposition, no metabolic drug-drug interactions are expected. PK drug-drug interactions between tremelimumab in combination with durvalumab and platinum-based chemotherapy were assessed in the POSEIDON study and showed no clinically meaningful PK interactions between tremelimumab, durvalumab, nab-paclitaxel, gemcitabine, pemetrexed, carboplatin or cisplatin in the concomitant treatment.

Assessment of an exposure-efficacy relationship was conducted using OS, PFS, and ORR as efficacy parameters in patients from POSEIDON.

OS and PFS were explored by Kaplan-Meier estimates and analyzed by Cox proportional-hazards models based on data from patients in the T + D + SoC arm.

ORR was dichotomized as partial response (PR) or complete response (CR), vs. stable disease or progression of disease (PD) and analyzed using a logistic regression model relating the probability of being a responder to durvalumab and tremelimumab exposure metrics.

For some of the tremelimumab PK parameters (AUCDose 5, Cmin, Dose 5, and Cmin, Dose 1), there was a trend that patients with exposure in the 1st quartile had shorter OS compared to those in the 2nd quartile. Similarly, patients in the 2nd quartile had also a shorter OS than those in the 3rd quartile. However, no difference was observed between 3rd and 4th quartile. Further, for all quartiles but the 1st, the Kaplan-Meier curves of OS were above that of the SoC arm.

Similar to what was observed for OS, the Kaplan-Meier curves of PFS were for all quartiles, but the 1st, above that of the SoC arm for the same tremelimumab PK parameters (AUCDose 5, Cmin, Dose 5, and Cmin, Dose 1).

In order to assess whether confounding factors could explain the fact that the 1st quartile had a worse OS and PFS than SoC, a case match analysis was performed, and this analysis suggested that the observed relationship with tremelimumab exposure was possibly confounded by disease-related covariates.

In terms of ORR, the plots appeared to suggest an increase in the probability of being a responder with increasing exposure to tremelimumab.

There appeared to be no clear trend between durvalumab exposure and the probability of being a responder.

Since the exposure-efficacy relationships was only evaluated through Kaplan-Meier plots with OS and PFS between tremelimumab vs SoC arms, the evaluation was in the first place considered insufficient. Additional statistical analyses (K-M and cox-regression analyses) conducted between T+D+chemo vs D+chemo arms were requested.

<div style=\"page-break-after: always\"></div>

As a result, the exposure-response CPH model for OS was updated based on durvalumab and tremelimumab treated patients from T + D + SoC versus D + SoC arms. OS KM plots for tremelimumab exposure metrics by quartiles at dose 1 and at dose 5, respectively, were provided.

The KM curve of D + SoC arm was above that of the SoC arm, and in the middle of those of different tremelimumab exposure quartiles. The impact of a number of identified covariates was assessed via the computation of the Hazard Ratio.

According to the applicant, the exposure-response CPH model for PFS was also updated based on durvalumab and tremelimumab treated patients from T + D + SoC versus D + SoC arms. The impact of a number of identified covariates was assessed via the computation of the Hazard Ratio.

For assessment of an exposure-safety relationship, the evaluated safety endpoints were Grade 3 and above treatment-related AEs from POSEIDON, Grade 3 and above AESIs, AEs leading to durvalumab treatment discontinuation and AEs leading to tremelimumab treatment discontinuation, focusing on the durvalumab + tremelimumab + SoC arm only. None of the tremelimumab or durvalumab exposure metrics were identified to have an influence on safety events in a logistic regression analysis.

In addition, a body weight-AE analysis found no clear sign of a higher frequency of AEs in subjects with low body weight.

The findings related to immunogenicity indicate a low immunogenicity risk of tremelimumab.

With respect to the concentration-QTc-analysis, modeling results did not identify a significant linear relationship between tremelimumab or durvalumab serum concentrations and ΔQTcF.

## 2.3.5. Conclusions on clinical pharmacology

Considering the nature of the product, the pharmacology package is considered adequate and the dosing of tremelimumab is considered appropriate with the proposed modification to use weight-based dosing for patients below 34kg, as discussed above.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study(ies)

See section 2.3.2.

<div style=\"page-break-after: always\"></div>

## 2.4.2. Main study(ies)

POSEIDON: A phase III, randomised, multicentre, open-label, comparative global study to determine the efficacy of durvalumab or durvalumab and tremelimumab in combination with platinum-based chemotherapy for firstline treatment in patients with metastatic non-small cell lung cancer

Figure 16. Study design - POSEIDON

<!-- image -->

- ·FollowedbyDurvalumab15o0mgQ4Wuntildiseaseprogression

*Investigator choiceofchemotherapy,StandardofCare(SoC):NsQ(Pemetrexed+PlatinumorAbraxane+Carbo);SQ(Gemcitabine+Platinum orAbraxane+Carbo) **ByBICR

Dual primary endpoints were BICR-assessed PFS according to RECIST 1.1 and OS compared between arms 2 and 3 (D+SoC vs. SoC) from the ITT population. As key secondary endpoints, BICR-PFS and OS comparisons were done between arms 1 and 3 (T+D+SoC vs. SoC), also in the ITT.

Tumour scans and response assessment according to RECIST 1.1 were performed at screening (as baseline) with follow-ups at week 6 ±1 week from the date of randomization, at week 12 ±1 week from the date of randomization, and then every 8 weeks ±1 week until radiological disease progression.

The applicant states that although the study was open-label, the study team was blinded to aggregate treatment information, and during the programming and preparation of statistical outputs, data were dummy blinded prior to database lock and study unblinding.

Crossover was not permitted as part of the study.

## Methods

## · Study Participants

POSEIDON was conducted at study centres in North and Latin America, Europe, Asia Pacific and Africa. Patients were recruited from 142 centres across Brazil (13 centres), Bulgaria (6 centres), Germany (10 centres), Hong Kong (1 centre), Hungary (5 centres), Japan (18 centres), South Korea (9 centres), Mexico (9 centres), Peru (5 centres), Poland (4 centres), Russia (9 centres), South Africa (7 centres), Taiwan (10 centres), Thailand (6 centres), Ukraine (10 centres), United Kingdom (5 centres), United States (12 centres) and Vietnam (3 centres).

## Key inclusion criteria:

- Histologically or cytologically documented Stage IV NSCLC not amenable to curative surgery or radiation (according to Version 8 of the IASLC Staging Manual in Thoracic Oncology; IASLC Staging Manual in Thoracic Oncology).

<div style=\"page-break-after: always\"></div>

- Patients must have tumours that lack activating EGFR mutations (e.g., exon 19 deletion or exon 21 L858R, exon 21 L861Q, exon 18 G719X, or exon 20 S768I mutation) and ALK fusions. If a patient has squamous histology or is known to have a tumour with a KRAS mutation, then EGFR and ALK testing is not required.
- No prior chemotherapy or any other systemic therapy for metastatic NSCLC. Patients who have received prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for advanced disease are eligible, provided that progression has occurred &gt;12 months from end of last therapy.
- Tumour PD-L1 status, confirmed by a reference laboratory using the Ventana SP263 PD-L1 immunohistochemistry (IHC) assay, must be known prior to randomization. As such, all patients must be able to undergo a fresh tumour biopsy during screening or to provide an available tumour sample taken &lt;3 months prior to enrollment.
- ECOG performance status of 0 or 1 at enrollment and randomization.
- At least 1 lesion, not previously irradiated, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have a short axis ≥ 15 mm) with CT or MRI and that is suitable for accurate repeated measurements as per RECIST 1.1 guidelines.
- No prior exposure to immune-mediated therapy including, but not limited to, other anti-CTLA4, anti-PD-1, anti-PD-L1, and anti-PD-L2 antibodies, excluding therapeutic anticancer vaccines.
- Adequate hepatic, renal and bone-marrow function.

## Key exclusion criteria:

- Mixed small-cell lung cancer and NSCLC histology or sarcomatoid variant.
- Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable.
- No radiation therapy is allowed, unless it is 1) definitive radiation that had been administered at least 12 months prior, 2) palliative radiation to brain, with associated criteria for stability or lack of symptoms, or 3) palliative radiation to painful bony lesions
- Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of the IP. Note: Local surgery of isolated lesions for palliative intent is acceptable.
- History of allogenic organ transplantation.
- Uncontrolled intercurrent illness
- Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.]). Exceptions: vitiligo, alopecia, hypothyroidism, chronic skin conditions that do not require systemic therapy, celiac disease controlled by diet alone.
- History of leptomeningeal carcinomatosis.

<div style=\"page-break-after: always\"></div>

- Brain metastases or spinal cord compression unless the patient's condition is stable (asymptomatic; no evidence of new or emerging brain metastases) and off steroids for at least 14 days prior to the start of the IP.
- History of active primary immunodeficiency.
- Active infection including tuberculosis, HBV, HCV and HIV 1/2.
- Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab or tremelimumab, except physiological dose of systemic corticosteroids (&lt; 10 mg/day prednisone or equivalent).
- Receiving live attenuated vaccine within 30 days before or after the start of Imjudo or durvalumab.
- Pregnant or breastfeeding women.

## Treatments

The full dosing scheme of POSEIDON is presented in Table.

Table 18. Dosing scheme - POSEIDON

| Treatmentarms                        | Duringchemotherapy(combination)stage 1 cycle=3weeks(21days)   | Duringchemotherapy(combination)stage 1 cycle=3weeks(21days)   | Duringchemotherapy(combination)stage 1 cycle=3weeks(21days)   | Duringchemotherapy(combination)stage 1 cycle=3weeks(21days)   | Post-chemotherapy(maintenance)stage 1cycle=4weeks(28days)   | Post-chemotherapy(maintenance)stage 1cycle=4weeks(28days)   | Post-chemotherapy(maintenance)stage 1cycle=4weeks(28days)   |
|--------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
|                                      | Cycle 1 Week 0                                                | Cycle 2 Week 3                                                | Cycle 3 Week 6                                                | Cycle 4 Week 9                                                | Week12                                                      | Week 16                                                     | Week20toPD                                                  |
| T+D+SoCchemotherapy (TreatmentArm 1) | T+D+SoC                                                       | T+D+SoC                                                       | T+D+SoC                                                       | T+D+SoC                                                       | D +pemetrexeda                                              | ++⊥ pemetrexeda                                             | D+pemetrexeda                                               |
| D+SoCchemotherapy (Treatment Arm 2)  | D + SoC                                                       | D + SoC                                                       | D+ SoC                                                        | D + SoC                                                       | D+pemetrexeda                                               | D + pemetrexeda                                             | D+pemetrexeda                                               |
| SoCchemotherapyalone （TreatmentArm3) | SoC                                                           | SoC                                                           | SoC                                                           | SoCc                                                          | pemetrexeda                                                 | pemetrexeda                                                 | pemetrexeda                                                 |

T=tremelimumab; D=durvalumab; SoC=standard of care chemotherapy; PD=progressive disease.

The chosen platinum doublet was prespecified at randomisation before first study treatment and subsequent changes of regimen were not allowed, although switch between cisplatin and carboplatin were permitted. The following histology-based chemotherapy regimens were applicable to all 3 treatment arms:

- Nab-paclitaxel + carboplatin (squamous and non-squamous histologies): Nab-paclitaxel 100 mg/m2 on Days 1, 8, and 15 of each 21-day cycle + carboplatin AUC 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (i.e., 4 cycles for the T + D + SoC chemotherapy and D + SoC chemotherapy arms and 4 to 6 cycles for the SoC chemotherapy arm).
- Gemcitabine + cisplatin (squamous histology only): Gemcitabine 1000 or 1250 mg/m2 via IV infusion on Days 1 and 8 of each 21-day cycle + cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (i.e., 4 cycles for the T + D + SoC chemotherapy and D + SoC chemotherapy arms and 4 to 6 cycles for the SoC chemotherapy arm).
- Gemcitabine + carboplatin (squamous histology only): Gemcitabine 1000 or 1250 mg/m2 via IV infusion on Days 1 and 8 of each 21-day cycle + carboplatin AUC 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (i.e., 4 cycles for the T + D + SoC chemotherapy and D + SoC chemotherapy arms and 4 to 6 cycles for the SoC chemotherapy arm).
- Pemetrexed + carboplatin (non-squamous histology only): Pemetrexed 500 mg/m2 and carboplatin AUC 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (i.e., 4

<div style=\"page-break-after: always\"></div>

cycles for the T + D + SoC chemotherapy and D + SoC chemotherapy arms and 4 to 6 cycles for the SoC chemotherapy arm); then continued pemetrexed 500 mg/m2 maintenance (i.e., Q4W for the T + D + SoC chemotherapy and D + SoC chemotherapy arms.

- Pemetrexed + cisplatin (non-squamous histology only): Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (i.e., 4 cycles for the T + D + SoC chemotherapy and D + SoC chemotherapy arms and 4 to 6 cycles for the SoC chemotherapy arm); then continued pemetrexed 500 mg/m2 maintenance (i.e., Q4W for the T + D + SoC chemotherapy and D + SoC chemotherapy arms.

*Note: For patients with non-squamous histology who received pemetrexed during induction, pemetrexed maintenance therapy could have been given either Q3W or Q4W dependent on investigator decision and local standards.

Arm 1: During chemotherapy, tremelimumab 75 mg IV Q3W + durvalumab 1500 mg IV Q3W + chemotherapy Q3W for 4 cycles. A fifth dose of tremelimumab 75 mg was to be given at Week 16 alongside durvalumab Dose 6. Post chemotherapy, durvalumab 1500 mg IV Q4W.

Arm 2: During chemotherapy, durvalumab 1500 mg IV Q3W and chemotherapy Q3W for 4 cycles. Post chemotherapy, durvalumab 1500 mg IV Q4W.

Arm 3: Chemotherapy Q3W alone for 4 cycles (any of the abovementioned 5 regimens). Patients could receive additional 2 cycles (a total of 6 cycles post-randomization), as clinically indicated, at Investigator's discretion.

The study design did not allow cross over among treatment arms.

Duration of treatment: Patients were treated until clinical progression or radiological progression unless there was unacceptable toxicity, withdrawal of consent, or another discontinuation criterion was met.

Reductions and delays: Dose reductions of durvalumab and tremelimumab were not permitted. SoCrelated toxicity management and dose adjustment, including dose reductions and delays, should be performed as indicated in the local prescribing information for the relevant agent. In the event that an AE could reasonably be attributed to SoC, dose adjustment of SoC was attempted before modifying the administration of durvalumab ± tremelimumab. In the event that SoC was delayed, durvalumab ± tremelimumab was also delayed.

Switch of platinum agent: In the event of unfavourable tolerability, patients could switch between cisplatin and carboplatin therapy at any point on study (assuming eligibility for the switched therapy is met).

Treatment beyond progression: Patients in arms 1 and 2 with objective radiological progression who, in the investigator's opinion, continued to receive benefit from their assigned treatment and who met the criteria for treatment in the setting of (PD) could continue to receive durvalumab monotherapy for as long as they were gaining clinical benefit.

Retreatment: Patients in Treatment Arm 1 (T + D + SoC chemotherapy) with radiological progression who, in the investigator's opinion, continued to receive benefit from their assigned treatment and who met the criteria for retreatment in the setting of PD, could have retreatment with durvalumab + tremelimumab combination therapy (only once).

*Note: For patients randomized to Treatment Arm 3, treatment beyond progression and retreatment was not permitted.

<div style=\"page-break-after: always\"></div>

## Objectives

The study objectives and criteria for evaluation of study POSEIDON are presented in Table 19.

Table 19. Objectives and endpoints - POSEIDON

| Objective                                                                                                                                                                                             | Endpoints/variables                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| To assess the efficacy of durvalumab monotherapy + SoC chemotherapy comparedwithSoC chemotherapy alone in terms of PFS and OS in all patients                                                         | PFSin all patients using BICR assessments according to RECIST 1.1 OS in all patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Secondary                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| To assess the efficacy of durvalumab + tremelimumab combination therapy + SoC chemotherapy compared with SoC chemotherapy alone in terms of PFS and OS                                                | PFS in all patients using BICR assessments according to RECIST 1.1 (key secondary objective) OS in all patients (key secondary objective)                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Tofurther assesstheefficacyof durvalumab+ tremelimumabcombination therapy + SoC chemotherapy compared with SoC chemotherapy alone in terms of PFS, OS, ORR, BOR, DoR, APF12 and PFS2                  | PFS in patients with PD-L1 TC <50%, patients with PD-L1 TC <25% and patients with PD-L1 TC <1% using BICR assessments according to RECIST 1.1 OS in patients with PD-L1 TC <50%, patients with PD-L1 TC <25% and patients with PD-L1 TC <1% ORR, DoR, BOR and APF12 in patients with PD-L1 TC <50%,patients with PD-L1 TC <25%, patients with PD-L1 TC <1% and all patients using BICR assessments according to RECIST 1.1 PFS2 in patients with PD-L1 TC <50%, patients with PD-L1 TC <25%, patients with PD-L1 TC <1% and all patients using local standard clinical practice  |
| Tofurther assesstheefficacyof durvalumab monotherapy+SoCchemotherapy compared withSoC chemotherapy alone in terms of PFS. OS,ORR,DoR,BOR,APF12andPFS2                                                 | PFS in patients with PD-L1 TC <50%, patients with PD-L1 TC <25% and patients with PD-L1 TC <1% using BICR assessments according to RECIST 1.1 OS in patients with PD-L1 TC <50%, patients with PD-L1 TC <25% and patients with PD-L1 TC <1% ORR, DoR, BOR and APF12 in patients with PD-L1 TC <50%, patients with PD-L1 TC <25%, patients with PD-L1 TC <1% and all patients using BICR assessments according to RECIST 1.1 PFS2 in patients with PD-L1 TC <50%, patients with PD-L1 TC <25%, patients with PD-L1 TC <1% and all patients using local standard clinical practice |
| To assess the efficacy of durvalumab + tremelimumabcombination therapy+SoC chemotherapy compared with durvalumab monotherapy + SoC chemotherapy in terms of PFS, OS and ORR                           | PFS and ORR in patients with PD-L1 TC <50%, patients with PD-L1 TC <25%, patients with PD-L1 TC <1% and all patients using BICR assessments according to RECIST 1.1 OS in patients with PD-L1 TC <50%, patients with PD-L1 TC <25%, patients with PD-L1 TC <1% and all patients                                                                                                                                                                                                                                                                                                  |
| Toassess the associationof TMBwith the efficacy of durvalumab+tremelimumab combination therapy+SoC chemotherapy compared with SoC chemotherapy alone in terms ofPFS, OS,ORR, BOR, DoR, APF12 and PFS2 | PFS, ORR, BOR, DoR, APF12 in patients with TMB high using BICR assessments according to RECIST 1.1 PFS2 in patients with TMB high using local standard clinical practice OS in patients with TMB high                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| Objective                                                                                                                                                                                                                                                                                                       | Endpoints/variables                                                                                                                                                                                  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Toassessthe associationof TMBwith the efficacyofdurvalumab+tremelimumab combination therapy+SoC chemotherapy compared with durvalumab monotherapy + SoC chemotherapy in terms of PFS, OS, ORR, BOR, DoR,APF12 and PFS2                                                                                          | PFS, ORR, BOR, DoR,APF12 in patients with TMB high using BICR assessments according to RECIST 1.1 PFS2 in patients with TMB high using local standard clinical practice OS in patients with TMB high |
| ToassesstheassociationofTMBwiththe efficacy of durvalumab monotherapy+SoC chemotherapy compared with SoC chemotherapy in termsofPFS,OS,ORR,BOR,DoR, APF12andPFS2                                                                                                                                                | PFS,ORR, BOR,DoR,APF12 in patients with TMB high using BICR assessments according to RECIST 1.1 PFS2 in patients with TMB high using local standard clinical practice OS in patients with TMB high   |
| To assess the PK of durvalumab + tremelimumabcombinationtherapy and durvalumab monotherapy                                                                                                                                                                                                                      | Concentrations of durvalumab and tremelimumab                                                                                                                                                        |
| Toinvestigate the immunogenicity of durvalumab and tremelimumab                                                                                                                                                                                                                                                 | Presence of ADAs for durvalumab and tremelimumab                                                                                                                                                     |
| To assess disease-related symptoms and HRQoL in patients treated with durvalumab + tremelimumab combination therapy+SoC chemotherapy and durvalumab monotherapy + SoC chemotherapy compared with SoC chemotherapy alone using the EORTC QLQ-C30v3,the QLQ-LC13module,and WHO/ECOG performancestatus assessments | EORTC QLQ-C30 EORTC QLQ-LC13 Changes inWHO/ECOG performance status                                                                                                                                   |
| Safety                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                      |
| To assess the safety and tolerability profile of durvalumab+tremelimumabcombination therapy + SoC chemotherapy and durvalumab monotherapy + SoC chemotherapy compared withSoC chemotherapy alone                                                                                                                | AEs, physical examinations, laboratory findings, and vital signs                                                                                                                                     |

## Outcomes/endpoints

Efficacy endpoints in POSEIDON were defined as presented in Table 20.

Table 20. Definitions of efficacy in POSEIDON

| Endpoint   | Definition                                                                                                                                                                                                                                                                 |
|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| OS         | Time from the date of randomization until death due to any cause.                                                                                                                                                                                                          |
| PFS a      | Time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomized therapy or receives another anticancer therapy prior to progression. |
| ORR a      | The percentage of patients with at least 1 visit response of complete response (CR) or partial response (PR).                                                                                                                                                              |
| DoR a      | The time from the date of first documented response until the first date of documented progression or death in the absence of disease progression.                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| Endpoint                                                  | Definition                                                                                                                                                                                                                                                        |
|-----------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BOR a                                                     | The best response a patient has had following randomization, but prior to starting any subsequent cancer therapy and up to and including RECIST 1.1 progression or the last evaluable assessment in the absence of RECIST 1.1 progression, as determined by BICR. |
| AFP12 a                                                   | The Kaplan-Meier estimate of PFS at 12 months.                                                                                                                                                                                                                    |
| PFS2 b                                                    | The time from the date of randomization to the earliest of the progression event subsequent to that used for the endpoint PFS or death.                                                                                                                           |
| PROs (EORTC QLQ-C30, EORTC QLQ-LC13, EQ-5D-5L, PRO-CTCAE) | EORTC QLQ-C30 and EORTC QLQ-LC13: time to deterioration, symptom improvement rate, HRQoL/function improvement rate. EQ-5D-5L: weighted health state index. PRO-CTCAE: AEs of specific CTCAE symptoms.                                                             |

## Sample size

The study will enrol approximately 2000 patients to randomize approximately 1000 patients in a 1:1:1 ratio to durvalumab + tremelimumab combination therapy + SoC chemotherapy, durvalumab monotherapy + SoC chemotherapy, or SoC chemotherapy alone (approximately 333 patients in each treatment arm), including at least 250 patients in each treatment arm with PD-L1 TC &lt;50%.

The study is sized for dual primary endpoints to characterize the PFS and OS benefits of durvalumab monotherapy + SoC chemotherapy versus SoC chemotherapy alone in the intent-to- treat (ITT) population.

Dual Primary Endpoints:

Durvalumab monotherapy + SoC chemotherapy versus SoC chemotherapy alone (PFS in ITT population): Assuming the true PFS HR is 0.67 and the median PFS in SoC chemotherapy alone arm is 6 months, 497 PFS events from the global cohort (75% maturity) will provide greater than 90% power to demonstrate statistical significance at the 2-sided alpha level of 0.9% (with overall alpha for PFS 1%), allowing for 1 interim analysis conducted at approximately 80% of the target events. The smallest treatment difference that is statistically significant will be an HR of 0.79. Assuming a recruitment period of 16 months, this analysis is anticipated to be 25 months from FPI.

Durvalumab monotherapy + SoC chemotherapy versus SoC chemotherapy alone (OS in ITT population): Assuming the true OS HR is 0.7 and the median OS in SoC arm is 12.9 months, 532 OS events (80% maturity) will provide greater than 90% power to demonstrate statistical significance at the 2-sided alpha level of a 3.3% (with overall alpha for OS 4%), allowing for 3 interim analyses conducted at approximately 45%, 61% and 84% of the target events. The smallest treatment difference that is statistically significant will be an HR of 0.83. Assuming a recruitment period of 16 months, this analysis is anticipated to be 46 months from FPI.

Key secondary Endpoints:

Durvalumab + tremelimumab combination therapy + SoC chemotherapy versus SoC chemotherapy alone (PFS in ITT population): Assuming the true PFS HR is 0.51 and the median

<div style=\"page-break-after: always\"></div>

PFS in SoC chemotherapy alone arm is 6 months, 465 PFS events from the global cohort (70% maturity) will provide greater than 90% power to demonstrate statistical significance at the 2-sided alpha level of 0.9% (with overall alpha for PFS 1%), allowing for 1 interim analysis conducted at approximately 80% of the target events (information fraction). The smallest treatment difference that is statistically significant will be an HR of 0.78. Assuming a recruitment period of 16 months, this analysis is anticipated to be 25 months from FPI.

Durvalumab + tremelimumab combination therapy + SoC chemotherapy versus SoC chemotherapy alone (OS in ITT population): Assuming the true OS HR is 0.7 and the median OS in SoC arm is 12.9 months, 532 OS events (80% maturity) will provide greater than 90% power to demonstrate statistical significance at the 2-sided alpha level of a 3.3% (with overall alpha for OS 4%), allowing for 3 interim analyses conducted at approximately 45%, 61% and 84% of the target events (information fraction). The smallest treatment difference that is statistically significant will be an HR of 0.83. Assuming a recruitment period of 16 months, this analysis is anticipated to be 46 months from FPI.

## Randomisation and Blinding (masking)

The randomization scheme was produced by a computer software program that incorporates a standard procedure for generating randomization numbers. One randomization list was produced for each of the randomization stratum. A blocked randomization was generated, and all centers used the same list to minimize any imbalance in the number of patients assigned to each treatment arm. Patients were identified to the IVRS/IWRS per country regulations. Randomization codes were assigned strictly sequentially, within each stratum, as patients become eligible for randomization. Patients who fulfill all of the inclusion criteria and none of the exclusion criteria were randomized in a 1:1:1 ratio according to the following stratification scheme:

- PD-L1 tumour expression status (PD-L1 expression on at least 50% of tumour cells [PD-L1 TC ≥ 50%] versus PD-L1 TC &lt;50%)
- Disease stage (Stage IVA versus Stage IVB)
- Histology (non-squamous versus squamous)

## · Blinding (masking)

The study is open label. A BICR of images will be performed. Results of these independent reviews will not be communicated to Investigators, and the management of patients will be based solely upon the results of the RECIST 1.1 assessment conducted by the Investigator. The BICR of all radiological scans will be performed to derive the ORR, PFS, DoR, BoR, and APF12 endpoints according to RECIST 1.1. The BICR will include assessment by RECIST 1.1. The imaging scans will be reviewed by 2 independent radiologists and will be adjudicated, if required, by a third independent radiologist who will choose the assessments of 1 of the 2 primary reviewers.

This study will use an external Independent Data Monitoring Committee (IDMC) to assess ongoing safety analyses as well as the interim efficacy analysis.

<div style=\"page-break-after: always\"></div>

## Statistical methods

## Full analysis set

The full analysis set (FAS) will include all randomized patients. Treatment arms were to be compared on the basis of randomized study treatment, regardless of the treatment actually received. Patients who were randomized but did not subsequently go on to receive study treatment were included in the analysis in the treatment arm to which they were randomized.

## Analysis of primary and secondary endpoints

## Progression-free survival

The dual primary PFS analysis was to be based on the BICR tumour assessments according to RECIST 1.1. The full analysis set will be used. The analysis used a stratified log-rank test adjusting for PD-L1 tumour expression (PD-L1 ≥ 50% versus PD-L1 &lt;50%), histology (squamous versus non-squamous), and disease stage (Stage IVA and Stage IVB) for generation of the p-value. The covariates in the statistical modelling were to be based on the values entered into interactive voice response system (IVRS) at randomization, even if it is subsequently discovered that these values were incorrect.

The hazard ratio (HR) and its CI will be estimated from a stratified Cox proportional hazards model (with ties = Efron and PD-L1 tumour expression (PD-L1 ≥ 50% versus PD-L1 &lt;50%), histology (squamous versus non-squamous), and disease stage (Stage IVA and Stage IVB) included in the STRATA statement) and the CI calculated using a profile likelihood approach.

Key secondary PFS analysis was to be performed using the same methodology as for the dual primary PFS analysis described above.

Kaplan-Meier plots of PFS were to be presented by treatment arm and PD-L1 tumour status and TMB subgroup, where appropriate. Summaries of the number and percentage of subjects experiencing a PFS event and the type of event (RECIST 1.1 or death) were to be provided along with median PFS for each treatment. The assumption of proportionality was to be assessed.

Censoring rules for PFS: Subjects who have not progressed or died at the time of analysis were to be censored at the time of the latest date of assessment from their last evaluable RECIST 1.1 assessment. However, if the subject progresses or dies after two or more missed visits, the subject will be censored at the time of the latest evaluable RECIST 1.1 assessment prior to the two missed visits (Note: NE visit is not considered as missed visit). If the subject has no evaluable visits or does not have baseline data they will be censored at Day 1 unless they die within two visits of baseline (12 weeks plus 1 week allowing for a late assessment within the visit window), in which case the date of death is used when deriving PFS.

Sensitivity analyses: The following sensitivity analyses will be performed for the treatment comparisons of the dual primary and key secondary endpoints based on the FAS:

- A sensitivity analysis will be performed to assess possible evaluation-time bias that may be introduced if scans are not performed at the protocol-scheduled time points. The midpoint between the time of progression and the previous evaluable RECIST assessment (using the final date of the assessment) will be analysed using a stratified log-rank test.
- Attrition bias will be assessed by repeating the dual primary/key secondary PFS analysis except that the actual PFS event times, rather than the censored times, of subjects who progressed or died in the absence of progression immediately following two or more non-evaluable tumour assessments will be included. In addition, and within the same sensitivity analysis, subjects who take subsequent therapy (note that for this analysis radiotherapy is not considered a

<div style=\"page-break-after: always\"></div>

subsequent anticancer therapy) prior to their last evaluable RECIST assessment or progression or death will be censored at their last evaluable assessment prior to taking the subsequent therapy.

- Ascertainment bias will be assessed by analysing the site investigator data. The stratified logrank test will be repeated on the programmatically derived PFS using the site investigator data.
- An additional sensitivity analysis will be performed with the covariates used in the statistical model derived from eCRF data rather than using the values from IVRS.

Consistency of treatment effect between subgroups: Interactions between treatment and stratification factors will be tested to rule out any qualitative interaction using the approach of Gail and Simon (Gail and Simon 1985). This test will be performed separately for the treatment comparisons of the dual primary and key secondary endpoints based on the FAS.

## Overall survival

OS will be analysed using stratified log-rank tests, using the same methodology as described for the PFS endpoints.

The assumption of proportionality will be assessed in the same way as for PFS.

Censoring rules for OS: Any subject not known to have died at the time of analysis will be censored based on the last recorded date on which the subject was known to be alive.

Sensitivity analysis and additional supportive summaries: A three-component stratified maxcombo test will be used as a sensitivity analysis with the same stratification factors as the primary analysis.

A sensitivity analysis for OS will examine the censoring patterns to rule out attrition bias with regards to the treatment comparisons of the dual primary and key secondary endpoints, achieved by a KaplanMeier plot of time to censoring where the censoring indicator of OS is reversed.

A sensitivity analysis may be conducted to assess for the potential impact of COVID-19 deaths on OS.

Exploratory analyses of OS adjusting for the impact of subsequent immunotherapy or other investigational treatment may be performed if a sufficient proportion of subjects switch.

## Objective response rate

The ORR will be compared using logistic regression models adjusting for the same factors as the PFS endpoints. The results of the analysis will be presented in terms of an odds ratio (an odds ratio greater than 1 will favor the experimental arms) together with its associated profile likelihood 95% CI (e.g. using the option 'LRCI' in SAS procedure GENMOD) and p-value (based on twice the change in loglikelihood resulting from the addition of a treatment factor to the model).

If there are not enough responses for a meaningful analysis using logistic regression then a Fisher's exact test using mid p-values will be presented.

## Interim analysis

Interim analyses for efficacy will be performed by IDMC as described below: One interim analysis of PFS will be performed when approximately 80% of the target PFS events have occurred across Arms 2 and 3. Three interim analyses of OS will be performed; the first at the time of the interim PFS analysis (approximately 45% of the target OS events in Arms 2 and 3), the second at the time of the primary PFS analysis (approximately 61% of the target OS events in Arms 2 and 3) and the third when approximately 84% of the target OS events have occurred in Arms 2 and 3. The interim analyses will

<div style=\"page-break-after: always\"></div>

be performed for the analyses specified in MTP. It is expected that global recruitment will have completed prior to the results of the interim analyses being available.

The Lan DeMets spending function that approximates an O'Brien Fleming approach will be used to account for multiplicity introduced by including the one interim analysis for superiority. The boundaries for the treatment comparison will be derived based upon the exact number of events at the time of analyses.

## Multiple testing procedures for controlling the type 1 error rate

In order to strongly control the type I error at 5% (2-sided), a multiple testing procedure (MTP) with gatekeeping strategy will be used across the dual primary endpoints and the secondary endpoints included in MTP.

The dual primary endpoints: PFS and OS (durvalumab monotherapy +SoC chemotherapy versus SoC chemotherapy alone) in the ITT population (with PFS using BICR assessments per RECIST 1.1).

The key secondary endpoints: PFS and OS (durvalumab + tremelimumab combination therapy + SoC chemotherapy and SoC chemotherapy alone) in the ITT population (with PFS using BICR assessments per RECIST 1.1).

Hypotheses will be tested using a multiple testing procedure with an alpha-exhaustive recycling strategy (Burman et al 2009). With this approach, hypotheses will be tested in a pre-defined order as outlined in Figure 6. According to alpha (test mass) splitting and alpha recycling, if the higher level hypothesis in the MTP is rejected for superiority, the next lower level hypothesis will then be tested. The test mass that becomes available after each rejected hypothesis is recycled to lower level hypotheses not yet rejected. This testing procedure stops when the entire test mass is allocated to non- rejected hypotheses. Implementation of this pre-defined ordered testing procedure, including recycling, will strongly control type I error at 5% (2-sided), among all the dual primary endpoints and the secondary endpoints included in MTP.

## Figure 17. Multiple testing procedures for controlling the type 1 error rate

<div style=\"page-break-after: always\"></div>

<!-- image -->

Combo durvalumab + tremelimumab combination therapy + SoC chemotherapy; ITT Intent-to-treat; Mono durvalumab monotherapy + SoC chemotherapy; OS Overall survival; PFS Progression-free survival; SoC Standard of care; vs versus; bTMB20 high blood tumor mutational burden&gt;=20 mut/Mb; bTMB16 high blood tumor mutational burden &gt;=16 mut/Mb; bTMB12 high blood tumor mutational burden &gt;=12 mut/Mb.

## Amendment history

The following changes of analysis from protocol are based on CSP v4.0, dated 25-SEP-2018:

The statistical analysis plan (SAP) has been formulated to indicate that the following exploratory objective may not be produced, for the reason that the AZ imaging expert confirmed that AZ does not currently have the capacity of obtaining the data using irRECIST:

To explore irRECIST as an assessment methodology for clinical benefit of durvalumab + tremelimumab combination therapy + SoC chemotherapy and durvalumab monotherapy + SoC chemotherapy compared with SoC chemotherapy alone with assessment by BICR has been changed to a potential.

The analysis of expected duration of response (EDoR) was not a required analysis, so not included for DoR endpoints in the SAP. This is consistent with other durvalumab studies.

The analysis of comparison of APF12 between treatment arms is removed to be consistent with other durvalumab studies.

## Additional changes not included in SAP version 5.0

A post-hoc sensitivity analysis of ORR was added requiring confirmation of response no sooner than 4 weeks after the initial CR/PR was conducted.

Symptom improvement rate was analysed using logistic regression, using Proc Logistic instead of Proc Genmod.

## Results

<div style=\"page-break-after: always\"></div>

## · Participant flow

A total of 1807 patients were screened into the POSEIDON study: of these, 1013 patients were randomized in a 1:1:1 ratio into one of the study arms (T + D + SoC, D + SoC or SoC alone arms) at 142 study centres across 18 countries in North and Latin America, Europe, Asia Pacific, and Africa. Patient disposition is summarised in the following figure.

Figure 18. Patient disposition - POSEIDON

<!-- image -->

<div style=\"page-break-after: always\"></div>

Note: The category 'condition worsened' corresponds to 'disease progression'.

A total of 760 patients failed screening. The majority of them did so because of eligibility criteria, particularly concerning EGFR/ALK status (36% of all screen failures), missing PD-L1 status (19%), or investigator judgement (8%).

The proportions of patients who discontinued any study treatment on account of adverse events are nearly identical in the experimental T+D+SoC and D+SoC arms (23% in each) and nearly double the proportion of discontinuations from the control SoC arm (13%).

## Protocol deviations:

Table 21. Important protocol deviations - POSEIDON

|                                                                                                       | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|-------------------------------------------------------------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Important protocol deviationsa                                                                        | T+D+SoC (N=338)          | D+SoC (N=338)            | SoC (N=337)              | Total (N=1013)           |
| Number of patients with at least 1 important deviation                                                | 10 (3.0)                 | 6 (1.8)                  | 11 (3.3)                 | 27 (2.7)                 |
| Baseline RECIST 1.1 scan >42 daysbefore randomization                                                 | 1 (0.3)                  | 1 (0.3)                  | 1 (0.3)                  | 3 (0.3)                  |
| No baseline RECIST 1.1 assessment on or before date ofrandomization                                   | 0                        | 0                        | 1 (0.3)                  | 1 (0.1)                  |
| Received prohibited concomitant systemic anti-cancer medications (including other anti-cancer agents) | 0                        | 0                        | 1 (0.3)                  | 1 (0.1)                  |
| Patient deviatesfrom inclusion criteria 3,4 or 5, or from exclusion criteria5asper theCSP             | 2 (0.6)                  | 1 (0.3)                  | 3 (0.9)                  | 6 (0.6)                  |
| Patient randomized but who did not receive study treatment                                            | 7 (2.1)                  | 3 (0.9)                  | 6 (1.8)                  | 16 (1.6)                 |
| Patientrandomizedwhoreceived treatmentother than that towhich they wererandomized to                  | 1 (0.3)                  | 1 (0.3)                  | 0                        | 2 (0.2)                  |
| Number of patients with at least 1 COVID-19 related importantprotocol deviation                       | 0                        | 0                        | 0                        | 0                        |

Important deviations are before the start of treatment and during treatment.

Note that the same patient may have had more than 1 important protocol deviation.

One patient was randomized to the T + D + SoC treatment arm and received SoC but no durvalumab and tremelimumab, and

1 patient was randomized to the D + SoC treatment arm and received SoC chemotherapy but no durvalumab.

One patient was randomized to the T + D + SoC treatment arm but did not receive SoC. This was not considered a protocol deviation (the patient was included in the T + D + SoC treatment arm).

Percentages are calculated from number of patients in the full analysis set in that treatment group.

CSP=clinical study protocol; D=durvalumab; N=number of patients in treatment am; SoC=standard of care chemotherapy; RECIST 1.1=Response Evaluation Criteria in Solid Tumors, version 1.1; T=tremelimumab.

Data cut-off date: 12MAR2021.

## Recruitment

The first patient was screened on 01-JUN- 2017, and the first patient was randomized on 27-JUN2017.

The last patient was randomised on 19-SEP-2018.

The median duration of survival follow-up (DCO 12-MAR-2021) in all patients across the 3 treatment arms was 12.52 months (range: 0.0 to 44.5). The median duration of follow up in all patients in the T

<div style=\"page-break-after: always\"></div>

+ D + SoC arm was 13.63 months (range: 0.3 to 43.9), D + SoC was 12.73 months (range 0.0 to 44.5), and in the SoC alone arm was 11.17 months (range: 0.0 to 43.9).

## Conduct of the study

Table 22. Protocol versions with dates

| Clobal DocumentName                 | Version No   | Version Date   |
|-------------------------------------|--------------|----------------|
| D419MC00004 Clinical Study Protocol | V1.0         | 10Mar2017      |
| D419MC00004 Clmical Study Protocol  | V2.0         | 12 Dec2017     |
| D419MC00004 Clinical Study Protocol | V3           | 16Mar2018      |
| D419MC00004 Climical Study Protocol |              | 25 Sep 2018    |
| D419MC00004 Clinical Study Protocol | V5           | 20 Apr 2020    |

Table 23. Protocol amendments and other changes along study conduct - POSEIDON

| Amendment number/date                                   | Key details of amendment                                                                                                                                                                                                                                                                                              | Main reason(s) for amendment                                                                                                     |
|---------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| Original CSP (10 March 2017)                            | Original CSP (10 March 2017)                                                                                                                                                                                                                                                                                          | Original CSP (10 March 2017)                                                                                                     |
| Amendments1to3(afterfirstpatientrandomizedon27June2017) | Amendments1to3(afterfirstpatientrandomizedon27June2017)                                                                                                                                                                                                                                                               | Amendments1to3(afterfirstpatientrandomizedon27June2017)                                                                          |
| Amendment 1 Protocol version 2.0 12 December 2017       | A new inclusion criterion (8) regarding patient life expectancy was introduced.                                                                                                                                                                                                                                       | To align with other clinical studies in lung cancer                                                                              |
| Amendment 1 Protocol version 2.0 12 December 2017       | Modifications to inclusion criteria 2 regardinginformed consent) and 11 (now 12) regarding laboratory values                                                                                                                                                                                                          | Clarification                                                                                                                    |
| Amendment 1 Protocol version 2.0 12 December 2017       | Exclusion criterion 15 was divided into 2 criteria for spinal cord compression (now 15) and brain metastases (now 16) andfurther modifications added.                                                                                                                                                                 | Clarification                                                                                                                    |
| Amendment 1 Protocol version 2.0 12 December 2017       | The maintenance schedule for pemetrexed was changed to Q3W or Q4W for Treatment Arm 3 (SoC), dependent on investigator decision and local standards.                                                                                                                                                                  | To account for regional differences.                                                                                             |
| Amendment 1 Protocol version 2.0 12 December 2017       | Scheduleofassessmentsforthetreatment andretreatment periods was updated.                                                                                                                                                                                                                                              | Clarification and to align with other changes to the CSP                                                                         |
|                                                         | Newtext added todescribetreatment afterthefinaldata cut-off                                                                                                                                                                                                                                                           | Clarification                                                                                                                    |
|                                                         | Modifications to text regarding which assessments should be done during retreatment.                                                                                                                                                                                                                                  | Clarification                                                                                                                    |
|                                                         | It was clarified that one of theeligibilitycriteriafor retreatment was having completed 5 dosing cycles comprising thecombinationofdurvalumaband tremelimumabportion of the regimen.                                                                                                                                  | Toalignto thetreatmentschedule.                                                                                                  |
|                                                         | It was also clarified that a patient whose weight fell to 30 kg or below would receive weight-based dosing.                                                                                                                                                                                                           | Tobeconsistentwith therestofthetreatmentregimensin the protocol.                                                                 |
|                                                         | PD-L1TC<25%analysissetwasremovedfrom theobjectives and relevant sections of the CSP.                                                                                                                                                                                                                                  | It was initially included for potential analysis; however, no planned analysis was of interest at the time.                      |
| Amendment 2 Protocol version 3.0 16 March 2018          | Sample size was increased from 801 to 1000 and OS final analysis maturityincreasedfrom75%to80%.                                                                                                                                                                                                                       | To adequately power OS of PD-L1<50%population.                                                                                   |
| Amendment 2 Protocol version 3.0 16 March 2018          | A new sub-section (Section 1.3.2.4: Standard of Care) was added to Section 1.3.2 Overall risks.                                                                                                                                                                                                                       | To address MHRA recommendation to include warnings of ototoxicity and nephrotoxicity for chemotherapy regimens as per the SmPCs. |
| Amendment 2 Protocol version 3.0 16 March 2018          | Section3.8 (Restrictions)was updated as follows: An additional note was added to instruct investigators to advise Male patients to consider cryoconservation of sperm prior to treatment because of the possibility of infertility due to gemcitabine therapy. Contraception duration for SoC regimens was clarified. | MHRArecommendation                                                                                                               |
| Amendment 2 Protocol version 3.0 16 March 2018          | A requirement of 20 unstained sections was added to Section 5.5.1 (Collection of patient samples for stratification by PD-L1)                                                                                                                                                                                         | IncaseatissueblockwasnotsubmittedforPD-L1analysis                                                                                |

<div style=\"page-break-after: always\"></div>

| Amendment number/date                              | Keydetailsofamendment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Mainreason(s)foramendment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Amendment 3 Protocol version 4.0 25 September 2018 | Primaryandkeysecondaryobjectivesandendpointswere updated as follows: OS (D + SoC vs SoC) in the ITT population moved from secondarytodualprimaryobjective. PFS (T + D + SoC vs SoC) in the ITT population moved from dual primary tokey secondary objective OS (T + D+ SoC vs SoC) in the ITT population added as key secondary objective. OSandPFSinpatientswithPD-L1 TC<50%moved from key secondary to secondary endpoints The protocol was updated accordingly including power, critical values of HRs for PFS and OS analyses, projected number and percentage of PFS and OS events at interim/final analyses, projected alpha allocation at interim/final analyses andprojectedstudyduration. | OS remains the‘gold standard’endpoint for immunotherapies; emerging data inimmuno-oncology suggest that the treatment benefit of immunotherapies canmore stronglymanifest in OS comparedtoPFS(Borghaeiet al2015,Brahmer et al 2015, Fehrenbacher et al 2016).Furthermore, emerging data (KEYNOTE-189,KEYNOTE 407)indicatedtheimportance of OS data of PD-1/PD-L1 in combination with chemotherapy (Gandhiet al[KEYNOTE-189]2018;Paz-Areset al2018) It became evident during thecourse of the study that PD-L1 expression alone did not appear to fully explain the OS benefit seen in patients treated with immunotherapies (Carbone et al2017,Huiet al2017) |
| Amendment 3 Protocol version 4.0 25 September 2018 | PD-L1 TC<25% analysis set (removed in Amendment 1, Protocolversion2.0)nowreinstatedforefficacysecondary endpoints.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | To bring in line with PD-L1 TC<50% and TC<1%.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Amendment 3 Protocol version 4.0 25 September 2018 | Secondary objectives added to assess the association of TMB with the efficacy of D+SoC chemotherapy compared with SoC chemotherapy alone, T + D + SoC chemotherapy compared with SoC chemotherapy alone, and D + SoC chemotherapy compared with T + D + SoC chemotherapy.                                                                                                                                                                                                                                                                                                                                                                                                                          | Secondary endpoints added forTMBhighpatients interms ofPFS, OS,ORR,BOR,DoR,APF12andPFS2foreachtreatment comparison. Data from multiple recent studies suggested that TMB may play an important role as a biomarker for patient selection.                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Amendment 3 Protocol version 4.0 25 September 2018 | MTP was updated. One additional OS interim analysis was added at the timepoint of PFS interim analysis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | To reflect the updated primary/secondary endpoints.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| OS and all other data [12 March 2021])             | OS and all other data [12 March 2021])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | OS and all other data [12 March 2021])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Amendment 4 Protocol version 5.0 20 April 2020     | Updated overall risksfor durvalumab and tremelimumab therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | To align with latest durvalumab and tremelimumab IBs.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Amendment 4 Protocol version 5.0 20 April 2020     | Updated language based on the revised CSP template Appendix Hy's Law v3 to clarify how to identify and report case of potential Hy's law and Hy's Law cases.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | To align with the latest version of how to identify and report cases of potential Hy's law per SOP.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

A routine GCP inspection of study D419MC00004 (POSEIDON) was conducted at one investigational site in Germany (21-25 February 2022), the main CRO in the USA (11-17 March 2022), and the sponsor in Canada (21-25 March 2022). One critical finding was reported during the CRO inspection; major and minor findings were observed at all sites (see section 3.2).

<div style=\"page-break-after: always\"></div>

## Baseline data

## Table 24.Baseline and patient characteristics, ITT - POSEIDON

<!-- image -->

|                                           | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|-------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                                           | I+D+SoC (N=338)          | D+SoC (N=338)            | SoC (N=337)              | Total (N=1013)           |
| Age (years)a                              |                          |                          |                          |                          |
|                                           | 338                      | 338                      | 337                      | 1013                     |
| Mean (SD)                                 | 62.6 (9.43)              | 63.5 (9.10)              | 63.1 (9.87)              | 63.1 (9.47)              |
| Median (range)                            | 63.0 (27-87)             | 64.5 (32-87)             | 64.0 (32-84)             | 64.0 (27-87)             |
| Age group (years) n (%)a                  |                          |                          |                          |                          |
| ≥18 -<50                                  | 29 (8.6)                 | 27 (8.0)                 | 30 (8.9)                 | 86 (8.5)                 |
| ≥50 -<65                                  | 162 (47.9)               | 142 (42.0)               | 146 (43.3)               | 450 (44.4)               |
| ≥65 -<75                                  | 112 (33.1)               | 130 (38.5)               | 121 (35.9)               | 363 (35.8)               |
| ≥75                                       | 35 (10.4)                | 39 (11.5)                | 40 (11.9)                | 114 (11.3)               |
| Sex n (%)                                 |                          |                          |                          |                          |
| Male                                      | 269 (79.6)               | 253 (74.9)               | 248 (73.6)               | 770 (76.0)               |
| Female                                    | 69 (20.4)                | 85 (25.1)                | 89 (26.4)                | 243 (24.0)               |
| Race n (%)                                |                          |                          |                          |                          |
| White                                     | 205 (60.7)               | 182 (53.8)               | 179 (53.1)               | 566 (55.9)               |
| Black or African American                 | 8 (2.4)                  | 4 (1.2)                  | 8 (2.4)                  | 20 (2.0)                 |
| Asian                                     | 99 (29.3)                | 123 (36.4)               | 128 (38.0)               | 350 (34.6)               |
| Native Hawaiian or other Pacific Islander | 2 (0.6)                  | 0                        | 0                        | 2 (0.2)                  |
| AmericanIndianorAlaskaNative              | 12 (3.6)                 | 17 (5.0)                 | 9 (2.7)                  | 38 (3.8)                 |
| Other                                     | 12 (3.6)                 | 12 (3.6)                 | 13 (3.9)                 | 37 (3.7)                 |
| Ethnic group n (%)                        |                          |                          |                          |                          |
| Hispanic or Latino                        | 51 (15.1)                | 54 (16.0)                | 55 (16.3)                | 160 (15.8)               |
| Not Hispanic or Latino                    | 287 (84.9)               | 284 (84.0)               | 282 (83.7)               | 853 (84.2)               |
| Body Mass Index group (kg/m²) n (%)       |                          |                          |                          |                          |
| n                                         | 335                      | 338                      | 335                      | 1008                     |
| Underweight (<18.5)                       | 21 (6.3)                 | 23 (6.8)                 | 29 (8.7)                 | 73 (7.2)                 |
| Normal (18.5-25)                          | 184 (54.9)               | 187 (55.3)               | 181 (54.0)               | 552 (54.8)               |
| Overweight (25-30)                        | 93 (27.8)                | 96 (28.4)                | 91 (27.2)                | 280 (27.8)               |
| Obese (>30)                               | 37 (11.0)                | 32 (9.5)                 | 34 (10.1)                | 103 (10.2)               |
| Missing                                   | 3                        | 0                        | 2                        | 5                        |
| Smoking status n (%)                      |                          |                          |                          |                          |
| Never                                     | 59 (17.5)                | 84 (24.9)                | 79 (23.4)                | 222 (21.9)               |
| Current                                   | 84 (24.9)                | 64 (18.9)                | 66 (19.6)                | 214 (21.1)               |
| Former                                    | 195 (57.7)               | 190 (56.2)               | 191 (56.7)               | 576 (56.9)               |
| Missing                                   | 0                        | 0                        | 1 (0.3)                  | 1 (0.1)                  |

Age at randomization.

Percentages are calculated from number of patients in the full analysis set in that treatment group.

<div style=\"page-break-after: always\"></div>

## Table 25. Patient Recruitment by Region (Full Analysis Set)

|               | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|---------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Region        | T + D + SoC (N = 338)    | D + SoC (N = 338)        | SoC (N = 337)            | Total (N = 1013)         |
| Europe        | 151 (44.7)               | 129 (38.2)               | 123 (36.5)               | 403 (39.8)               |
| Asia          | 96 (28.4)                | 120 (35.5)               | 124 (36.8)               | 340 (33.6)               |
| North America | 44 (13.0)                | 46 (13.6)                | 40 (11.9)                | 130 (12.8)               |
| South America | 34 (10.1)                | 32 (9.5)                 | 41 (12.2)                | 107 (10.6)               |
| Africa        | 13 (3.8)                 | 11 (3.3)                 | 9 (2.7)                  | 33 (3.3)                 |

## Table 26. Disease characteristics at screening, ITT - POSEIDON

|                                | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|--------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                                | T+D+SoC (N=338)          | D+SoC (N=338)            | SoC (N=337)              | Total (N=1013)           |
| ECOG performance status*       |                          |                          |                          |                          |
| Normal activity (0)            | 110 (32.5)               | 109 (32.2)               | 119 (35.3)               | 338 (33.4)               |
| Restricted activity (1)        | 228 (67.5)               | 229 (67.8)               | 217 (64.4)               | 674 (66.5)               |
| Missing                        | 0                        | 0                        | 1 (0.3)                  | 1 (0.1)                  |
| AJCC Staging                   |                          |                          |                          |                          |
| IIIA                           | 1 (0.3)                  | 0                        | 0                        | 1 (0.1)                  |
| IIIB                           | 1 (0.3)                  | 1 (0.3)                  | 0                        | 2 (0.2)                  |
| IVA                            | 171 (50.6)               | 170 (50.3)               | 166 (49.3)               | 507 (50.0)               |
| IVB                            | 165 (48.8)               | 167 (49.4)               | 170 (50.4)               | 502 (49.6)               |
| Missing                        | 0                        | 0                        | 1 (0.3)                  | 1 (0.1)                  |
| Histology type                 |                          |                          |                          |                          |
| Squamous                       | 124 (36.7)               | 128 (37.9)               | 122 (36.2)               | 374 (36.9)               |
| Squamous cell carcinoma        | 124 (36.7)               | 127 (37.6)               | 122 (36.2)               | 373 (36.8)               |
| Other                          | 0                        | 1 (0.3)                  | 0                        | 1 (0.1)                  |
| Non-Squamous                   | 214 (63.3)               | 209 (61.8)               | 214 (63.5)               | 637 (62.9)               |
| Adenocarcinoma                 | 208 (61.5)               | 203 (60.1)               | 211 (62.6)               | 622 (61.4)               |
| Large cell carcinoma           | 2 (0.6)                  | 5 (1.5)                  | 3 (0.9)                  | 10 (1.0)                 |
| Other                          | 4 (1.2)                  | 1 (0.3)                  | 0                        | 5 (0.5)                  |
| Other                          | 0                        | 1 (0.3)                  | 0                        | 1 (0.1)                  |
| Missing                        | 0                        | 0                        | 1 (0.3)                  | 1 (0.1)                  |
| Overall disease classification |                          |                          |                          |                          |
| Metastaticb                    | 337 (99.7)               | 336 (99.4)               | 336 (99.7)               | 1009 (99.6)              |
| Locally advanced               | 0                        | 2 (0.6)                  | 0                        | 2 (0.2)                  |
| Missing                        | 1 (0.3)                  | 0                        | 1 (0.3)                  | 2 (0.2)                  |
| PD-L1 statusd                  |                          |                          |                          |                          |

<div style=\"page-break-after: always\"></div>

| TC<50%   | 237 (70.1)   | 243 (71.9)   | 240 (71.2)   | 720 (71.1)   |
|----------|--------------|--------------|--------------|--------------|
| TC≥50%   | 101 (29.9)   | 94 (27.8)    | 97 (28.8)    | 292 (28.8)   |
| Missing  | 0            | 1 (0.3)      | 0            | 1 (0.1)      |

- Locally advanced - patient has only locally advanced sites of disease.
- d of the eCRF.

Table 27. Distribution of patients according to PD-L1 status by SP263 assay

|                                                    | Number of patients   | Number of patients   | Number of patients   | Number of patients   |
|----------------------------------------------------|----------------------|----------------------|----------------------|----------------------|
|                                                    | Durva + Treme BoC    | Durva + SoC          | SoC                  | Total                |
| Patients randomised                                | 338                  | 338                  | 337                  | 1013                 |
| Patients included in full analysis set [a]         | 338                  | 338                  | 337                  | 1013                 |
| Patients included in PD-Ll TC<50t analysis set [b] | 237                  | 243                  | 240                  | 720                  |
| Patients excluded from PD-L1 IC<50t analysis set   | 101                  | 95                   | 97                   | 293                  |
| PD-L1 status PD-L1 TC >=50                         | 101                  | 94                   | 97                   | 292                  |
| No PD-L1 status                                    | 0                    | 1                    | 0                    | 1                    |
| Patients included in PD-Ll TC<25t analysis set [e] | 220                  | 221                  | 220                  | 661                  |
| Patients excluded from PD-L1 IC<25t analysis set   | 118                  | 117                  | 117                  | 352                  |
| PD-L1status PD-L1TC>=25                            | 118                  | 116                  | 117                  | 351                  |
| No PD-L1 status                                    | 0                    | 1                    | 0                    | 1                    |
| Patients included in PD-Ll TC<lk analysis set [d]  | 125                  | 113                  | 130                  | 368                  |
| Patients excluded from PD-Ll TC<l analysis set     | 213                  | 225                  | 207                  | 645                  |
|                                                    | 213                  | 224                  | 207                  | 644                  |
| No PD-L1 status                                    | 0                    | 1                    | 0                    | 1                    |

Table 28. Prior anticancer therapy, ITT - POSEIDON

|                             | Number(%)of patients   | Number(%)of patients   | Number(%)of patients   | Number(%)of patients   |
|-----------------------------|------------------------|------------------------|------------------------|------------------------|
| Previoustreatmentmodalities | T+D+SoC (N=338)        | D+SoC (N=338)          | SoC (N=337)            | Total (N=1013)         |
| Cytotoxic chemotherapy      | 13 (3.8)               | 11 (3.3)               | 14 (4.2)               | 38 (3.8)               |
| Adjuvant                    | 10 (3.0)               | 7 (2.1)                | 8 (2.4)                | 25 (2.5)               |
| Neo-adjuvant                | 2 (0.6)                | 1 (0.3)                | 0                      | 3 (0.3)                |
| Definitive                  | 1 (0.3)                | 2 (0.6)                | 7 (2.1)                | 10 (1.0)               |
| Missing                     | 1 (0.3)                | 1 (0.3)                | 0                      | 2 (0.2)                |
| Radiotherapy                | 50 (14.8)              | 43 (12.7)              | 52 (15.4)              | 145 (14.3)             |
| Adjuvant                    | 8 (2.4)                | 6 (1.8)                | 2 (0.6)                | 16 (1.6)               |
| Neo-adjuvant                | 1 (0.3)                | 2 (0.6)                | 2 (0.6)                | 5 (0.5)                |
| Palliative                  | 34 (10.1)              | 32 (9.5)               | 42 (12.5)              | 108 (10.7)             |
| Definitive                  | 9 (2.7)                | 2 (0.6)                | 7 (2.1)                | 18 (1.8)               |
| Not applicable              | 0                      | 1 (0.3)                | 0                      | 1 (0.1)                |

<div style=\"page-break-after: always\"></div>

## Numbers analysed

Table 29. Analysis sets - POSEIDON

|                                                                                  | Number of patients   | Number of patients   | Number of patients   | Number of patients   |
|----------------------------------------------------------------------------------|----------------------|----------------------|----------------------|----------------------|
|                                                                                  | T+D+SoC              | D+SoC                | SoC                  | Total                |
| Patients randomized                                                              | 338                  | 338                  | 337                  | 1013                 |
| Patients included in the full analysis set                                       | 338                  | 338                  | 337                  | 1013                 |
| Patients included in the PD-L1 TC<50% analysis set                               | 237                  | 243                  | 240                  | 720                  |
| Patients included in the PD-L1 TC<25% analysis set                               | 220                  | 221                  | 220                  | 661                  |
| Patients included in the PD-L1 TC<1% analysis set                                | 125                  | 113                  | 130                  | 368                  |
| PatientswithnoPD-L1status                                                        | 0                    | 1                    | 0                    | 1                    |
| Patients included in the bTMB20high analysis set                                 | 75                   | 77                   | 75                   | 227                  |
| Patients included in the bTMB16high analysis set                                 | 108                  | 94                   | 102                  | 304                  |
| Patients includedin thebTMB12 high analysis set                                  | 152                  | 137                  | 140                  | 429                  |
| Patients with no bTMB status                                                     | 61                   | 72                   | 96                   | 229                  |
| Patients included in the safety analysis set                                     | 330                  | 334                  | 333                  | 997                  |
| Patients excluded from the safety analysis set (did not receive study treatment) | 7                    | 3                    | 6                    | 16                   |
| Patients included in the PK analysis seta                                        | 327                  | 330                  | 9                    | 666                  |
| Patients excluded from thePK analysis setb                                       | 11                   | 8                    | 328                  | 347                  |
| No post-dose data available                                                      | 4                    | 5                    | 322                  | 331                  |

Table 30. Analysis Sets (Full Analysis Set)

|                                                          | Number (%) of Patients   | Number (%) of Patients   | Number (%) of Patients   | Number (%) of Patients   |
|----------------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                                                          | T + D + SoC (N = 338)    | D + SoC (N = 338)        | SoC (N = 337)            | Total (N = 1013)         |
| Patients with measurable disease at baseline per BICR    | 335 (99.1)               | 330 (97.6)               | 332 (98.5)               | 997 (98.4)               |
| Patients without measurable disease at baseline per BICR | 3 (0.9)                  | 8 (2.4)                  | 5 (1.5)                  | 16 (1.6)                 |

## Outcomes and estimation

The CSR reported the final analysis for the study, based on the DCO dates of 24-JUL-2019 (RECISTrelated endpoints) and 12-MAR-2021 (all other data).

At the time of the PFS analysis DCO date (24-JUL-2019), the PFS data had reached 75.7% maturity (511 PFS events from 675 patients in the D + SoC and SoC alone arms).

At the time of the OS analysis DCO (12-MAR-2021), the OS data had reached 81.3% maturity (549 OS events from 675 patients in the D + SoC and SoC alone arms).

Outcomes of the multiple testing procedure (MTP) - POSEIDON:

The primary OS endpoint (D+SoC vs SoC) in study POSEIDON did not meet statistical significance. However, the other primary PFS endpoint that compared the same arms showed statistical superiority and thus alpha was propagated to the next testing level, in which OS and PFS were evaluated as key secondary endpoints in the T+D+SoC vs. SoC arms.

<div style=\"page-break-after: always\"></div>

Table 31. Outcomes of the multiple testing procedure (MTP) - POSEIDON

<!-- image -->

Based on a Lan and DeMets alpha spending function with O'Brien Fleming type boundary with the actual number of events observed.

<div style=\"page-break-after: always\"></div>

## Key secondary endpoint: Overall survival

Table 32. Overall survival in the ITT, DCO 12-MAR-2021

|                                       | Number (%) of patients   | Number (%) of patients   |                   |
|---------------------------------------|--------------------------|--------------------------|-------------------|
|                                       | T + D + SoC (N = 338)    | D + SoC (N=338)          | SoC (N = 337)     |
| HR a,b , T+D+SoC vs SoC               | 0.77                     | 0.86                     |                   |
| 95% CI for HR                         | 0.650, 0.916             | 0.724, 1.016             |                   |
| 2-sided p-value c                     | 0.00304                  | 0.07581                  |                   |
| Death, n (%)                          | 251 (74.3)               | 264 (78.1)               | 285 (84.6)        |
| Censored patients, n (%)              | 87 (25.7)                | 74 (21.9)                | 52 (15.4)         |
| Still in survival follow-up d         | 80 (23.7)                | 65 (19.2)                | 40 (11.9)         |
| Terminated prior to death e           | 7 (2.1)                  | 9 (2.7)                  | 12 (3.6)          |
| Lost to follow-up                     | 2 (0.6)                  | 2 (0.6)                  | 2 (0.6)           |
| Withdrawn consent                     | 5 (1.5)                  | 6 (1.8)                  | 10 (3.0)          |
| Other                                 | 0                        | 1 (0.3)                  | 0                 |
| Median OS (months) f (95% CI) h       | 14.0 (11.7, 16.1)        | 13.1 (11.4, 14.7)        | 11.7 (10.5, 13.1) |
| OS rate at 12 months (%) f (95% CI) h | 54.8 (49.3, 60.0)        | 53.2 (47.7, 58.4)        | 49.1 (43.6, 54.4) |
| OS rate at 18 months (%) f (95% CI) h | 41.3 (36.0, 46.5)        | 38.1 (32.9, 49.3)        | 34.1 (29.0, 39.2) |
| OS rate at 24 months (%) f (95% CI) h | 32.9 (27.9, 37.9)        | 29.6 (24.8, 34.6)        | 22.1 (17.8, 26.8) |
| OS rate at 36 months (%) f (95% CI) h | 25.3 (20.8, 30.2)        | 20.3 (16.1, 25.0)        | 13.3 (9.8, 17.4)  |

a The HR and CI are estimated from a stratified Cox proportional hazards model with the Efron method to control for ties, the stratification factors PD-L1 (PDL1 ≥50% vs PD -L1 &lt;50%), histology (squamous vs non-squamous), and disease stage (Stage IVA vs Stage IVB) in the strata statement, and the CI calculated using a profile likelihood approach.

b A HR &lt;1 favors T + D + SoC chemotherapy to be associated with a longer OS than SoC chemotherapy alone.

c P-values were generated using the stratified log-rank test adjusting for PD-L1 (PDL1 ≥50% vs PD -L1 &lt;50%), histology (squamous vs non-squamous), and disease stage (Stage IVA vs Stage IVB) and using the Breslow approach for handling ties.

d Includes patients known to be alive at data cutoff.

e Includes patients with unknown survival status or patients who were lost to follow-up.

f Calculated using Kaplan-Meier technique.

Patients not known to have died at the time of analysis were censored based on the last recorded date on which the patient was known to be alive.

There was 1 patient who died 1 day prior to randomization and was censored at Day 1.

<div style=\"page-break-after: always\"></div>

Figure 19. Overall survival in the ITT, Kaplan-Meier curve, DCO 12-MAR-2021

<!-- image -->

Key secondary endpoint: Progression free survival by BICR

Table 33. PFS by BICR in the ITT, DCO 24-JUL-2019

|                                                              | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|--------------------------------------------------------------|--------------------------|--------------------------|--------------------------|
|                                                              | T + D + SoC (N = 338)    | D + SoC (N = 338)        | SoC (N = 337)            |
| HR a,b vs T+D+SoC vs SoC                                     | 0.72                     | 0.74                     |                          |
| 95% CI a                                                     | 0.600, 0.860             | 0.620, 0.885             |                          |
| 2-sided p-value c                                            | 0.00031                  | 0.00093                  |                          |
| Total number of events, n (%) d                              | 238 (70.4)               | 253 (74.9)               | 258 (76.6)               |
| RECIST 1.1 progression                                       | 174 (51.5)               | 193 (57.1)               | 202 (59.9)               |
| Death in the absence of progression                          | 64 (18.9)                | 60 (17.8)                | 56 (16.6)                |
| Censored patients, n (%)                                     | 100 (29.6)               | 85 (25.1)                | 79 (23.4)                |
| Censored RECIST progression e                                | 0                        | 0                        | 2 (0.6)                  |
| Censored death f                                             | 11 (3.3)                 | 8 (2.4)                  | 24 (7.1)                 |
| Progression-free at time of analysis                         | 83 (24.6)                | 72 (21.3)                | 43 (12.8)                |
| Lost to follow-up                                            | 0                        | 0                        | 0                        |
| Withdrawn consent                                            | 4 (1.2)                  | 3 (0.9)                  | 9 (2.7)                  |
| Discontinued study                                           | 2 (0.6)                  | 2 (0.6)                  | 1 (0.3)                  |
| Median progression free survival (months) g (95% CI) g       | 6.2 (5.0, 6.5)           | 5.5 (4.7, 6.5)           | 4.8 (4.6, 5.8)           |
| Progression free survival rate at 12 months (%) g (95% CI) g | 26.6 (21.7, 31.7)        | 24.4 (19.7, 29.5)        | 13.1 (9.3, 17.6)         |

<div style=\"page-break-after: always\"></div>

- k RECIST progression event occurred after 2 or more missed visits or within 2 visits of baseline without any evaluable visits or baseline data.
- l Death occurred after 2 or more missed visits in the absence of progression.
- m Calculated using the Kaplan-Meier technique.

RECIST version 1.1 based on BICR assessment.

There was 1 patient who died 1 day prior to randomization and was censored at Day 1.

Median duration of PFS follow-up in all patients was 5.39 months in the T+D+SoC arm, 4.86 months in the D+ SoC arm and 4.63 months in the SoC arm.

Figure 20. PFS by BICR in the ITT, Kaplan-Meier curve, DCO 24-JUL-2019

<!-- image -->

Number of patientsat risk

Numberof events/Numberof randomizedpatients

<!-- image -->

| Durva + Treme + SoC Durva + SoC   |   338 |   243 |   161 |   94 |   56 |   32 |   13 |   5 | 238/338   |
|-----------------------------------|-------|-------|-------|------|------|------|------|-----|-----------|
| Durva + Treme + SoC Durva + SoC   |   338 |   246 |   158 |   88 |   53 |   35 |   11 |   4 | 253/338   |
| Durva + Treme + SoC Durva + SoC   |   337 |   219 |   121 |   43 |   23 |   12 |    3 |   2 | 258/337   |

## Secondary endpoint: Progression free survival by investigator

Table 34. PFS by investigator in the ITT, DCO 24-JUL-2019

|                                                            | Durva + Treme + SoC Durva + SoC (N=338)   | (N=338)          | SoC (N=337)   |
|------------------------------------------------------------|-------------------------------------------|------------------|---------------|
| Total events [a], n (8)                                    | 247 (73.1)                                | 265 (78.4)       | 284 (84.3)    |
| RECIST progression                                         | 190 (56.2)                                | 200 (59.2)       | 221 (65.6)    |
| Target Lesions [b]                                         | 98 (29.0)                                 | 101 (29.9)       | 117 (34.7)    |
| Non Target Lesions [b]                                     | 67 (19.8)                                 | 53 (15.7)        | 78 (23.1)     |
| New Lesions [b]                                            | 114 (33.7)                                | 109 (32.2)       | 118 (35.0)    |
| Death in the absence of progression                        | 57 (16.9)                                 | 65 (19.2)        | 63 (18.7)     |
| Censored patients, n (8)                                   | 91 (26.9)                                 | 73 (21.6)        | 53 (15.7)     |
| Censored RECIST progression [c]                            | 1 (0.3)                                   | 0                | 2 (0.6)       |
| Censored death [d]                                         | 8 (2.4)                                   | 4 (1.2)          | 10 (3.0)      |
| Progression-free at time of analysis                       | 76 (22.5)                                 | 65 (19.2)        | 32 (9.5)      |
| Lost to follow-up                                          | 0                                         | 0                | 0             |
| Withdrawn consent                                          | 4 (1.2)                                   | 2 (0.6)          | 8 (2.4)       |
| Discontinued study                                         | 2 (0.6)                                   | 2 (0.6)          | (0.3)         |
| Median progression-free survival (months) [e]              | 6.4                                       | 6.4              | 5.3           |
| 958 CI for median progression-free survival [e]            | 5.6, 6.7                                  | 5.0, 6.6         | 4.7, 6.1      |
| Progression-free survival rate at 12 months (&) [e]        | 28.2                                      | 23.5             | 11.2          |
| 958 CI for progression-free survival rate at 12 months [e] | 23.3,33.3                                 | 18.9, 28.4       | 7.9, 15.1     |
| Hazard ratio,Durva + Treme + SoC vs SoC [f]                | 0.66                                      |                  |               |
| 958CI for hazard ratio 2-sided p-value [g]                 | 0.552,0.786 <0.001                        |                  |               |
| Hazard ratio, Durva + SoC vs SoC [f]                       |                                           | 0.68 0.573,0.810 |               |
| 958CI for hazard ratio                                     |                                           |                  |               |
| 2-sided p-value [g]                                        |                                           | <0.001           |               |
| Hazard ratio, Durva + Treme + SoC vs Durva + SoC [f]       | 0.99                                      |                  |               |
| 958CI for hazard ratio 2-sided p-value [g]                 | 0.827, 1.176 0.885                        |                  |               |

<div style=\"page-break-after: always\"></div>

Figure 21. PFS by investigator in the ITT, Kaplan-Meier curve, DCO 24-JUL-2019

<!-- image -->

Table 35. Disagreements between investigator and BIRC in the ITT, DCO 24-JUL-2019

|                                          |                           |                           |            | Difference     | Difference     |
|------------------------------------------|---------------------------|---------------------------|------------|----------------|----------------|
|                                          |                           |                           |            | Durva +Treme + | Durva +Treme + |
|                                          | Durva+Treme+SoCDurva +SoC | Durva+Treme+SoCDurva +SoC | SoC        | SoC vs         | Durva+SoCvs    |
| Progression                              | (N=338)                   | (N=338)                   | (N=337)    | SoC            | SoC            |
| RECIST progression [a] declared by，n (&) |                           |                           |            |                |                |
| Investigator and central review          | 151(44.7)                 | 169 (50.0)                | 179(53.1)  | NA             | NA             |
|                                          | 75 (22.2)                 | 84(24.9)                  | 101 (30.0) | NA             | NA             |
| than by Investigator                     | 58 (17.2)                 | 67 (19.8)                 | 60 (17.8)  | NA             | NA             |
| than by central review                   | 18 (5.3)                  | 18(5.3)                   | 18 (5.3)   | NA             | NA             |
| Investigator but not central review      | 40 (11.8)                 | 31 (9.2)                  | 44 (13.1)  | NA             | NA             |
| Central review but not Investigator      | 23 (6.8)                  | 24 (7.1)                  | 25 (7.4)   | NA             | NA             |
| No Progression by both，n (&)             | 124 (36.7)                | 114  (33.7)               | 89 (26.4)  | NA             | NA             |
| Early Discrepancy Rate [b]               | 0.30                      | 0.25                      | 0.28       | 0.03           | -0.03          |
| Late Discrepancy Rate [c]                | 0.58                      | 0.65                      | 0.58       | 0.00           | 0.07           |

Secondary endpoint: PFS2 analysis (time-to-second-progression)

Table 36. Time to second progression (by local clinical practice) in the ITT, DCO 24-JUL2019

|                                                  | Durva + Treme +SoC (N=338)   | Durva + SoC (N=338)   | SoC (N=337)   |
|--------------------------------------------------|------------------------------|-----------------------|---------------|
| Total events [a]，n (8)                           | 209 (61.8)                   | 217 (64.2)            | 232 (68.8)    |
| Second progression                               | 65 (19.2)                    | 70 (20.7)             | 88 (26.1)     |
| Symptomatic progression                          | 4 (1.2)                      | 10 (3.0)              | 7 (2.1)       |
| Objective radiologicalprogression                | 61 (18.0)                    | 59 (17.5)             | 81 (24.0)     |
| Other                                            | 0                            | 1 (0.3)               | 0             |
| Death in the absence of second progression       | 144 (42.6)                   | 147 (43.5)            | 144 (42.7)    |
| Censored patients,n (&)                          | 129 (38.2)                   | 121 (35.8)            | 105 (31.2)    |
| No second progression                            | 123 (36.4)                   | 117 (34.6)            | 96 (28.5)     |
| Lost to follow-up                                | 0                            | 0                     | 0             |
| Withdrawn consent                                | 4 (1.2)                      | (0.6)                 | 8 (2.4)       |
| Discontinued study [b]                           | 2 (0.6)                      | 2 (0.6)               | 1 (0.3)       |
| Median time to second progression (months) [c]   | 10.2                         | 10.0                  | 9.1           |
| 958 CI for median time to second progression [c] | 9.1,11.6                     | 8.9,10.8              | 8.3,9.8       |
| Hazard ratio,Durva + Treme + SoC vs SoC [d]      | 0.72                         |                       |               |
| 958 CI for hazard ratio                          | 0.596,0.874                  |                       |               |
| 2-sided p-value [e]                              | <0.001                       |                       |               |
| Hazard ratio,Durva + SoC vs SoC [d]              |                              | 0.78                  |               |
| 95sCI for hazardratio                            |                              | 0.646,0.942           |               |
| 2-sided p-value [e]                              |                              | 0.010                 |               |

<div style=\"page-break-after: always\"></div>

| Durva + Treme+ SoC   |   338 |   287 |   232 |   166 |   96 |   49 |   22 |   6 |   0 | 0 209/338   |
|----------------------|-------|-------|-------|-------|------|------|------|-----|-----|-------------|
| Durva+ SoC           |   338 |   292 |   229 |   165 |   85 |   47 |   16 |   5 |   1 | 0 217/338   |
| SoC                  |   337 |   271 |   207 |   134 |   63 |   26 |   12 |   6 |   0 | 0 232/337   |

Figure 22. Time to second progression (by local clinical practice) in the ITT, Kaplan-Meier curve, DCO 24-JUL-2019

<!-- image -->

Table 37. Subsequent anticancer therapy regimens in the ITT, DCO 12-MAR-2021

|                                                                  | Number (%o) of patients   | Number (%o) of patients   | Number (%o) of patients   | Number (%o) of patients   |
|------------------------------------------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| Anticancer therapy regimen?                                      | T+D+SoC (N=338)           | D+SoC (N=338)             | SoC (N=337)               | Total (N=1013)            |
| Number of patients with post- discontinuation anticancer therapy | 138 (40.8)                | 150 (44.4)                | 203 (60.2)                | 491 (48.5)                |
| Regimen category                                                 |                           |                           |                           |                           |
| Systemic therapy                                                 | 123 (36.4)                | 139 (41.1)                | 194 (57.6)                | 456 (45.0)                |
| Cytotoxic chemotherapy                                           | 107 (31.7)                | 128 (37.9)                | 122 (36.2)                | 357 (35.2)                |
| Single agent                                                     | 76 (22.5)                 | 95 (28.1)                 | 87 (25.8)                 | 258 (25.5)                |
| Platinum doublet                                                 | 37 (10.9)                 | 31 (9.2)                  | 24 (7.1)                  | 92 (9.1)                  |
| Other combination                                                | 16 (4.7)                  | 28 (8.3)                  | 28 (8.3)                  | 72 (7.1)                  |
| Immunotherapy                                                    | 22 (6.5)                  | 22 (6.5)                  | 112 (33.2)                | 156 (15.4)                |
| 10 only                                                          | 17 (5.0)                  | 20 (5.9)                  | 97 (28.8)                 | 134 (13.2)                |
| 10 + chemo                                                       | 1 (0.3)                   | 0                         | 9 (2.7)                   | 10 (1.0)                  |
| 10 + other                                                       | 4 (1.2)                   | 3 (0.9)                   | 6 (1.8)                   | 13 (1.3)                  |
| Targeted therapy                                                 | 14 (4.1)                  | 13 (3.8)                  | 19 (5.6)                  | 46 (4.5)                  |
| Other                                                            | 4 (1.2)                   | 2 (0.6)                   | 6 (1.8)                   | 12 (1.2)                  |
| Radiotherapy                                                     | 48 (14.2)                 | 57 (16.9)                 | 65 (19.3)                 | 170 (16.8)                |

1st subsequent therapy includes 2nd line therapy plus maintenance, 2nd subsequent therapy includes 3rd line therapy and ≥3rd subsequent therapy includes &gt;3rd line therapies. Regimen categories manually identified from preferred terms combined by regimen number. Patients with therapies in more than one category are counted once in each of those categories. Percentages are calculated from number of patients in the full analysis set in that treatment arm. Data for 2 patients was not available. One patient received subsequent letrozole for breast cancer treatment.

<div style=\"page-break-after: always\"></div>

## Secondary endpoints: response rate and Duration of response

## Table 38. ORR and DOR by BICR in patients with measurable disease at baseline, Durva + treme + chemo vs chemo, DCO 24-JUL-2019

|                                                       | RECIST 1.1            | RECIST 1.1            | RECIST 1.1               | RECIST 1.1               |
|-------------------------------------------------------|-----------------------|-----------------------|--------------------------|--------------------------|
|                                                       | Unconfirmed responses | Unconfirmed responses | Confirmed responses only | Confirmed responses only |
|                                                       | T + D + SoC (N = 335) | SoC (N = 332)         | T + D + SoC (N = 335)    | SoC (N = 332)            |
| ORR                                                   |                       |                       |                          |                          |
| ORR, n (%)                                            | 155 (46.3)            | 111 (33.4)            | 130 (38.8)               | 81 (24.4)                |
| Odds ratio a , T+D+SoC vs SoC                         | 1.72                  | 1.72                  | 2.00                     | 2.00                     |
| 95% CI for odds ratio                                 | 1.260, 2.367          | 1.260, 2.367          | 1.428, 2.807             | 1.428, 2.807             |
| 2-sided p-value                                       | <0.001                | <0.001                | <0.001                   | <0.001                   |
| Best overall response, n (%)                          |                       |                       |                          |                          |
| Complete response b                                   | 2 (0.6)               | 0                     | 2 (0.6)                  | 0                        |
| Partial response b                                    | 153 (45.7)            | 111 (33.4)            | 128 (38.2)               | 81 (24.4)                |
| Stable disease ≥6 weeks c                             | 120 (35.8)            | 150 (45.2)            | 120 (35.8)               | 150 (45.2)               |
| Disease progression                                   | 48 (14.3)             | 61 (18.4)             | 48 (14.3)                | 61 (18.4)                |
| Not evaluable                                         | 12 (3.6)              | 10 (3.0)              | 12 (3.6)                 | 10 (3.0)                 |
| Duration of response                                  |                       |                       |                          |                          |
| Number of responders who subsequently progressed/died | 87                    | 84                    | 65                       | 60                       |
| DoR from onset of response (months)                   |                       |                       |                          |                          |
| Median (25th, 75th percentiles) d,e                   | 7.4 (3.5, NR)         | 4.2 (3.0, 6.9)        | 9.5 (5.0, NR)            | 5.1 (3.7, 7.5)           |
| Percentage remaining in response e                    |                       |                       |                          |                          |
| 6 months                                              | 57.2                  | 31.0                  | 67.0                     | 40.4                     |
| 12 months                                             | 42.5                  | 16.4                  | 49.7                     | 21.4                     |
| 18 months                                             | 34.7                  | NR                    | 40.7                     | NR                       |

n An odds ratio &gt;1 favors T + D + SoC compared to SoC chemotherapy alone.

o Response does not require confirmation.

p In practice, considering '5 weeks' as threshold to allow for the 1-week permitted time-window.

q DoR is the time from the first documentation of complete response or partial response until the date of progression, death in absence of progression, or the last evaluable RECIST assessment for patients who progress or die after 2 or more missed visits.

r Calculated using the Kaplan-Meier technique.

The analysis was performed using logistic regression adjusting for PD-L1 (PD-L 1 ≥50% vs PD -L1 &lt;50%), histology (squamous vs non-squamous), and disease stage (Stage IVA vs Stage IVB), with the CI calculated using a profile likelihood approach and the pvalue calculated based on twice the change in log-likelihood resulting from the addition of a treatment factor to the model.

There was 1 patient who died 1 day prior to randomization and was censored at Day 1.

<div style=\"page-break-after: always\"></div>

Figure 23. K-M plot of DOR by BICR in unconfirmed responders, DCO 24-JUL-2019

<!-- image -->

## Secondary endpoints: Patient reported outcomes (PROs)

Overall compliance rates for EORTC QLQ-C30 and EORTC QLQ-L13 were 73.0% and 72.8% in the Durva + treme + chemo arm and 65.0% and 64.8% in the chemo arm.

Table 39: Baseline global health status, DCO 12-MAR-2021

Tab1e14.2.8.1

<!-- image -->

Table 40: Baseline physical functioning, DCO 12-MAR-2021

<!-- image -->

|                              |                    |                | Durva+Treme+SoCDurva+SoC   | BoC (N=337)    |
|------------------------------|--------------------|----------------|----------------------------|----------------|
| EORTCscale/item              | Summary statistics | (N=338)        |                            |                |
| QLQ-C30 Physical Functioning | n                  | 325            |                            | 321            |
|                              | Mean (SD)          | 75.69 (20.748) | (21.131)                   | 75.22 (21.171) |
|                              | Median             | 80.00          | 75.60 80.00                |                |
|                              |                    |                |                            | 80.00          |
|                              |                    |                | 0.0,100.0                  |                |
|                              |                    | 0.0.100.0      |                            |                |
|                              |                    |                |                            | 6.7,100.0      |

<div style=\"page-break-after: always\"></div>

Figure 24: Forest plot of time-to-deterioration (TTD) in EORTC QLQ-C30 and QLQ-L13 in the ITT, Durva + treme + chemo vs. chemo, DCO 12-MAR-2021

<!-- image -->

Figure 25: K-M plot of TTD in EORTC QLQ-C30 and QLQ-L13 in the ITT, DCO 12-MAR-2021

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Ancillary analyses

## Subgroup analyses:

## Figure 26. Forest plot of OS in the ITT, Durva + treme + chemo vs. chemo, DCO 12-MAR2021

FAS- IxRS [a]

AGE&lt; 65

AGE &gt;=65 to&lt;75

AGE &gt;=75

BMI: Underweight (&lt;18.5)

BMI: Normal (18.5-25)

BMI: 0verweight (25-30)

BMI: Obese (&gt;30)

Weight&lt; 57.0kg

Weight &gt;=57.0kg to &lt; 67.2kg

Weight &gt;=67.2kg to &lt; 77.0kg

Weight &gt;=77.0kg

ECoG: Normal activity

ECoG:Restricted activity

PD-L1 &gt;=50

PD-L1&lt;50

PD-L1 &gt;=25

PD-L1&lt;25

PD-L1 &gt;=1$

PD-L1&lt; 1

bTMB &gt;=20

bTMB&lt;20

bTMB &gt;=16

bTMB &lt; 16

&gt;=12

bTMB

bTMB unknown bTMB&lt; 12

Male

Female

Histology: Squamous

Histology: Non-Squamous

Chemo: Abraxane

Chemo: Pemetrexed

Chemo: Gemcitabine

Smoking Status: Never

Smoking Status: Current

Smoking Status: Former

Asian

Non-Asian

Brain Metastases: Yes

Brain Metastases: No

AJCC Disease Stage: IVA

AJCC Disease Stage: IVB

<!-- image -->

0.25

0.5

1

Hazard Ratio(95 CI)

| Number of events/ Durva+Treme+SoC   | patients (&) SoC   | Hazard Ratio (95CI)   |
|-------------------------------------|--------------------|-----------------------|
| 251/338(74.3)                       | 285/337(84.6)      | 0.77(0.65,0.92)       |
| 137/191(71.7)                       | 143/176(81.3)      | 0.79 (0.62,1.00)      |
| 84/112 (75.06)                      | 106 /121 (87.66)   | 0.68 (0.51,0.91)      |
| 30/35(85.7)                         | 36/40(90.0%)       | 1.05 (0.64,1.71)      |
| 15/21(71.4)                         | 27/29(93.1)        | 0.49(0.25,0.91)       |
| 134/184(72.8)                       | 151/181(83.4)      | 0.85 (0.67,1.07)      |
| 74/93(79.6)                         | 76/91(83.56)       | 0.72 (0.52,1.00)      |
| 25/37(67.66)                        | 29/34(85.3)        | 0.58(0.34,1.00)       |
| 50/71（70.4%)                        | 74/85(87.1)        | 0.69(0.48,0.98)       |
| 65/88(73.9)                         | 74/91(81.36)       | 0.81 (0.58, 1.13)     |
| 60/79(75.9%)                        | 72/85(84.7%)       | 0.87 (0.61，1.22)      |
| 73/97(75.38)                        | 64/75(85.36)       | 0.66(0.47，0.92)       |
| 73/110(66.48)                       | 93/119(78.28)      | 0.80(0.59,1.09)       |
| 178/228(78.1)                       | 192/218(88.1)      | 0.72(0.59,0.89)       |

| Number of events / patients (&) Durva+Treme+SoC   | Number of events / patients (&) Durva+Treme+SoC   |                         |                       | Hazard Ratio (95CI)   | Hazard Ratio (95CI)    | Hazard Ratio (95CI)   |
|---------------------------------------------------|---------------------------------------------------|-------------------------|-----------------------|-----------------------|------------------------|-----------------------|
| 69/101 182/237                                    | (68.3) （ 76.8%)                                   | 205/240                 | 80/97（82.5) (85.4)    | 0.82                  | 0.65(0.47,0.89) (0.67, | 1.00)                 |
| 80 /118 171/220                                   | 67.8$) 77.7%)                                     | 93/117 192 /220         | 79.5) 87.36)          | 0.68 0.81             | 0.50, 0.66,            | 0.92) 1.00)           |
| 151/213 100 /125                                  | 70.9%) （ 80.0%)                                   | 170/207 115 /130        | 82.1$) 88.5)          | 0.76 0.77             | 0.61, 0.58,            | 0.95) 1.00)           |
| 52/.75 160 /202                                   | 69.3) 79.2)                                       | 66/ 75 147/166          | 88.0) (9*88           | 0.61 0.79             | 0.42, 0.63,            | 0.88) 0.99)           |
| 79/108 133/169                                    | 73.1) 78.7%)                                      | 92/102 121/139          | 90.28) 87.1$)         | 0.65 0.80             | 0.48, 0.62,            | 0.88) 1.02)           |
| 115 /152 97 /125 39/61                            | 75.7) 77.6%) 63.9%)                               | 126/140 87 /101 72/96   | 90.0%) 86.1$) 75.0%)  | 0.66 0.83 0.71        | 0.51, 0.62, 0.48,      | 0.85) 1.12) 1.05)     |
| 202/269 49 9769                                   | 75.1) 71.0%)                                      | 220 /248 65 6/89        | 88.7) 73.0%)          | 0.70 96*0             | 0.58, 0.66,            | 0.85) 1.38)           |
| 106/124 145/214                                   | (8 85.5%) （ 67.88)                                | 111 /122 173 3/214      | 91.0%) (80.8%)        | 0.88 0.70             | 0.68, 0.56,            | 1.16) 0.87)           |
| 16 6/23 97 /111 138/204                           | 69.68) 87.4%) 67.6%)                              | 17 19 102 /111 166 /207 | 89.5%) 91.9%) (80.2%) | 0.55 0.90 0.72        | 0.27, 0.68, 0.57,      | 1.11) 1.19) 0.90)     |
| 50 /59 142 /195 59/84                             | 84.7%) 72.8%) （70.2%)                             | 64 79 164 /191 56       | 81.0%) 85.9%) (84.8%) | 1.15 0.75 0.54        | 0.79, 0.60, 0.37,      | 1.67) 0.94) 0.79)     |
| 72/.99 179/239                                    | 72.78) ( 74.9%)                                   | 103/128 182/209         | 80.5) 87.1)           | 0.97 0.65             | 0.71, 0.53,            | 1.30) 0.80)           |
| 23/33 228/305                                     | 69.7%) 74.8%)                                     | 38/.45 247/292          | (84.4%) (84.6%)       | 0.87 0.75             | 0.51, 0.62,            | 1.45) 0.89)           |
| 121/171 130 /165                                  | 70.8%) 78.8%)                                     | 138/166 146/170         | 83.1) 85.9%)          | 0.72 0.84             | 0.56, 0.66,            | 0.91) 1.06)           |

<div style=\"page-break-after: always\"></div>

Figure 27. Forest plot of PFS by BICR in the ITT, Durva + treme + chemo vs. chemo, DCO 12MAR-2021

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Sensitivity analyses:

Table 41.Sensitivity analysis of OS adjusting for eCRF stratification variables

<!-- image -->

|                                                                 |     |                                 |                    | Comparison with SoC   | Comparison with SoC   | Comparison with SoC   |
|-----------------------------------------------------------------|-----|---------------------------------|--------------------|-----------------------|-----------------------|-----------------------|
| Group                                                           | N   | Number（&)of patientswith events | Median (months)[a] | Hazard ratio [b]      | 958CI[b]              | 2-sided p-value[c]    |
| Using eCRF-derived stratification variables [d] Durva+Treme+SoC | 336 | 251 (74.7)                      | 13.9               | 0.79                  | 0.667,0.940           | 0.008                 |
| Durva + SoC                                                     | 335 | 262 (78.2)                      | 13.3               | 0.86                  | 0.728，1.023           | 0.089                 |
| SoC                                                             | 336 | 284(84.5)                       | 11.6               |                       |                       |                       |

Table 42. Sensitivity analysis of OS, effect of covariates in Cox proportional hazards model

<!-- image -->

|                                                                                      |     |                                  | Comparison with SoC   | Comparison with SoC   | Comparison with SoC   |
|--------------------------------------------------------------------------------------|-----|----------------------------------|-----------------------|-----------------------|-----------------------|
| Model/Group                                                                          | N   | Number（&）of patients with events | Hazard ratio          | 958CI                 | 2-sided p-value       |
| Model including treatment and stratification factors (primary)[a] Durva + Treme +SoC | 338 | 251(74.3)                        | 0.78                  | 0.658,0.925           | 0.004                 |
| Durva + SoC                                                                          | 338 | 264 (78.1)                       | 0.86                  | 0.724,1.014           | 0.072                 |
| SoC                                                                                  | 337 | 285 (84.6)                       |                       |                       |                       |
| Primary model with additional covariates [b]                                         |     |                                  |                       |                       |                       |
| Durva + Treme + SoC                                                                  | 338 | 251(74.3)                        | 0.76                  | 0.635,0.903           | 0.002                 |
| Durva + SoC                                                                          | 338 | 264(78.1)                        | 0.83                  | 0.704,0.986           | 0.034                 |
| SoC                                                                                  | 336 | 284(84.5)                        |                       |                       |                       |

## Table 43. Sensitivity analysis of OS, Max-Combo

<!-- image -->

| Comparison           | Test                         |                   | p-value                     |
|----------------------|------------------------------|-------------------|-----------------------------|
| Durva+Treme+SoCvsSoC | Fleming-Harrington Max-Combo | (0,0) (0,1) (1,1) | 0.0030 0.0015 0.0050 0.0029 |
| Durva+SoCvsSoC       | Fleming-Harrington Max-Combo | (0,0) (0,1) (1,1) | 0.0755 0.1171 0.0586 0.0969 |

Table 44. Sensitivity analysis of OS, RMST

<!-- image -->

|                      | Max.Event   |                 |                                       | RMsTEstimate                          | Differencebetween Difference   | Differencebetween Difference   | Ratiobetween groups   | Ratiobetween groups   | Ratiobetween groups   | Ratiobetween groups   | Ratiobetween groups   |
|----------------------|-------------|-----------------|---------------------------------------|---------------------------------------|--------------------------------|--------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| Comparison           |             | Time (Months)   | TreatmentArm                          | (Months)                              |                                | (95CI)                         | p-value               | Ratio（g5eCI）          | p-value               |                       |                       |
| Durva+Treme+SoCvsSoC | 37.32       | Durva Treme SoC | SoC                                   | 17.86（16.43,19.28） 15.19（13.92,16.47) | 2.67（0.75，4.58）                |                                | 0.00626               | 1.18(1.05，1.32)       | 0.00619               |                       |                       |
| Durva+SoCvsSoC       | 40.08       | Durva +SoC SoC  | 17.47（15.99,18.95） 15.54（14.19,16.89) |                                       | 1.93(-0.07,3.93)               |                                | 0.05909               | 1.12(1.00,1.27)       | 0.05867               |                       |                       |

<div style=\"page-break-after: always\"></div>

Table 45. Sensitivity analyses of PFS by BICR in the ITT, Durva + treme + chemo vs. chemo, DCO 24-JUL-2019

|                                                          | Number (%) of patients with events   |   Median PFS (months) a |   HR b | 95% CI b     | 2-sided p-value c   |
|----------------------------------------------------------|--------------------------------------|-------------------------|--------|--------------|---------------------|
| Analysis to assess possible evaluation time bias d, e, f | T + D + SoC: 238/338 (70.4%)         |                     5.5 |   0.72 | 0.600, 0.860 | <0.001              |
| Analysis to assess possible evaluation time bias d, e, f | SoC chemotherapy: 258/337 (76.6%)    |                     4.1 |   0.72 | 0.600, 0.860 | <0.001              |
| Analysis to assess possible attrition bias d, g          | T + D + SoC: 238/338 (70.4%)         |                     6.3 |   0.74 | 0.614, 0.883 | <0.001              |
| Analysis to assess possible attrition bias d, g          | SoC chemotherapy: 248/337 (73.6%)    |                     4.9 |   0.74 | 0.614, 0.883 | <0.001              |
| Analysis to assess possible ascertainment bias e, h      | T + D + SoC: 247/338 (73.1%)         |                     6.4 |   0.66 | 0.552, 0.786 | <0.001              |
| Analysis to assess possible ascertainment bias e, h      | SoC chemotherapy: 284/337 (84.3%)    |                     5.3 |   0.66 | 0.552, 0.786 | <0.001              |
| Using eCRF-derived stratification variables d, e, i      | T + D + SoC: 238/336 (70.8%)         |                     6.2 |   0.72 | 0.603, 0.865 | <0.001              |
| Using eCRF-derived stratification variables d, e, i      | SoC chemotherapy: 258/336 (76.8%)    |                     4.8 |   0.72 | 0.603, 0.865 | <0.001              |

- a Calculated using the Kaplan-Meier technique.
- b The HR and CI are estimated from a stratified Cox proportional hazards model with the Efron method to control for ties, the stratification factors PD-L1 (PDL1 ≥50% vs PD -L1 &lt;50%), histology (squamous vs non-squamous), and disease stage (Stage IVA vs Stage IVB) in the strata statement, and the CI calculated using a profile likelihood approach. A hazard ratio &lt;1 favors D +T + SoC or D + SoC to be associated with a longer PFS than SoC chemotherapy.
- c P-values were generated using the stratified log-rank test adjusting for PD-L1 (PDL1 ≥50% vs PD -L1 &lt;50%), histology (squamous vs nonsquamous), and disease stage (Stage IVA vs Stage IVB) and using the Breslow approach for handling ties.
- d Progression is determined by BICR assessment, RECIST 1.1.
- e Patients who have not progressed or died, or who progress or die after 2 or more missed visits, are censored at the latest evaluable RECIST assessment or at Day 1 if there are no evaluable visits or no baseline data and patient did not die within 2 visits of baseline.
- f The midpoint between the time of progression and the previous evaluable RECIST assessment (using the final date of the assessment) is analyzed.
- g Patients who have not progressed or died will be censored at the time of the latest date of assessment from their last evaluable RECIST assessment, or at Day 1 if there are no evaluable visits. In addition, patients initiating subsequent therapy prior to their last evaluable RECIST assessment, progression or death in absence of progression, will be censored at their last evaluable assessment prior to starting subsequent therapy.
- h Progression is determined by site investigator assessment, RECIST 1.1.
- i Covariates used in the statistical model are derived from eCRF data rather than using the values from IVRS.

Figure 28. Forest plot of primary and sensitivity analyses of PFS by BICR in the ITT, Durva + treme + chemo vs. chemo, DCO 24-JUL-2019

<!-- image -->

## Exploratory analyses:

Contribution of each component:

<div style=\"page-break-after: always\"></div>

Table 46. Contribution of components POSEIDON

|                                                              | Treatment arm                                                | Treatment arm                                                | Treatment arm                                                |
|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
| Efficacy measure                                             | T + D + SoC                                                  | D + SoC                                                      | SoC                                                          |
| Overall survival a                                           |                                                              |                                                              |                                                              |
| N                                                            | 338                                                          | 338                                                          | 337                                                          |
| HR b, c , T + D + SoC vs SoC (95% CI)                        | 0.77 (0.650, 0.916)                                          |                                                              |                                                              |
| 2-sided p-value d                                            | 0.00304                                                      |                                                              |                                                              |
| HR b, e , D + SoC vs SoC (95% CI)                            |                                                              | 0.86 (0.724, 1.016)                                          |                                                              |
| 2-sided p-value d                                            |                                                              | 0.07581                                                      |                                                              |
| HR b, f , T + D + SoC vs D + SoC (95% CI)                    | 0.92 (0.776, 1.100)                                          |                                                              |                                                              |
| 2-sided p-value d                                            | 0.373                                                        |                                                              |                                                              |
| Death, n (%)                                                 | 251 (74.3)                                                   | 264 (78.1)                                                   | 285 (84.6)                                                   |
| Median OS (months) g (95% CI) g                              | 14.0 (11.7, 16.1)                                            | 13.3 (11.4, 14.7)                                            | 11.7 (10.5, 13.1)                                            |
| Progression-free survival h, i                               |                                                              |                                                              |                                                              |
| N                                                            | 338                                                          | 338                                                          | 337                                                          |
| HR b, c , T + D + SoC vs SoC (95% CI)                        | 0.72 (0.600, 0.860)                                          |                                                              |                                                              |
| 2-sided p-value d                                            | 0.00031                                                      |                                                              |                                                              |
| HR b, e , D + SoC vs SoC (95% CI)                            |                                                              | 0.74 (0.620, 0.885)                                          |                                                              |
| 2-sided p-value d                                            |                                                              | 0.00093                                                      |                                                              |
| HR b, f , T + D + SoC vs D + SoC (95% CI)                    | 0.97 (0.815, 1.166)                                          |                                                              |                                                              |
| 2-sided p-value d                                            | 0.796                                                        |                                                              |                                                              |
| Total events, n (%)                                          | 238 (70.4)                                                   | 253 (74.9)                                                   | 258 (76.6)                                                   |
| Median (months) g (95% CI) g                                 | 6.2 (5.0, 6.5)                                               | 5.5 (4.7, 6.5)                                               | 4.8 (4.6, 5.8)                                               |
| Objective response rate h, i, j, k                           |                                                              |                                                              |                                                              |
| N                                                            | 335                                                          | 330                                                          | 332                                                          |
| Number (%) of patients with a confirmed response             | 130 (38.8)                                                   | 137 (41.5)                                                   | 81 (24.4)                                                    |
| Odds ratio m , D + T + SoC vs D + SoC (95% CI)               | 0.89 (0.646, 1.218)                                          |                                                              |                                                              |
| 2-sided p-value                                              | 0.461                                                        |                                                              |                                                              |
| Duration of response (confirmed)                             |                                                              |                                                              |                                                              |
| N                                                            | 130                                                          | 137                                                          | 81                                                           |
| Number of responders who subsequently progressed or died     | 65                                                           | 83                                                           | 60                                                           |
| Duration of response from onset of response (months) g, k, n | Duration of response from onset of response (months) g, k, n | Duration of response from onset of response (months) g, k, n | Duration of response from onset of response (months) g, k, n |
| Median (25th, 75th percentiles)                              | 9.5 (5.0, NR)                                                | 7.0 (3.9, NR)                                                | 5.1 (3.7, 7.5)                                               |

Efficacy according to PD-L1 subgroups

Table 47. OS according to PD-L1 subgroups in the ITT, Durva + treme + chemo vs. chemo, DCO 12-MAR-2021

|                         | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients              |
|-------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|-------------------------------------|
| Analysis set            | Full analysis set        | Full analysis set        | PD-L1 TC <50%            | PD-L1 TC <50%            | PD-L1 TC <25%            | PD-L1 TC <25%            | PD-L1 TC <1%                        |
|                         | T + D + SoC (N = 338)    | SoC (N = 337)            | T + D + SoC (N = 237)    | SoC (N = 240)            | T + D + SoC (N = 220)    | SoC (N = 220)            | T + D + SoC (N = 125) SoC (N = 130) |
| HR, T+D+SoC vs SoC a, b | 0.77                     | 0.77                     | 0.82                     | 0.82                     | 0.83                     | 0.83                     | 0.75                                |

<div style=\"page-break-after: always\"></div>

| 95% CI for HR                   | 0.650, 0.916      | 0.650, 0.916      | 0.673, 1.006      | 0.673, 1.006      | 0.674, 1.020      | 0.674, 1.020      | 0.568, 0.980     | 0.568, 0.980     |
|---------------------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|------------------|------------------|
| 2-sided p-value                 | 0.00304 c         | 0.00304 c         | 0.057 d           | 0.057 d           | 0.077 d           | 0.077 d           | 0.035 d          | 0.035 d          |
| Death, n (%)                    | 251 (74.3)        | 285 (84.6)        | 182 (76.8)        | 205 (85.4)        | 171 (77.7)        | 192 (87.3)        | 100 (80.0)       | 115 (88.5)       |
| Censored patients, n (%)        | 87 (25.7)         | 52 (15.4)         | 55 (23.2)         | 35 (14.6)         | 49 (22.3)         | 28 (12.7)         | 25 (20.0)        | 15 (11.5)        |
| Median OS (months) g (95% CI) g | 14.0 (11.7, 16.1) | 11.7 (10.5, 13.1) | 13.3 (10.3, 15.7) | 12.0 (10.6, 14.1) | 13.1 (10.0, 15.5) | 12.2 (10.6, 14.4) | 12.7 (9.9, 15.5) | 11.0 (8.7, 12.7) |

a The HR and CI are estimated from a stratified Cox proportional hazards model with the Efron method to control for ties, the stratification factors PD-L1 (PDL1 ≥50% vs PD -L1 &lt;50%), histology (squamous vs non-squamous), and disease stage (Stage IVA vs Stage IVB) in the strata statement, and the CI calculated using a profile likelihood approach.

b

A HR &lt;1 favors T + D + SoC chemotherapy to be associated with a longer OS than SoC chemotherapy alone.

c P-values were generated using the stratified log-rank test adjusting for PD-L1 (PDL1 ≥50% vs PD L1 &lt;50%), histology (squamous vs non -squamous), and disease stage (Stage IVA vs Stage IVB) and using the Breslow approach for handling ties.

d P-values were generated using the stratified log-rank test adjusting for histology (squamous vs non-squamous), and disease stage (Stage IVA vs Stage IVB) and using the Breslow approach for handling ties.

e

f

g

Includes patients known to be alive at data cutoff.

Includes patients with unknown survival status or patients who were lost to follow-up.

Calculated using Kaplan-Meier technique.

Figure 29. Overall survival in the PD-L1 TC&lt;1% population, DCO 12-MAR-2021

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 30. Overall survival in the PD-L1 TC ≥ 1% population, DCO 12-MAR-2021

<!-- image -->

Table 48: Progression-free survival (BICR; RECIST 1.1), full analysis set and PDL1 analysis sets, T + D + SoC vs SoC, DCO 24-JUL-2019

| Analysi s set                     | Full analysis set      | Full analysis set   | PD-L1 TC <50%          | PD-L1 TC <50%   | PD-L1 TC <25%          | PD-L1 TC <25%   | PD-L1 TC <1%           | PD-L1 TC <1%   |
|-----------------------------------|------------------------|---------------------|------------------------|-----------------|------------------------|-----------------|------------------------|----------------|
|                                   | T + D + So C (N = 338) | SoC (N = 337)       | T + D + So C (N = 237) | SoC (N = 240)   | T + D + So C (N = 220) | SoC (N = 220)   | T + D + So C (N = 125) | SoC (N = 130)  |
| HR a,b vs T+D+So C vs SoC         | 0.72 a, b              | 0.72 a, b           | 0.77 b, c              | 0.77 b, c       | 0.79 b, c              | 0.79 b, c       | 0.74 b, c              | 0.74 b, c      |
| 95% CI                            | 0.600, 0.860 a         | 0.600, 0.860 a      | 0.627, 0.957 c         | 0.627, 0.957 c  | 0.632, 0.978 c         | 0.632, 0.978 c  | 0.554, 0.986 c         | 0.554, 0.986 c |
| 2-sided p-value                   | 0.00031 d              | 0.00031 d           | 0.018 e                | 0.018 e         | 0.031 e                | 0.031 e         | 0.040 e                | 0.040 e        |
| Total events, n (%) f             | 238 (70.4)             | 258 (76.6 )         | 175 (73.8)             | 183 (76.3 )     | 164 (74.5)             | 170 (77.3 )     | 97 (77.6)              | 101 (77.7 )    |
| Median PFS (months ) g (95% CI) g | 6.2 (5.0, 6.5)         | 4.8 (4.6, 5.8)      | 6.0 (4.7, 6.5)         | 4.8 (4.6, 6.1)  | 6.0 (4.7, 6.5)         | 4.8 (4.6, 6.1)  | 6.1 (4.6, 6.5)         | 4.7 (4.6, 6.2) |

- b A HR &lt;1 favors T + D + SoC chemotherapy to be associated with a longer PFS than SoC chemotherapy alone.
- c The HR and CI are estimated from a stratified Cox proportional hazards model with the Efron method to control for ties, the stratification factors histology (squamous vs non-squamous), and disease stage (Stage IVA vs Stage IVB) in the strata statement, and the CI calculated using a profile likelihood approach.
- d P-values were generated using the stratified log-rank test adjusting for PD-L1 (PDL1 ≥50% vs PD -L1 &lt;50%), histology (squamous vs nonsquamous), and disease stage (Stage IVA s Stage IVB) and using the Breslow approach for handling ties.
- e P-values were generated using the stratified log-rank test adjusting for histology (squamous vs non-squamous), and disease stage (Stage IVA vs Stage IVB) and using the Breslow approach for handling ties.
- f Patients who have not progressed or died, or who progress or die after 2 or more missed visits, are censored at the latest evaluable RECIST assessment or at Day 1 if there are no evaluable visits or no baseline data and patient did not die within 2 visits of baseline.
- g Calculated using the Kaplan-Meier technique.

<div style=\"page-break-after: always\"></div>

## Summary of main study(ies)

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 49. Summary of Efficacy for POSEIDON

<!-- image -->

| A phase III, randomised, multicentre, open-label, comparative global study to determine the efficacy of durvalumab or durvalumab and tremelimumab in combination with platinum- based chemotherapy for first-line treatment in patients with metastatic non-small-cell lung cancer (POSEIDON)   | A phase III, randomised, multicentre, open-label, comparative global study to determine the efficacy of durvalumab or durvalumab and tremelimumab in combination with platinum- based chemotherapy for first-line treatment in patients with metastatic non-small-cell lung cancer (POSEIDON)   | A phase III, randomised, multicentre, open-label, comparative global study to determine the efficacy of durvalumab or durvalumab and tremelimumab in combination with platinum- based chemotherapy for first-line treatment in patients with metastatic non-small-cell lung cancer (POSEIDON)   | A phase III, randomised, multicentre, open-label, comparative global study to determine the efficacy of durvalumab or durvalumab and tremelimumab in combination with platinum- based chemotherapy for first-line treatment in patients with metastatic non-small-cell lung cancer (POSEIDON)   | A phase III, randomised, multicentre, open-label, comparative global study to determine the efficacy of durvalumab or durvalumab and tremelimumab in combination with platinum- based chemotherapy for first-line treatment in patients with metastatic non-small-cell lung cancer (POSEIDON)   | A phase III, randomised, multicentre, open-label, comparative global study to determine the efficacy of durvalumab or durvalumab and tremelimumab in combination with platinum- based chemotherapy for first-line treatment in patients with metastatic non-small-cell lung cancer (POSEIDON)   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                | EudraCT number 2017-000920-81; Study code D419MC00004; NCT03164616                                                                                                                                                                                                                              | EudraCT number 2017-000920-81; Study code D419MC00004; NCT03164616                                                                                                                                                                                                                              | EudraCT number 2017-000920-81; Study code D419MC00004; NCT03164616                                                                                                                                                                                                                              | EudraCT number 2017-000920-81; Study code D419MC00004; NCT03164616                                                                                                                                                                                                                              | EudraCT number 2017-000920-81; Study code D419MC00004; NCT03164616                                                                                                                                                                                                                              |
|                                                                                                                                                                                                                                                                                                 | Phase III, multicentre, open-label, three-arm, randomised 1:1:1, active control. Cross-over not allowed.                                                                                                                                                                                        | Phase III, multicentre, open-label, three-arm, randomised 1:1:1, active control. Cross-over not allowed.                                                                                                                                                                                        | Phase III, multicentre, open-label, three-arm, randomised 1:1:1, active control. Cross-over not allowed.                                                                                                                                                                                        | Phase III, multicentre, open-label, three-arm, randomised 1:1:1, active control. Cross-over not allowed.                                                                                                                                                                                        | Phase III, multicentre, open-label, three-arm, randomised 1:1:1, active control. Cross-over not allowed.                                                                                                                                                                                        |
| Design                                                                                                                                                                                                                                                                                          | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                                                  | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                                                  | Not applicable, event driven Not applicable Not applicable                                                                                                                                                                                                                                      | Not applicable, event driven Not applicable Not applicable                                                                                                                                                                                                                                      | Not applicable, event driven Not applicable Not applicable                                                                                                                                                                                                                                      |
| Hypothesis                                                                                                                                                                                                                                                                                      | Superiority                                                                                                                                                                                                                                                                                     | Superiority                                                                                                                                                                                                                                                                                     | Superiority                                                                                                                                                                                                                                                                                     | Superiority                                                                                                                                                                                                                                                                                     | Superiority                                                                                                                                                                                                                                                                                     |
| Treatment groups                                                                                                                                                                                                                                                                                | T + D + SoC chemotherapy (Treatment Arm 1)                                                                                                                                                                                                                                                      | T + D + SoC chemotherapy (Treatment Arm 1)                                                                                                                                                                                                                                                      | SoC chemotherapy Q3W + tremelimumab 75 mg IV Q3W + durvalumab 1500 mg IV Q3W for 4 cycles. A fifth dose of tremelimumab 75 mg is to be given at Week 16 alongside durvalumab Dose 6. Post chemotherapy, durvalumab 1500 mg IV Q4W. n=338                                                        | SoC chemotherapy Q3W + tremelimumab 75 mg IV Q3W + durvalumab 1500 mg IV Q3W for 4 cycles. A fifth dose of tremelimumab 75 mg is to be given at Week 16 alongside durvalumab Dose 6. Post chemotherapy, durvalumab 1500 mg IV Q4W. n=338                                                        | SoC chemotherapy Q3W + tremelimumab 75 mg IV Q3W + durvalumab 1500 mg IV Q3W for 4 cycles. A fifth dose of tremelimumab 75 mg is to be given at Week 16 alongside durvalumab Dose 6. Post chemotherapy, durvalumab 1500 mg IV Q4W. n=338                                                        |
| Treatment groups                                                                                                                                                                                                                                                                                | D + SoC chemotherapy (Treatment Arm 2)                                                                                                                                                                                                                                                          | D + SoC chemotherapy (Treatment Arm 2)                                                                                                                                                                                                                                                          | SoC chemotherapy Q3W + durvalumab 1500 mg IV Q3W 4 cycles. Post chemotherapy, durvalumab 1500 mg IV Q4W. n=338                                                                                                                                                                                  | SoC chemotherapy Q3W + durvalumab 1500 mg IV Q3W 4 cycles. Post chemotherapy, durvalumab 1500 mg IV Q4W. n=338                                                                                                                                                                                  | SoC chemotherapy Q3W + durvalumab 1500 mg IV Q3W 4 cycles. Post chemotherapy, durvalumab 1500 mg IV Q4W. n=338                                                                                                                                                                                  |
| Treatment groups                                                                                                                                                                                                                                                                                | SoC chemotherapy alone (Treatment Arm 3)                                                                                                                                                                                                                                                        | SoC chemotherapy alone (Treatment Arm 3)                                                                                                                                                                                                                                                        | Up to 6 doses of histology-based SoC chemotherapy: abraxane + carboplatin, pemetrexed + cisplatin or carboplatin, or gemcitabine + cisplatin or carboplatin n=337                                                                                                                               | Up to 6 doses of histology-based SoC chemotherapy: abraxane + carboplatin, pemetrexed + cisplatin or carboplatin, or gemcitabine + cisplatin or carboplatin n=337                                                                                                                               | Up to 6 doses of histology-based SoC chemotherapy: abraxane + carboplatin, pemetrexed + cisplatin or carboplatin, or gemcitabine + cisplatin or carboplatin n=337                                                                                                                               |
| Endpoints and definitions                                                                                                                                                                                                                                                                       | Primary                                                                                                                                                                                                                                                                                         | OS Arm 2 vs. 3                                                                                                                                                                                                                                                                                  | Time from date of randomisation until date of death by any cause.                                                                                                                                                                                                                               | Time from date of randomisation until date of death by any cause.                                                                                                                                                                                                                               | Time from date of randomisation until date of death by any cause.                                                                                                                                                                                                                               |
| Endpoints and definitions                                                                                                                                                                                                                                                                       | Primary                                                                                                                                                                                                                                                                                         | BICR-PFS Arm 2 vs. 3                                                                                                                                                                                                                                                                            | Time from randomisation to the date of objective disease progression by RECIST 1.1 per blinded independent central review (BICR) assessment, or death due to any cause.                                                                                                                         | Time from randomisation to the date of objective disease progression by RECIST 1.1 per blinded independent central review (BICR) assessment, or death due to any cause.                                                                                                                         | Time from randomisation to the date of objective disease progression by RECIST 1.1 per blinded independent central review (BICR) assessment, or death due to any cause.                                                                                                                         |
| Endpoints and definitions                                                                                                                                                                                                                                                                       | Secondary                                                                                                                                                                                                                                                                                       | OS Arm 1 vs. 3                                                                                                                                                                                                                                                                                  | Time from date of randomisation until date of death by any cause.                                                                                                                                                                                                                               | Time from date of randomisation until date of death by any cause.                                                                                                                                                                                                                               | Time from date of randomisation until date of death by any cause.                                                                                                                                                                                                                               |
| Endpoints and definitions                                                                                                                                                                                                                                                                       | Secondary                                                                                                                                                                                                                                                                                       | BICR-PFS Arm 1 vs. 3                                                                                                                                                                                                                                                                            | Time from randomisation to the date of objective disease progression by RECIST 1.1 per BICR assessment, or death due to any cause.                                                                                                                                                              | Time from randomisation to the date of objective disease progression by RECIST 1.1 per BICR assessment, or death due to any cause.                                                                                                                                                              | Time from randomisation to the date of objective disease progression by RECIST 1.1 per BICR assessment, or death due to any cause.                                                                                                                                                              |
| Endpoints and definitions                                                                                                                                                                                                                                                                       | Secondary                                                                                                                                                                                                                                                                                       | Confirmed BICR-ORR                                                                                                                                                                                                                                                                              | Confirmed overall response rate per BICR (this is a post-hoc analysis, the predefined ORR was unconfirmed responses)                                                                                                                                                                            | Confirmed overall response rate per BICR (this is a post-hoc analysis, the predefined ORR was unconfirmed responses)                                                                                                                                                                            | Confirmed overall response rate per BICR (this is a post-hoc analysis, the predefined ORR was unconfirmed responses)                                                                                                                                                                            |
| Database lock                                                                                                                                                                                                                                                                                   | 18-SEP-2019 for final PFS analyses and 20-APR-2021 for final OS analyses                                                                                                                                                                                                                        | 18-SEP-2019 for final PFS analyses and 20-APR-2021 for final OS analyses                                                                                                                                                                                                                        | 18-SEP-2019 for final PFS analyses and 20-APR-2021 for final OS analyses                                                                                                                                                                                                                        | 18-SEP-2019 for final PFS analyses and 20-APR-2021 for final OS analyses                                                                                                                                                                                                                        | 18-SEP-2019 for final PFS analyses and 20-APR-2021 for final OS analyses                                                                                                                                                                                                                        |
| Analysis description Primary Analysis                                                                                                                                                                                                                                                           | Analysis description Primary Analysis                                                                                                                                                                                                                                                           | Analysis description Primary Analysis                                                                                                                                                                                                                                                           | Analysis description Primary Analysis                                                                                                                                                                                                                                                           | Analysis description Primary Analysis                                                                                                                                                                                                                                                           | Analysis description Primary Analysis                                                                                                                                                                                                                                                           |
| Analysis population and time point description                                                                                                                                                                                                                                                  | ITT (N=1013) Data cutoff for final analyses of PFS 24-JUL-2019 Data cutoff for final analyses of OS 12-MAR-2021                                                                                                                                                                                 | ITT (N=1013) Data cutoff for final analyses of PFS 24-JUL-2019 Data cutoff for final analyses of OS 12-MAR-2021                                                                                                                                                                                 | ITT (N=1013) Data cutoff for final analyses of PFS 24-JUL-2019 Data cutoff for final analyses of OS 12-MAR-2021                                                                                                                                                                                 | ITT (N=1013) Data cutoff for final analyses of PFS 24-JUL-2019 Data cutoff for final analyses of OS 12-MAR-2021                                                                                                                                                                                 | ITT (N=1013) Data cutoff for final analyses of PFS 24-JUL-2019 Data cutoff for final analyses of OS 12-MAR-2021                                                                                                                                                                                 |
| Descriptive statistics estimate variability                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                 |
| and                                                                                                                                                                                                                                                                                             | Treatment group T +                                                                                                                                                                                                                                                                             | Treatment group T +                                                                                                                                                                                                                                                                             | Treatment group T +                                                                                                                                                                                                                                                                             | D + SoC chemotherapy (Treatment Arm 1)                                                                                                                                                                                                                                                          | SoC chemotherapy alone (Treatment Arm 3)                                                                                                                                                                                                                                                        |
| and                                                                                                                                                                                                                                                                                             | Number of subjects                                                                                                                                                                                                                                                                              | Number of subjects                                                                                                                                                                                                                                                                              | Number of subjects                                                                                                                                                                                                                                                                              | 338                                                                                                                                                                                                                                                                                             | 337                                                                                                                                                                                                                                                                                             |
| and                                                                                                                                                                                                                                                                                             | OS, patients with event (%)                                                                                                                                                                                                                                                                     | OS, patients with event (%)                                                                                                                                                                                                                                                                     | OS, patients with event (%)                                                                                                                                                                                                                                                                     | 251 (74.3)                                                                                                                                                                                                                                                                                      | 285 (84.6)                                                                                                                                                                                                                                                                                      |
| and                                                                                                                                                                                                                                                                                             | Median OS a , months                                                                                                                                                                                                                                                                            | Median OS a , months                                                                                                                                                                                                                                                                            | Median OS a , months                                                                                                                                                                                                                                                                            | 14.0                                                                                                                                                                                                                                                                                            | 11.7                                                                                                                                                                                                                                                                                            |
| and                                                                                                                                                                                                                                                                                             | 95% CI                                                                                                                                                                                                                                                                                          | 95% CI                                                                                                                                                                                                                                                                                          | 95% CI                                                                                                                                                                                                                                                                                          | 11.7, 16.1                                                                                                                                                                                                                                                                                      | 10.5, 13.1                                                                                                                                                                                                                                                                                      |
| and                                                                                                                                                                                                                                                                                             | BICR-PFS, patients with event (%)                                                                                                                                                                                                                                                               | BICR-PFS, patients with event (%)                                                                                                                                                                                                                                                               | BICR-PFS, patients with event (%)                                                                                                                                                                                                                                                               | 238 (70.4)                                                                                                                                                                                                                                                                                      | 258 (76.6)                                                                                                                                                                                                                                                                                      |
| and                                                                                                                                                                                                                                                                                             | Median BICR-PFS a ,                                                                                                                                                                                                                                                                             | Median BICR-PFS a ,                                                                                                                                                                                                                                                                             | Median BICR-PFS a ,                                                                                                                                                                                                                                                                             | 6.2                                                                                                                                                                                                                                                                                             | 4.8                                                                                                                                                                                                                                                                                             |
| and                                                                                                                                                                                                                                                                                             | months 95% CI                                                                                                                                                                                                                                                                                   | months 95% CI                                                                                                                                                                                                                                                                                   | months 95% CI                                                                                                                                                                                                                                                                                   | 5.0, 6.5                                                                                                                                                                                                                                                                                        | 4.6, 5.8                                                                                                                                                                                                                                                                                        |
| and                                                                                                                                                                                                                                                                                             | Confirmed BICR ORR (n)                                                                                                                                                                                                                                                                          | Confirmed BICR ORR (n)                                                                                                                                                                                                                                                                          | Confirmed BICR ORR (n)                                                                                                                                                                                                                                                                          | 38.8 (130)                                                                                                                                                                                                                                                                                      | 24.4 (81)                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|                                | 95% CI   | 12.5, 21.1        | 12.5, 21.1                                          | 3.8, 9.6                                            |
|--------------------------------|----------|-------------------|-----------------------------------------------------|-----------------------------------------------------|
| Effect estimate per comparison | OS       | Comparison groups | T + D + SoC chemotherapy vs. SoC chemotherapy alone | T + D + SoC chemotherapy vs. SoC chemotherapy alone |
| Effect estimate per comparison |          | Stratified HR b   | 0.77                                                | 0.77                                                |
| Effect estimate per comparison |          | 95% CI            | 0.650, 0.916                                        | 0.650, 0.916                                        |
| Effect estimate per comparison |          | P-value c         | 0.00304                                             | 0.00304                                             |
| Effect estimate per comparison |          | Comparison        | T + D + SoC chemotherapy vs. SoC                    | T + D + SoC chemotherapy vs. SoC                    |
| Effect estimate per comparison | BICR-PFS | Stratified HR b   | 0.72                                                | 0.72                                                |
| Effect estimate per comparison |          | 95% CI            | 0.600, 0.860                                        | 0.600, 0.860                                        |
| Effect estimate per comparison |          | P-value c         | 0.00031                                             | 0.00031                                             |

Notes:

a  Based on Kaplan-Meier method

b  The HR and CI are estimated from a stratified Cox proportional hazards model with the Efron method to control for ties, the stratification factors PD-L1 (PDL1 ≥50% vs PD -L1 &lt;50%), histology (squamous vs non-squamous), and disease stage (Stage IVA vs Stage IVB) in the strata statement, and the CI calculated using a profile likelihood approach.

c  P-values were generated using the stratified log-rank test adjusting for PD-L1 (PDL1 ≥50% vs PD -L1 &lt;50%), histology (squamous vs non-squamous), and disease stage (Stage IVA vs Stage IVB) and using the Breslow approach for handling ties.

## Clinical studies in special populations

Table 50. Summary of Patient Age by Study (Full Analysis Set)

|                        | Number (%) of Patients   | Number (%) of Patients   | Number (%) of Patients   | Number (%) of Patients   | Number (%) of Patients   |
|------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                        | Age < 65                 | Age 65 to 74             | Age 75 to 84             | Age≥85                   | All Patients             |
| Total Patients         | 1529 (51.8)              | 1104 (37.4)              | 314 (10.6)               | 7 (0.2)                  | 2954                     |
| Controlled Trials      |                          |                          |                          |                          |                          |
| POSEIDON (D419MC00004) | 538 (53.1)               | 365 (36.0)               | 108 (10.7)               | 2 (0.2)                  | 1013                     |
| MYSTIC (D419AC00001)   | 551 (49.3)               | 430 (38.5)               | 134 (12.0)               | 3 (0.3)                  | 1118                     |
| NEPTUNE (D419AC00003)  | 440 (53.5)               | 309 (37.5)               | 72 (8.7)                 | 2 (0.2)                  | 823                      |

## In vitro biomarker test for patient selection for efficacy

As explained in the inclusion criteria of pivotal study POSEIDON, the collection of archival/residual diagnostic tumour tissue was mandatory, for potential analysis of various markers by IHC or other methods.

One of the exploratory objectives of the trial was to measure PD-L1 expression via the Ventana SP263 PD-L1 IHC assay and/or TMB to fully investigate the relationship between a patient's PD-L1 and/or TMB and efficacy outcomes with durvalumab, tremelimumab, and SoC regimens.

Data concerning PD-L1 expression were presented in the ancillary analyses section. Data concerning TMB expression and efficacy are not considered clinically relevant and are not presented in this report.

## Supportive study(ies)

Table 51 depicts the main similarities and differences among pivotal study POSEIDON and supportive studies MYSTIC and NEPTUNE.

<div style=\"page-break-after: always\"></div>

Table 51. Key similarities and differences among POSEIDON, MYSTIC and NEPTUNE.

|                      | POSEIDON                                               | MYSTIC                                                 | NEPTUNE                                                |
|----------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
| Patient population   | Advanced or metastatic NSCLC eligible for 1L treatment | Advanced or metastatic NSCLC eligible for 1L treatment | Advanced or metastatic NSCLC eligible for 1L treatment |
| Primary analysis set | All-comers                                             | PD- L1 TC≥25%                                          | bTMB>20 mut/megabase                                   |
| Stratification       | • Histology • PD-L1 (TC≥50%; TC<50%) • Disease stage   | • Histology • PD- L1 (TC≥25%; TC<25%)                  | • Histology • PD- L1 (TC≥25%; TC<25%) • Smoking status |
| Treatment arm        | • T + D + SoC • D + SoC • SoC                          | • T + D • D • SoC                                      | • T + D • SoC                                          |

## Study MYSTIC

MMYSTIC (D419AC00001) is a randomized, open-label, multicenter, global, Phase III study to determine the efficacy and safety of treatment with durvalumab (MEDI4736) in combination with tremelimumab (MEDI1123) or durvalumab monotherapy versus platinum-based standard of care (SoC) chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type advanced or metastatic non-small cell lung cancer (NSCLC). A schematic diagram of the overall study design is shown in Figure M. Table MYS summarises OS and PFS results in the primary efficacy dataset (PD-L1 ≥ 25%).

Figure 31. Overall study design of MYSTIC

<!-- image -->

- Statifietion by PD-L1 membrng-expmmion in tumoral tiwue (23%, =259e). Sites will ba supplied with PD-L1 stahus upon request at direase progession.

Offer of standard chomotherapy per Investigator diseretion.

Stndard of Care it an Investigator choice fom the follwing: paclitaxel + cabepltin, gemcitabina + cisplatin (cr carboplatin) (equwou only). pemetaxed + cisplatin (orcarbeplatin) (oogrnpn mnogedpaxwromod tumongy qoo smoumba-monj oournepmem paxoqomed *qoeged ogpgo roy poe (4quo smouenbs-oou)

Table 52. OS and PFS in the PD-L1 ≥ 25% analysis dataset of study MYSTIC

|                           | PD-L1 TC ≥25%   | PD-L1 TC ≥25%   | PD-L1 TC ≥25%   |
|---------------------------|-----------------|-----------------|-----------------|
| Efficacy parameter        | D + T           | D               | SoC             |
|                           | N = 163         | N = 163         | N = 162         |
| Overall survival          |                 |                 |                 |
| HR a, b, c , D + T vs SoC | 0.85            |                 |                 |
| 98.77% CI for HR          | 0.611, 1.173    |                 |                 |
| 2-sided p-value           | 0.202           |                 |                 |
| HR a, b, c , D vs SoC     |                 | 0.76            |                 |

<div style=\"page-break-after: always\"></div>

|                               | PD-L1 TC ≥25%             | PD-L1 TC ≥25%             | PD-L1 TC ≥25%             |
|-------------------------------|---------------------------|---------------------------|---------------------------|
| Efficacy parameter            | D + T                     | D                         | SoC                       |
| Efficacy parameter            | N = 163                   | N = 163                   | N = 162                   |
| 97.54% CI for HR              |                           | 0.564, 1.019              |                           |
| 2-sided p-value               |                           | 0.036                     |                           |
| Total events, n (%)           | 113 (69.3)                | 108 (66.3)                | 128 (79.0)                |
| Median OS (95% CI), months d  | 11.9 (9.0, 17.7)          | 16.3 (12.2, 20.8)         | 12.9 (10.5, 15.0)         |
| OS at 18 months (95% CI),% d  | 42.4 (34.7, 49.9)         | 47.8 (39.9, 55.3)         | 33.6 (26.4, 41.0)         |
| OS at 24 months (95% CI),% d  | 35.4 (28.1, 42.8)         | 38.3 (30.7, 45.7)         | 22.7 (16.5, 29.5)         |
| Progression-free survival     | Progression-free survival | Progression-free survival | Progression-free survival |
| HR e, f ,g , D + T vs SoC     | 1.05                      |                           |                           |
| 99.5% CI for HR               | 0.722, 1.534              |                           |                           |
| 2-sided p-value               | 0.705                     |                           |                           |
| HR e, f ,g , D vs SoC         |                           | 0.87                      |                           |
| 99.5% CI for HR               |                           | 0.593, 1.285              |                           |
| 2-sided p-value               |                           | 0.324                     |                           |
| Total events, n (%) h         | 118 (72.4)                | 106 (65.0)                | 112 (69.1)                |
| Median PFS (95% CI), months d | 3.9 (2.8, 5.0)            | 4.7 (3.1, 6.3)            | 5.4 (4.6, 5.8)            |
| PFS at 12 months (95% CI) d   | 25.8 (18.9, 33.1)         | 32.3 (24.8, 39.9)         | 14.3 (8.4, 21.7)          |

a The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous vs non-squamous), with ties handled by the Breslow approach.

b The 2-sided p-value was calculated using a stratified log-rank test adjusting for histology (squamous vs non squamous), with ties handled by the Breslow approach.

c The adjusted alpha levels for the treatment comparison were derived based upon the exact number of OS events using the Lan and DeMets approach that approximates the O'Brien Fleming spending function.

d Calculated using the Kaplan-Meier technique.

e The analysis was performed using stratified log-rank test adjusting for histology (squamous vs non squamous), with ties handled by the Breslow approach.

f The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous vs non-squamous), with ties handled by the Breslow approach.

g An HR of &lt;1 favors D + T or D to be associated with a longer PFS than SoC.

h Patients who have not progressed or died, or who progress or die after 2 or more missed visits, are censored at the latest evaluable RECIST assessment, or day 1 if there are no evaluable visits. Patients with a RECIST progression within 2 visits of baseline who do not have any evaluable visits or do not have a baseline assessment are censored at Day 1.

Data cutoff for OS: 04OCT2018.

Data cutoff: for PFS: 01JUN2017.

PFS is based on BICR assessment using RECIST 1.1.

<div style=\"page-break-after: always\"></div>

Figure 32. Kaplan-Meier plot of OS in the ITT of MYSTIC, DCO 04-OCT-2018

<!-- image -->

## Study NEPTUNE

NEPTUNE was a Phase III, randomized, open-label study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with EGFR and ALK wild-type advanced or metastatic NSCLC. Crossover from SoC to durvalumab monotherapy or durvalumab + tremelimumab combination therapy was not permitted. The primary efficacy objective was to evaluate the OS benefits of durvalumab + tremelimumab vs. SoC used as 1L treatment. During the course of the study and based on the emerging results from MYSTIC study, the primary endpoint for NEPTUNE was amended after completion of enrolment to prospectively investigate OS in bTMB ≥ 20 mut/Mb population (results in Table 53). A schematic diagram of the overall study design is shown in Figure 33.

Figure 33. Overall study design of NEPTUNE

<!-- image -->

- The same study design was applied to the China cohort. The number of patients in Figure 1 reflects those for the Global cohort. Enrollment in China was to continue after the Global cohort enrollment was completed.
- b Offer of standard chemotherapy per Investigator's discretion
- SoC is an Investigator choice from the following: paclitaxel + carboplatin, gemcitabine + cisplatin (or carboplatin) (squamous only). pemetrexed + cisplatin (or carboplatin) (non-squamous only), and for eligible patients, pemetrexed maintenance (non-squamous only following pemetrexed/platinum induction

<div style=\"page-break-after: always\"></div>

Table 53. OS in the bTMB ≥ 20 analysis dataset of study NEPTUNE

|                                 | bTMB ≥20 analysis set     | bTMB ≥20 analysis set     |
|---------------------------------|---------------------------|---------------------------|
|                                 | D + T                     | SoC                       |
| Efficacy parameter              | N = 69                    | N = 60                    |
| HR (95% CI), D + T vs SoC       | 0.71 (0.485, 1.045) a,b,c | 0.71 (0.485, 1.045) a,b,c |
| 2-sided p-value                 | 0.0808                    | 0.0808                    |
| Total events, n (%)             | 54 (78.3)                 | 53 (88.3)                 |
| Median OS (95% CI), months d    | 11.7 (8.6, 15.2)          | 9.1 (7.8, 12.6)           |
| OS at 12 months (95% CI), (%) d | 49.3 (37.1, 60.4)         | 40.8 (28.3, 52.9)         |
| OS at 18 months (95% CI), (%) d | 36.2 (25.1, 47.4)         | 20.4 (11.3, 31.4)         |
| OS at 24 months (95% CI), (%) d | 26.1 (16.4, 36.8)         | 13.6 (6.4, 23.6)          |

Figure 34. Kaplan-Meier plot of OS in the ITT of NEPTUNE, DCO 24-JUN-2019

<!-- image -->

## 2.4.3. Discussion on clinical efficacy

The applicant has submitted an application to extend the indication for tremelimumab, an anti-CTLA-4 immune checkpoint inhibitor, for use in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adults with metastatic NSCLC without EGFR or ALK aberrations. The application is based on efficacy data from POSEIDON, a pivotal phase III, three-arm, randomised, multi-centre, open-label study which compared durvalumab + chemotherapy (D+SoC, Arm 2) and tremelimumab + durvalumab + chemotherapy (T+D+SoC, Arm 1) to standard-of-care histology-specific platinum-based chemotherapy (SoC, Arm 3).

A total of 1013 patients were randomised between June 2017 and September 2018. The dual primary endpoints of BICR-PFS and OS were analysed in the ITT of the D+SoC vs. SoC arms, while identical secondary endpoints were evaluated in the ITT of the T+D+SoC vs. SoC arms.

<div style=\"page-break-after: always\"></div>

## Design and conduct of clinical studies

The applicant held several regulatory interactions with the US FDA during the development of tremelimumab in NSCLC, but scientific advice has not been sought from the CHMP.

Experimental and control arms: The overall design of POSEIDON resembles that of other recent landmark trials in the treatment-naïve setting of metastatic driver-negative NSCLC regardless of PD-L1 expression, with platinum-based chemotherapy as control arm. Currently, multiple regiments for these patients are approved and recommendable across Europe, most of them containing one or more immune checkpoint inhibitors (i.e., pembrolizumab or atezolizumab or nivolumab + ipilimumab) added to histology-selected platinum doublets. Even when this implies that platinum-based chemotherapy by itself has been long outdated as standard of care in this setting, it was still an appropriate choice of treatment at the time of design and conduct of POSEIDON.

The fact that crossover was not allowed to avoid confounding OS is understood. Noting that a significant number of patients from the control arm would likely receive immune checkpoint inhibitors at progression, an exploratory PFS2 analysis was planned.

Induction vs. maintenance effect: In both experimental arms (D+SoC and T+D+SoC), after induction chemotherapy + durvalumab +/- tremelimumab, durvalumab was to be maintained Q4W until progressive disease. Although such design does not allow to disentangle effect magnitude of induction vs. maintenance immune checkpoint inhibition, this does not constitute an impediment to evaluate the B/R profile of the add-on products in this palliative setting.

Study participants: Inclusion/exclusion criteria in the POSEIDON trial did not suffer any major amendments along study conduct and appropriately reflect the target population as in the proposed therapeutic indication. Although the inclusion criteria declare that staging is to be determined per the IASLC staging manual in thoracic oncology 2016 by Rami-Porta et al, such parameters correspond to the AJCC 8th edition by Amin et al. The requirements for inclusion of patients with brain metastases are appropriate and in line with similar trials. PD-L1 testing by the SP263 IHC assay was centralised during the screening phase and before randomisation, which is endorsed.

Objectives/endpoints: The current extension of indication application for tremelimumab is based in efficacy results from the secondary objectives of this study. An improvement in survival is considered the most compelling outcome of a pivotal trial in Oncology, especially when supported by a reciprocal prolongation of PFS. The definitions for OS and RECIST 1.1-based BICR-PFS according to the protocol and SAP are appropriate. The definitions for the other secondary endpoints of ORR, DoR, PFS2 and PROs are also endorsed.

Statistical methods: Sample size calculations are adequate. The stratification factors [PD-L1 tumour expression status (&lt;50%; ≥ 50%), stage (IVA vs IVB) and histology (non-squamous vs squamous)] are clinically relevant and thus appropriate in this disease context. Censoring rules for PFS and OS are acceptable. The planned sensitivity and supplementary analyses to assess robustness of PFS and OS results are adequate, no additional analyses have been requested. Concerning interim analyses (one for PFS at approximately 80% of targeted events and three for OS at approximately 45%, 61% and 84%), an alpha spending function was used to account for multiplicity due to multiple looks, which is acceptable. Regarding the hierarchical testing procedure, if at least OS or PFS of D+SoC vs. SoC were statistically significant, the corresponding alpha portion was transferred to the T+D+SoC vs. SoC comparison. This strategy controls the type I error.

Participant flow and recruitment: 1807 patients were screened for eligibility. The screen failure rate (42%) is higher than expected, but understandable in view of stringent inclusion/exclusion criteria: the majority of patients failed screening because of EGFR/ALK status, missing PD-L1 status or investigator

<div style=\"page-break-after: always\"></div>

judgement. The proportion of patients who did not receive the assigned treatment across all three arms of POSEIDON is minimal and follows the characteristic attrition pattern in open-label trials: slightly more patients withdrew consent in the control arm. Recruitment of the whole study took approximately 1 year and 3 months. Median duration of follow-up of ~1 year in the ITT is considered borderline for assessment of B/R in the given clinical setting.

Conduct of the study: Important protocol deviations occurred in a small proportion of patients and are overall balanced among arms. A major amendment modified the dual primary endpoints as of protocol V 4.0 (25-SEP-2018), when all patients had already been recruited (last patient randomised 19-SEP-2018) and before the first interim analysis of PFS/OS on 07-JAN-2019. OS for the comparison of D+SoC vs. SoC was upgraded, while PFS of T+D+SoC vs. SoC was downgraded, establishing the comparisons of D+SoC vs. SoC in the first level (primary endpoints), while relegating the comparisons of T+D+SoC vs. SoC to secondary endpoints. According to the applicant, this change was justified on emerging external data from other immunotherapy trials. Since the statistical integrity of the trial could have been compromised due to changes in SAP, analyses according to original test hierarchy and study populations (first 804 patients randomised) were requested, which obtained successful results for PFS and OS testing of T+D+SoC vs. SoC.

Baseline data: The demographic characteristics of patients were relatively balanced among all three arms of treatment and correspond to what is expected within the clinical setting of advanced drivernegative NSCLC: median age was 64 years (27 to 87 years); 76% were male; 56% white, 35% Asian, 2% black; current/past smokers 78%; 33% had ECOG PS 0. Disease characteristics were also balanced among arms: 50% had stage IVA and 50% IVB; 63% had non-squamous tumours and 37% squamous; brain/CNS metastases were present in 10.5% of patients; presence of KRAS mutations was evaluated in ~15% (149/1013) of the ITT, and documented in 21% (31/149) of those tested. The distribution of patients according to tumour PD-L1 status across diverse thresholds (&lt;/ ≥ 50%, &lt;/ ≥ 25%, &lt;/ ≥ 1%) was balanced among all three arms of treatment and represents the global pattern of PD-L1 expression in advanced NSCLC.

## Efficacy data and additional analyses

The primary OS endpoint (D+SoC vs SoC) in study POSEIDON did not meet statistical significance. However, the other primary PFS endpoint that compared the same arms showed statistical superiority and thus alpha was propagated to the next testing level, in which OS and PFS were evaluated as key secondary endpoints in the T+D+SoC vs. SoC arms.

OS: At data cutoff 12-MAR-2021 and with a median survival follow-up of 12.5 months, 800 deaths had occurred (79% of OS maturity) in the ITT population of study POSEIDON. Treatment with T+D+SoC showed a statistically significant survival benefit as compared with SoC: HR for OS was 0.77 (95% CI 0.65, 0.92), p-value 0.00304. K-M estimates of median OS were 14.0 months in the T+D+SoC arm and 11.7 months in the SoC arm. Survival performance of the chemotherapy-only control arm in POSEIDON is comparable to other pivotal trials in a similar PD-L1 all-comer setting of metastatic NSCLC: range of 10.6 in KEYNOTE-189 to 13.9 months in IMpower130. The K-M curves of T+D+SoC vs. SoC separate as of the 10th month, noting a delayed treatment effect from added anti-CTLA-4/PDL1 therapy. Important censoring occurs as of the 30th month of follow-up, but landmark analysis at 24 months (OS24) shows a considerably higher proportion of patients alive in the T+D+SoC (33%) as compared to the SoC (22%) arm.

Acknowledging differences in study design -particularly selection of squamous (SQ) or non-squamous (NSQ) histologies, or allowing both- and limitations from cross-trial comparisons, it is to note that longer median survival was observed in akin studies in which only anti-PD-1/PD-L1 agents were added

<div style=\"page-break-after: always\"></div>

to backbone platinum-based chemotherapy in the experimental arm: 22.0 months in the chemo + pembrolizumab arm in metastatic NSQ NSCLC (KEYNOTE-189; Rodríguez-Abreu et al, JCO 2020); 21.9 months in the chemo + cemiplimab arm in advanced SQ/NSQ NSCLC (EMPOWER-Lung3; Gogishvili et al, ESMO 2021); 19.5 months in the chemo + atezolizumab arm in metastatic SQ/NSQ NSCLC (IMpower150, Tecentriq SmPC); 18.6 NSQ NSCLC (IMpower130; Cappuzzo et al, Ann Onc 2018); 17.1 months in the chemo + however, the addition of both anti-CTLA-4 and anti-PD-1 agents to backbone platinum-based chemotherapy produced almost identical median OS results as those observed in POSEIDON: 14.1 months in the histology-based chemotherapy + nivolumab + ipilimumab arm in patients with metastatic SQ/NSQ NSCLC (CheckMate 9LA; Paz-Ares et al, Lancet Oncol 2021).

months in the chemo + atezolizumab arm in metastatic pembrolizumab arm in metastatic SQ NSCLC (KEYNOTE-407; Paz-Ares et al, JTO 2020). Interestingly, BICR-PFS: At data cutoff 24-JUL-2019, 749 PFS events (74% maturity) had occurred across the three arms of POSEIDON. K-M estimated median PFS was numerically higher in the T+D+SoC arm (6.2 months) as compared with the SoC arm (4.8 months), while HR for PFS outlines the statistical advantage from T+D+SoC vs. SoC: 0.72 (95% CI 0.60, 0.86), p-value 0.00031. The K-M curves separate as of the second month and remain separated, highlighting the PFS advantage of T+D+SoC. Overall, PFS results from the experimental (both T+D+SoC and D+SoC arms) and control arms of POSEIDON are comparable to those from other pivotal trials in the same setting. Results of PFS by investigator are overall comparable to BICR assessment and the HR for INV-PFS is consistent with that of BICR-PFS, discrepant declarations of the RECIST event occurred in a reasonably low number of instances. BICR-ORR/DoR: Rather than using the ITT, the calculations of ORR were done using patients with measurable disease as the denominator. This is acceptable in a phase III trial since OS and PFS are prioritised in hierarchical testing. Both confirmed and unconfirmed responses (almost all of them partial) were numerically higher in the T+D+SoC arm as compared to the control SoC arm. However, the proportion of responders (unconfirmed responses) was nearly identical between both experimental arms: 46.3% in T+D+SoC vs. 48.5% in D+SoC. Responses (unconfirmed responses) were more durable in the T+D+SoC arm (median DoR 7.4 months) as compared to the SoC arm (4.2 months), supporting the delayed treatment effect hypothesis portrayed in the OS analysis. Subsequent treatment/PFS2: A notably higher proportion of patients received subsequent treatments in the SoC arm (60%) as compared to either of the experimental arms (41% in T+D+SoC, 44% in D+SoC). As expected, the proportion of second-line immunotherapy was higher in the immunotherapy-naïve SoC arm (49%, 95 out of 193) as compared to both T+D+SoC (9%, 11/121) and D+SoC (9%, 12/137). Across the three arms of POSEIDON, 66% (435/658) of the PFS2 events were deaths in the absence of second progression. Albeit the median time to second progression or death (PFS2) was comparable among all three arms (10.2 months in T+D+SoC, 10.0 in D+SoC and 9.1 in SoC), HR for PFS2 (0.72) suggests sustained benefit from T+D+SoC vs. SoC.

Ancillary analyses: OS and PFS benefits from T+D+SoC vs. SoC seem to be maintained across most of the prespecified subgroups. However, in elderly patients ( ≥ 75 years of age) a HR of 1.05 (95% CI: 0.64, 1.71) for OS was reported for T+D+SoC (n=35) vs. SoC (n=40). Due to the exploratory nature of this subgroup analysis no definitive conclusions can be drawn. This said, considering that an overall worse safety profile was observed in this subgroup of patients, a warning was included in section 4.4 of the SmPC stating that in elderly the combination therapy should be used with caution after careful consideration of the potential benefit/risk on an individual basis. Exploratory efficacy and safety results in this subgroup are outlined in sections 4.8 and 5.1 of the SmPC, respectively.

Importantly, the efficacious advantage -in terms of OS, PFS and ORR- of T+D+SoC vs. SoC is maintained regardless of PD-L1 expression status, i.e., above and below diverse PD-L1 cut-offs. Of

<div style=\"page-break-after: always\"></div>

note, a similar outcome regarding PD-L1 subgroups was observed in the CheckMate-9LA trial, when the nivolumab + ipilimumab + chemotherapy arm was compared against the chemotherapy arm in an akin population of advanced NSCLC (p. 99/157, EPAR EMEA/H/C/WS1783).

The sensitivity analyses of OS and PFS are consistent with the primary analysis of both variables.

Exploratory analysis of T+D+SoC vs. D+SoC: The survival K-M curves of the experimental arms remain close along the first year of follow-up, and subsequently show a wider separation, suggesting the benefit from added tremelimumab is established in the long term. This hypothesis is reinforced when looking at the duration of response data, as the K-M curves between T+D+SoC and D+SoC exhibit wider separation than those from OS or PFS. Importantly, OS subgroup analyses in the PD-L1 &lt;1% population -about one third of the ITT- suggest the magnitude of survival benefit from T+D+SoC is particularly higher in this subgroup, as compared to that seen in across the other PD-L1 cut-offs, while the contribution of tremelimumab appears to be less clear as PD-L1 expression increases. However, these comparisons portray an exploratory nature -they were not statistically powered- and thus no firm conclusions can be drawn.

Supportive data from MYSTIC and NEPTUNE: Including POSEIDON, all three trials were open-label, randomised, had a similar metastatic NSCLC targeted population, and dual primary endpoints of OS and PFS. The essential difference was that MYSTIC and NEPTUNE did now allow a platinum-based backbone chemotherapy in the experimental arms, while POSEIDON did. The overall efficacy outcome of MYSTIC and NEPTUNE -none met their primary endpoints- was not different from other trials in which anti-PD-L1 monotherapy failed to show benefits for the ITT population, suggesting that the subgroup of patients who drive the beneficial trend for ICI-monotherapy were high-PD-L1 expressors (usually defined as PD-L1 ≥ 50%). Whether OS and PFS data from the ITT of either trial are supportive of efficacy benefits from adding tremelimumab to D+SoC is debatable, but in any case, it can be inferred that a detrimental OS/PFS effect is not evident.

## 2.4.4. Conclusions on the clinical efficacy

Although the primary OS endpoint for the comparison of durvalumab + chemotherapy vs. chemotherapy was not met in study POSEIDON, the favourable PFS comparison of these arms allowed testing of the secondary endpoints of OS and PFS in the tremelimumab + durvalumab + chemotherapy (T+D+SoC) vs. chemotherapy (SoC) arms. In the targeted population of patients with metastatic EGFR/ALK-negative NSCLC regardless of tumour PD-L1 expression, OS and PFS from treatment with T+D+SoC were statistically superior to SoC chemotherapy. Secondary endpoints of ORR, DoR and PFS2 endorsed such benefits, as did subgroup and sensitivity analyses.

## 2.5. Clinical safety

## Introduction

The pivotal study to support this indication is POSEIDON, a phase III, randomised, multicentre, threearm, open-label study, designed to compare the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (D+SoC) with that of SoC alone chemotherapy (SoC) for the first -line treatment in patients with metastatic NSCLC. Additionally, the study also planned to compare the efficacy and safety of tremelimumab, durvalumab and SoC chemotherapy combination (T+D+SoC) with that of SoC chemotherapy in the same patient population.

<div style=\"page-break-after: always\"></div>

Safety dataset: The safety analysis set (SAS) of POSEIDON included all patients who received at least 1 dose of study treatment and comprised 997 patients: T + D + SoC (n = 330); D + SoC (n = 334); and SoC chemotherapy (n = 333). Of note, 1 patient who was randomized to the T + D + SoC arm and 1 patient who was randomized to the D + SoC arm only received SoC chemotherapy (see protocol deviations) and were included in the SoC chemotherapy arm of the safety analysis set.

For further support in the evaluation of the safety profile of tremelimumab, the applicant provided data from a safety pool ('T + D pan-tumour pool') that included 2280 patients from 9 studies, who had received at least one dose of durvalumab at 1500 mg Q4W, 20 mg/kg Q4W or 10 mg/kg Q2W, in combination with tremelimumab at 75 mg Q4W or 1 mg/kg Q4W for any line of therapy across tumour types (Table 54). The main advantage of including the results from the T+D pan-tumour pool in the safety assessment report is to be able to elucidate the contribution of immunotherapy components to the combination safety profile as in the included studies patients only received T+D.

Table 54. Summary of clinical studies in T + D pan-tumour pool

| Study 06 (D4190C00006) Phase I    | Durvalumab 20 mg/kg Q4W + tremelimumab 1 mg/kg Q4W for 4 doses followed by durvalumab monotherapy 20 mg/kg Q4W for up to 9 doses in patients with advanced NSCLC (n = 355) DCO 19-NOV-2019                                            |
|-----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study 10 (D4190C00010) Phase I    | Durvalumab 20 mg/kg Q4W + tremelimumab 1 mg/kg Q4W for up to 4 doses followed by durvalumab monotherapy 20 mg/kg Q4W for up to 12 months in patients with advanced solid tumours (n = 341) DCO 31-MAR-2018                            |
| Japan 02 (D4190C00002) Phase I    | Durvalumab 20 mg/kg Q4W + tremelimumab 1 mg/kg Q4W for up to 4 doses followed by durvalumab monotherapy 20 mg/kg Q4W for up to 12 months in patients with advanced solid tumours (n = 124) DCO 31-MAR-2018                            |
| Study 22 (D4190C00022) Phase I/II | Durvalumab 1500mg Q4W + tremelimumab 75 mg Q4W for up to 4 doses, followed by durvalumab 1500 mg Q4W until disease progression in patients with advanced hepatocellular carcinoma (n = 127) DCO 6-NOV-2020                            |
| ARCTIC (D4191C00004) Phase III    | Sub-study B: Durvalumab 20 mg/kg Q4W + tremelimumab 1 mg/kg Q4W for up to 4 doses followed by durvalumab monotherapy 10 mg/kg Q2W for up to 18 doses in patients with advanced NSCLC (n = 173) DCO 9-FEB-2018                         |
| MYSTIC (D419AC00001) Phase III    | Durvalumab 20 mg/kg Q4W + tremelimumab 1 mg/kg Q4W for up to 4 doses followed by durvalumab monotherapy 20 mg/kg Q4W until disease progression in patients with advanced NSCLC (n = 371) DCO 4-OCT-2018                               |
| NEPTUNE (D419AC00003) Phase III   | Durvalumab 20 mg/kg Q4W + tremelimumab 1 mg/kg Q4W for up to 4 doses followed by durvalumab monotherapy 20 mg/kg Q4W until disease progression in patients with advanced NSCLC (n = 410) DCO 24-JUN-2019                              |
| CONDOR (D4193C00003) Phase II     | Durvalumab 20 mg/kg Q4W + tremelimumab 1 mg/kg Q4W for up to 4 doses followed by durvalumab monotherapy 10 mg/kg Q2W for up to 18 doses in patients with squamous cell carcinoma of the head and neck (n = 133) DCO 27-AUG-2018       |
| EAGLE (D4193C00002) Phase III     | Durvalumab 20mg/kg Q4W + tremelimumab 1 mg/kg Q4W for up to 4 doses followed by durvalumab monotherapy 10 mg/kg Q2W until disease progression in patients with squamous cell carcinoma of the head and neck (n = 246) DCO 10-SEP-2018 |

AEs: The integrated analysis of adverse events (AEs) for the safety pools was based on all treatment-emergent adverse events (TEAEs) as defined in each individual study. MedDRA v23.1 was used for coding of AE data. Data from studies originally reported in previous versions of MedDRA were upversioned to MedDRA v23.1 for the integrated safety database.

<div style=\"page-break-after: always\"></div>

AESIs: Adverse events of special interest (AESIs) are defined as AEs with potential inflammatory or immune-mediated mechanism that may require frequent monitoring and/or interventions such as corticosteroids, immunosuppressants, and/or endocrine therapy. Endocrine therapies include standard endocrine supplementation, as well as treatment of symptoms resulting from endocrine disorders (eg. therapies for hyperthyroidism include beta blockers [eg. propranolol], calcium channel blockers [eg. verapamil, diltiazem], methimazole, propylthiouracil, and sodium perchlorate).

imAEs: Immune-mediated adverse events (imAEs) are AESIs (excluding infusion related/hypersensitivity/anaphylactic reaction) consistent with an immune-mediated mechanism that require treatment with systemic corticosteroids, high-dose steroids, immunosuppressants, or endocrine therapy.

The AESI categories include dermatitis/rash, pneumonitis, diarrhoea/colitis, endocrinopathies (adrenal insufficiency, hyperthyroid events, hypothyroid events, hypophysitis, thyroiditis, and Type I diabetes mellitus), hepatic events, intestinal perforations, myocarditis, myositis, renal events, pancreatic events, myasthenia gravis, Guillain-Barre syndrome and other rare/miscellaneous events. Infusion related reactions and hypersensitivity/anaphylactic reactions are AESIs; however, these are not assessed for imAE designation because they are common to mAb drugs in general and occur due to a mechanism of action different from that for imAEs.

Adjudication of imAEs: A suspected immune-mediated adverse event (imAE) was identified as AESI treated with systemic steroids, other immunosuppressants, and/or endocrine therapy, except pneumonitis AESIs, which are all suspected imAE. All suspected imAEs underwent medical review, which was performed in a blinded manner.

A confirmed imAE is a suspected imAE that, after medical review, is deemed consistent with an immune-mediated mechanism of action, and where there is no clear alternative etiology. The process for adjudicating imAEs starting from the study level AE reporting dataset through to confirmed imAE included the steps depicted in Figure 35, and the process of adjudicating imAEs is presented in detail in the imAE Charter.

Figure 35. The process for adjudicating imAEs

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Patient exposure

## Table 55. Duration of overall exposure, SAS POSEIDON and pan-tumour pool

| Exposure               | characteristic        | POSEIDON              | POSEIDON        | POSEIDON      | T + D pan-tumour pool (N = 2280)   |
|------------------------|-----------------------|-----------------------|-----------------|---------------|------------------------------------|
|                        |                       | T + D + SoC (N = 330) | D + SoC (N=334) | SoC (N = 333) |                                    |
| Total duration (weeks) | Mean (SD)             | 49.6 (48.15)          | 45.3 (44.7)     | 25.8 (29.00)  | 26.9 (30.52)                       |
| treatment a            | Median (Min, Max)     | 29.9 (1, 190)         | 28.7 (0.1, 188) | 18.0 (1, 184) | 16.0 (1, 218)                      |
| treatment a            | Total treatment years | 313.8                 | 289.9           | 164.9         | 1176.4                             |

a Total treatment duration = (last dose date + X days or death date or DCO whichever occurs earlier - first dose date +1) / 7 . X is defined as the planned frequency in dosing (in days) - 1. X is based on the planned dosing frequency of the patient's last dose and defined as per the individual study's SAP.

## Table 56. Exposure to durvalumab and tremelimumab, SAS POSEIDON and pantumour pool

|                                    |                         | POSEIDON T + D + SoC   | POSEIDON T + D + SoC   | T + D Pan-tumour pool   | T + D Pan-tumour pool   |
|------------------------------------|-------------------------|------------------------|------------------------|-------------------------|-------------------------|
| Exposure characteristic            | Exposure characteristic | Durvalumab (N = 330)   | Tremelimumab (N = 330) | Durvalumab (N = 2280)   | Tremelimumab (N = 2280) |
| Total number of infusions          | Mean (SD)               | 12.5 (11.74)           | 4.3 (1.43)             | 7.3 (8.49)              | 3.0 (1.32)              |
| Total number of infusions          | Median (Min, Max)       | 8.0 (1, 49)            | 5.0 (1, 9)             | 4.0 (1, 61)             | 3.0 (1, 9)              |
| Total treatment duration (weeks) a | Mean (SD)               | 48.8 (47.98)           | 17.8 (7.36)            | 26.8 (30.47)            | 15.3 (11.79)            |
| Total treatment duration (weeks) a | Median (Min, Max)       | 29.8 (1, 190)          | 20.0 (1, 38)           | 16.0 (1, 218)           | 15.6 (1, 100)           |
| Total treatment duration (weeks) a | Total treatment years   | 308.8                  | 112.4                  | 1171.9                  | 670.0                   |

a Total treatment duration = (last dose date + X days or death date or DCO whichever occurs earlier - first dose date +1) / 7 . X is defined as the planned frequency in dosing (in days) - 1. X is based on the planned dosing frequency of the patient's last dose and defined as per the individual study's SAP.

<div style=\"page-break-after: always\"></div>

Table 57. Exposure to chemotherapy, SAS POSEIDON

|                                                  | Number of (%) patients   | Number of (%) patients   | Number of (%) patients   | Number of (%) patients   |
|--------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                                                  | T+D+SoC (N=330)          | D+SoC (N=334)            | SoC (N=333)              | Total (N=997)            |
| Received SoC in combination stage                | 329a                     | 334                      | 333                      | 996                      |
| Pemetrexed doublet                               | 198 (60.2)               | 198 (59.3)               | 204 (61.3)               | 600 (60.2)               |
| Pemetrexed + cisplatin                           | 31 (9.4)                 | 29 (8.7)                 | 33 (9.9)                 | 93 (9.3)                 |
| Pemetrexed + carboplatin                         | 167 (50.8)               | 169 (50.6)               | 171 (51.4)               | 507 (50.9)               |
| Gemcitabine doublet                              | 107 (32.5)               | 107 (32.0)               | 112 (33.6)               | 326 (32.7)               |
| Gemcitabine + cisplatin                          | 15 (4.6)                 | 17 (5.1)                 | 20 (6.0)                 | 52 (5.2)                 |
| Gemcitabine + carboplatin                        | 92 (28.0)                | 90 (26.9)                | 92 (27.6)                | 274 (27.5)               |
| Abraxane doublet (Abraxane + carboplatin)        | 24 (7.3)                 | 29 (8.7)                 | 17 (5.1)                 | 70 (7.0)                 |
| Received pemetrexed doublet in maintenance stage | 149                      | 159                      | 131                      | 439                      |
| Pemetrexed maintenanceb                          | 149 (75.3)               | 159 (80.3)               | 131 (64.2)               | 439 (73.2)               |

Percentages are calculated from number of patients in the safety analysis set in that treatment arm that received at least one dose of the chemotherapy regimen in the combination stage.

Patients who received chemotherapy during re-treatment are also included.

Chemotherapy exposure for patients who switched from cisplatin to carboplatin (N=12) is summarized based on the chemotherapy regimen received at the start of treatment.

<div style=\"page-break-after: always\"></div>

Table 58. Duration of chemotherapy exposure, SAS POSEIDON

|                                                  | T+D+SoC (N=330)    | D+SoC (N=334)      | SoC (N=333)        |
|--------------------------------------------------|--------------------|--------------------|--------------------|
| Total treatment duration (weeks)a                |                    |                    |                    |
| Mean (SD)                                        | 35.35 (41.733)     | 32.70 (39.346)     | 25.83 (29.004)     |
| Median (Min, Max)                                | 15.00 (1.1, 189.6) | 15.50 (0.1, 187.3) | 18.00 (0.7, 184.4) |
| Total treatment years                            | 222.9              | 209.3              | 164.9              |
| Number of infusions                              |                    |                    |                    |
| Mean (SD)                                        | 10.7 (9.77)        | 10.1 (9.16)        | 9.1 (8.33)         |
| Median (Min, Max)                                | 8.0 (1, 49)        | 8.0 (1, 48)        | 8.0 (1, 57)        |
| Number of cycles receivedb                       |                    |                    |                    |
| Mean (SD)                                        | 9.3 (10.31)        | 8.7 (9.66)         | 7.6 (8.42)         |
| Median (Min, Max)                                | 4.0 (1, 49)        | 4.0 (1, 48)        | 6.0 (1, 57)        |
| Number of patients that switched treatment n (%) | 4 (1.2)            | 1 (0.3)            | 7 (2.1)            |

Twelve patients switched from cisplatin to carboplatin.

Percentages are calculated from mumber of patients in the safety analysis set in that treatment arm.

Chemotherapy of a patient who received it during re-treatment is included in this table also.

<div style=\"page-break-after: always\"></div>

## Adverse events

Overview of all AEs:

## Table 59. Overview of adverse events in SAS POSEIDON and pan-tumour pool

|                                                                     | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a         |
|---------------------------------------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------------|
| Category of AE                                                      | T + D + SoC (N = 330)      | D + SoC (N = 334)          | SoC (N = 333)              | T + D Pan- tumor pool (N = 2280) |
| Any AE                                                              | 321 (97.3)                 | 321 (96.1)                 | 320 (96.1)                 | 2160 (94.7)                      |
| Any AE of maximum CTCAE Grade 3 or Grade 4 b                        | 176 (53.3)                 | 183 (54.8)                 | 172 (51.7)                 | 1127 (49.4)                      |
| Any AE with outcome = death                                         | 41 (12.4)                  | 34 (10.2)                  | 30 ( 9.0)                  | 153 ( 6.7)                       |
| Any SAE (including events with outcome = death) c                   | 146 (44.2)                 | 134 (40.1)                 | 117 (35.1)                 | 1020 (44.7)                      |
| Any AE leading to discontinuation of any study treatment            | 73 (22.1)                  | 68 (20.4)                  | 51 (15.3)                  | 367 (16.1)                       |
| Any AE leading to discontinuation of durvalumab or tremelimumab     | 57 (17.3)                  | 0                          | 0                          | 367 (16.1)                       |
| Any AE leading to dose modification of any study treatment d        | 206 (62.4)                 | 197 (59.0)                 | 179 (53.8)                 | 622 (27.3)                       |
| Any AE leading to dose modification of durvalumab or tremelimumab d | 174 (52.7)                 | 172 (51.5)                 | 0                          | 622 (27.3%)                      |
| AEs leading to dose delay/interruption of any study treatment e     | 189 (57.3)                 | 186 (55.7)                 | 143 (42.9)                 | 622 (27.3)                       |
| AEs leading to dose reduction of chemotherapy f                     | 38 (11.5)                  | 32 (9.6)                   | 54 (16.2)                  | 0                                |
| Infusion reaction AEs g                                             | 14 (4.2)                   | 10 (3.0)                   | 7 (2.1)                    | 45 (2.0)                         |

a Patients with multiple events in the same category are counted only once in that category. Patients with events in more than one category are counted once in each of those categories.

b Maximum CTCAE grade per patient is considered.

c Seriousness, as assessed by the Investigator. An AE with missing seriousness is considered serious.

d Includes AEs on the AE CRF form with action taken indicating dose reduction, dose delay or dose interruption, and AEs meeting study level dose delay definitions, where applicable.

Includes AEs with an onset date on or after the date of first dose or pre-treatment AEs that increase in severity on or after the date of first dose up to and including 90 days following the date of last dose of study medication or up to and including the date of initiation of the first subsequent therapy (whichever occurs first). Disease progression AEs reported in Study 06 and Study 10 are not included in this summary.

e AEs on the AE eCRF page with Action taken=\"Drug interrupted\" for at least one treatment or with Treatment cycle delayed = \"Yes\" on any exposure eCRF page.

f AEs on the AE eCRF page with Action taken=\"Dose reduced\" for at least one chemotherapy.

g As assessed by the investigator.

<div style=\"page-break-after: always\"></div>

Table 60. Overview of most common AEs (incidence ≥ 10% in any arm) in SAS POSEIDON and pan-tumour pool

| Preferred term                       | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a         |
|--------------------------------------|----------------------------|----------------------------|----------------------------------|
| Preferred term                       | POSEIDON                   | POSEIDON                   | T + D Pan-tumour pool (N = 2280) |
| Preferred term                       | T + D + SoC (N = 330)      | SoC (N = 333)              | T + D Pan-tumour pool (N = 2280) |
| Patients with any AE                 | 321 (97.3)                 | 320 (96.1)                 | 2160 (94.7)                      |
| Anaemia                              | 164 (49.7)                 | 163 (48.9)                 | 365 (16.0)                       |
| Nausea                               | 137 (41.5)                 | 122 (36.6)                 | 449 (19.7)                       |
| Neutropenia                          | 99 (30.0)                  | 78 (23.4)                  | 27 ( 1.2)                        |
| Decreased appetite                   | 93 (28.2)                  | 82 (24.6)                  | 499 (21.9)                       |
| Fatigue                              | 81 (24.5)                  | 74 (22.2)                  | 537 (23.6)                       |
| Diarrhoea                            | 71 (21.5)                  | 51 (15.3)                  | 526 (23.1)                       |
| Rash                                 | 64 (19.4)                  | 22 (6.6)                   | 298 (13.1)                       |
| Constipation                         | 63 (19.1)                  | 79 (23.7)                  | 382 (16.8)                       |
| Thrombocytopenia                     | 60 (18.2)                  | 57 (17.1)                  | 41 (1.8)                         |
| Vomiting                             | 60 (18.2)                  | 45 (13.5)                  | 268 (11.8)                       |
| Asthenia                             | 56 (17.0)                  | 41 (12.3)                  | 302 (13.2)                       |
| Pyrexia                              | 53 (16.1)                  | 23 (6.9)                   | 326 (14.3)                       |
| Pneumonia                            | 47 (14.2)                  | 32 (9.6)                   | 208 ( 9.1)                       |
| Alanine aminotransferase increased   | 46 (13.9)                  | 44 (13.2)                  | 182 ( 8.0)                       |
| Aspartate aminotransferase increased | 42 (12.7)                  | 38 (11.4)                  | 193 ( 8.5)                       |
| Leukopenia                           | 42 (12.7)                  | 39 (11.7)                  | 15 ( 0.7)                        |
| Arthralgia                           | 41 (12.4)                  | 21 (6.3)                   | 270 (11.8)                       |
| Hypothyroidism                       | 39 (11.8)                  | 4 (1.2)                    | 248 (10.9)                       |
| Neutrophil count decreased           | 39 (11.8)                  | 59 (17.7)                  | 22 (1.0)                         |
| Headache                             | 37 (11.2)                  | 25 (7.5)                   | 160 (7.0)                        |
| Pruritus                             | 36 (10.9)                  | 15 (4.5)                   | 424 (18.6)                       |
| Alopecia                             | 33 (10.0)                  | 20 ( 6.0)                  | 23 ( 1.0)                        |
| Cough                                | 33 (10.0)                  | 22 ( 6.6)                  | 306 (13.4)                       |
| Dyspnoea                             | 32 ( 9.7)                  | 26 ( 7.8)                  | 348 (15.3)                       |
| Back pain                            | 25 ( 7.6)                  | 15 ( 4.5)                  | 235 (10.3)                       |
| Weight decreased                     | 23 ( 7.0)                  | 20 ( 6.0)                  | 242 (10.6)                       |

a Number (%) of patients with AEs, sorted in decreasing frequency of PT

Patients with multiple AEs are counted once for each PT.

Includes AEs with an onset date on or after the date of first dose or pre-treatment AEs that increase in severity on or after the date of first dose up to and including 90 days following the date of last dose of study medication or up to and including the date of initiation of the first subsequent therapy (whichever occurs first). Disease progression AEs reported in Study 06 and Study 10 are not included in this summary.

COVID-19 events only apply to POSEIDON and Study 22.

MedDRA version 23.1.

Table 61. AEs by maximum reported CTCAE grade, SAS POSEIDON and pan-tumour pool

|                   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|-------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Category of AE    | POSEIDON                 | POSEIDON                 | POSEIDON                 | T + D Pan- tumour pool   |
|                   | T + D + SoC              | D + SoC                  | SoC 333)                 | (N = 2280)               |
| Any AE            | (N = 330)                | (N=334)                  | (N =                     |                          |
|                   | 321 (97.3)               | 321 (96.1)               | 320 (96.1)               | 2160 (94.7)              |
| Grade 1           | 21 ( 6.4)                | 17 (5.1)                 | 26 ( 7.8)                | 241 (10.6)               |
| Grade 2           | 83 (25.2)                | 87 (26.0)                | 92 (27.6)                | 638 (28.0)               |
| Grade 3           | 135 (40.9)               | 140 (41.9)               | 136 (40.8)               | 927 (40.7)               |
| Grade 4           | 41 (12.4)                | 43 (12.9)                | 36 (10.8)                | 200 ( 8.8)               |
| Grade 5           | 41 (12.4)                | 34 (10.2)                | 30 ( 9.0)                | 153 ( 6.7)               |
| Grade 3 or higher | 217 (65.8)               | 183 (54.8)               | 202 (60.7)               | 1280 (56.1)              |

<div style=\"page-break-after: always\"></div>

|                | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|----------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Category of AE | POSEIDON                 | POSEIDON                 | POSEIDON                 | T + D Pan- tumour pool   |
|                | T + D + SoC (N = 330)    | D + SoC (N=334)          | SoC (N = 333)            | (N = 2280)               |
| Grade 3 or 4   | 176 (53.3)               | 217 (65.0)               | 172 (51.7)               | 1127 (49.4)              |

Table 62. G3/4 AEs with incidence ≥ 2%, SAS POSEIDON and pan-tumour pool

|                                                    | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a          |
|----------------------------------------------------|----------------------------|----------------------------|-----------------------------------|
| Preferred term                                     | POSEIDON                   | POSEIDON                   | T + D Pan- tumour pool (N = 2280) |
|                                                    | T + D + SoC (N = 330)      | SoC (N = 333)              | T + D Pan- tumour pool (N = 2280) |
| Patients with any AE of maximum CTCAE Grade 3 or 4 | 176 (53.3)                 | 172 (51.7)                 | 1127 (49.4)                       |
| Anaemia                                            | 68 (20.6)                  | 75 (22.5)                  | 112 (4.9)                         |
| Neutropenia                                        | 56 (17.0)                  | 41 (12.3)                  | 4 (0.2)                           |
| Neutrophil count decreased                         | 25 (7.6)                   | 25 (7.5)                   | 3 (0.1)                           |
| Pneumonia                                          | 23 (7.0)                   | 10 (3.0)                   | 109 (4.8)                         |
| Thrombocytopenia                                   | 18 (5.5)                   | 17 (5.1)                   | 11 (0.5)                          |
| Lipase increased                                   | 13 (3.9)                   | 6 (1.8)                    | 100 (4.4)                         |
| Amylase increased                                  | 12 (3.6)                   | 6 (1.8)                    | 57 (2.5)                          |
| Asthenia                                           | 12 (3.6)                   | 8 (2.4)                    | 64 (2.8)                          |
| Leukopenia                                         | 9 (2.7)                    | 12 (3.6)                   | 1 (<0.1)                          |
| Platelet count decreased                           | 9 (2.7)                    | 17 (5.1)                   | 9 (0.4)                           |
| White blood cell count decreased                   | 9 (2.7)                    | 9 (2.7)                    | 1 (<0.1)                          |
| Fatigue                                            | 8 (2.4)                    | 9 (2.7)                    | 50 (2.2)                          |
| Hypertension                                       | 8 (2.4)                    | 2 (0.6)                    | 40 (1.8)                          |
| Febrile neutropenia                                | 7 (2.1)                    | 2 (0.6)                    | 0                                 |
| Hypokalaemia                                       | 7 (2.1)                    | 6 (1.8)                    | 53 (2.3)                          |
| Hyponatraemia                                      | 6 (1.8)                    | 12 (3.6)                   | 85 (3.7)                          |
| Nausea                                             | 6 (1.8)                    | 7 (2.1)                    | 31 (1.4)                          |
| Alanine aminotransferase increased                 | 5 (1.5)                    | 7 (2.1)                    | 40 (1.8)                          |
| Diarrhoea                                          | 5 (1.5)                    | 5 (1.5)                    | 60 (2.6)                          |
| Gamma-glutamyl transferase increased               | 5 (1.5)                    | 1 (0.3)                    | 56 (2.5)                          |
| Aspartate aminotransferase increased               | 2 (0.6)                    | 1 (0.3)                    | 51 (2.2)                          |
| Dyspnoea                                           | 2 (0.6)                    | 5 (1.5)                    | 72 (3.2)                          |

a Each patient has only been represented with the maximum reported CTCAE grade at either the start of AE or after increasing in severity for each system organ class / preferred term.

## AESIs:

Table 63. Adverse Events of Special Interest - Categories Reported for &gt;2% Patients in POSEIDON (Safety Analysis Set)

| AESI               | Number (%) of Patients   | Number (%) of Patients     | Number (%) of Patients   | Number (%) of Patients     | Number (%) of Patients   | Number (%) of Patients     |
|--------------------|--------------------------|----------------------------|--------------------------|----------------------------|--------------------------|----------------------------|
| Category           | T + D + SoC (N = 330)    | T + D + SoC (N = 330)      | D + SoC (N = 334)        | D + SoC (N = 334)          | SoC (N = 333)            | SoC (N = 333)              |
|                    | Any grade                | Maximum CTCAE Grade 3 or 4 | Any Grade                | Maximum CTCAE Grade 3 or 4 | Any Grade                | Maximum CTCAE Grade 3 or 4 |
| Dermatitis/ rash   | 116 (35.2)               | 7 (2.1)                    | 82 (24.6)                | 5 (1.5)                    | 45 (13.5)                | 2 (0.6)                    |
| Diarrhoea/ colitis | 81 (24.5)                | 13 (3.9)                   | 63 (18.9)                | 6 (1.8)                    | 51 (15.3)                | 6 (1.8)                    |
| Hepatic events     | 77 (23.3)                | 16 (4.8)                   | 66 (19.8)                | 14 (4.2)                   | 56 (16.8)                | 9 (2.7)                    |

<div style=\"page-break-after: always\"></div>

Table 63. Adverse Events of Special Interest - Categories Reported for &gt;2% Patients in POSEIDON (Safety Analysis Set)

| AESI Category                         | Number (%) of Patients   | Number (%) of Patients     | Number (%) of Patients   | Number (%) of Patients     | Number (%) of Patients   | Number (%) of Patients     |
|---------------------------------------|--------------------------|----------------------------|--------------------------|----------------------------|--------------------------|----------------------------|
| AESI Category                         | T + D + SoC (N = 330)    | T + D + SoC (N = 330)      | D + SoC (N = 334)        | D + SoC (N = 334)          | SoC (N = 333)            | SoC (N = 333)              |
| AESI Category                         | Any grade                | Maximum CTCAE Grade 3 or 4 | Any Grade                | Maximum CTCAE Grade 3 or 4 | Any Grade                | Maximum CTCAE Grade 3 or 4 |
| Other Rare/ miscellaneous             | 47 (14.2)                | 4 (1.2)                    | 34 (10.2)                | 5 (1.5)                    | 23 (6.9)                 | 2 (0.6)                    |
| Pancreatic events                     | 45 (13.6)                | 23 (7.0)                   | 31 (9.3)                 | 13 (3.9)                   | 20 (6.0)                 | 12 (3.6)                   |
| Hypothyroid events                    | 44 (13.3)                | 0 (0.0)                    | 27 (8.1)                 | 0 (0.0)                    | 7 (2.1)                  | 0 (0.0)                    |
| Renal events                          | 24 (7.3)                 | 1 (0.3)                    | 17 (5.1)                 | 4 (1.2)                    | 17 (5.1)                 | 0 (0.0)                    |
| Hyperthyroid events                   | 22 (6.7)                 | 0 (0.0)                    | 26 (7.8)                 | 1 (0.3)                    | 3 (0.9)                  | 0 (0.0)                    |
| Pneumonitis                           | 16 (4.8)                 | 4 (1.2)                    | 13 (3.9)                 | 4 (1.2)                    | 2 (0.6)                  | 2 (0.6)                    |
| Infusion/ hypersensitivit y reactions | 15 (4.5)                 | 2 (0.6)                    | 10 (3.0)                 | 2 (0.6)                    | 8 (2.4)                  | 0                          |
| Adrenal insufficiency                 | 8 (2.4)                  | 2 (0.6)                    | 4 (1.2)                  | 1 (0.3)                    | 0 (0.0)                  | 0 (0.0)                    |

Pancreatic events:

Table 64: Adverse Events of Special Interest/Immune-mediated Adverse Events - Category of Pancreatic Events - Reported for Patients in POSEIDON (Safety Analysis Set)

|                                             | Number (%) of Patients a   | Number (%) of Patients a   | Number (%) of Patients a   | Number (%) of Patients a   | Number (%) of Patients a   | Number (%) of Patients a   |
|---------------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
|                                             | T + D + SoC (N = 330)      | T + D + SoC (N = 330)      | D + SoC (N = 334)          | D + SoC (N = 334)          | SoC (N = 333)              | SoC (N = 333)              |
| Category/ Subcategory MedDRA Preferred Term | Any Grade                  | Maximum CTCAE Grade 3 or 4 | Any Grade                  | Maximum CTCAE Grade 3 or 4 | Any Grade                  | Maximum CTCAE Grade 3 or 4 |
| Pancreatic events                           |                            |                            |                            |                            |                            |                            |
| AESI                                        | 7 (2.1)                    | 1 (0.3)                    | 4 (1.2)                    | 0                          | 2 (0.6)                    | 0                          |
| Autoimmune pancreatitis                     | 1 (0.3)                    | 0                          | 0                          | 0                          | 0                          | 0                          |
| Pancreatitis                                | 6 (1.8)                    | 1 (0.3)                    | 4 (1.2)                    | 0                          | 2 (0.6)                    | 0                          |
| AEPI                                        | 39 (11.8)                  | 22 (6.7)                   | 27 (8.1)                   | 13 (3.9)                   | 19 (5.7)                   | 12 (3.6)                   |
| Amylase increased                           | 28 (8.5)                   | 12 (3.6)                   | 24 (7.2)                   | 8 (2.4)                    | 16 (4.8)                   | 6 (1.8)                    |
| Hyperamylasaemia                            | 2 (0.6)                    | 1 (0.3)                    | 0                          | 0                          | 0                          | 0                          |
| Hyperlipasaemia                             | 1 (0.3)                    | 1 (0.3)                    | 0                          | 0                          | 0                          | 0                          |
| Lipase increased                            | 21 (6.4)                   | 13 (3.9)                   | 12 (3.6)                   | 7 (2.1)                    | 7 (2.1)                    | 6 (1.8)                    |
| imAE                                        | 6 (1.8)                    | 4 (1.2)                    | 3 (0.9)                    | 2 (0.6)                    | 0                          | 0                          |
| Amylase increased                           | 1 (0.3)                    | 0                          | 1 (0.3)                    | 0                          | 0                          | 0                          |
| Autoimmune pancreatitis                     | 1 (0.3)                    | 0                          | 0                          | 0                          | 0                          | 0                          |
| Lipase increased                            | 3 (0.9)                    | 3 (0.9)                    | 2 (0.6)                    | 2 (0.6)                    | 0                          | 0                          |
| Pancreatitis                                | 2 (0.6)                    | 1 (0.3)                    | 1 (0.3)                    | 0                          | 0                          | 0                          |

imAEs:

<div style=\"page-break-after: always\"></div>

Tremelimumab is associated with immune mediated adverse reactions. Most of these, including severe reactions, resolved following initiation of appropriate medical therapy or withdrawal of tremelimumab.

Table 65. ImAEs in SAS POSEIDON and pan-tumour pool

|                                                      | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a          |
|------------------------------------------------------|----------------------------|----------------------------|-----------------------------------|
|                                                      | POSEIDON                   | POSEIDON                   | T + D Pan- tumour pool (N = 2280) |
| AE Category                                          | T + D + SoC (N=330)        | SoC (N=333)                |                                   |
| Any AE                                               | 105 (31.8)                 | 14 (4.2)                   | 628 (27.5)                        |
| Any AE of maximum CTCAE Grade 3 or 4                 | 32 (9.7)                   | 4 (1.2)                    | 223 (9.8)                         |
| Any SAE (including events with outcome of death) b   | 30 (9.1)                   | 3 (0.9)                    | 224 (9.8)                         |
| Any AE with outcome of death                         | 1 (0.3)                    | 0 (0.0)                    | 9 (0.4)                           |
| Received systemic corticosteroids                    | 78 (23.6)                  | 10 (3.0)                   | 458 (20.1)                        |
| Received high-dose steroids                          | 60 (18.2)                  | 5 (1.5)                    | 343 (15.0)                        |
| Received endocrine therapy                           | 39 (11.8)                  | 4 (1.2)                    | 234 (10.3)                        |
| Received other immunosuppressants                    | 3 (0.9)                    | 0 (0.0)                    | 36 (1.6)                          |
| Any AE leading to discontinuation of study treatment | 17 (5.2)                   | 2 (0.6)                    | 148 (6.5)                         |
| Event outcome resolved                               | 54 (16.4)                  | 10 (3.0)                   | 337 (14.8)                        |
| Event outcome not resolved                           | 50 (15.2)                  | 4 (1.2)                    | 282 (12.4)                        |

a Patients with multiple events in the same category are counted only once in that category. Patients with events in more than one category are counted once in each of those categories.

b Seriousness, as assessed by the Investigator. An AE with missing seriousness is considered serious.

Includes AEs with an onset date on or after the date of first dose or pre-treatment AEs that increase in severity on or after date of first dose up to and including 90 days following the date of last dose of study medication, or up to and including the date of initiation of the first subsequent therapy (whichever occurs first).

Percentages are calculated from number of patients in the treatment group (N).

Reasons of NOT RECOVERED/NOT RESOLVED, RECOVERING/RESOLVING, and UNKNOWN map to an outcome of Not Resolved.

Reasons of RECOVERED/RESOLVED, RECOVERED/RESOLVED WITH SEQUELAE map to an outcome of Resolved.

Table 66. imAEs that occurred in ≥ 2% of patients in SAS POSEIDON

|                       | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   |
|-----------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
|                       | T + D + SoC (N=330)        | T + D + SoC (N=330)        | D + SoC (N=334)            | D + SoC (N=334)            | SoC (N=333)                | SoC (N=333)                |
| imAE Category         | Any grade                  | CTCAE Grade 3 or 4         |                            | CTCAE Grade 3 or 4         | Any grade                  | CTCAE Grade 3 or 4         |
|                       |                            |                            | Any grade                  |                            |                            |                            |
| Hypothyroid events    | 27 (8.2)                   | 0                          | 19 (5.7)                   | 0                          | 3 (0.9)                    | 0                          |
| Dermatitis/rash       | 23 (7.0)                   | 4 (1.2)                    | 8 (2.4)                    | 2 (0.6)                    | 7 (2.1)                    | 2 (0.6)                    |
| Diarrhea/colitis      | 14 (4.2)                   | 5 (1.5)                    | 6 (1.8)                    | 2 (0.6)                    | 1 (0.3)                    | 0                          |
| Hepatic events        | 11 (3.3)                   | 6 (1.8)                    | 10 (3.0)                   | 7 (2.1)                    | 0                          | 0                          |
| Pneumonitis           | 14 (4.2)                   | 4 (1.2)                    | 9 (2.7)                    | 3 (0.9)                    | 2 (0.6)                    | 2 (0.6)                    |
| Hyperthyroid events   | 9 (2.7)                    | 0                          | 4 (1.2)                    | 1 (0.3)                    | 1 (0.3)                    | 0                          |
| Adrenal insufficiency | 8 (2.4)                    | 2 (0.6)                    | 4 (1.2)                    | 1 (0.3)                    | 0                          | 0                          |

Includes AEs with an onset date on or after the date of first dose or pre-treatment AEs that increase in severity on or after date of first dose up to and including 90 days following the date of last dose of study medication, or up to and including the date of initiation of the first subsequent therapy (whichever occurs first). Percentages are calculated from number of patients in the treatment group (N).

Described below, the incidence of imAEs in the combined safety database with tremelimumab in combination with durvalumab (T + D pan-tumour pool). This information has been added to the paragraph 'Description of selected adverse reactions' in section 4.8 of the SmPC:

<div style=\"page-break-after: always\"></div>

- immune-mediated pneumonitis occurred in 86 (3.8%) patients, including Grade 3 in 30 (1.3%) patients, Grade 4 in 1 (&lt; 0.1%) patient, and Grade 5 (fatal) in 7 (0.3%) patients. The median time to onset was 57 days (range: 8 - 912 days). All patients received systemic corticosteroids and 79 of the 86 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Seven patients also received other immunosuppressants. Treatment was discontinued in 39 patients. Resolution occurred in 51 patients.

- immune-mediated hepatitis occurred in 80 (3.5%) patients, including Grade 3 in 48 (2.1%) patients, Grade 4 in 8 (0.4%) patients and Grade 5 (fatal) in 2 (&lt; 0.1%) patients. The median time to onset was 36 days (range: 1 - 533 days). All patients received systemic corticosteroids and 68 of the 80 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Eight patients also received other immunosuppressants. Treatment was discontinued in 27 patients. Resolution occurred in 47 patients.

- immune-mediated colitis or diarrhoea occurred in 167 (7.3%) patients, including Grade 3 in 76 (3.3%) patients and Grade 4 in 3 (0.1%) patients. The median time to onset was 57 days (range: 3 - 906 days). All patients received systemic corticosteroids and 151 of the 167 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Twenty-two patients also received other immunosuppressants. Treatment was discontinued in 54 patients. Resolution occurred in 141 patients.

Intestinal perforation and large intestine perforation were uncommonly reported in patients receiving tremelimumab in combination with durvalumab.

- immune-mediated hypothyroidism occurred in 209 (9.2%) patients, including Grade 3 in 6 (0.3%) patients. The median time to onset was 85 days (range: 1 - 624 days). Thirteen patients received systemic corticosteroids and 8 of the 13 received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Treatment discontinued in 3 patients. Resolution occurred in 52 patients. Immune-mediated hypothyroidism was preceded by immune-mediated hyperthyroidism in 25 patients or immune-mediated thyroiditis in 2 patients.

- immune-mediated hyperthyroidism occurred in 62 (2.7%) patients, including Grade 3 in 5 (0.2%) patients. The median time to onset was 33 days (range: 4 - 176 days). Eighteen patients received systemic coticosteroids, and 11 of the 18 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Fifty-three patients required other therapy (thiamazole, carbimazole, propylthiouracil, perchlorate, calcium channel blocker or beta-blocker), One patient discontinued treatment due to hyperthyroidism. Resolution occurred in 47 patients.

- immune-mediated thyroiditis occurred in 15 (0.7%) patients, including Grade 3 in 1 (&lt; 0.1%) patient. The median time to onset was 57 days (range: 22 - 141 days). Five patients received systemic corticosteroids and 2 of the 5 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Thirteen patients required other therapy including, hormone replacement therapy, thiamazole, carbimazole, propylthiouracil, perchlorate, calcium channel blocker, or beta-blocker. No patients discontinued treatment due to immune-mediated thyroiditis. Resolution occurred in 5 patients.

- immune-mediated adrenal insufficiency occurred in 33 (1.4%) patients, including Grade 3 in 16 (0.7%) patients and Grade 4 in 1 (&lt; 0.1%) patient. The median time to onset was 105 days (range: 20-428 days). Thirty-two patients received systemic corticosteroids, and 10 of the 32 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Treatment was discontinued in one patient. Resolution occurred in 11 patients.

- immune-mediated type 1 diabetes mellitus occurred in 6 (0.3%) patients, including Grade 3 in 1 (&lt; 0.1%) patient and Grade 4 in 2 (&lt; 0.1%) patients. The median time to onset was 58 days (range:

<div style=\"page-break-after: always\"></div>

7 - 220 days). All patients required insulin. Treatment was discontinued for 1 patient. Resolution occurred in 1 patient.

- immune-mediated hypophysitis/hypopituitarism occurred in 16 (0.7%) patients, including Grade 3 in 8 (0.4%) patients. The median time to onset for the events was 123 days (range: 63 - 388 days). All patients received systemic corticosteroids and 8 of the 16 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Four patients also required endocrine therapy. Treatment was discontinued in 2 patients. Resolution occurred in 7 patients.

- immune-mediated nephritis occurred in 9 (0.4%) patients, including Grade 3 in 1 (&lt; 0.1%) patient. The median time to onset was 79 days (range: 39 - 183 days). All patients received systemic corticosteroids and 7 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Treatment was discontinued in 3 patients. Resolution occurred in 5 patients.

- immune-mediated rash or dermatitis (including pemphigoid) occurred in 112 (4.9%) patients, including Grade 3 in 17 (0.7%) patients. The median time to onset was 35 days (range: 1 - 778 days). All patients received systemic corticosteroids, and 57 of the 112 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Treatment was discontinued in 10 patients. Resolution occurred in 65 patients.

## Infusion-related and hypersensitivity/anaphylaxis reactions:

In POSEIDON, AESIs of infusion related reactions (grouped term) were reported in 13 patients (3.9%) in the T + D + SoC arm and 5 patients (1.5%) in the SoC alone arm. The majority of the events were of CTCAE Grade 1 or 2 in severity with 1 patient (0.3%) in the T + D + SoC arm experiencing a CTCAE Grade 3 event. In the T + D + Chemo pool and the T + D pan tumour pool, AESIs of infusion related reaction were reported in 17 patients (2.9%) and 45 patients (2.0%), respectively. There were no Grade 4 or 5 events.

In POSEIDON, AESIs of hypersensitivity/anaphylactic reactions (grouped term) were reported in 3 patients (0.9%) each in the T + D + SoC arm and the SoC alone arm. In the D + T + Chemo pool and the T + D pan-tumour pool, AESIs of hypersensitivity/anaphylactic reactions were reported in 5 patients (0.8%) and 22 patients (1.0%), respectively.

## ADRs:

The list of incidence of ADRs shown in Table 3 of the SmPC for patients treated with tremelimumab in combination with durvalumab and platinum-based chemotherapy is based on the data from 330 patients in the T + D + SoC arm of the POSEIDON study (Table 67). The frequency of ADRs with frequency 'Not known' for both regimens (tremelimumab 75 mg in combination with durvalumab and platinum-based chemotherapy for the treatment of NSCLC, and tremelimumab 300 mg in combination with durvalumab for the treatment of HCC) has been re-estimated based on a larger safety pool ('T75 + D pan-tumour pool') that includes 3319 patients.

<div style=\"page-break-after: always\"></div>

Table 67. Adverse Drug Reactions in the three arms of the POSEIDON trial

<!-- image -->

|                                                 | Number (%) of Patients a                        | Number (%) of Patients a                        | Number (%) of Patients a                        | Number (%) of Patients a                        | Number (%) of Patients a                        | Number (%) of Patients a                        | Number (%) of Patients a                        | Number (%) of Patients a                        | Number (%) of Patients a                        |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
|                                                 | T+D+SoC                                         | T+D+SoC                                         | T+D+SoC                                         | POSEIDON D+SoC                                  | POSEIDON D+SoC                                  | POSEIDON D+SoC                                  | SoC (N = 333)                                   | SoC (N = 333)                                   | SoC (N = 333)                                   |
| ADRsystemorganclass/ ADRterm                    | (N =330) Any CTCAE Grade CIOMISIII Category b   | (N =330) Any CTCAE Grade CIOMISIII Category b   | Max Grade 3 or 4                                | Any CTCAE Grade CIOMSIII Category b             | Any CTCAE Grade CIOMSIII Category b             | Max Grade 3 01 4                                | Any CTCAE Grade CIOMSIII Category b             | Any CTCAE Grade CIOMSIII Category b             | Max Grade 3 or 4                                |
| Blood andlymphaticsystem disorders              | Blood andlymphaticsystem disorders              | Blood andlymphaticsystem disorders              | Blood andlymphaticsystem disorders              | Blood andlymphaticsystem disorders              | Blood andlymphaticsystem disorders              | Blood andlymphaticsystem disorders              | Blood andlymphaticsystem disorders              | Blood andlymphaticsystem disorders              | Blood andlymphaticsystem disorders              |
| Anaemia c                                       | 164 (49.7)                                      | Very common                                     | 68 (20.6)                                       | 151 (45.2)                                      | Very common                                     | 59 (17.7)                                       | 163 (48.9)                                      | Very common                                     | 75 (22.5)                                       |
| Febrile neutropenia c                           | 10 (3.0)                                        | Common                                          | 7 (2.1)                                         | 7 (2.1)                                         | Common                                          | 6 (1.8)                                         | 5 (1.5)                                         | Common                                          | 2 (0.6)                                         |
| Immunethrombocytopenia                          | 1 (0.3)                                         | Uncommon                                        | 0                                               | 0                                               | Not known                                       | 0                                               | 0                                               | Not known                                       | 0                                               |
| Leukopenia c                                    | 64 (19.4)                                       | Very common                                     | 18 (5.5)                                        | 54 (16.2)                                       | Very common                                     | 18 (5.4)                                        | 64 (19.2)                                       | Very common                                     | 20 (6.0)                                        |
| Neutropenia c                                   | 136 (41.2)                                      | Very common                                     | 79 (23.9)                                       | 122 (36.5)                                      | Very common                                     | 70 (21.0)                                       | 134 (40.2)                                      | Very common                                     | 66 (19.8)                                       |
| Pancytopenia c                                  | 6 (1.8)                                         | Common                                          | 2 (0.6)                                         | 7 (2.1)                                         | Common                                          | 6 (1.8)                                         | 3 (0.9)                                         | Uncommon                                        | 2 (0.6)                                         |
| Thrombocytopenia c                              | 81 (24.5)                                       | Very common                                     | 27 (8.2)                                        | 64 (19.2)                                       | Very common                                     | 27 (8.1)                                        | 83 (24.9)                                       | Very common                                     | 34 (10.2)                                       |
| Cardiacdisorders                                | Cardiacdisorders                                | Cardiacdisorders                                | Cardiacdisorders                                | Cardiacdisorders                                | Cardiacdisorders                                | Cardiacdisorders                                | Cardiacdisorders                                | Cardiacdisorders                                | Cardiacdisorders                                |
| Myocarditis                                     | 1 (0.3)                                         | Uncommon                                        | 0                                               | 0                                               | Not known                                       | 0                                               | 0                                               | Not known                                       | 0                                               |
| Endocrine disorders                             | Endocrine disorders                             | Endocrine disorders                             | Endocrine disorders                             | Endocrine disorders                             | Endocrine disorders                             | Endocrine disorders                             | Endocrine disorders                             | Endocrine disorders                             | Endocrine disorders                             |
| Adrenal insufficiency                           | 7 (2.1)                                         | Common                                          | 2 (0.6)                                         | 4 (1.2)                                         | Common                                          | 1 (0.3)                                         | 0                                               | Not known                                       | 0                                               |
| Diabetes insipidus                              | 1 (0.3)                                         | Uncommon                                        | 1 (0.3)                                         | 0                                               | Not known                                       | 0                                               | 0                                               | Not known                                       | 0                                               |
| Hyperthyroidism                                 | 22 (6.7)                                        | Common                                          | 0                                               | 26 (7.8)                                        | Common                                          | 1 (0.3)                                         | 3 (0.9)                                         | Uncommon                                        | 0                                               |
| Hypopituitarism/ Hypophysitis                   | 5 (1.5)                                         | Common                                          | 1 (0.3)                                         | 2 (0.6)                                         | Uncommon                                        | 1 (0.3)                                         | 0                                               | Not known                                       | 0                                               |
| Hypothyroidism                                  | 44 (13.3)                                       | Very common                                     | 0                                               | 26 (7.8)                                        | Common                                          | 0                                               | 7 (2.1)                                         | Common                                          | 0                                               |
| Thyroiditis                                     | 4 (1.2)                                         | Common                                          | 0                                               | 4 (1.2)                                         | Common                                          | 0                                               | 1 (0.3)                                         | Uncommon                                        | 0                                               |
| Type 1 diabetes mellitus                        | 1 (0.3)                                         | Uncommon                                        | 1 (0.3)                                         | 1 (0.3)                                         | Uncommon                                        | 1 (0.3)                                         | 0                                               | Not known                                       | 0                                               |
| Gastrointestinal disorders                      | Gastrointestinal disorders                      | Gastrointestinal disorders                      | Gastrointestinal disorders                      | Gastrointestinal disorders                      | Gastrointestinal disorders                      | Gastrointestinal disorders                      | Gastrointestinal disorders                      | Gastrointestinal disorders                      | Gastrointestinal disorders                      |
| Abdominal pain                                  | 24 (7.3)                                        | Common                                          | 0                                               | 31 (9.3)                                        | Common                                          | 2 (0.0)                                         | 18 (5.4)                                        | Common                                          | 0                                               |
| Amylase increased d                             | 28 (8.5)                                        | Common                                          | 12 (3.6)                                        | 24 (7.2)                                        | Common                                          | 8 (2.4)                                         | 16 (4.8)                                        | Common                                          | 6 (1.8)                                         |
| Colitis                                         | 18 (5.5)                                        | Common                                          | 7 (2.1)                                         | 4 (1.2)                                         | Common                                          | 1 (0.3)                                         | 1 (0.3)                                         | Uncommon                                        | 1 (0.3)                                         |
| Constipation c                                  | 63 (19.1)                                       | Very common                                     | 0                                               | 72 (21.6)                                       | Very common                                     | 0                                               | 79 (23.7)                                       | Very common                                     | 2 (0.6)                                         |
| Diamhoea                                        | 71 (21.5)                                       | Very common                                     | 5 (1.5)                                         | 60 (18.0)                                       | Very common                                     | 5 (1.5)                                         | 51 (15.3)                                       | Very common                                     | 5 (1.5)                                         |
| Intestinal perforation d                        | 0                                               | Not known                                       | 0                                               | 0                                               | Not known                                       | 0                                               | 0                                               | Not known                                       | 0                                               |
| Large intestine perforation                     | 0                                               | Not known                                       | 0                                               | 0                                               | Not known                                       | 0                                               | 0                                               | Not known                                       | 0                                               |
| Lipase increased d                              | 21 (6.4)                                        | Common                                          | 13 (3.9)                                        | 12 (3.6)                                        | Common                                          | 7 (2.1)                                         | 7 (2.1)                                         | Common                                          | 6 (1.8)                                         |
| Nausea c                                        | 137 (41.5)                                      | Very common                                     | 6 (1.8)                                         | 121 (36.2)                                      | Very common                                     | 2 (0.6)                                         | 122 (36.6)                                      | Verycommon                                      | 7 (2.1)                                         |
| Pancreatitis                                    | 7 (2.1)                                         | Common                                          | 1 (0.3)                                         | 4 (1.2)                                         | Common                                          | 0                                               | 2 (0.0)                                         | Uncommon                                        | 0                                               |
| Stomatitis                                      | 32 (9.7)                                        | Common                                          | 0                                               | 31 (9.3)                                        | Common                                          | 1 (0.3)                                         | 20 (6.0)                                        | Common                                          | 1 (0.3)                                         |
| Vomitingc                                       | 60 (18.2)                                       | Very common                                     | 4 (1.2)                                         | 52 (15.6)                                       | Very common                                     | 4 (1.2)                                         | 45 (13.5)                                       | Very common                                     | 5 (1.5)                                         |
| Generaldisordersandadministrationsiteconditions | Generaldisordersandadministrationsiteconditions | Generaldisordersandadministrationsiteconditions | Generaldisordersandadministrationsiteconditions | Generaldisordersandadministrationsiteconditions | Generaldisordersandadministrationsiteconditions | Generaldisordersandadministrationsiteconditions | Generaldisordersandadministrationsiteconditions | Generaldisordersandadministrationsiteconditions | Generaldisordersandadministrationsiteconditions |
| Fatigue c                                       | 119 (36.1)                                      | Very common                                     | 17 (5.2)                                        | 109 (32.6)                                      | Very common                                     | 17 (5.1)                                        | 106 (31.8)                                      | Very common                                     | 15 (4.5)                                        |
| Oedema peripheral                               | 28 (8.5)                                        | Common                                          | 0                                               | 23 (6.9)                                        | Common                                          | 2 (0.0)                                         | 30 (9.0)                                        | Common                                          | 0                                               |
| Pyrexia                                         | 53 (16.1)                                       | Very common                                     | 0                                               | 31 (9.3)                                        | Common                                          | 0                                               | 23 (6.9)                                        | Common                                          | 0                                               |

<div style=\"page-break-after: always\"></div>

| Hepatobiliary disorders                       | Hepatobiliary disorders                       | Hepatobiliary disorders                       | Hepatobiliary disorders                       | Hepatobiliary disorders                       | Hepatobiliary disorders                       | Hepatobiliary disorders                       | Hepatobiliary disorders                       | Hepatobiliary disorders                       | Hepatobiliary disorders                       |
|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| AST increased/ALT increased                   | 58 (17.6)                                     | Very common                                   | 7 (2.1)                                       | 52 (15.0)                                     | Very common                                   | 10 (3.0)                                      | 51 (15.3)                                     | Very common                                   | 8 (2.4)                                       |
| Hepatitis                                     | 13 (3.9)                                      | Common                                        | 3 (0.9)                                       | 7 (2.1)                                       | Common                                        | 3 (0.9)                                       | 2 (0.6)                                       | Uncommon                                      | 0                                             |
| Infections andinfestations                    | Infections andinfestations                    | Infections andinfestations                    | Infections andinfestations                    | Infections andinfestations                    | Infections andinfestations                    | Infections andinfestations                    | Infections andinfestations                    | Infections andinfestations                    | Infections andinfestations                    |
| Dentaland oral sof tissue infections          | 2 (0.6)                                       | Uncommon                                      | 1 (0.3)                                       | 4 (1.2)                                       | Common                                        | 1 (0.3)                                       | 3 (0.9)                                       | Uncommon                                      | 0                                             |
| Influenza                                     | 11 (3.3)                                      | Common                                        | 0                                             | 10 (3.0)                                      | Common                                        | 1 (0.3)                                       | 4 (1.2)                                       | Common                                        | 0                                             |
| Oral candidiasis                              | 8 (2.4)                                       | Common                                        | 1 (0.3)                                       | 2 (0.6)                                       | Uncommon                                      | 0                                             | 6 (1.8)                                       | Common                                        | 0                                             |
| Pneumonia                                     | 49 (14.8)                                     | Very common                                   | 24 (7.3)                                      | 34 (10.2)                                     | Very common                                   | 16 (4.8)                                      | 33 (9.9)                                      | Common                                        | 10 (3.0)                                      |
| Upper respiratory tract infections            | 51 (15.5)                                     | Very common                                   | 2 (0.6)                                       | 33 (9.9)                                      | Common                                        | 0                                             | 29 (8.7)                                      | Common                                        | 3 (0.9)                                       |
| Injuy, poisoning and procedural complications | Injuy, poisoning and procedural complications | Injuy, poisoning and procedural complications | Injuy, poisoning and procedural complications | Injuy, poisoning and procedural complications | Injuy, poisoning and procedural complications | Injuy, poisoning and procedural complications | Injuy, poisoning and procedural complications | Injuy, poisoning and procedural complications | Injuy, poisoning and procedural complications |
| Infusionrelatedreaction                       | 13 (3.9)                                      | Common                                        | 1 (0.3)                                       | 7 (2.1)                                       | Common                                        | 0                                             | 5 (1.5)                                       | Common                                        | 0                                             |
| Metabolismandnutritiondisorder's              | Metabolismandnutritiondisorder's              | Metabolismandnutritiondisorder's              | Metabolismandnutritiondisorder's              | Metabolismandnutritiondisorder's              | Metabolismandnutritiondisorder's              | Metabolismandnutritiondisorder's              | Metabolismandnutritiondisorder's              | Metabolismandnutritiondisorder's              | Metabolismandnutritiondisorder's              |
| Decreased appetite                            | 93 (28.2)                                     | Very common                                   | 5 (1.5)                                       | 72 (1.6)                                      | Very common                                   | 2 (0.6)                                       | 82 (24.6)                                     | Very common                                   | 4 (1.2)                                       |
| Musculoskeletalandconnectivetissuedisorders   | Musculoskeletalandconnectivetissuedisorders   | Musculoskeletalandconnectivetissuedisorders   | Musculoskeletalandconnectivetissuedisorders   | Musculoskeletalandconnectivetissuedisorders   | Musculoskeletalandconnectivetissuedisorders   | Musculoskeletalandconnectivetissuedisorders   | Musculoskeletalandconnectivetissuedisorders   | Musculoskeletalandconnectivetissuedisorders   | Musculoskeletalandconnectivetissuedisorders   |
| Myalgia                                       | 14 (4.2)                                      | Common                                        | 0                                             | 15 (4.5)                                      | Common                                        | 0                                             | 9 (2.7)                                       | Common                                        | 0                                             |
| Myositis                                      | 1 (0.3)                                       | Uncommon                                      | 1 (0.3)                                       | 0                                             | Not known                                     | 0                                             | 1 (0.3)                                       | Uncommon                                      | 0                                             |
| Polymyositis                                  | 1 (0.3)                                       | Uncommon                                      | 1 (0.3)                                       | 0                                             | Not known                                     | 0                                             | 0                                             | Not known                                     | 0                                             |

|                                               | Number (%) of Patients a POSEIDON             | Number (%) of Patients a POSEIDON             | Number (%) of Patients a POSEIDON             | Number (%) of Patients a POSEIDON             | Number (%) of Patients a POSEIDON             | Number (%) of Patients a POSEIDON             | Number (%) of Patients a POSEIDON             | Number (%) of Patients a POSEIDON             | Number (%) of Patients a POSEIDON             |
|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
|                                               | T+D+SoC (N =330)                              | T+D+SoC (N =330)                              | T+D+SoC (N =330)                              | D+SoC (N=334)                                 | D+SoC (N=334)                                 | D+SoC (N=334)                                 | SoC (N =333)                                  | SoC (N =333)                                  | SoC (N =333)                                  |
| ADR system organ class/ ADRterm               | Any CTCAE Grade CIONISIII Category b          | Any CTCAE Grade CIONISIII Category b          | Max Grade 3 or 4                              | Any CTCAE Grade CIOMISIII Category b          | Any CTCAE Grade CIOMISIII Category b          | Max Grade 3 or 4                              | Any CTCAE Grade CIOMISIII Category b          | Any CTCAE Grade CIOMISIII Category b          | MaxGrade3or 4                                 |
| Nervoussystem disorders                       | Nervoussystem disorders                       | Nervoussystem disorders                       | Nervoussystem disorders                       | Nervoussystem disorders                       | Nervoussystem disorders                       | Nervoussystem disorders                       | Nervoussystem disorders                       | Nervoussystem disorders                       | Nervoussystem disorders                       |
| Encephalitis                                  | 2 (0.6)                                       | Uncommon                                      | 2 (0.6)                                       | 0                                             | Not known                                     | 0                                             | 0                                             | Not known                                     | 0                                             |
| Myasthenia gravis                             | 0                                             | Not known                                     | 0                                             | 0                                             | Not known                                     | 0                                             | 0                                             | Not known                                     | 0                                             |
| Neuropathy peripheral e                       | 21 (6.4)                                      | Common                                        | 0                                             | 32 (9.6)                                      | Common                                        | 1 (0.3)                                       | 30 (9.0)                                      | Common                                        | 1 (0.3)                                       |
| Guillain-Barre syndrome                       | 0                                             | Not known                                     | 0                                             | 0                                             | Not known                                     | 0                                             | 0                                             | Not known                                     | 0                                             |
| Meningitis                                    | 0                                             | Not known                                     | 0                                             | 0                                             | Not known                                     | 0                                             | 0                                             | Not known                                     | 0                                             |
| Renal and urinary disorders                   | Renal and urinary disorders                   | Renal and urinary disorders                   | Renal and urinary disorders                   | Renal and urinary disorders                   | Renal and urinary disorders                   | Renal and urinary disorders                   | Renal and urinary disorders                   | Renal and urinary disorders                   | Renal and urinary disorders                   |
| Bloodcreatinineincreased                      | 21 (6.4)                                      | Common                                        | 1 (0.3)                                       | 12 (3.6)                                      | Common                                        | 0                                             | 12 (3.6)                                      | Common                                        | 0                                             |
| Dysuria                                       | 5 (1.5)                                       | Common                                        | 0                                             | 7 (2.1)                                       | Common                                        | 0                                             | 7 (2.1)                                       | Common                                        | 0                                             |
| Nephritis                                     | 2 (0.6)                                       | Uncommon                                      | 0                                             | 3 (0.9)                                       | Uncommon                                      | 3 (0.9)                                       | 0                                             | Not known                                     | 0                                             |
| Respiratory,thoracicand mediastinal disorders | Respiratory,thoracicand mediastinal disorders | Respiratory,thoracicand mediastinal disorders | Respiratory,thoracicand mediastinal disorders | Respiratory,thoracicand mediastinal disorders | Respiratory,thoracicand mediastinal disorders | Respiratory,thoracicand mediastinal disorders | Respiratory,thoracicand mediastinal disorders | Respiratory,thoracicand mediastinal disorders | Respiratory,thoracicand mediastinal disorders |
| Cough/Productive cough                        | 40 (12.1)                                     | Very common                                   | 0                                             | 49 (14.7)                                     | Very common                                   | 0                                             | 28 (8.4)                                      | Common                                        | 1 (0.3)                                       |
| Dysphonia                                     | 8 (2.4)                                       | Common                                        | 0                                             | 8 (2.4)                                       | Common                                        | 0                                             | 3 (0.9)                                       | Uncommon                                      | 0                                             |
| Interstitial lung disease                     | 2 (0.6)                                       | Uncommon                                      | 0                                             | 0                                             | Not known                                     | 0                                             | 1 (0.3)                                       | Uncommon                                      | 1 (0.3)                                       |
| Pneumonitis                                   | 14 (4.2)                                      | Common                                        | 4 (1.2)                                       | 13 (3.9)                                      | Common                                        | 4 (1.2)                                       | 1 (0.3)                                       | Uncommon                                      | 1 (0.3)                                       |
| Skinandsubcutaneoustissuedisorders            | Skinandsubcutaneoustissuedisorders            | Skinandsubcutaneoustissuedisorders            | Skinandsubcutaneoustissuedisorders            | Skinandsubcutaneoustissuedisorders            | Skinandsubcutaneoustissuedisorders            | Skinandsubcutaneoustissuedisorders            | Skinandsubcutaneoustissuedisorders            | Skinandsubcutaneoustissuedisorders            | Skinandsubcutaneoustissuedisorders            |
| Alopecia c                                    | 33 (10.0)                                     | Very common                                   | 0                                             | 36 (10.8)                                     | Very common                                   | 0                                             | 20 (6.0)                                      | Common                                        | 0                                             |
| Dermatitis                                    | 2 (0.6)                                       | Uncommon                                      | 0                                             | 9 (2.7)                                       | Common                                        | 0                                             | 2 (0.6)                                       | Uncommon                                      | 0                                             |
| Night sweats                                  | 2 (0.6)                                       | Uncommon                                      | 0                                             | 0                                             | Not known                                     | 0                                             | 1 (0.3)                                       | Uncommon                                      | 0                                             |
| Pemphigoid                                    | 1 (0.3)                                       | Uncommon                                      | 1 (0.3)                                       | 1 (0.3)                                       | Uncommon                                      | 1 (0.3)                                       | 0                                             | Not known                                     | 0                                             |
| Pruritus                                      | 36 (10.9)                                     | Very common                                   | 0                                             | 30 (9.0)                                      | Common                                        | 0                                             | 15 (4.5)                                      | Common                                        | 0                                             |
| Rash                                          | 85 (25.8)                                     | Very common                                   | 5 (1.5)                                       | 57 (17.1)                                     | Very common                                   | 4(1.2)                                        | 29 (8.7)                                      | Common                                        | 2 (0.6)                                       |

- P Only applies toD+T combinationADRs.

Only applies to chemotherapy ADRs in the POSEIDON study.

A patient can have one or morePTsreported under a givenSOC.

Maximum CTCAE grade per patient is considered.

IncludesAEswith an onsetdate onorafterthedate of firstdose orpre-treatmentAEs thatincreaseinseverityonorafterthe date offirst dose uptoand including90 days following thedate of last dose of study medication orup to and including the date of initiation of thefirst subsequent therapy (whichever occurs first). ADR terms aregrouped PTs.Grouped term included multiplePTs.

Table 68. Adverse Drug Reactions in the T + D Pan tumor Pool

|                                      | Number (%) of patients a                                             | Max CTCAE                            |
|--------------------------------------|----------------------------------------------------------------------|--------------------------------------|
| ADR system organ class/ ADR term     | T + D Pan-tumor pool (N = 2280) Any CTCAE Grade CIOMS III category b | Grade 3 or 4                         |
| Blood and lymphatic system disorders | Blood and lymphatic system disorders                                 | Blood and lymphatic system disorders |

<div style=\"page-break-after: always\"></div>

| ADR system organ class/ ADR term          | Number (%) of patients a T + D Pan-tumor pool (N = 2280)   | Number (%) of patients a T + D Pan-tumor pool (N = 2280)   | Number (%) of patients a T + D Pan-tumor pool (N = 2280)   |
|-------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|
|                                           | Any CTCAE Grade CIOMS III category b                       | Any CTCAE Grade CIOMS III category b                       | Max CTCAE Grade 3 or 4                                     |
| Immune thrombocytopenia                   | 0                                                          | Not known                                                  | 0                                                          |
| Cardiac disorders                         |                                                            |                                                            |                                                            |
| Myocarditis                               | 2 (<0.1)                                                   | Rare                                                       | 2 (<0.1)                                                   |
| Endocrine disorders                       |                                                            |                                                            |                                                            |
| Adrenal insufficiency                     | 33 (1.4)                                                   | Common                                                     | 13 (0.6)                                                   |
| Diabetes insipidus                        | 0                                                          | Not known                                                  | 0                                                          |
| Hyperthyroidism                           | 179 (7.9)                                                  | Common                                                     | 7 (0.3)                                                    |
| Hypopituitarism/Hypophysitis              | 16 (0.7)                                                   | Uncommon                                                   | 7 (0.3)                                                    |
| Hypothyroidism                            | 268 (11.8)                                                 | Very common                                                | 5 (0.2)                                                    |
| Thyroiditis                               | 24 (1.1)                                                   | Common                                                     | 1 (<0.1)                                                   |
| Type 1 diabetes mellitus                  | 6 (0.3)                                                    | Uncommon                                                   | 1 (<0.1)                                                   |
| Gastrointestinal disorders                |                                                            |                                                            |                                                            |
| Abdominal pain                            | 279 (12.2)                                                 | Very common                                                | 36 (1.6)                                                   |
| Amylase increased c                       | 136 (6.0)                                                  | Common                                                     | 57 (2.5)                                                   |
| Colitis                                   | 87 (3.8)                                                   | Common                                                     | 46 (2.0)                                                   |
| Diarrhoea                                 | 526 (23.1)                                                 | Very common                                                | 60 (2.6)                                                   |
| Intestinal perforation c                  | 2 (<0.1)                                                   | Rare                                                       | 2 (<0.1)                                                   |
| Large intestine perforation c             | 3 (0.1)                                                    | Uncommon                                                   | 2 (<0.1)                                                   |
| Lipase increased c                        | 152 (6.7)                                                  | Common                                                     | 100 (4.4)                                                  |
| Pancreatitis                              | 23 (1.0)                                                   | Common                                                     | 11 (0.5)                                                   |
| General disorders and administration site | conditions                                                 |                                                            |                                                            |
| Oedema peripheral                         | 211 (9.3)                                                  | Common                                                     | 7 (0.3)                                                    |
| Pyrexia                                   | 326 (14.3)                                                 | Very common                                                | 9 (0.4)                                                    |
| Hepatobiliary disorders increased         |                                                            |                                                            |                                                            |
| AST increased/ALT                         | 247 (10.8)                                                 | Very common                                                | 68 (3.0)                                                   |
| Hepatitis                                 | 37 (1.6)                                                   | Common                                                     | 29 (1.3)                                                   |
| Infections and infestations               |                                                            |                                                            |                                                            |
| Dental and oral soft tissue infections    | 19 (0.8)                                                   | Uncommon                                                   | 1 (<0.1)                                                   |
| Influenza                                 | 28 (1.2)                                                   | Common                                                     | 7 (0.3)                                                    |
| Oral candidiasis                          | 41 (1.8)                                                   | Common                                                     | 0                                                          |
| Pneumonia                                 | 218 (9.6)                                                  | Common                                                     | 113 (5.0)                                                  |
| Upper respiratory tract infections        | 216 (9.5)                                                  | Common                                                     | 6 (0.3)                                                    |
| Injury, poisoning and procedural          | complications                                              |                                                            |                                                            |
| Infusion related reaction                 | 45 (2.0)                                                   | Common                                                     | 2 (<0.1)                                                   |
| Musculoskeletal and connective tissue     | disorders                                                  |                                                            |                                                            |
| Myalgia                                   | 96 (4.2)                                                   | Common                                                     | 4 (0.2)                                                    |
| Myositis                                  | 4 (0.2)                                                    | Uncommon                                                   | 3 (0.1)                                                    |
| Polymyositis                              | 2 (<0.1)                                                   | Rare                                                       | 1 (<0.1)                                                   |
| Nervous system disorders                  |                                                            |                                                            |                                                            |
| Myasthenia gravis                         | 1 (<0.1)                                                   | Rare                                                       | 0                                                          |
| Encephalitis                              | 1 (<0.1)                                                   | Rare                                                       | 0                                                          |
| Guillain-Barre syndrome                   | 1 (<0.1)                                                   | Rare                                                       | 1 (<0.1)                                                   |
| Meningitis                                | 1 (<0.1)                                                   | Rare                                                       | 0                                                          |
| Renal and urinary disorders               |                                                            |                                                            |                                                            |
| Blood creatinine increased                | 80 (3.5)                                                   | Common                                                     | 3 (0.1)                                                    |
| Dysuria                                   | 28 (1.2)                                                   | Common                                                     | 0                                                          |
| Nephritis                                 | 4 (0.2)                                                    | Uncommon                                                   | 1 (<0.1)                                                   |
| Respiratory, thoracic and mediastinal     | disorders                                                  |                                                            |                                                            |
| Cough/Productive cough                    | 381 (16.7)                                                 | Very common                                                | 3 (0.1)                                                    |
| Dysphonia                                 | 44 (1.9)                                                   | Common                                                     | 0                                                          |
| Interstitial lung disease                 | 20 (0.9)                                                   | Uncommon                                                   | 4 (0.2)                                                    |
| Pneumonitis                               | 92 (4.0)                                                   | Common                                                     | 28 (1.2)                                                   |
| Skin and subcutaneous tissue disorders    |                                                            |                                                            |                                                            |
| Dermatitis                                | 19 (0.8)                                                   | Uncommon                                                   | 1 (<0.1)                                                   |
| Night sweats                              | 31 (1.4)                                                   | Common                                                     | 0                                                          |
| Pemphigoid                                | 7 (0.3)                                                    | Uncommon                                                   | 1 (<0.1)                                                   |
| Pruritus Rash                             | 424 (18.6) 490 (21.5)                                      | Very common Very common                                    | 9 (0.4) 18 (0.8)                                           |

<div style=\"page-break-after: always\"></div>

## ADR system organ class/ ADR term

| Number (%) of patients a                                             |                        |
|----------------------------------------------------------------------|------------------------|
| T + D Pan-tumor pool (N = 2280) Any CTCAE Grade CIOMS III category b | Max CTCAE Grade 3 or 4 |

- a Number (%) of patients with AEs, sorted in alphabetical order by ADR system organ class and ADR PT.

b The CIOMS III category applies to any CTCAE Grade events. CIOMS III convention and is defined as: (1) very common (≥ 1/10); (2) common (≥ 1/100 to &lt; 1/10); (3) uncommon (≥ 1/1,000 to &lt; 1/100); (4) rare (≥ 1/10,000 to &lt; 1/1,000); (5) very rare (&lt; 1/10,000); and (6) not known (cannot be estimated from available data).

c Only applies to D + T combination ADRs.

Chemotherapy ADRs are not included in this table as they are not relevant to T + D pan-tumor pool.

A patient can have one or more PT reported under a given SOC.

Maximum CTCAE grade per patient is considered.

Includes AEs with an onset date on or after the date of first dose or pre-treatment AEs that increase in severity on or after the date of first dose up to and including 90 days following the date of last dose of study medication or up to and including the date of initiation of the first subsequent therapy (whichever occurs first).

ADR terms are grouped PTs. Grouped term included multiple PTs.

MedDRA version 23.1.

Urticaria events in the Infusion related reaction ADR term include Urticaria starting on same day or 1 day after latest dose. Disease progression AEs reported in Study 6 and Study 10 are not included in this summary.

AE, adverse events; ADR, adverse drug reaction; ALT, alanine transaminase; AST, aspartate transaminase; CIOMS, Council for International Organizations of Medical Sciences; D, durvalumab; Max, maximum; MedDRA, Medical Dictionary for Regulatory Activities; PT, preferred term; SOC, system organ class; SoC, standard of care; T, tremelimumab

The frequency category 'not known' for adverse reactions for both regimens (tremelimumab 75 mg in combination with durvalumab and platinum-based chemotherapy for the treatment of NSCLC, and tremelimumab 300 mg in combination with durvalumab for the treatment of HCC), unless otherwise stated in the SmPC, has been re-estimated based on a larger safety pool ('T75 + D pan-tumour pool'). The T75 + D pool includes 3319 patients who have received at least 1 dose of durvalumab given at a dose of 20 mg/kg Q4W (or equivalent) IV in combination with tremelimumab 1 mg/kg Q4W (or equivalent), for any line of therapy (across tumour types). The frequency of these adverse reactions is shown in Table 69.

Table 69. Adverse Drug Reactions in the T75 + D Pan tumour Pool

| MedDRA system organ class preferred term   | Number (%) of patients Pan-tumor T75+D pool (N = 3319)   | Number (%) of patients Pan-tumor T75+D pool (N = 3319)   | Number (%) of patients Pan-tumor T75+D pool (N = 3319)   |
|--------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
|                                            | CIOMS III a Any CTCAE grade                              | CIOMS III a Any CTCAE grade                              | Maximum CTCAE Grade 3-4                                  |
| Endocrine disorders                        |                                                          |                                                          |                                                          |
| Type 1 diabetes mellitus                   | Uncommon                                                 | 9 (0.3)                                                  | 2 (< 0.1)                                                |
| Diabetes insipidus                         | Rare                                                     | 1 (< 0.1)                                                | 0                                                        |
| Gastrointestinal disorders                 |                                                          |                                                          |                                                          |
| Intestinal perforation c                   | Rare                                                     | 2 (< 0.1)                                                | 2 (< 0.1)                                                |
| Large intestine perforation c              | Uncommon                                                 | 4 (0.1)                                                  | 3 (< 0.1)                                                |
| Nervous systems disorders                  |                                                          |                                                          |                                                          |
| Myasthenia gravis b                        | Rare                                                     | 2 (< 0.1)                                                | 1 (< 0.1)                                                |
| Meningitis                                 | Rare                                                     | 1 (< 0.1)                                                | 0                                                        |
| Guillain-Barre syndrome                    | Rare                                                     | 1 (< 0.1)                                                | 1 (< 0.1)                                                |
| Encephalitis b                             | Rare                                                     | 2 (< 0.1)                                                | 0                                                        |
| Renal and urinary disorders                |                                                          |                                                          |                                                          |
| Cystitis noninfective                      | Rare                                                     | 2 (<0.1)                                                 | 0                                                        |

<div style=\"page-break-after: always\"></div>

## Serious adverse event/deaths/other significant events

## SAEs:

## Table 70. SAEs with incidence ≥ 1% SAS POSEIDON and pan-tumour pool

|                          | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a         |
|--------------------------|----------------------------|----------------------------|----------------------------------|
| term                     | POSEIDON                   | POSEIDON                   | T + D Pan-tumour pool (N = 2280) |
| Preferred                | T + D + SoC (N = 330)      | SoC (N = 333)              | T + D Pan-tumour pool (N = 2280) |
| Any SAE b                | 146 (44.2)                 | 117 (35.1)                 | 1020 (44.7)                      |
| Pneumonia                | 36 (10.9)                  | 16 (4.8)                   | 132 (5.8)                        |
| Anaemia                  | 18 (5.5)                   | 21 (6.3)                   | 22 (1.0)                         |
| Diarrhoea                | 8 (2.4)                    | 2 (0.6)                    | 56 (2.5)                         |
| Pyrexia                  | 8 (2.4)                    | 1 (0.3)                    | 42 (1.8)                         |
| Thrombocytopenia         | 8 (2.4)                    | 3 (0.9)                    | 4 (0.2)                          |
| Febrile neutropenia      | 7 (2.1)                    | 4 (1.2)                    | 0                                |
| Acute kidney injury      | 6 (1.8)                    | 1 (0.3)                    | 18 (0.8)                         |
| Pneumonitis              | 6 (1.8)                    | 1 (0.3)                    | 45 (2.0)                         |
| Colitis                  | 5 (1.5)                    | 0                          | 39 (1.7)                         |
| Pulmonary embolism       | 5 (1.5)                    | 9 (2.7)                    | 34 (1.5)                         |
| Sepsis                   | 5 (1.5)                    | 2 (0.6)                    | 21 (0.9)                         |
| Cerebrovascular accident | 4 (1.2)                    | 1 (0.3)                    | 8 (0.4)                          |
| Neutropenia              | 4 (1.2)                    | 3 (0.9)                    | 2 (<0.1)                         |
| Death                    | 3 (0.9)                    | 1 (0.3)                    | 10 (0.4)                         |
| Dyspnoea                 | 3 (0.9)                    | 2 (0.6)                    | 42 (1.8)                         |
| Hyponatraemia            | 3 (0.9)                    | 1 (0.3)                    | 18 (0.8)                         |
| Dehydration              | 2 (0.6)                    | 2 (0.6)                    | 23 (1.0)                         |
| Enterocolitis            | 2 (0.6)                    | 0                          | 9 (0.4)                          |
| Vomiting                 | 2 (0.6)                    | 0                          | 27 (1.2)                         |
| Pleural effusion         | 0                          | 2 (0.6)                    | 27 (1.2)                         |
| Abdominal pain           | 0                          | 0                          | 24 (1.1)                         |
| Back pain                | 0                          | 0                          | 24 (1.1)                         |

Based on the data presented by the Applicant, the contribution of tremelimumab in the occurrence of SAEs is evident and cannot be disregarded: tremelimumab was involved in 8 of the 14 fatal SAEs.

<div style=\"page-break-after: always\"></div>

Deaths: Table 71. All deaths (full analysis set - POSEIDON)

|                                                                                        | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|----------------------------------------------------------------------------------------|--------------------------|--------------------------|--------------------------|
| Category                                                                               | T+D+SoC (N=338)          | D+SoC (N=338)            | SoC (N=337)              |
| Total number of deaths                                                                 | 251 (74.3)               | 265 (78.4)               | 285 (84.6)               |
| Death related to disease under investigation onlya                                     | 202 (59.8)               | 224 (66.3)               | 246 (73.0)               |
| Death related to disease under investigation? and an AE with outcome of death          | 17 (5.0)                 | 9 (2.7)                  | 13 (3.9)                 |
| AE onset prior to subsequent therapy                                                   | 15 (4.4)                 | 9 (2.7)                  | 12 (3.6)                 |
| AE onset after start of subsequent therapy                                             | 2 (0.6)                  | 0                        | 1 (0.3)                  |
| AE with outcome of death only                                                          | 28 (8.3)                 | 26 (7.7)                 | 17 (5.0)                 |
| AE onset prior to subsequent therapyb                                                  | 26 (7.7)                 | 26 (7.7)                 | 17 (5.0)                 |
| AE onset after start of subsequent therapy                                             | 2 (0.6)                  | 0                        | 0                        |
| Death after end of safety follow up period and not due to disease under investigationd | 2 (0.6)                  | 5 (1.5)                  | 6 (1.8)                  |
| Unknown reason for death                                                               | 2 (0.6)                  | 0                        | 3 (0.9)                  |
| Other deathse                                                                          | 0                        | 1 (0.3)                  | 0                        |

Table 72. AEs with outcome of death by preferred term (incidence ≥ 2 patients) in SAS POSEIDON and pan-tumour pool

|                                  | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   |
|----------------------------------|----------------------------|----------------------------|----------------------------|
|                                  | POSEIDON                   | POSEIDON                   | T + D Pan-tumour pool      |
| Preferred term                   | T + D + SoC (N = 330)      | SoC (N = 333)              | (N = 2280)                 |
|                                  | 41 (12.4)                  |                            |                            |
| Patients with any AE with        |                            | 30 (9.0)                   | 153 ( 6.7)                 |
| Pneumonia                        | 7 ( 2.1)                   | 7 (2.1)                    | 14 ( 0.6)                  |
| Sepsis                           | 3 ( 0.9)                   | 1 (0.3)                    | 7 (0.3)                    |
| Septic shock                     | 0                          | 0                          | 6 (0.3)                    |
| Febrile neutropenia              | 1 ( 0.3)                   | 2 (0.6)                    | 0                          |
| Pancytopenia                     | 0                          | 1 (0.3)                    | 0                          |
| Cerebrovascular accident         | 2 ( 0.6)                   | 1 (0.3)                    | 3 (0.1)                    |
| Depressed level of consciousness | 0                          | 0                          | 2 (< 0.1)                  |
| Ischaemic stroke                 | 1 ( 0.3)                   | 0                          | 2 (<0.1)                   |
| Acute coronary syndrome          | 1 ( 0.3)                   |                            | 3 (0.1)                    |
| Cardiac arrest                   | 0                          | 0                          | 4 (0.2)                    |
| Cardiac failure                  | 2 ( 0.6)                   | 1 (0.3)                    | 5 (0.2)                    |
| Cardiopulmonary failure          | 2 ( 0.6)                   | 1 (0.3)                    | 0                          |
| Acute respiratory failure        | 0                          | 0                          | 4 (0.2)                    |
| Asphyxia                         | 0                          | 0                          | 2 (< 0.1)                  |

<div style=\"page-break-after: always\"></div>

|                                       | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a         |
|---------------------------------------|----------------------------|----------------------------|----------------------------------|
|                                       | POSEIDON                   | POSEIDON                   | T + D Pan-tumour pool (N = 2280) |
| Preferred term                        | T + D + SoC (N = 330)      | SoC (N = 333)              | T + D Pan-tumour pool (N = 2280) |
| Chronic obstructive pulmonary disease | 1 (0.3)                    | 1 (0.3)                    | 2 (<0.1)                         |
| Dyspnoea                              | 1 (0.3)                    | 0                          | 3 ( 0.1)                         |
| Interstitial lung disease             | 0                          | 0                          | 2 (< 0.1)                        |
| Pneumonia aspiration                  | 0                          | 0                          | 4 ( 0.2)                         |
| Pneumonitis                           | 1 (0.3)                    | 0                          | 7 ( 0.3)                         |
| Pulmonary embolism                    | 1 (0.3)                    | 5 (1.5)                    | 10 (0.4)                         |
| Pulmonary haemorrhage                 | 0                          | 2 (0.6)                    | 2 (<0.1)                         |
| Respiratory failure                   | 0                          | 0                          | 3 (0.1)                          |
| Acute kidney injury                   | 2 (0.6)                    | 0                          | 3 (0.1)                          |
| Death                                 | 3 ( 0.9)                   | 1 (0.3)                    | 10 (0.4)                         |
| Multiple organ dysfunction syndrome   | 0                          | 0                          | 3 (0.1)                          |
| Sudden cardiac death                  | 0                          | 0                          | 3 (0.1)                          |
| Sudden death                          | 0                          | 0                          | 5 (0.2)                          |

## Laboratory findings

Table 73. Changes in Haematology parameters, SAS POSEIDON and pan-tumour pool

|                   | n/N (%) of patients     | n/N (%) of patients           | n/N (%) of patients     | n/N (%) of patients           | n/N (%) of patients     | n/N (%) of patients           |
|-------------------|-------------------------|-------------------------------|-------------------------|-------------------------------|-------------------------|-------------------------------|
|                   | POSEIDON                | POSEIDON                      | POSEIDON                | POSEIDON                      | T + D Pan-tumour pool   | T + D Pan-tumour pool         |
|                   | T + D + SoC (N = 330)   | T + D + SoC (N = 330)         | SoC (N = 333)           | SoC (N = 333)                 | (N = 2280)              | (N = 2280)                    |
| Parameter         | ≥ 2 CTCAE grade changes | CTCAE grade changes to 3 or 4 | ≥ 2 CTCAE grade changes | CTCAE grade changes to 3 or 4 | ≥ 2 CTCAE grade changes | CTCAE grade changes to 3 or 4 |
| Hemoglobin        | 120/326 (36.8)          | 77/326 (23.6)                 | 120/323 (37.2)          | 81/323 (25.1)                 | 127/2167 (5.9)          | 110/2167 (5.1)                |
| Leukocytes        | 166/326 (50.9)          | 70/326 (21.5)                 | 167/323 (51.7)          | 59/323 (18.3)                 | 62/2167 (2.9)           | 19/2167 (0.9)                 |
| Lymphocytes (low) | 140/326 (42.9)          | 64/326 (19.6)                 | 117/323 (36.2)          | 60/323 (18.6)                 | 443/2137 (20.7)         | 289/2137 (13.5)               |
| Neutrophils       | 197/326 (60.4)          | 120/326 (36.8)                | 186/323 (57.6)          | 102/323 (31.6)                | 81/2114 (3.8)           | 20/2114 (0.9)                 |
| Platelets         | 61/326 (18.7)           | 35/326 (10.7)                 | 54/323 (16.7)           | 38/323 (11.8)                 | 47/2161 (2.2)           | 24/2161 (1.1)                 |

Table 74. Changes in chemistry parameters, SAS POSEIDON and pan-tumour pool

|           | n/N (%) of patients     | n/N (%) of patients           | n/N (%) of patients     | n/N (%) of patients           | n/N (%) of patients     | n/N (%) of patients           |
|-----------|-------------------------|-------------------------------|-------------------------|-------------------------------|-------------------------|-------------------------------|
|           | POSEIDON                | POSEIDON                      | POSEIDON                | POSEIDON                      | T + D Pan-tumour pool   | T + D Pan-tumour pool         |
| Parameter | T + D + SoC (N = 330)   | T + D + SoC (N = 330)         | SoC (N = 333)           | SoC (N = 333)                 | (N = 2280)              | (N = 2280)                    |
|           | ≥ 2 CTCAE grade changes | CTCAE grade changes to 3 or 4 | ≥ 2 CTCAE grade changes | CTCAE grade changes to 3 or 4 | ≥ 2 CTCAE grade changes | CTCAE grade changes to 3 or 4 |
| ALT       | 45/324 (13.9)           | 20/324 (6.2)                  | 37/321 (11.5)           | 15/321 (4.7)                  | 164/2158 (7.6)          | 93/2158 (4.3)                 |

<div style=\"page-break-after: always\"></div>

|                      | n/N (%) of patients     | n/N (%) of patients           | n/N (%) of patients     | n/N (%) of patients           | n/N (%) of patients     | n/N (%) of patients           |
|----------------------|-------------------------|-------------------------------|-------------------------|-------------------------------|-------------------------|-------------------------------|
|                      | POSEIDON                | POSEIDON                      | POSEIDON                | POSEIDON                      | T + D Pan-tumour pool   | T + D Pan-tumour pool         |
|                      | T + D + SoC (N = 330)   | T + D + SoC (N = 330)         | SoC (N = 333)           | SoC (N = 333)                 | (N = 2280)              | (N = 2280)                    |
| Parameter            | ≥ 2 CTCAE grade changes | CTCAE grade changes to 3 or 4 | ≥ 2 CTCAE grade changes | CTCAE grade changes to 3 or 4 | ≥ 2 CTCAE grade changes | CTCAE grade changes to 3 or 4 |
| Albumin              | 45/324 (13.9)           | 6/324 (1.9)                   | 29/ 319 (9.1)           | 3/319 (0.9)                   | 310/2146 (14.4)         | 36/2146 (1.7)                 |
| Alkaline phosphatase | 16/323 (5.0)            | 11/323 (3.4)                  | 4/ 321 (1.2)            | 4/321 (1.2)                   | 99/2151 (4.6)           | 77/2151 (3.6)                 |
| Amylase              | 54/307 (17.6)           | 29/307 (9.4)                  | 31/308 (10.1)           | 18/308 (5.8)                  | 140/1460 (9.6)          | 90/1460 (6.2)                 |
| AST                  | 31/324 (9.6)            | 17/324 (5.2)                  | 23/321 (7.2)            | 7/321 (2.2)                   | 145/2151 (6.7)          | 101/2151 (4.7)                |
| Corrected calcium    | 17/317 (5.4)            | 6/317 (1.9)                   | 18/316 (5.7)            | 5/316 (1.6)                   | 122/1997 (6.1)          | 66/1997 (3.3)                 |
| Low                  | 10/317 (3.2)            | 3/317 (0.9)                   | 11/316 (3.5)            | 3/316 (0.9)                   | 46/1997 (2.3)           | 15/1997 (0.8)                 |
| High                 | 7/317 (2.2)             | 3/317 (0.9)                   | 7/316 (2.2)             | 2/316 (0.6)                   | 78/1997 (3.9)           | 52/1997 (2.6)                 |
| Creatinine           | 87/324 (26.9)           | 13/324 (4.0)                  | 61/321 (19.0)           | 6/321 (1.9)                   | 160/2039 (7.8)          | 15/2039 (0.7)                 |
| GGT                  | 3/45 (6.7)              | 1/45 (2.2)                    | 4/43 (9.3)              | 2/43 (4.7)                    | 236/1935 (12.2)         | 231/1935 (11.9)               |
| Glucose              | 59/322 (18.3)           | 20/322 (6.2)                  | 47/319 (14.7)           | 12/319 (3.8)                  | 240/2020 (11.9)         | 114/2020 (5.6)                |
| Low                  | 8/322 (2.5)             | 0/322                         | 4/319 (1.3)             | 3/319 (0.9)                   | 29/2020 (1.4)           | 7/2020 (0.3)                  |
| High                 | 55/322 (17.1)           | 20/322 (6.2)                  | 43/319 (13.5)           | 10/319 (3.1)                  | 215/2020 (10.6)         | 108/2020 (5.3)                |
| Lipase               | 59/301 (19.6)           | 41/301 (13.6)                 | 24/291 (8.2)            | 15/291 (5.2)                  | 212/1445 (14.7)         | 176/1445 (12.2)               |
| Magnesium            | 3/49 (6.1)              | 2/49 (4.1)                    | 1/48 (2.1)              | 0/48                          | 42/1955 (2.1)           | 37/1955 (1.9)                 |
| Low                  | 3/49 (6.1)              | 2/49 (4.1)                    | 1/48 (2.1)              | 0/48                          | 22/1955 (1.1)           | 17/1955 (0.9)                 |
| High                 | 0/49                    | 0/49                          | 0/48                    | 0/48                          | 22/1955 (1.1)           | 22/1955 (1.1)                 |
| Potassium            | 56/323 (17.3)           | 28/ 323 (8.7)                 | 36/ 320 (11.3)          | 18/320 (5.6)                  | 183/2037 (9.0)          | 107/2037 (5.3)                |
| Low                  | 21/323 (6.5)            | 21/323 (6.5)                  | 8/320 (2.5)             | 9/320 (2.8)                   | 69/2037 (3.4)           | 70/2037 (3.4)                 |
| High                 | 36/323 (11.1)           | 7/323 (2.2)                   | 29/320 (9.1)            | 9/320 (2.8)                   | 114/2037 (5.6)          | 38/2037 (1.9)                 |
| Sodium               | 43/323 (13.3)           | 41/323 (12.7)                 | 35/319 (11.0)           | 35/319 (11.0)                 | 238/2039 (11.7)         | 219/2039 (10.7)               |
| Low                  | 40/323 (12.4)           | 41/323 (12.7)                 | 34/319 (10.7)           | 35/319 (11.0)                 | 209/2039 (10.3)         | 211/2039 (10.3)               |
| High                 | 4/323 (1.2)             | 0/323                         | 1/319 (0.3)             | 0/319                         | 30/2039 (1.5)           | 8/2039 (0.4)                  |
| Total bilirubin      | 13/323 (4.0)            | 3/323 (0.9)                   | 5/321 (1.6)             | 1/321 (0.3)                   | 90/2154 (4.2)           | 37/2154 (1.7)                 |

Table 75. Abnormal thyroid tests, SAS POSEIDON and pan-tumour pool

|                                 | Number (%) of patients   | Number (%) of patients   | Number (%) of patients            |
|---------------------------------|--------------------------|--------------------------|-----------------------------------|
| Category                        | POSEIDON                 | POSEIDON                 | T + D Pan- tumour pool (N = 2280) |
|                                 | T + D + SoC (N = 330)    | SoC (N = 333)            |                                   |
| On-treatment elevated TSH > ULN | 103 (31.2)               | 80 (24.0)                | 727 (31.9)                        |

<div style=\"page-break-after: always\"></div>

|                                                                            | Number (%) of patients   | Number (%) of patients   | Number (%) of patients            |
|----------------------------------------------------------------------------|--------------------------|--------------------------|-----------------------------------|
|                                                                            | POSEIDON                 | POSEIDON                 | T + D Pan- tumour pool (N = 2280) |
| Category                                                                   | T + D + SoC (N = 330)    | SoC (N = 333)            | T + D Pan- tumour pool (N = 2280) |
| On-treatment elevated TSH > ULN with TSH ≤ ULN at baseline                 | 77 (23.3)                | 45 (13.5)                | 455 (20.0)                        |
| with at least one T 3 free/T 4 free < LLN                                  | 61 (18.5)                | 23 ( 6.9)                | 454 (19.9)                        |
| with all T 3 free/T 4 free ≥ LLN                                           | 35 (10.6)                | 44 (13.2)                | 223 (9.8)                         |
| with all T 3 free/T 4 free missing                                         | 7 ( 2.1)                 | 13 ( 3.9)                | 50 (2.2)                          |
| On-treatment low TSH < LLN                                                 | 115 (34.8)               | 50 (15.0)                | 622 (27.3)                        |
| On- treatment low TSH < LLN with TSH ≥ LLN at baseline                     | 102 (30.9)               | 40 (12.0)                | 530 (23.2)                        |
| with at least one T 3 free/T4 free > ULN                                   | 41 (12.4)                | 7 ( 2.1)                 | 301 (13.2)                        |
| with all T 3 free/T 4 free ≤ ULN                                           | 61 (18.5)                | 37 (11.1)                | 274 (12.0)                        |
| With all T 3 free/T 4 free missing                                         | 13 ( 3.9)                | 6 ( 1.8)                 | 47 (2.1)                          |
| Number of patients with at least one baseline and post-baseline TSH result | 310 (93.9)               | 298 (89.5)               | 2070 (90.8)                       |
| On-treatment elevated TSH > ULN and above baseline                         | 96 (29.1)                | 68 (20.4)                | 643 (28.2)                        |
| On-treatment decreased TSH < LLN and below baseline                        | 113 (34.2)               | 47 (14.1)                | 585 (25.7)                        |

## Safety in special populations

Age:

Table 76. AEs by category and age group, SAS POSEIDON and pan-tumour pool

|                                                    | Age Group   | Number (%) of Patients a                      | Number (%) of Patients a              | Number (%) of Patients a                             | Number (%) of Patients a                     | Number (%) of Patients a                                    |
|----------------------------------------------------|-------------|-----------------------------------------------|---------------------------------------|------------------------------------------------------|----------------------------------------------|-------------------------------------------------------------|
| AEs by Category                                    | Age Group   | POSEIDON                                      | POSEIDON                              | T + D + Chemo pool (N1=45) (N2=295) (N3=198) (N4=58) | Chemo pool (N1=51) (N2=279) (N3=209) (N4=60) | T + D Pan- tumour pool (N1=259) (N2=1041) (N3=774) (N4=206) |
| AEs by Category                                    | Age Group   | T + D + SoC (N1=29) (N2=158) (N3=108) (N4=35) | SoC (N1=31) (N2=143) (N3=120) (N4=39) | T + D + Chemo pool (N1=45) (N2=295) (N3=198) (N4=58) | Chemo pool (N1=51) (N2=279) (N3=209) (N4=60) | T + D Pan- tumour pool (N1=259) (N2=1041) (N3=774) (N4=206) |
| Patients with AE                                   | <50         | 26 (89.7)                                     | 30 (96.8)                             | 42 (93.3)                                            | 49 (96.1)                                    | 245 (94.6)                                                  |
| Patients with AE                                   | ≥ 50 - <65  | 155 (98.1)                                    | 136 (95.1)                            | 291 (98.6)                                           | 268 (96.1)                                   | 984 (94.5)                                                  |
| Patients with AE                                   | ≥ 65 - <75  | 105 (97.2)                                    | 115 (95.8)                            | 194 (98.0)                                           | 201 (96.2)                                   | 733 (94.7)                                                  |
| Patients with AE                                   | ≥ 75        | 35 (100.0)                                    | 39 (100.0)                            | 58 (100.0)                                           | 60 (100.0)                                   | 198 (96.1)                                                  |
| Patients with SAEs b                               | <50         | 11 (37.9)                                     | 3 (9.7)                               | 15 (33.3)                                            | 7 (13.7)                                     | 97 (37.5)                                                   |
| Patients with SAEs b                               | ≥ 50 - <65  | 57 (36.1)                                     | 45 (31.5)                             | 114 (38.6)                                           | 90 (32.3)                                    | 451 (43.3)                                                  |
| Patients with SAEs b                               | ≥ 65 - <75  | 52 (48.1)                                     | 47 (39.2)                             | 98 (49.5)                                            | 85 (40.7)                                    | 360 (46.5)                                                  |
| Patients with SAEs b                               | ≥ 75        | 26 (74.3)                                     | 22 (56.4)                             | 40 (69.0)                                            | 32 (53.3)                                    | 112 (54.4)                                                  |
| Patients with any AE of CTCAE Grade 3 or Grade 4 c | < 50        | 13 (44.8)                                     | 13 (41.9)                             | 22 (48.9)                                            | 24 (47.1)                                    | 135 (52.1)                                                  |
| Patients with any AE of CTCAE Grade 3 or Grade 4 c | ≥ 50 - <65  | 97 (61.4)                                     | 76 (53.1)                             | 197 (66.8)                                           | 156 (55.9)                                   | 544 (52.3)                                                  |
| Patients with any AE of CTCAE Grade 3 or Grade 4 c | ≥ 65 - <75  | 68 (63.0)                                     | 75 (62.5)                             | 131 (66.2)                                           | 136 (65.1)                                   | 405 (52.3)                                                  |
| Patients with any AE of CTCAE Grade 3 or Grade 4 c | ≥ 75        | 25 (71.4)                                     | 25 (64.1)                             | 40 (69.0)                                            | 40 (66.7)                                    | 130 (63.1)                                                  |
| Patients with any AE leading to outcome of death   | <50         | 1 (3.4)                                       | 2 (6.5)                               | 1 (2.2)                                              | 2 (3.9)                                      | 10 (3.9)                                                    |
| Patients with any AE leading to outcome of death   | ≥ 50 - <65  | 11 (7.0)                                      | 10 (7.0)                              | 18 (6.1)                                             | 16 (5.7)                                     | 67 (6.4)                                                    |
| Patients with any AE leading to outcome of death   | ≥ 65 - <75  | 15 (13.9)                                     | 12 (10.0)                             | 30 (15.2)                                            | 19 (9.1)                                     | 52 (6.7)                                                    |
| Patients with any AE leading to outcome of death   | ≥ 75        | 14 (40.0)                                     | 6 (15.4)                              | 19 (32.8)                                            | 8 (13.3)                                     | 24 (11.7)                                                   |
| Patients with                                      | <50         | 1 (3.4)                                       | 4 (12.9)                              | 5 (11.1)                                             | 5 (9.8)                                      | 31 (12.0)                                                   |
| any AE leading                                     | ≥ 50 - <65  | 26 (16.5)                                     | 18 (12.6)                             | 47 (15.9)                                            | 26 (9.3)                                     | 149 (14.3)                                                  |
| any AE leading                                     | ≥ 65 - <75  | 29 (26.9)                                     | 20 (16.7)                             | 53 (26.8)                                            | 32 (15.3)                                    | 136 (17.6)                                                  |
| to discontinuation of any study treatment          | ≥ 75        | 17 (48.6)                                     | 9 (23.1)                              | 25 (43.1)                                            | 13 (21.7)                                    | 51 (24.8)                                                   |

<div style=\"page-break-after: always\"></div>

a Percentages are calculated from N1, N2, N3, and N4 for &lt;50 years, ≥50 -&lt;65 years, ≥65 -&lt;75 years, and ≥75 years, respectively. Number of patients with events divided by the total number of patients in the age group, multiplied by 100. b Seriousness, as assessed by the Investigator. An Ae with missing seriousness is considered serious.

N1 = Total number of &lt;50 years patients, N2 = Total number of ≥50 -&lt;65 years patients, N3 = Total number of ≥65 -  &lt;75 years patients, N4 = Total number of ≥ 75 years patients.

Patients with multiple AEs are counted once for the PT.

Table 77. Adverse Events by Age Group in POSEIDON T + D + SoC Arm (Safety Analysis Set)

|                                                  | Number (%) of Patients a   | Number (%) of Patients a   | Number (%) of Patients a   | Number (%) of Patients a   |
|--------------------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
| AE Group                                         | Age < 65 n = 187           | Age 65-74 n = 108          | Age 75-84 n = 33           | Age ≥ 85 n = 2             |
| Total AEs                                        | 181 (96.8)                 | 105 (97.2)                 | 33 (100.0)                 | 2 (100.0)                  |
| Total serious AEs                                | 68 (36.4)                  | 52 (48.1)                  | 24 (72.7)                  | 2 (100.0)                  |
| Fatal                                            | 12 (6.4)                   | 15 (13.9)                  | 12 (36.4)                  | 2 (100.0)                  |
| Hospitalisation/prolong existing hospitalisation | 60 (32.1)                  | 48 (44.4)                  | 21 (63.6)                  | 1 (50.0)                   |
| Life-threatening                                 | 14 (7.5)                   | 17 (15.7)                  | 6 (18.2)                   | 1 (50.0)                   |
| Disability/incapacity                            | 5 (2.7)                    | 2 (1.9)                    | 1 (3.0)                    | 0                          |
| Other (medically significant)                    | 25 (13.4)                  | 18 (16.7)                  | 7 (21.2)                   | 1 (50.0)                   |
| AE leading to drop-out                           | 27 (14.4)                  | 29 (26.9)                  | 16 (48.5)                  | 1 (50.0)                   |
| Psychiatric disorders                            | 25 (13.4)                  | 21 (19.4)                  | 5 (15.2)                   | 0                          |
| Nervous system disorders                         | 62 (33.2)                  | 44 (40.7)                  | 10 (30.3)                  | 1 (50.0)                   |
| Accident and injuries                            | 13 (7.0)                   | 10 (9.3)                   | 5 (15.2)                   | 0                          |
| Cardiac disorders Vascular disorders             | 16 (8.6) 21 (11.2)         | 12 (11.1) 22 (20.4)        | 5 (15.2) 7 (21.2)          | 0 0                        |
| Central nervous system vascular disorders        | 9 (4.8)                    |                            | 0                          | 1 (50.0)                   |
|                                                  |                            | 8 (7.4)                    |                            | 2 (100.0)                  |
| Infections and infestations                      | 88 (47.1)                  | 54 (50.0)                  | 17 (51.5)                  | 0                          |
| Anticholinergic syndrome                         | 0                          | 0                          | 0                          |                            |
| Quality of life decreased                        | 0                          | 0                          | 0                          | 0                          |
| ataxia, fractures Other AEs b                    |                            |                            |                            |                            |
| Lipase increased                                 | 11 (5.9)                   | 5 (4.6)                    | 4 (12.1)                   | 1 (50.0)                   |
| Amylase increased                                | 16 (8.6)                   | 8 (7.4)                    | 4 (12.1)                   | 0                          |
| Back pain                                        | 15 (8.0)                   | 6 (5.6)                    | 4 (12.1)                   | 0                          |
| Dehydration                                      | 3 (1.6)                    | 6 (5.6)                    | 4 (12.1)                   | 0                          |
| Dyspepsia                                        | 6 (3.2)                    | 2 (1.9)                    | 4 (12.1)                   | 0                          |
| Mucosal inflammation                             | 6 (3.2)                    | 7 (6.5)                    | 4 (12.1)                   | 0                          |
| Pain in extremity                                | 6 (3.2)                    | 7 (6.5)                    | 4 (12.1)                   | 0                          |

Patients with multiple events in the same category are counted only once in that category. Patients with events in more than one category are counted once in each of those categories.

AEs by PTs with a ≥ 3% higher incidence in patients ≥ 75 years compared with patients &lt; 65 years or 65-74 years and occurring in

≥ 10% of patients that are ≥ 75 years..

Includes AEs with an onset date or pre-treatment AEs that increase in severity on or after the date of first dose and up to and including the earlier of 90 days following the date of last dose of study treatment or the date of initiation of the first subsequent therapy (whichever occurred first).

## Sex:

Table 78. Adverse Events by Category and Sex (Safety Analysis Set)

|                      | Sex    | Number (%) of Patients a     | Number (%) of Patients a   | Number (%) of Patients a             | Number (%) of Patients a   | Number (%) of Patients a                  |
|----------------------|--------|------------------------------|----------------------------|--------------------------------------|----------------------------|-------------------------------------------|
|                      | Sex    | POSEIDON                     | POSEIDON                   | T + D + Chemo pool (N1=464) (N2=132) | Chemo pool (N1=428)        | T + D Pan- tumour pool (N1=1585) (N2=695) |
|                      | Sex    | T + D + SoC (N1=264) (N2=66) | SoC (N1=247) (N2=86)       | T + D + Chemo pool (N1=464) (N2=132) | (N2=171)                   | T + D Pan- tumour pool (N1=1585) (N2=695) |
| Patients with any AE | Male   | 256 (97.0)                   | 235 (95.1)                 | 454 (97.8)                           | 410 (95.8)                 | 1497 (94.4)                               |
| Patients with any AE | Female | 65 (98.5)                    | 85 (98.8)                  | 131 (99.2)                           | 168 (98.2)                 | 663 (95.4)                                |

<div style=\"page-break-after: always\"></div>

|                                                                        |        | Number (%) of Patients a     | Number (%) of Patients a   | Number (%) of Patients a    | Number (%) of Patients a   | Number (%) of Patients a         |
|------------------------------------------------------------------------|--------|------------------------------|----------------------------|-----------------------------|----------------------------|----------------------------------|
|                                                                        |        | POSEIDON                     | POSEIDON                   | T + D + Chemo pool (N1=464) | Chemo pool                 | T + D Pan- tumour pool (N1=1585) |
| AEs by Category                                                        | Sex    | T + D + SoC (N1=264) (N2=66) | SoC (N1=247) (N2=86)       | (N2=132)                    | (N1=428) (N2=171)          | (N2=695)                         |
| Patients with any SAE b                                                | Male   | 114 (43.2)                   | 92 (37.2)                  | 203 (43.8)                  | 151 (35.3)                 | 706 (44.5)                       |
| Patients with any SAE b                                                | Female | 32 (48.5)                    | 25 (29.1)                  | 64 (48.5)                   | 63 (36.8)                  | 314 (45.2)                       |
| Patients with any AE of CTCAE G3 or G4 c                               | Male   | 158 (59.8)                   | 138 (55.9)                 | 295 (63.6)                  | 253 (59.1)                 | 815 (51.4)                       |
| Patients with any AE of CTCAE G3 or G4 c                               | Female | 45 (68.2)                    | 51 (59.3)                  | 95 (72.0)                   | 103 (60.2)                 | 399 (57.4)                       |
| Patients with any AE leading to outcome of death                       | Male   | 35 (13.3)                    | 27 (10.9)                  | 59 (12.7)                   | 37 (8.6)                   | 122 ( 7.7)                       |
| Patients with any AE leading to outcome of death                       | Female | 6 (9.1)                      | 3 (3.5)                    | 9 (6.8)                     | 8 (4.7)                    | 31 ( 4.5)                        |
| Patients with any AE leading to discontinuation of any study treatment | Male   | 58 (22.0)                    | 43 (17.4)                  | 97 (20.9)                   | 59 (13.8)                  | 253 (16.0)                       |
| Patients with any AE leading to discontinuation of any study treatment | Female | 15 (22.7)                    | 8 (9.3)                    | 33 (25.0)                   | 17 (9.9)                   | 114 (16.4)                       |

Percentages are calculated from N1 and N2 for male and female, respectively. Number of patients with events divided by the total number of patients in the sex group, multiplied by 100.

Seriousness, as assessed by the Investigator. An AE with missing seriousness is considered serious.

## Weight quartiles:

Table 79. Treatment-emergent Adverse Events with Maximum Grade 3 or 4 - Incidence ≥ 5% of Patients in any Weight Group (Safety Analysis Set)

|                                      |                | Number (%) of patients a                            | Number (%) of patients a                        | Number (%) of patients a                    |
|--------------------------------------|----------------|-----------------------------------------------------|-------------------------------------------------|---------------------------------------------|
| Preferred term                       | Weight group b | T + D + SoC (N1 = 68) (N2 = 87) (N3 = 77) (N4 = 95) | D + SoC (N1 = 84) (N2 = 82) (N3 = 80) (N4 = 88) | SoC (N1 = 85) (N2 = 90) (N3 = 83) (N4 = 75) |
| Any AE of maximum CTCAE grade 3 or 4 | < Q1           | 45 (66.2)                                           | 51 (60.7)                                       | 44 (51.8)                                   |
| Any AE of maximum CTCAE grade 3 or 4 | ≥ Q1 to < Q2   | 43 (49.4)                                           | 42 (51.2)                                       | 45 (50.0)                                   |
| Any AE of maximum CTCAE grade 3 or 4 | ≥ Q2 to < Q3   | 43 (55.8)                                           | 39 (48.8)                                       | 40 (48.2)                                   |
| Any AE of maximum CTCAE grade 3 or 4 | ≥ Q3           | 45 (47.4)                                           | 51 (58.0)                                       | 43 (57.3)                                   |
| Alanine aminotransferase increased   | < Q1           | 2 (2.9)                                             | 1 (1.2)                                         | 2 (2.4)                                     |
| Alanine aminotransferase increased   | ≥ Q1 to < Q2   | 1 (1.1)                                             | 0                                               | 0                                           |
| Alanine aminotransferase increased   | ≥ Q2 to < Q3   | 0                                                   | 3 (3.8)                                         | 3 (3.6)                                     |
| Alanine aminotransferase increased   | ≥ Q3           | 2 (2.1)                                             | 5 (5.7)                                         | 2 (2.7)                                     |
| Amylase increased                    | < Q1           | 4 (5.9)                                             | 4 (4.8)                                         | 1 (1.2)                                     |
| Amylase increased                    | ≥ Q1 to < Q2   | 4 (4.6)                                             | 2 (2.4)                                         | 1 (1.1)                                     |
| Amylase increased                    | ≥ Q2 to < Q3   | 1 (1.3)                                             | 1 (1.3)                                         | 3 (3.6)                                     |
| Amylase increased                    | ≥ Q3           | 3 (3.2)                                             | 1 (1.1)                                         | 1 (1.3)                                     |
| Anaemia                              | < Q1           | 16 (23.5)                                           | 20 (23.8)                                       | 25 (29.4)                                   |
| Anaemia                              | ≥ Q1 to < Q2   | 18 (20.7)                                           | 16 (19.5)                                       | 20 (22.2)                                   |
| Anaemia                              | ≥ Q2 to < Q3   | 19 (24.7)                                           | 11 (13.8)                                       | 15 (18.1)                                   |
| Anaemia                              | ≥ Q3           | 14 (14.7)                                           | 12 (13.6)                                       | 15 (20.0)                                   |
| Asthenia                             | < Q1           | 2 (2.9)                                             | 2 (2.4)                                         | 2 (2.4)                                     |
| Asthenia                             | ≥ Q1 to < Q2   | 4 (4.6)                                             | 1 (1.2)                                         | 2 (2.2)                                     |
| Asthenia                             | ≥ Q2 to < Q3   | 2 (2.6)                                             | 0                                               | 0                                           |
| Asthenia                             | ≥ Q3           | 4 (4.2)                                             | 2 (2.3)                                         | 4 (5.3)                                     |
| Fatigue                              | < Q1           | 1 (1.5)                                             | 4 (4.8)                                         | 3 (3.5)                                     |
|                                      | ≥ Q1 to < Q2   | 3 (3.4)                                             | 5 (6.1)                                         | 2 (2.2)                                     |
|                                      | ≥ Q2 to < Q3   | 2 (2.6)                                             | 0                                               | 2 (2.4)                                     |
|                                      | ≥ Q3           | 2 (2.1)                                             | 3 (3.4)                                         | 2 (2.7)                                     |
| Febrile neutropenia                  | < Q1           | 4 (5.9)                                             | 2 (2.4)                                         | 1 (1.2)                                     |

<div style=\"page-break-after: always\"></div>

|                                  |                | Number (%) of patients a                            | Number (%) of patients a                        | Number (%) of patients a                    |
|----------------------------------|----------------|-----------------------------------------------------|-------------------------------------------------|---------------------------------------------|
| Preferred term                   | Weight group b | T + D + SoC (N1 = 68) (N2 = 87) (N3 = 77) (N4 = 95) | D + SoC (N1 = 84) (N2 = 82) (N3 = 80) (N4 = 88) | SoC (N1 = 85) (N2 = 90) (N3 = 83) (N4 = 75) |
| Preferred term                   | ≥ Q1 to < Q2   | 1 (1.1)                                             | 2 (2.4)                                         | 0                                           |
| Preferred term                   | ≥ Q2 to < Q3   | 1 (1.3)                                             | 1 (1.3)                                         | 1 (1.2)                                     |
| Preferred term                   | ≥ Q3           | 1 (1.1)                                             | 1 (1.1)                                         | 0                                           |
| Hypertension                     | < Q1           | 4 (5.9)                                             | 1 (1.2)                                         | 0                                           |
| Hypertension                     | ≥ Q1 to < Q2   | 0                                                   | 0                                               | 2 (2.2)                                     |
| Hypertension                     | ≥ Q2 to < Q3   | 1 (1.3)                                             | 0                                               | 0                                           |
| Hypertension                     | ≥ Q3           | 3 (3.2)                                             | 1 (1.1)                                         | 0                                           |
| Hypokalaemia                     | < Q1           | 4 (5.9)                                             | 4 (4.8)                                         | 3 (3.5)                                     |
| Hypokalaemia                     | ≥ Q1 to < Q2   | 1 (1.1)                                             | 1 (1.2)                                         | 1 (1.1)                                     |
| Hypokalaemia                     | ≥ Q2 to < Q3   | 1 (1.3)                                             | 0                                               | 2 (2.4)                                     |
| Hypokalaemia                     | ≥ Q3           | 0                                                   | 0                                               | 0                                           |
| Hyponatraemia                    | < Q1           | 2 (2.9)                                             | 5 (6.0)                                         | 4 (4.7)                                     |
| Hyponatraemia                    | ≥ Q1 to < Q2   | 3 (3.4)                                             | 0                                               | 3 (3.3)                                     |
| Hyponatraemia                    | ≥ Q2 to < Q3   | 1 (1.3)                                             | 1 (1.3)                                         | 4 (4.8)                                     |
| Hyponatraemia                    | ≥ Q3           | 0                                                   | 1 (1.1)                                         | 1 (1.3)                                     |
| Leukopenia                       | < Q1           | 1 (1.5)                                             | 1 (1.2)                                         | 6 (7.1)                                     |
| Leukopenia                       | ≥ Q1 to < Q2   | 2 (2.3)                                             | 4 (4.9)                                         | 2 (2.2)                                     |
| Leukopenia                       | ≥ Q2 to < Q3   | 3 (3.9)                                             | 1 (1.3)                                         | 2 (2.4)                                     |
| Leukopenia                       | ≥ Q3           | 3 (3.2)                                             | 2 (2.3)                                         | 2 (2.7)                                     |
| Lipase increased                 | < Q1           | 3 (4.4)                                             | 1 (1.2)                                         | 0                                           |
| Lipase increased                 | ≥ Q1 to < Q2   | 9 (10.3)                                            | 2 (2.4)                                         | 4 (4.4)                                     |
| Lipase increased                 | ≥ Q2 to < Q3   | 0                                                   | 2 (2.5)                                         | 0                                           |
| Lipase increased                 | ≥ Q3           | 1 (1.1)                                             | 2 (2.3)                                         | 2 (2.7)                                     |
| Neutropenia                      | < Q1           | 9 (13.2)                                            | 5 (6.0)                                         | 12 (14.1)                                   |
| Neutropenia                      | ≥ Q1 to < Q2   | 15 (17.2)                                           | 15 (18.3)                                       | 10 (11.1)                                   |
| Neutropenia                      | ≥ Q2 to < Q3   | 14 (18.2)                                           | 9 (11.3)                                        | 9 (10.8)                                    |
| Neutropenia                      | ≥ Q3           | 18 (18.9)                                           | 17 (19.3)                                       | 10 (13.3)                                   |
| Neutrophil count decreased       | < Q1           | 5 (7.4)                                             | 10 (11.9)                                       | 8 (9.4)                                     |
| Neutrophil count decreased       | ≥ Q1 to < Q2   | 6 (6.9)                                             | 4 (4.9)                                         | 8 (8.9)                                     |
| Neutrophil count decreased       | ≥ Q2 to < Q3   | 10 (13.0)                                           | 5 (6.3)                                         | 6 (7.2)                                     |
| Neutrophil count decreased       | ≥ Q3           | 4 (4.2)                                             | 6 (6.8)                                         | 3 (4.0)                                     |
| Platelet count decreased         | < Q1           | 3 (4.4)                                             | 4 (4.8)                                         | 5 (5.9)                                     |
| Platelet count decreased         | ≥ Q1 to < Q2   | 2 (2.3)                                             | 3 (3.7)                                         | 3 (3.3)                                     |
| Platelet count decreased         | ≥ Q2 to < Q3   | 2 (2.6)                                             | 3 (3.8)                                         | 3 (3.6)                                     |
| Platelet count decreased         | ≥ Q3           | 2 (2.1)                                             | 1 (1.1)                                         | 6 (8.0)                                     |
| Pneumonia                        | < Q1           | 8 (11.8)                                            | 7 (8.3)                                         | 4 (4.7)                                     |
| Pneumonia                        | ≥ Q1 to < Q2   | 7 (8.0)                                             | 3 (3.7)                                         | 3 (3.3)                                     |
| Pneumonia                        | ≥ Q2 to < Q3   | 4 (5.2)                                             | 3 (3.8)                                         | 1 (1.2)                                     |
| Pneumonia                        | ≥ Q3           | 4 (4.2)                                             | 2 (2.3)                                         | 2 (2.7)                                     |
| Thrombocytopenia                 | < Q1           | 4 (5.9)                                             | 1 (1.2)                                         | 7 (8.2)                                     |
| Thrombocytopenia                 | ≥ Q1 to < Q2   | 4 (4.6)                                             | 8 (9.8)                                         | 3 (3.3)                                     |
| Thrombocytopenia                 | ≥ Q2 to < Q3   | 3 (3.9)                                             | 3 (3.8)                                         | 3 (3.6)                                     |
| White blood cell count decreased | ≥ Q3 < Q1      | 7 (7.4) 3 (4.4)                                     | 4 (4.5) 5 (6.0)                                 | 4 (5.3) 4 (4.7)                             |
| White blood cell count decreased | ≥ Q1 to < Q2   | 2 (2.3)                                             | 2 (2.4)                                         | 1 (1.1)                                     |
| White blood cell count decreased | ≥ Q2 to < Q3   | 3 (3.9)                                             | 1 (1.3)                                         | 3 (3.6)                                     |
| White blood cell count decreased | ≥ Q3           | 1 (1.1)                                             | 2 (2.3)                                         | 1 (1.3)                                     |

a Patients are counted once for each preferred term. Number (%) of patients with AEs, sorted by alphabetical order for preferred term. Each patient has only been represented with the maximum reported CTCAE grade at either the start of AE or after increasing in severity for each system organ class/preferred term.

b The boundaries for the weight quartiles are derived from the overall POSEIDON population with known baseline weight (n = 1009) and are Q1 = 57.0 kg, Q2 = 67.2 kg and Q3 = 77.0 kg, respectively.

Percentages calculated from number of patients in the safety analysis set in that weight group in that treatment group.

## Race:

<div style=\"page-break-after: always\"></div>

Table 80. Adverse Events by Category and Race (Safety Analysis Set)

| AEs                                                                    | Race       | Number (%) of Patients a     | Number (%) of Patients a   | Number (%) of Patients a             | Number (%) of Patients a     | Number (%) of Patients a                  |
|------------------------------------------------------------------------|------------|------------------------------|----------------------------|--------------------------------------|------------------------------|-------------------------------------------|
| AEs                                                                    | Race       | POSEIDON                     | POSEIDON                   | T + D + Chemo pool (N1=144) (N2=452) | Chemo pool (N1=167) (N2=432) | T + D Pan- tumour pool (N1=581) (N2=1699) |
| AEs                                                                    | Race       | T + D + SoC (N1=97) (N2=233) | SoC (N1=127) (N2=206)      | T + D + Chemo pool (N1=144) (N2=452) | Chemo pool (N1=167) (N2=432) | T + D Pan- tumour pool (N1=581) (N2=1699) |
| Patients with any AE                                                   | Asian      | 96 (99.0)                    | 123 (96.9)                 | 143 (99.3)                           | 163 (97.6)                   | 553 (95.2)                                |
| Patients with any AE                                                   | Non- Asian | 225 (96.6)                   | 197 (95.6)                 | 442 (97.8)                           | 415 (96.1)                   | 1607 (94.6)                               |
| Patients with any SAE b                                                | Asian      | 56 (57.7)                    | 53 (41.7)                  | 84 (58.3)                            | 73 (43.7)                    | 270 (46.5)                                |
| Patients with any SAE b                                                | Non- Asian | 90 (38.6)                    | 64 (31.1)                  | 183 (40.5)                           | 141 (32.6)                   | 750 (44.1)                                |
| Patients with any AE of CTCAE G3 or G4 c                               | Asian      | 72 (74.2)                    | 77 (60.6)                  | 108 (75.0)                           | 108 (64.7)                   | 289 (49.7)                                |
| Patients with any AE of CTCAE G3 or G4 c                               | Non- Asian | 131 (56.2)                   | 112 (54.4)                 | 282 (62.4)                           | 248 (57.4)                   | 925 (54.4)                                |
| Patients with any AE leading to outcome of death                       | Asian      | 13 (13.4)                    | 9 (7.1)                    | 21 (14.6)                            | 10 (6.0)                     | 38 (6.5)                                  |
| Patients with any AE leading to outcome of death                       | Non- Asian | 28 (12.0)                    | 21 (10.2)                  | 47 (10.4)                            | 35 (8.1)                     | 115 (6.8)                                 |
| Patients with any AE leading to discontinuation of any study treatment | Asian      | 18 (18.6)                    | 16 (12.6)                  | 35 (24.3)                            | 20 (12.0)                    | 92 (15.8)                                 |
| Patients with any AE leading to discontinuation of any study treatment | Non- Asian | 55 (23.6)                    | 35 (17.0)                  | 95 (21.0)                            | 56 (13.0)                    | 275 (16.2)                                |

Percentages are calculated from N1 and N2 for Asian and Non-Asian, respectively. Number of patients with events divided by the total number of patients in the race group, multiplied by 100.

Seriousness, as assessed by the Investigator. An AE with missing seriousness is considered serious.

<div style=\"page-break-after: always\"></div>

Geographic region:

Table 81. Adverse Events by Category and Geographic Region (Safety Analysis Set)

|                                                                        | Geographic    | Number (%) of Patients a                     | Number (%) of Patients a              | Number (%) of Patients a                             | Number (%) of Patients a                     | Number (%) of Patients a                                   |
|------------------------------------------------------------------------|---------------|----------------------------------------------|---------------------------------------|------------------------------------------------------|----------------------------------------------|------------------------------------------------------------|
|                                                                        | Geographic    | POSEIDON                                     | POSEIDON                              | T + D + Chemo pool (N1=137) (N2=357) (N3=62) (N4=40) | Chemo pool (N1=162) (N2=335) (N3=56) (N4=46) | T + D Pan- tumour pool (N1=547) (N2=1005) (N3=667) (N4=61) |
|                                                                        | Region        | T + D + SoC (N1=94) (N2=160) (N3=42) (N4=34) | SoC (N1=123) (N2=130) (N3=39) (N4=41) | T + D + Chemo pool (N1=137) (N2=357) (N3=62) (N4=40) | Chemo pool (N1=162) (N2=335) (N3=56) (N4=46) | T + D Pan- tumour pool (N1=547) (N2=1005) (N3=667) (N4=61) |
| Patients with any AE                                                   | Asia          | 93 (8.9)                                     | 119 (96.7)                            | 136 (99.3)                                           | 158 (97.5)                                   | 519 (94.9)                                                 |
| Patients with any AE                                                   | Europe        | 153 (95.6)                                   | 123 (94.6)                            | 348 (97.5)                                           | 320 (95.5)                                   | 928 (92.3)                                                 |
| Patients with any AE                                                   | North America | 41 (97.6)                                    | 37 (94.9)                             | 61 (98.4)                                            | 54 (96.4)                                    | 655 (98.2)                                                 |
| Patients with any AE                                                   | South America | 34 (100.0)                                   | 41 (100.0)                            | 40 (100.0)                                           | 46 (100.0)                                   | 58 (95.1)                                                  |
| Patients with any SAE b                                                | Asia          | 54 (57.4)                                    | 50 (40.7)                             | 81 (59.1)                                            | 69 (42.6)                                    | 250 (45.7)                                                 |
| Patients with any SAE b                                                | Europe        | 60 (37.5)                                    | 47 (36.2)                             | 141 (39.5)                                           | 114 (34.0)                                   | 410 (40.8)                                                 |
| Patients with any SAE b                                                | North America | 18 (42.9)                                    | 10 (25.6)                             | 27 (43.5)                                            | 18 (32.1)                                    | 331 (49.6)                                                 |
| Patients with any SAE b                                                | South America | 14 (41.2)                                    | 10 (24.4)                             | 18 (45.0)                                            | 13 (28.3)                                    | 29 (47.5)                                                  |
| Patients with any AE of CTCAE G3 or G4 c                               | Asia          | 70 (74.5)                                    | 74 (60.2)                             | 105 (76.6)                                           | 104 (64.2)                                   | 265 (48.4)                                                 |
| Patients with any AE of CTCAE G3 or G4 c                               | Europe        | 85 (53.1)                                    | 78 (60.0)                             | 216 (60.5)                                           | 199 (59.4)                                   | 492 (49.0)                                                 |
| Patients with any AE of CTCAE G3 or G4 c                               | North America | 24 (57.1)                                    | 15 (38.5)                             | 41 (66.1)                                            | 27 (48.2)                                    | 425 (63.7)                                                 |
| Patients with any AE of CTCAE G3 or G4 c                               | South America | 24 (70.6)                                    | 22 (53.7)                             | 28 (70.0)                                            | 26 (56.5)                                    | 32 (52.5)                                                  |
| Patients any to death                                                  | Asia          | 11 (11.7)                                    | 9 (7.3)                               | 19 (13.9)                                            | 9 (5.6)                                      | 36 (6.6)                                                   |
| Patients any to death                                                  | Europe        | 21 (13.1)                                    | 17 (13.1)                             | 37 (10.4)                                            | 30 (9.0)                                     | 92 (9.2)                                                   |
| Patients any to death                                                  | North America | 5 (11.9)                                     | 2 (5.1)                               | 7 (11.3)                                             | 4 (7.1)                                      | 15 (2.2)                                                   |
| Patients any to death                                                  | South America | 4 (11.8)                                     | 2 (4.9)                               | 5 (12.5)                                             | 2 (4.3)                                      | 10 (16.4)                                                  |
| Patients with any AE leading to discontinuation of any study treatment | Asia          | 16 (17.0)                                    | 16 (13.0))                            | 32 (23.4)                                            | 19 (11.7)                                    | 83 (15.2)                                                  |
| Patients with any AE leading to discontinuation of any study treatment | Europe        | 37 (23.1)                                    | 24 (18.5)                             | 73 (20.4)                                            | 45 (13.4)                                    | 180 (17.9)                                                 |
| Patients with any AE leading to discontinuation of any study treatment | North America | 13 (31.0)                                    | 4 (10.3)                              | 16 (25.8)                                            | 5 (8.9)                                      | 93 (13.9)                                                  |
| Patients with any AE leading to discontinuation of any study treatment | South America | 7 (20.6)                                     | 7 (17.1)                              | 9 (22.5)                                             | 7 (15.2)                                     | 11 (18.0)                                                  |

Percentages are calculated from N1, N2, N3, and N4 for Asia, Europe, North America, and South America, respectively. Number of patients with events divided by the total number of patients in the geographic region group, multiplied by 100.

Seriousness, as assessed by the Investigator. An AE with missing seriousness is considered serious.

<div style=\"page-break-after: always\"></div>

ECOG performance status:

Table 82. Adverse Events by Category and ECOG/WHO Performance Status (Safety Analysis Set)

|                                                                        | Baseline ECOG/WHO Performance Status   | Number (%) of Patients a      | Number (%) of Patients a   | Number (%) of Patients a             | Number (%) of Patients a     | Number (%) of Patients a                  |
|------------------------------------------------------------------------|----------------------------------------|-------------------------------|----------------------------|--------------------------------------|------------------------------|-------------------------------------------|
|                                                                        | Baseline ECOG/WHO Performance Status   | POSEIDON                      | POSEIDON                   | T + D + Chemo pool (N1=215) (N2=381) | Chemo pool (N1=206) (N2=393) | T + D Pan- tumour pool (N1=825) (N2=1455) |
|                                                                        | Baseline ECOG/WHO Performance Status   | T + D + SoC (N1=108) (N2=222) | SoC (N1=117) (N2=216)      | T + D + Chemo pool (N1=215) (N2=381) | Chemo pool (N1=206) (N2=393) | T + D Pan- tumour pool (N1=825) (N2=1455) |
| Patients with any AE                                                   | 0                                      | 104 (96.3)                    | 114 (97.4)                 | 211 (98.1)                           | 199 (96.6)                   | 791 (95.9)                                |
| Patients with any AE                                                   | ≥1                                     | 217 (97.7)                    | 206 (95.4)                 | 374 (98.2)                           | 379 (96.4)                   | 1369 (94.1)                               |
| Patients with any SAE b                                                | 0                                      | 43 (39.8)                     | 39 (33.3)                  | 91 (42.3)                            | 72 (35.0)                    | 327 (39.6)                                |
| Patients with any SAE b                                                | ≥1                                     | 103 (46.4)                    | 78 (36.1)                  | 176 (46.2)                           | 142 (36.1)                   | 693 (47.6)                                |
| Patients with any AE of CTCAE G3 or G4 c                               | 0                                      | 60 (55.6)                     | 58 (49.6)                  | 136 (63.3)                           | 107 (51.9)                   | 406 (49.2)                                |
| Patients with any AE of CTCAE G3 or G4 c                               | ≥1                                     | 143 (64.4)                    | 131 (60.6)                 | 254 (66.7)                           | 249 (63.4)                   | 808 (55.5)                                |
| Patients with any AE leading to outcome of death                       | 0                                      | 10 (9.3)                      | 11 (9.4)                   | 19 (8.8)                             | 14 (6.8)                     | 39 (4.7)                                  |
| Patients with any AE leading to outcome of death                       | ≥1                                     | 31 (14.0)                     | 19 (8.8)                   | 49 (12.9)                            | 31 (7.9)                     | 114 (7.8)                                 |
| Patients with any AE leading to discontinuation of any study treatment | 0                                      | 23 (21.3)                     | 21 (17.9)                  | 48 (22.3)                            | 24 (11.7)                    | 138 (16.7)                                |
| Patients with any AE leading to discontinuation of any study treatment | ≥1                                     | 50 (22.5)                     | 30 (13.9)                  | 82 (21.5)                            | 52 (13.2)                    | 229 (15.7)                                |

Percentages are calculated from N1 and N2, for baseline ECOG/WHO Performance Status=0 and baseline ECOG/WHO Performance Status≥1, respectively. Number of patients with events divided by the total number of patients in the baseline ECOG/WHO Performance Status group, multiplied by 100.

Seriousness, as assessed by the Investigator. An AE with missing seriousness is considered serious.

## Immunological events

POSEIDON: Of the 286 durvalumab evaluable patients in the same arm, 42 (14.7%) tested positive for durvalumab at any visit. Of the 278 tremelimumab ADA-evaluable patients in the T + D + SoC arm, 44 (15.8%) tested positive for tremelimumab ADA at any visit. The overall safety and tolerability profile of patients with ADAs was similar to those without ADAs.

T + D pan-tumour pool: Of the 1379 durvalumab-evaluable patients, 86 (6.2%) tested positive for durvalumab at any visit. Of the 1337 tremelimumab ADA-evaluable patients, 171 (12.8%) tested positive for tremelimumab at any visit.

## Safety related to drug-drug interactions and other interactions

Durvalumab and tremelimumab are immunoglobulins, therefore, no formal pharmacokinetic drug-drug interaction studies have been conducted.

<div style=\"page-break-after: always\"></div>

## Discontinuation due to adverse events

Table 83. AEs leading to discontinuation of any study treatment in ≥ 2 patients, SAS POSEIDON and pan-tumour pool

|                                                            | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a          |
|------------------------------------------------------------|----------------------------|----------------------------|-----------------------------------|
|                                                            | POSEIDON                   | POSEIDON                   | T + D Pan- tumour pool (N = 2280) |
| Preferred term                                             | T + D + SoC (N = 333)      | SoC (N = 330)              | T + D Pan- tumour pool (N = 2280) |
| Any AE leading to discontinuation of any study treatment b | 73 (22.1)                  | 51 (15.3)                  | 367 (16.1)                        |
| Pneumonia                                                  | 8 (2.4)                    | 7 (2.1)                    | 9 (0.4)                           |
| Anaemia                                                    | 5 (1.5)                    | 4 (1.2)                    | 1 (<0.1)                          |
| Acute kidney injury                                        | 4 (1.2)                    | 1 (0.3)                    | 4 (0.2)                           |
| Blood creatinine increased                                 | 4 (1.2)                    | 0                          | 1 (<0.1)                          |
| Pneumonitis                                                | 3 (0.9)                    | 1 (0.3)                    | 35 (1.5)                          |
| Sepsis                                                     | 3 (0.9)                    | 0                          | 6 (0.3)                           |
| Pulmonary embolism                                         | 2 (0.6)                    | 4 (1.2)                    | 6 (0.3)                           |
| Colitis                                                    | 2 (0.6)                    | 0                          | 23 (1.0)                          |
| Diarrhoea                                                  | 2 (0.6)                    | 0                          | 26 (1.1)                          |
| Nausea                                                     | 2 (0.6)                    | 1 (0.3)                    | 2 (<0.1)                          |
| Drug-induced liver injury                                  | 2 (0.6)                    | 0                          | 5 (0.2)                           |
| Autoimmune nephritis                                       | 2 (0.6)                    | 0                          | 0                                 |
| Fatigue                                                    | 2 (0.6)                    | 1 (0.3)                    | 5 (0.2)                           |
| Neutrophil count decreased                                 | 2 (0.6)                    | 1 (0.3)                    | 0                                 |

a Number (%) of patients with an AE leading to discontinuation of any study treatment, sorted by international order for SOC and alphabetically for PT.

b Action taken, study treatment permanently discontinued.

Patients with multiple AEs leading to discontinuation are counted once for each SOC/PT.

Table 84. AEs leading to discontinuation of tremelimumab or durvalumab in ≥ 2 patients, SAS POSEIDON (Arm 1) and pan-tumour pool.

|                                                                   | Number (%) of patients a   | Number (%) of patients a   |
|-------------------------------------------------------------------|----------------------------|----------------------------|
| Preferred term                                                    | POSEIDON                   | T + D Pan-tumour pool      |
|                                                                   | T + D + SoC (N = 330)      | (N = 2280)                 |
| Any AE leading to discontinuation of tremelimumab or durvalumab b | 57 (17.3)                  | 367 (16.1)                 |
| Pneumonia                                                         | 7 (2.1)                    | 9 (0.4)                    |
| Anaemia                                                           | 3 (0.9)                    | 1 (<0.1)                   |
| Acute kidney injury                                               | 3 (0.9)                    | 4 (0.2)                    |
| Blood creatinine increased                                        | 3 (0.9)                    | 1 (<0.1)                   |
| Pneumonitis                                                       | 3 (0.9)                    | 35 (1.5)                   |
| Sepsis                                                            | 3 (0.9)                    | 6 (0.3)                    |
| Pulmonary embolism                                                | 2 (0.6)                    | 6 (0.3)                    |
| Colitis                                                           | 2 (0.6)                    | 23 (1.0)                   |
| Drug-induced liver injury                                         | 2 (0.6)                    | 5 (0.2)                    |
| Autoimmune nephritis                                              | 2 (0.6)                    | 0                          |

b Action taken, study treatment permanently discontinued.

Patients with multiple AEs leading to discontinuation are counted once for each SOC/PT.

## Post marketing experience

No data on post marketing experience have been submitted.

<div style=\"page-break-after: always\"></div>

## 2.5.1. Discussion on clinical safety

The requested indication is for tremelimumab in combination with durvalumab and chemotherapy. In order to understand the isolated safety profile of tremelimumab, an anti-CTLA4 antibody, a supplementary analysis of phase II and III trials in which it was administered as monotherapy was presented. The tremelimumab monotherapy pool contained 643 patients treated at 10 mg/kg or a fixed dose of 750 mg Q4W, regimens that do not compare to the dose intended for marketing authorisation (75 mg Q4W). Although tables for the most common PTs for each of the categories were not tabulated by frequency, it was determined that diarrhoea was the most common likely-related AE, with an incidence of 40% (any grade) and 13% of patients presenting ≥ G3 diarrhoea. Of note, immune-mediated colitis is a well-known AE from anti-CTLA-4 treatment.

To evaluate the safety profile of tremelimumab in combination, safety results were also provided for all three arms of pivotal trial POSEIDON (T+D+SoC, D+SoC and SoC), a 'T+D+chemo pool' and a 'T+D pan-tumour pool'. The supportive pooled data have been used to try to elucidate the contribution of T + D to the safety profile of the proposed combination. The size and content of the presented safety database are deemed sufficient for B/R assessment in the targeted advanced NSCLC population.

The frequency of ADRs categorized as 'Not known' was estimated based on a pooled data set of patients treated with tremelimumab in combination with durvalumab (T75 + D pan-tumour pool, n = 3319).

Out of the entire pipeline of phase I, II and III trials where tremelimumab was given in monotherapy or in combination at multiple doses/regimens for diverse cancers, the latter was established by selecting 8 trials (2 in solid tumours, 4 NSCLC, 2 HNSCC) in which tremelimumab was administered at 1 mg/kg Q4W x 4 in combination with durvalumab, and 1 single trial (HCC) in which tremelimumab was administered at the flat 75 mg dose, the one intended for approval. The selection of these trials and exclusion of others (e.g. DANUBE) has been well justified.

The 'T+D+chemo pool' included the T+D+SoC chemotherapy arms of POSEIDON (NSCLC) and CASPIAN (ES-SCLC). There is at least another ongoing trial with a T+D+chemo arm (NILE, patients with advanced urothelial carcinoma), but results were not available at the time of submission of this application.

Adjudication of imAEs in the POSEIDON study was done programmatically (following a prespecified algorithm, without independent review), which is acceptable.

Exposure: According to the protocol of POSEIDON, tremelimumab as part of the T+D+SoC arm was to be administered for up to 5 doses (C1-4, C6). About 66% of patients in the T+D+SoC arm of POSEIDON received 5 or more tremelimumab doses, roughly comparable to 61% in CASPIAN. Durvalumab was instead to be given along induction chemotherapy (Q3W x 4 cycles), and then maintained Q4W until patients met any of the discontinuation criteria. Durvalumab exposure was appropriate overall (mean of 12 cycles in both experimental arms, more than half patients receiving 8). Chemotherapy could be given for a maximum of 4 cycles in the experimental arms and 6 cycles in the control arm. Across the three arms, the majority of patients received 4 or more cycles of chemotherapy (80% in T+D+SoC, 82% D+SoC and 75% SoC), implying that added immunotherapy did not have an impact on chemotherapy exposure. The distribution of the 5 histology-specific chemotherapy doublets permitted in the study was balanced among the three arms and reflects global trends in physician's choice for this setting.

Overall, exposure parameters of chemotherapy, durvalumab and tremelimumab across the different arms of study POSEIDON are considered appropriate for the assessment of B/R.

<div style=\"page-break-after: always\"></div>

AEs occurred in almost all patients across the three arms of POSEIDON. While high-grade (G3/4) AEs occurred in about half of the patients from each arm, G5 AEs were slightly more frequent in the experimental arms (12% in T+D+SoC, 10% D+SoC, 9% SoC), as were SAEs (44%, 40% and 35%, respectively) and AEs leading to discontinuation of any treatment (22%, 24% and 15%, respectively).

25 out the 26 most frequent AEs (incidence ≥10% in any arm) exhibited numerically higher incidence in the T+D+SoC arm as compared to the SoC arm, while the opposite occurred only for neutrophil count decreased. Typical chemotherapy-related AEs (anaemia, nausea, neutropenia, decreased appetite and fatigue) were the five most frequent AEs across the three arms of POSEIDON, with slightly higher incidence in the T+D+SoC arm as compared to the SoC arm. Diarrhoea and rash, with potentially immune-related pathophysiology, were considerably more frequent in the T+D+SoC arm than in the SoC arm (22% and 19% vs. 15% and 7%, respectively).

The incidence of hypothyroidism, a well-known imAE, was noticeably higher in the T+D+SoC arm (12%) than in the D+SoC (6%) or SoC (1%) arms. In line with these data, the incidence of this AE was 11% across both T+D+chemo and T+D pan-tumour pools.

Highgrade (≥G3) AEs: Since the proportions of G3/4 AEs were similar in both T+D+SoC and SoC arms (53% and 52%, respectively), it can be inferred that the higher incidence of G≥3 AEs in the T+D+SoC arm (66% vs. 61% in SoC) is driven by G5 AEs (12.4% and 9%, respectively), which is worrisome. Noting that G5 AEs occurred in 10.2% of the D+SoC arm, it becomes apparent that the addition of tremelimumab increases the risk for toxic death.

The proportions of the most frequent G3/4 AEs were overall similar across the three arms of POSEIDON, highlighting events of chemotherapy-related myelotoxicity, increases in pancreatic and hepatic enzymes and pneumonia. Of note, high-grade imAEs were not among the most frequently observed events in the experimental arms.

AESIs/imAEs: AESIs included imAEs and infusion-related reactions (IRRs) or hypersensitivity/ anaphylaxis reactions.

The proportion of patients with imAEs was 32% in the T+D+SoC arm, 17% in the D+SoC and 4% in the SoC arm. The distribution of G3/4 imAEs (10%, 6% and 1%, respectively), serious imAEs (9%, 5% and 1%) and imAEs leading to discontinuation (5%, 4% and 1%) were similar. The distribution of specific imAEs in the D+SoC arm is typical for PD-L1 inhibition, with predominance of hypothyroidism (6%), hepatotoxicity (3%), pneumonitis (3%) and dermatitis/rash (2%).

Endocrinopathies, hepatotoxicity and rash/dermatitis are overall more manageable than other imAEs, have less impact in morbidity, and less likelihood for becoming serious events or worsening the overall outcome of a patient. Events of Stevens-Johnson Syndrome or toxic epidermal necrolysis have been reported in patients treated with PD-1 inhibitors. Patients should be monitored for signs and symptoms of rash or dermatitis and managed through dose interruption, treatment discontinuation and/or corticoisteroid treatment (see sections 4.2 and 4.4 of the SmPC).

On the other hand, diarrhoea/colitis and pneumonitis might present as challenges since they imply a symptomatic burden and often require hospitalisation. The T+D+SoC arm presented twice as many cases of immune-mediated diarrhoea/colitis than the D+SoC arm (14 vs. 6) and more cases of pneumonitis (14 vs. 9).

Despite an unexpected proportion of pancreatic events was reported as AESIs in the T+D+SoC arm (any-grade 14%, G3/4 1.2%), most of these correspond to laboratorial anomalies (elevations of amylase and lipase, among others).

<div style=\"page-break-after: always\"></div>

Of note, there was one death related to multiple imAEs: pancreatitis, hepatitis, myocarditis and nephritis: these events took place shortly after the second treatment cycle. Patients should be monitored for abnormal liver tests prior to and periodically during treatment with tremelimumab in combination with durvalumab, and as indicated based on clinical evaluation. Patients should be monitored for abnormal renal function tests prior to and periodically during treatment. Patients should also be monitored for signs and symptoms of immune-mediated pancreatitis and myocarditis. Immune mediated hepatitis, nephritis, pancreatitis and myocarditis should be managed through dose interruption, treatment discontinuation and/or corticoisteroid treatment (see sections 4.2 and 4.4 of the SmPC).

There was one death due to haemophagocytic lymphohistiocytosis in the D+SoC arm.

Given the mechanism of action of tremelimumab in combination with durvalumab, other potential immune mediated adverse reactions may occur. The following immune-related adverse reactions have been observed in patients treated with tremelimumab in combination with durvalumab: myasthenia gravis, myositis, polymyositis, meningitis, encephalitis, Guillain-Barré syndrome, immune thrombocytopenia and cystitis noninfective. Patients should be monitored for signs and symptoms and managed through dose interruption, treatment discontinuation and/or corticoisteroid treatment (see sections 4.2 and 4.4 of the SmPC).

IRRs and hypersensitivity/anaphylaxis reactions were rare across the three arms of POSEIDON, and nearly all were G1/2: there was only one patient who presented a G3 IRR in the T+D+SoC arm, and nobody presented ≥G4 events. Pa tients should be monitored for signs and symptoms of IRRs. IRRs should be managed through dose interruption, treatment discontinuation, prophylaxis and appropriate treatment (see sections 4.2 and 4.4 of the SmPC).

ADRs: The most common (&gt; 20%) adverse reactions observed in patients treated with T+D+SoC (n=330) in the POSEIDON trial were anaemia (49.7%), nausea (41.5%), neutropenia (41.2%), fatigue (36.1%), rash (25.8%) thrombocytopenia (24.5%), and diarrhoea (21.5%). The most common  (&gt; 2%) Grade ≥ 3 adverse reactions were neutropenia (23.9%), anaemia (20.6%), pneumonia (9.4%), thrombocytopenia (8.2%), leukopenia (5.5%), fatigue (5.2%), lipase increased (3.9%), amylase increased (3.6%), febrile neutropenia (2.4%), colitis (2.1%) and aspartate aminotransferase increased/alanine aminotransferase increased (2.1%).

SAEs: Pneumonia was the most frequent SAE in the trial, and its incidence in the T+D+SoC arm doubled that of the control arm SoC (11% vs. 5%). As expected, myelotoxic events (anaemia, thrombocytopenia, febrile neutropenia, neutropenia, pancytopenia), likely related to chemotherapy, were also frequent in all three arms of the trial, with comparable incidence among them.

Noting that diarrhoea and colitis are important identified risks of anti-CTLA-4 agent ipilimumab, it is of no surprise that the number of patients with serious diarrhoea was higher in the T+D+SoC arm (8 patients), as compared to the other two arms (1 each) of the pivotal trial, pointing out the potential pathophysiologic role of CTLA-4 block in the development of serious immune-mediated diarrhoea/colitis. To support this hypothesis, the incidence of this SAE was nearly identical across the T+D+SoC arm (2.4%), and the T+D+chemo and T+D pools (2.5% in each). Data for colitis, slightly less prevalent, mimics this pattern. Patients should be monitored for signs and symptoms of colitis/diarrhoea and intestinal perforation and managed through dose interruption, treatment discontinuation and/or corticoisteroid treatment (see sections 4.2 and 4.4 of the SmPC).

Serious pneumonitis, with a likely immune-mediated background -known imAE from durvalumaboccurred almost exclusively in the experimental arms (6 cases in T+D+SoC, 5 in D+SoC, 1 in SoC). Patients should be monitored for signs and symptoms of pneumonitis. Suspected pneumonitis should be confirmed with radiographic imaging and other infectious and disease-related aetiologies excluded,

<div style=\"page-break-after: always\"></div>

and managed through dose interruption, treatment discontinuation and corticosteroid treatment (see sections 4.2 and 4.4 of the SmPC).

Deaths: Regardless of causality, there were 41 AEs leading to death in the T+D+SoC arm, 34 in the D+SoC arm and 30 in the SoC arm. The most frequent category (system organ class) of AEs leading to death across all three arms of POSEIDON was infections and infestations (15, 8 and 9, respectively), with 7 events of fatal pneumonia in each arm (although there was another event of fatal respiratory tract infection in the T+D+SoC arm). Cardiac disorders followed in frequency as AEs with outcome of death, again with almost twice as many occurrences in the T+D+SoC arm, as compared to the other two arms: 8, 4 and 5, respectively. On the other hand, fatal events of pulmonary embolism occurred much frequently in the control arm: 1, 3 and 5, respectively.

Laboratory findings: Shifts in haematological parameters were comparable between the T+D+SoC and SoC arms of the pivotal trial. Increases of ALT/AST/bilirubin were noticeably higher in the T+D+SoC arm across different categories. This parallels the overall higher incidence of hepatobiliary disorders (8.2% patients in the T+D+SoC arm vs. 3.3% in the SoC arm). Paradoxically, a potential Hy's law definition was met in more patients from the SoC arm (9) as compared to the T+D+SoC arm (3).

Incidence of AE of hypothyroidism was declared in 11.8% in the T+D+SoC arm, 6.3% in the D+SoC arm and 1.2% in the SoC arm (p. 190/9160 ISS), highlighting likely immune-mediated pathophysiology in relationship to the addition of immune checkpoint inhibitors. The true incidence of subclinical -likely immune-mediated- hypothyroidism is probably higher, as the table on abnormal thyroid tests suggest, elevated TSH was evident in 31% of patients from the T+D+SoC arm, vs. 28 in the D+SoC arm, and 24% in the SoC arm. Patients should be monitored for abnormal thyroid function tests prior to and periodically during treatment and as indicated based on clinical evaluation. Immunemediated hypothyroidism, hyperthyroidism, and thyroiditis should be managed through dose interruption, symptomatic treatment or thyroid hormone replacement as clinically indicated (see sections 4.2 and 4.4 of the SmPC).

Immune mediated adrenal insufficiency occurred in patients receiving tremelimumab in combination with durvalumab. Patients should be monitored for clinical signs and symptoms of adrenal insufficiency. For symptomatic adrenal insufficiency, patients should be managed through dose interruption, corticoisteroid treatment and hormone replacement (see sections 4.2 and 4.4 of the SmPC).

Immune mediated type 1 diabetes mellitus, which can first present as diabetic ketoacidosis that can be fatal if not detected early, occurred in patients receiving tremelimumab in combination with durvalumab and chemotherapy. Patients should be monitored for clinical signs and symptoms of type 1 diabetes mellitus. For symptomatic type 1 diabetes mellitus, patients should be managed via treatment with insulin as clinically indicated (see sections 4.2, 4.4 and 4.8 of the SmPC).

Patients should be monitored for clinical signs and symptoms of hypophysitis or hypopituitarism. For symptomatic hypophysitis or hypopituitarism, patients should be managed as recommended through dose interruption and corticoisteroid treatment (see sections 4.2 and 4.4 of the SmPC).

Individual patient listings of ECG values have been provided. The risk of QT prolongation in relationship to tremelimumab appears low.

AEs by age subgroups: In the POSEIDON study in patients treated with tremelimumab in combination with durvalumab and platinum-based chemotherapy, some differences in safety were reported between elderly ( ≥ 65 years) and younger patients. The safety data from patients 75 years of age or older are limited to a total of 74 patients. There was a higher frequency of serious adverse reactions and discontinuation of any study treatment due to adverse reactions in 35 patients aged 75 years of

<div style=\"page-break-after: always\"></div>

age or older treated with tremelimumab in combination with durvalumab and platinum-based chemotherapy (45.7% and 28.6%, respectively) relative to 39 patients aged 75 years of age or older who received platinum-based chemotherapy only (35.9% and 20.5%, respectively). Careful consideration of the potential benefit/risk of this regimen on an individual basis is recommended (see sections 4.4 and 4.8 of the SmPC).

Overview of AEs by subgroups of other intrinsic and extrinsic characteristics does not show a specific pattern of safety concerns in a subgroup of considerable size. Data on safety by weight quartiles does not suggest major differences except for a higher incidence of maximum CTCAE Grade 3 or 4 in the subgroup of patients with the lowest body weight (i.e. &lt;57 kg). However, a particular toxicity trend for the occurrence of high-grade events was not observed.

AEs by ADA status: The proportions of patients with anti-tremelimumab antibodies in the T+D+SoC arm and T+D pan-tumour pool were similar (16% and 13%, respectively), but those for antidurvalumab antibodies were higher in POSEIDON (15% and 6%, respectively). The incidence of AEs across the diverse categories did not differ significantly for patients defined as ADA+ or ADA(durvalumab in both experimental arms and tremelimumab in arm T+D+SoC).

AEs leading to discontinuation: The overall proportion of patients that discontinued any treatment in the context of an AE was higher in the experimental arms (22% in T+D+SoC, 20% in D+SoC) than in the control arm (15%). The main AEs leading to discontinuation of any treatment across the three arms of POSEIDON were pneumonia, anaemia and acute kidney injury. The addition of tremelimumab or durvalumab does not translate into a higher rate of AEs leading to dose reduction of chemotherapy.

There are no data on the use of tremelimumab in pregnant women. Based on its mechanism of action, tremelimumab has the potential to impact maintenance of pregnancy and may cause foetal harm when administered to a pregnant woman. Tremelimumab is not recommended during pregnancy and in women of childbearing potential not using effective contraception during treatment and for at least 3 months after the last dose.

There is no information regarding the presence of tremelimumab in human milk, the absorption and effects on the breast-fed infant, or the effects on milk production. Human IgG2 is excreted in human milk. Because of the potential for adverse reactions from tremelimumab in breast-fed infants, breastfeeding women are advised not to breast-feed during treatment and for at least 3 months after the last dose.

Tremelimumab has no or negligible influence on the ability to drive and use machines.

## 2.5.2. Conclusions on clinical safety

Regardless of causality, all AEs categories (high-grade, serious, AEs leading to death or to treatment discontinuation, AESIs/imAEs) occurred in a numerically higher proportion of patients from the T+D+SoC arm as compared to the other two arms of pivotal trial POSEIDON.

Undoubtedly, the addition of double checkpoint inhibition (PD-L1 and CTLA-4) to a backbone platinum doublet imposes higher overall toxicity in the targeted population, which must be considered in the context of frail patients, particularly those of advanced age or multiple comorbidities. Immunemediated events are the main concern from the combination of tremelimumab and durvalumab: although most were manageable and did not considerably impact long-term clinical outcome (e.g. endocrinopathies, hepatotoxicity and rash/dermatitis), others constitute serious entities with a significant symptomatic burden (diarrhoea/colitis, pneumonitis), representing a considerable hazard to the wellbeing of patients in this palliative setting. To minimise the risk of immune-mediated adverse reactions, the distribution of a patient card has been established as an additional risk minimisation

<div style=\"page-break-after: always\"></div>

measure in the RMP of tremelimumab (see section 2.6).

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal

## 2.6. Risk management plan

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 2 is acceptable.

## Risk Management Plan

The Risk Management Plan (RMP) was prepared and submitted prior to CHMP Opinion for both the IMJUDO and TREMELIMUMAB ASTRAZENECA Marketing Authorisation Applications to include both of the indications (HCC and NSCLC) and no amendment to the RMP is proposed to support this application.

## Safety concerns

Table 85: List of important risks and missing information

| Summary of safety concerns   | Summary of safety concerns        |
|------------------------------|-----------------------------------|
| Important identified risks   | Immune-mediated adverse reactions |
| Important potential risks    | None                              |
| Missing information          | None                              |

## Pharmacovigilance plan

The PRAC, having considered the data submitted, is of the opinion that routine pharmacovigilance is sufficient to identify and characterise the risks of the product.

## Risk minimisation measures

Table 86: Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety concern                    | Risk minimisation measures                                                                                                                                       | Pharmacovigilance activities                                                                                                                           |
|-----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Identified Risks        | Important Identified Risks                                                                                                                                       | Important Identified Risks                                                                                                                             |
| Immune-mediated adverse reactions | Routine risk minimisation measures: • SmPC Sections 4.2, 4.2, and 4.8 • PL Sections 2 and 4 • Prescription-only medicine Additional risk minimisation measures : | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None. Additional pharmacovigilance activities: • None. |

<div style=\"page-break-after: always\"></div>

| Safety concern   | Risk minimisation measures                                                                                                                                                      | Pharmacovigilance activities   |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|
|                  | • Patient card to ensure patients and carers are aware of the symptoms of immune-mediated adverse reactions and understand the importance of early detection and prompt action. |                                |

## Additional risk minimisation measures

The distribution of a patient card has been established as an additional risk minimisation measure for IMJUDO. This patient card aims to raise awareness of potential symptoms of immune-mediated adverse reactions associated with the use of IMJUDO, promoting early detection and facilitating prompt management. This will reduce the clinical impact of immune-mediated adverse reactions.

## 2.7. Update of the Product information

As a consequence of this new indication, sections 2, 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2, 5.3 and 6.6 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

The adverse drug reactions table in section 4.8 (Table 3) has been updated to present safety information relating to HCC and NSCLC indications. The frequency of adverse reactions previously categorized as 'not known' has been revised based on the pool of 3319 patients (T75+D pool).

Additionally, section 5.3 has been updated to include a range for the exposure-based safety margin to clinical exposure (1.77-5.33), due to the different population PK reports used to calculate safety margins for HCC and NSCLC indications.

## 2.7.1. User consultation

No justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the Applicant. The changes to the package leaflet are minimal and were already reviewed in the context of the Tremelimumab AstraZeneca MA.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The approved therapeutic indication is:

IMJUDO in combination with durvalumab and platinum-based chemotherapy is indicated for the firstline treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.

The aim of added tremelimumab in the targeted population is to prolong overall survival (OS) and progression-free survival (PFS).

<div style=\"page-break-after: always\"></div>

## 3.1.2. Available therapies and unmet medical need

The first line (1L) treatment of metastatic NSCLC has evolved from cytotoxic chemotherapies based on physician's preference to a hallmark of personalized medicine, with subsets of patients treated according to the genetic alterations of their tumour and PD-L1 status, which predict for benefit from targeted therapies or immune checkpoint inhibitors (ICIs), respectively.

For patients without genetic drivers (e.g. EGFR, ALK, ROS1), treatment selection in clinical practice is usually based on PD-L1 expression or histology. For patients with high PD-L1 expression (i.e., PD-L1 expressed in ≥ 50% of tumour cells), monotherapy with either pembrolizumab or atezolizumab or cemiplimab are acceptable approved. Conversely, regardless of PD-L1 expression, a series of combinations of immunotherapy with histology-selected platinum-based chemotherapy have also shown survival benefits, which led to EMA approval:

- Pembrolizumab + carboplatin + paclitaxel/nab-paclitaxel for squamous histology
- Pembrolizumab + carboplatin + pemetrexed for non-squamous histology
- Atezolizumab + bevacizumab + carboplatin + paclitaxel for non-squamous histology
- Atezolizumab + carboplatin + nab-paclitaxel for non-squamous histology
- Nivolumab + ipilimumab + 2 cycles of platinum-doublet, regardless of histology

Although immunochemotherapy treatments are the 1L standard-of-care in patients with advanced metastatic NSCLC whose tumours do not harbour driver mutations, new treatment options are required that can explore the potential of immunotherapy strategies and benefit a broader patient population.

## 3.1.3. Main clinical studies

POSEIDON is a phase III, three-arm, randomised, multi-centre, open-label study in patients with metastatic NSCLC without EGFR or ALK aberrations, which compared durvalumab + chemotherapy (D+SoC, n=338) and tremelimumab + durvalumab + chemotherapy (T+D+SoC, n=338) to standardof-care histology-specific platinum-based chemotherapy (SoC, n=337).

The dual primary endpoints of BICR-PFS and OS were analysed in the ITT of the D+SoC vs. SoC arms, while identical secondary endpoints were evaluated in the ITT of the T+D+SoC vs. SoC arms.

## 3.2. Favourable effects

The primary OS endpoint (D+SoC vs SoC) in study POSEIDON did not meet statistical significance. However, the other primary PFS endpoint that compared the same arms showed statistical superiority and thus alpha was propagated to the next testing level, in which OS and PFS were evaluated as key secondary endpoints in the T+D+SoC vs. SoC arms.

- At data cutoff 12-MAR-2021 and with median survival follow-up of 12.5 months, 800 deaths had occurred (79% of OS maturity) in the ITT population. Treatment with T+D+SoC showed a statistically significant survival benefit as compared with SoC: HR for OS was 0.77 (95% CI 0.65, 0.92), p-value 0.00304. K-M estimates of median OS were 14.0 months in the T+D+SoC arm and 11.7 months in the SoC arm.
- At data cutoff 24-JUL-2019, 749 PFS events (74% maturity) had occurred across the three arms of the trial. K-M estimated median PFS was numerically higher in the T+D+SoC arm (6.2 months)

<div style=\"page-break-after: always\"></div>

than in the SoC arm (4.8 months), while HR for PFS outlines the statistical advantage from T+D+SoC vs. SoC: 0.72 (95% CI 0.60, 0.86), p-value 0.00031.

- Secondary endpoints of ORR, DoR and PFS2 endorsed the advantage of T+D+SoC over SoC, as did subgroup and diverse sensitivity analyses.
- The benefit of T+D+SoC vs. SoC -in terms of OS, PFS and ORR- is maintained regardless of PD-L1 expression status, i.e., above and below various PD-L1 cutoffs (1%, 25%, 50%).

## 3.3. Uncertainties and limitations about favourable effects

- Acknowledging differences in study design -particularly selection of squamous (SQ) or nonsquamous (NSQ) histologies or allowing both- and limitations from cross-trial comparisons, it is noted that longer median survival was observed in akin studies in which only anti-PD-1/PD-L1 agents were added to backbone platinum-based chemotherapy in the experimental arm.
- Even if the combination of T+D+SoC has demonstrated an improvement in OS, PFS and ORR compared with the SoC alone, the contribution of tremelimumab to this effect appears marginal in view of the results of a descriptive comparison with D+SoC. Since these analyses were not statistically powered, firm conclusions cannot be drawn.
- The OS benefit of T+D+SoC over SoC seems minimal in Asian patients and non-smokers. Of note, the smaller effect in the subgroup of non-smoker patients has already been observed in prior studies with immunotherapy. However, both subgroups were less represented in the T+D+SoC arm compared with the SoC arm.
- In elderly patients ( ≥ 75 years of age) a HR of 1.05 (95% CI: 0.64, 1.71) for OS was reported for T+D+SoC (n=35) vs. SoC (n=40). The uncertainty regarding efficacy (and safety) in this subgroup of patients is reflected in the SmPC.

## 3.4. Unfavourable effects

- AEs occurred in almost all patients across the three arms of POSEIDON. While high-grade (G3/4) AEs occurred in about half of the patients from each arm, G5 AEs were slightly more frequent in the experimental arms (12% in T+D+SoC, 10% D+SoC, 9% SoC), as were SAEs (44%, 40% and 35%, respectively) and AEs leading to discontinuation of any treatment (22%, 24% and 15%, respectively).
- Typical chemotherapy-related AEs (anaemia, nausea, neutropenia, decreased appetite and fatigue) were the five most frequent AEs across the three arms of the trial, with slightly higher incidence in the T+D+SoC arm as compared to the SoC arm. Diarrhoea and rash, with potentially immunerelated pathophysiology, were considerably more frequent in the T+D+SoC arm than in the SoC arm (22% and 19% vs. 15% and 7%, respectively).
- The higher incidence of G ≥ 3 AEs in the T+D+SoC arm (66% vs. 61% in SoC) is driven by G5 AEs (12.4% and 9%, respectively). The proportions of the most frequent G3/4 AEs were overall similar across the three arms of the trial, highlighting events of chemotherapy-related myelotoxicity, increases in pancreatic and hepatic enzymes and pneumonia.
- Regarding causality of AEs, it is difficult to elucidate which events could be caused by the chemotherapy component and which ones could be related to tremelimumab and/or durvalumab. Incidence of AEs reported with a ≥ 5% difference between both arms were: neutropenia (30.0% vs 23.4%), diarrhoea (21.5% vs. 15.3%), rash (19.4% vs. 6.6%), pyrexia (16.1% vs. 6.9%),

<div style=\"page-break-after: always\"></div>

arthralgia (12.4% vs. 6.3%), hypothyroidism (11.8% vs. 1.2%), pruritus (10.9% vs. 4.5%), and hyperthyroidism (5.8% vs. 0.6%).

- There were 41 AEs leading to death (G5 AEs) in the T+D+SoC arm, 34 in the D+SoC arm and 30 in the SoC arm. Most of these events were related to infections and cardiac disorders, noting that twice as many toxic deaths from infections occurred in the T+D+SoC arm, as compared to the other two arms (15, 8 and 9, respectively).
- The proportion of patients with imAEs was 32% in the T+D+SoC arm, 17% in the D+SoC and 4% in the SoC arm. The distribution of specific imAEs in the D+SoC arm is typical for PD-L1 inhibition, with predominance of hypothyroidism (6%), hepatotoxicity (3%), pneumonitis (3%) and dermatitis/rash (2%). The T+D+SoC arm presented twice as many cases of immune-mediated diarrhoea/colitis than the D+SoC arm (14 vs. 6) and more cases of pneumonitis (14 vs. 9). Hypothyroidism was more frequent in the T+D+SoC arm (12%) than in the D+SoC (6%) or SoC (1%) arms.
- Pneumonia was the most frequent SAE in the trial, and its incidence in the T+D+SoC arm doubled that of the control arm SoC (11% vs. 5%). Serious myelotoxic events, likely related to chemotherapy, were also frequent in all three arms of the trial, with comparable incidence among them. Serious pneumonitis and colitis/diarrhoea were more prevalent in the T+D+SoC arm than in the other two arms.
- The overall proportion of patients that discontinued any treatment in the context of an AE was higher in the experimental arms (22% in T+D+SoC, 20% in D+SoC) than in the control arm (15%). The main AEs leading to discontinuation of any treatment across the three arms of POSEIDON were pneumonia, anaemia and acute kidney injury.
- Patients who were 75 years or older (11% from the pivotal trial) presented a significantly higher proportion of SAEs (74% in T+D+SoC vs. 56% SoC), high-grade AEs (71% vs. 64%), G5 AEs (40% vs. 14%) and AEs leading to treatment discontinuation (49% vs. 23%) as compared to their younger counterparts. Caution should be exerted when considering treatment of tremelimumab + durvalumab + chemotherapy in patients older than 75 years. A specific warning in sections 4.4 and 4.8 was inserted.

## 3.5. Uncertainties and limitations about unfavourable effects

Not applicable.

## 3.6. Effects Table

Table 87. Effects Table for Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) and platinum-based chemotherapy for the 1L treatment of adults with metastatic NSCLC without EGFR or ALK aberrations. Data cut-off 12-MAR-2021 for OS and 24-JUL-2019 for PFS.

| Effect             | Short description                | Unit               | Arm 1 T+D+SoC n=338   | Arm 2 D+SoC n=338   | Arm 3 SoC chemo n=337   | Uncertainties / Strength of evidence                                         |
|--------------------|----------------------------------|--------------------|-----------------------|---------------------|-------------------------|------------------------------------------------------------------------------|
| Favourable Effects | Favourable Effects               | Favourable Effects | Favourable Effects    | Favourable Effects  | Favourable Effects      | Favourable Effects                                                           |
| OS                 | Median overall survival          | Months (95% CI)    | 14.0 (11.7, 16.1)     | 13.3 (11.4, 14.7)   | 11.7 (10.5, 13.1)       | At 79% OS events HR T+D+SoC vs. SoC 0.77 (95% CI 0.65, 0.92) p-value 0.00304 |
| BICR- PFS          | Median progression free survival | Months (95% CI)    | 6.2 (5.0, 6.5)        | 5.5 (4.7, 6.5)      | 4.8 (4.6, 4.8)          | At 74% PFS events HR T+D+SoC vs. SoC 0.72 (95% CI 0.60, 0.86)                |

<div style=\"page-break-after: always\"></div>

| Effect               | Short description                               | Unit                 | Arm 1 T+D+SoC n=338   | Arm 2 D+SoC n=338    | Arm 3 SoC chemo n=337   | Uncertainties / Strength of evidence                                       |
|----------------------|-------------------------------------------------|----------------------|-----------------------|----------------------|-------------------------|----------------------------------------------------------------------------|
|                      | by BICR                                         |                      |                       |                      |                         | p-value 0.00031                                                            |
| BICR- ORR-           | Overall response rate (confirmed) by BICR       | % (n)                | 130 (38.8)            | 137 (41.5)           | 81 (24.4)               | Denominator for calculations was patients with measurable disease, not ITT |
| Unfavourable Effects | Unfavourable Effects                            | Unfavourable Effects | Unfavourable Effects  | Unfavourable Effects | Unfavourable Effects    | Unfavourable Effects                                                       |
|                      |                                                 |                      | Arm 1 T+D+SoC n=330   | Arm 2 D+SoC n=334    | Arm 3 SoC chemo n=333   |                                                                            |
| ≥G3 AEs              | High-grade (severe) AEs                         | %                    | 66                    | 55                   | 61                      | SCS                                                                        |
| G5 AEs               | AEs leading to death                            | n (%)                | 41 (12.4)             | 34 (10.2)            | 30 (9.0)                | SCS                                                                        |
| SAEs                 | Serious AEs                                     | %                    | 44                    | 40                   | 35                      | SCS                                                                        |
| AEs disc.            | AEs leading to discontinuation of any treatment | %                    | 22                    | 20                   | 15                      | SCS                                                                        |
| imAEs                | Immune- mediated AEs                            | %                    | 32                    | 17                   | 4                       | SCS                                                                        |
|                      | Diarrhoea/ colitis                              | n (%)                | 14 (4.2)              | 6 (1.8)              | 2 (0.6)                 | SCS                                                                        |
|                      | Pneumonitis                                     | n (%)                | 14 (4.2)              | 9 (2.7)              | 1 (0.3)                 | SCS                                                                        |

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The addition of immune checkpoint inhibition (PD-1, PD-L1 or CTLA-4) to a platinum doublet has proven successful at prolonging survival in advanced driver-negative NSCLC: a series of trials conducted concurrently in the last few years -the majority depicting add-on design with platinumbased chemotherapy as control- have shown improved efficacy outcomes of the experimental arms. Indeed, current guidelines across the globe highlight a plethora of immunochemotherapy regimens that are recommended for the initial approach in a treatment-naïve setting. While most of these combinations are appropriate regardless of tumoural PD-L1 expression, PD-1/PD-L1 inhibitors as monotherapy are also adequate choices for high-expressors ( ≥ 50% of tumour cells).

Albeit strictly unsuccessful for its primary OS endpoint in the D+SoC vs. SoC arms, the overall efficacy outcome of pivotal trial POSEIDON parallels results of other similar studies, noting statistically improved OS and PFS for the T+D+SoC vs. SoC comparisons. Upon appropriate maturity of the database, beneficial effects were observed across different PD-L1 cut-offs. Importantly, however, the exploratory comparisons between the experimental arms seem to suggest a borderline efficacious advantage of the addition of tremelimumab to durvalumab and chemotherapy, challenging the clinical relevance of double immune checkpoint inhibition, especially in the light of added immune toxicity risks.

As thoroughly depicted in the safety section, all the categories of adverse events present numerically higher incidence in the experimental arms, particularly in the 4-drug combination implied in the therapeutic indication of tremelimumab. As expected, immune-mediated events prevailed in both experimental arms, and although the majority were low-grade and manageable (e.g. hypothyroidism, rash), potentially symptomatic events (e.g. diarrhoea/colitis, pneumonitis) occurred predominantly in the tremelimumab arm. Undeniably, if dual PD-L1 and CTLA-4 inhibition plus chemotherapy are

<div style=\"page-break-after: always\"></div>

considered for advanced NSCLC, toxicity and tolerability concerns are to be taken into account, particularly for more frail or elderly patients.

## 3.7.2. Balance of benefits and risks

Efficacy data from the POSEIDON trial are sufficiently mature: it seems unlikely that updated results would alter the current conclusions.

Although the combination of tremelimumab, durvalumab and platinum-based does not seem to fill an unmet medical need in the current therapeutic paradigm of advanced NSCLC, it could be considered another appropriate chemoimmunotherapy regimen in this palliative setting.

The addition of tremelimumab and durvalumab to chemotherapy results in considerably increased toxicity, in particular relating to higher incidence of serious and grade 5 adverse events. Furthermore, the symptomatic burden and safety risks from immune-mediate events whose incidence raise with CTLA-4 blockade -e.g. colitis/diarrhoea, pneumonitis -are a particular concern from added tremelimumab. Special caution must be exerted when considering this regimen for patients ≥ 75 years.

## 3.7.3. Additional considerations on the benefit-risk balance

Not applicable.

## 3.8. Conclusions

The overall benefit/risk balance of IMJUDO in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adults with metastatic NSCLC with no sensitising EGFR mutations or ALK positive mutations is positive, subject to the conditions stated in section 'Recommendations'.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable by consensus and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include in combination with durvalumab and platinum-based chemotherapy, the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations for Imjudo, based on the final analysis from the pivotal study D419MC00004, a Randomised, Multi-center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Patients with Metastatic Non Small-Cell Lung

<div style=\"page-break-after: always\"></div>

Cancer (NSCLC) (POSEIDON). As a consequence, sections 2, 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2, 5.3 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to include minor editorial changes.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet.

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I and IIIB are recommended.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion 'Imjudo-H-C-6016-II-0001'